Integrated functional genomics for improved manufacture of recombinant enveloped virus by Rodrigues, Ana Filipa
Ana Filipa Rodrigues 
Dissertation presented to obtain the Ph.D degree in Engineering and 
Technology Sciences – Biotechnology  
Instituto de Tecnologia Química e Biológica | Universidade Nova de Lisboa 
Oeiras, 
November, 2013 
Integrated functional genomics for improved 
manufacture of recombinant enveloped virus 
Transcriptional profiling and metabolic engineering of 
retrovirus producer cells 
Ana Filipa Albuquerque Ferreira Rodrigues 
Dissertation presented to obtain the Ph.D degree in  
Engineering and Technology Sciences, Biotechnology 
Instituto de Tecnologia Química e Biológica | Universidade Nova de Lisboa 
Oeiras, November, 2013 
Integrated functional genomics for improved 
manufacture of recombinant enveloped virus 
Transcriptional profiling and metabolic 
engineering of retrovirus producer cells 
 
INTEGRATED FUNCTIONAL GENOMICS FOR IMPROVED                                                                                
MANUFACTURE OF RECOMBINANT ENVELOPED VIRUS 
Transcriptional profiling and metabolic engineering of retrovirus producer cells 
 
Ana Filipa A. F. Rodrigues 
 
Dissertation presented to obtain a Ph.D degree in Engineering and Technology 
Sciences, Biotechnology, at the Instituto de Tecnologia Química e Biológica, 
Universidade Nova de Lisboa 
 
 
Supervisor:   Ana Sofia S. V. Coroadinha 
 
Co-Supervisor:    Wei-Shou Hu 
 
 
Oeiras, November 2013 
 
 
With the financial support from FCT, under contract SFRH/BD/48393/2008 
 
ii 
 
Integrated functional genomics for improved manufacture of recombinant enveloped virus  
Transcriptional profiling and metabolic engineering of retrovirus producer cells 
 
By Ana Filipa A.F.Rodrigues  
  
  
Second Edition: January 2014 
 
  
Front cover: composite image of (i) a two-channel microarray and (ii) a colony of 
retrovirus producer cells surrounded by a layer of target cells infected by the produced 
viruses. 
 
Back cover: retrovirus particle (iii). 
 
i) Adapted from http://www.people.vcu.edu/~mreimers/OGMDA/image.html. 
ii) High-titer clone isolated with the single step cloning-titration method (Chapter VII).  
iii) by Ana Filipa A.F. Rodrigues. 
 
ITQB-UNL/IBET Animal Cell Technology Unit  
Instituto de Tecnologia Química e Biológica/  
Instituto de Biologia Experimental e Tecnológica  
Av. Da República EAN, 2780-157 Oeiras, Portugal  
Phone: 00351 214469520; Fax: 00351 214421161   
http://tca.itqb.unl.pt  
http://www.itqb.unl.pt  
http://www.ibet.pt  
  
  
Copyright © 2014 by Ana Filipa A.F. Rodrigues  
All Rights Reserved  
Printed in Portugal  
iii 
 
 
From left to right: Prof. Manuel Carrondo, Dr. Pedro Cruz, Dr. Otto Merten, Prof. Wei-Shou 
Hu, Ana Filipa Rodrigues, Dr. Ana Sofia Coroadinha, Dr. Dagmar Wirth and Prof. Maria 
Arménia Carrondo 
 
Supervisors  
 
Dr. Ana Sofia Coroadinha, Head of the Cell Line Development and Molecular 
Biotechnology Laboratory, Animal Cell Technology Unit, IBET/ITQB-UNL, Oeiras, Portugal 
(supervisor). 
Prof. Wei-Shou Hu, Biotechnology Institute, Distinguished McKnight University Professor, 
Department of Chemical Engineering and Materials Science, University of Minnesota, 
Minneapolis, MN, USA (co-supervisor). 
 
Jury 
 
Dr. Otto-Wilhelm Merten, Head of the Applied Vectorology and Innovation group of 
Genethon, Genethon, Evry, France 
Dr. Dagmar Wirth, Head of the Model Systems for Infection Research Group, Helmholtz 
Centre for Infection Research, Braunschweig, Germany. 
Prof. Manuel J. T. Carrondo, Cathedratic Professor of Chemical and Biochemical 
Engineering at Faculdade de Ciências e Tecnologia,  UNL, Caparica, Portugal, and Director 
of Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal. 
Dr. Pedro Estilita P. M. Cruz, Investigator and CSO of ECBio, Portugal  
iv 
 
Foreword  
  
The present thesis dissertation is the result of four years of research at the Animal 
Cell  Technology  Unit  of Instituto  de  Tecnologia  Química  e  Biológica  – 
Universidade  Nova  de  Lisboa  and  Instituto  de  Biologia  Experimental  e  
Tecnológica (Oeiras,  Portugal)  and  at  the Biotechnology Institute, Department of 
Chemical Engineering and Materials Science, University of Minnesota (Minneapolis, 
MN, USA) under  the  supervision  of  Dr.  Ana Sofia Coroadinha and Prof. Wei-Shou 
Hu. 
  
This PhD thesis aimed at contributing with knowledge on the physiological 
constraints modulating retroviral vector production in human cell lines by using 
functional genomics tools and to improve their productivity performance by means 
of reverse metabolic engineering.  
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Abstract 
 
Biopharmaceuticals derived from recombinant viruses comprise a plethora of 
prophylactic and therapeutic products from vaccines to gene therapy vectors. 
Retroviruses occupy an important segment of this market. Replication-defective 
vectors have extensively been used as delivery vehicles in gene therapy protocols. 
Retrovirus-like-particles have shown promising results in vaccinology as immunogen 
display platforms. Replication-competent particles have efficiently been used as 
oncolytic agents.   
The manufacture of retroviral vectors faces many challenges. The titers obtained 
from cell culture bulk range 106 to 107 infectious particles per mL, demanding 10 to 
100 L of culture volume to treat a single patient. Also, viral preparations are 
characterized by low ratios of infectious to total particles further reducing the 
therapeutic efficiency of the infectious ones. Moreover, long-term vector production is 
dependent on animal blood serum, an ill-defined culture supplement and potential 
source of pathogen contamination, hindering the safety and standardization required 
in clinical-grade manufacture processes. Thus, the productivity performance of 
retroviral vector manufacture systems is below the therapeutic needs and far from 
meeting the biopharmaceutical industry demands for the transition clinical-to-market. 
This PhD thesis aimed at using functional genomics to understand the physiological 
constraints of retroviral vector production in human cell lines to improve their 
productivity performance by means of reverse metabolic engineering.  
 
In the first part of this work (Chapter II), the transcriptional and central carbon 
metabolite profiling of the transition ‘parental-to-producer’ of two retroviral vector 
producer cell lines – 293 FLEX and Te Fly – was evaluated. Eight pathways were 
identified to be recruited in the virus production state: amino acid catabolism, 
carbohydrate catabolism and integration of the energy metabolism, nucleotide 
metabolism, glutathione metabolism, pentose phosphate pathway, polyamines 
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biosynthesis and lipid metabolism. Their ability to modulate viral titers was validated 
by media manipulation, leading to improved productivities up to 6-fold. Within 
recruited pathways a mining strategy was devised to identify potential targets for gene 
manipulation in the view of enhanced viral titers. More than 30 genes were identified. 
In Chapter III the physiological determinants behind serum heterotrophy in 
retroviral vector production were investigated. A thorough study of viral production 
kinetics, vector characterization and cell growth and metabolic behavior was 
conducted, for 293 FLEX and Te Fly producer cells using different serum 
concentrations. The absence of the serum lipid fraction was identified to be a major 
cause for serum heterotrophy. Following these findings, in Chapter IV an adaptation to 
serum deprivation of the two cell lines was conducted, and analyzed the effects on 
lipid biosynthetic pathways and infectious vector production. Total lipid content as 
well as cellular cholesterol were quantified and lipid biosynthesis was assessed by 13C-
NMR spectroscopy. The effects of adaptation to serum deprivation in lipid biosynthesis 
were found to be cell line specific and directly correlated with infectious virus titers: 
293 FLEX cells faced severe lipid starvation and a 68-fold reduction in infectious vector 
titers. Te Fly cells were able to maintain total lipid content by rising de novo lipid 
biosynthesis, particularly cholesterol, with the consequent recovery of infectious 
vector productivities. Yet, for 293 FLEX no evident blockage in cholesterol biosynthesis 
was found. Therefore, in Chapter V.a, a whole-transcriptome microarray analysis of 
both cell lines under serum deprivation was conducted. Two potential blockage points 
in cholesterol biosynthesis were identified, exclusive of 293 FLEX cells: mevalonate 
kinase (MVK) and lanosterol synthase (LSS).  
In the first part of this thesis, several metabolic pathways and the corresponding 
genes were identified as potential targets to improve vector titers and viral 
preparation quality (e.g.: removal of serum from the culture medium).  
In the second part of this work (Chapters V.b to VIII), gathered knowledge was used 
for the rational design of metabolic manipulation strategies by means of gene over-
expression or down-regulation.  
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In Chapter V.b, lipid metabolism of 293 FLEX cells was manipulated by the over-
expression of mevalonate kinase (MVK), lanosterol synthase (LSS), and sterol 
regulatory element binding transcription factors 1 and 2 (SREBF1 and SREBF2). When 
individually over-expressing MVK and LSS serum heterotrophy was mildly alleviated 
but, when combined, it was totally reverted. The over-expression SREBF2 alone not 
only promoted the complete reversion of serum heterotrophy but resulted in higher 
infectious titers than those of standard serum supplementation conditions. This action 
was cholesterolgenesis-specific since the over-expression of sterol regulatory binding 
factor 1 (SBRF1), more related to fatty-acid biosynthesis, had no effect neither on viral 
productivity nor in the capability of reverting serum heterotrophy.  
In Chapter VI, the energy metabolism of 293 FLEX cells was targeted, namely by the 
down-regulation of the Warburg effect (WE) lactogenic phenotype. A proof-of-concept 
metabolic engineering study was conducted based on the down-regulation of two key 
molecular effectors of the WE: hypoxia inducible factor 1 (HIF1) and pyruvate 
dehydrogenase kinase (PDK), simultaneously tackling reduced lactate accumulation 
and enhanced channeling of glycolytic intermediates into the tricarboxylic acid cycle 
(TCA). For single gene manipulation, (HIF1 or PDK), clones producing up to 30-fold 
higher titers of infectious particles were isolated. Without substantial differences in 
glucose consumption, lactate production was diminished up to 4-fold, indicating the 
channeling of the consumed glucose into non-lactogenic routes. The physiological 
fingerprints associated to high-titer HIF1 down-regulated clones also showed 
significant recruitment of (non-lactogenesis) metabolic pathways previously related to 
virus production.  
For the isolation of high-producing phenotypes in WE down-regulated clones, 
hundreds of other low-producing clones were individually analyzed. Clone screening 
required over one year, making it impracticable to use the same strategy for the more 
than 30 gene candidates identified in the first part of the work. To overcome this 
bottleneck, a novel method for fast screening of the individual clone’s productivity was 
implemented: the single step cloning-titration method (Chapter VII). This method 
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makes use of split-GFP, a green fluorescent protein separated into 2 fragments – S10 
and S11 – which fluoresce only upon transcomplementation. Retrovirus producer cells 
secreting S11-viruses are cloned and co-cultured with S10-expressing cells and during 
the period of clone expansion S11 viruses infect S10 target cells reconstituting the GFP 
signal. Only the clones yielding high signal are isolated, avoiding cell expansion, cell 
banking and posterior growth/titration studies, of the low titer clones. Moreover, as 
each well contains a clone-derived colony, transcomplemented fluorescence data can 
be treated as an estimation of clone’s productivity and analyzed in terms of density 
distribution. The method combines the power of single-cell resolution with the 
dynamics of cell population analysis.  
The traditional approaches for cell engineering involve labor-intensive steps, 
turning multiple manipulations extremely difficult. Current state-of-the-art in multi-
gene mammalian cell engineering has been restricted to 2-3 genes. The development 
and implementation of the single step cloning-titration method unlocked the 
manipulation of multiple genes by reducing the one year process of clone screening to 
two weeks (Chapter VIII). Herein more than 30 gene candidates for vector productivity 
improvement were identified, and 17 have been tested:  lanosterol synthase (LSS), 
mevalonate kinase (MVK), sterol regulatory element binding factors 1 and 2 (SREBF1 
and SREBF2), isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), glutathione synthase 
(GSS), cystathionine β-synthase (CBS), cystathionase (CTH), heat shock 70kDa protein 5 
(HSPA5), ornithine decarboxylase 1 (ODC1) and its anti-enzyme inhibitor 1 (AZIN1), 
arginase 1 (ARG1), argininosuccinate synthase 1 (ASS1), the inhibitor of the α-subunit 
of hypoxia inducible factor 1 (HIF1AN), B-cell CLL/lymphoma 2 (BCL2) and X-box 
binding protein 1 (XBP1). Individually, these manipulations delivered clones producing 
up to 15-fold higher infectious particles titers (e.g: CBS). Future follow-up work will 
profit from the already validated genes showing to improve vector productivity, which 
will be combined in search of novel metabolic dynamics steering enhanced retroviral 
vector production.  
xii 
 
Apart from the therapeutic potential, retrovirus based vectors represent a class of 
highly complex biopharmaceuticals – RNA enveloped viruses – thereby, an attractive 
study model for metabolic optimization. Thus, the manipulations herein conducted are 
likely to be of interest to other enveloped virus replicating in mammalian cells (e.g. 
lentivirus). Additionally, the knowledge on the metabolic determinants of virus 
replication is still scarce and the use of integrated strategies to improve hosts 
productivity and upstream bioprocess an under-explored territory. This thesis 
contributed to change that landscape: deepening the understanding on the metabolic 
traits modulating virus production; identifying engineerable targets; leveraging the 
analytical tools to support gene manipulation and clone screening. All were combined 
in a pioneer multi-gene manipulation approach, the most extensive metabolic 
engineering study so far performed in mammalian cells, further enlightening virus-host 
interaction dynamics.  
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Resumo 
 
Os biofármacos derivados de vírus recombinantes abrangem inúmeros produtos 
profilácticos e terapêuticos desde vacinas a vectores de terapia génica. Os retrovírus 
ocupam um segmento importante deste mercado. Vectores sem capacidade 
replicativa tem sido extensivamente usados para entrega de material genético em 
protocolos de terapia génia. Partículas semelhantes a vírus tem demonstrado 
resultados promissores em vaccinologia como plataformas de apresentação de 
imunogénios. Partículas com capacidade replicativa tem sido eficientemente usadas 
como agentes oncolíticos. 
A manufactura de vectores retrovirais enfrenta vários desafios. Os títulos obtidos 
em cultura de células animais encontram-se na ordem das 106 às 107 partículas 
infecciosas por mL, requerendo 10 a 100 litros de volume de cultura para tratar um 
único paciente. Adicionalmente, as preparações virais são caracterizadas por baixas 
razões de conteúdo de partículas infecciosas por partículas totais. Mais ainda, a 
produção destes vectores  durante períodos longos de cultura depende de soro de 
sangue animal, limitando a segurança, standardização e qualidade necessárias aos 
processos de manufactura para uso clínico. Assim, a performance produtiva dos 
sistemas de manufactura de vectores retrovirais encontra-se abaixo das necessidades 
terapêuticas e longe de ir ao encontro das exigências da indústria biofarmacêutica 
para efectuar a transição do clínico para o mercado. 
Esta tese de doutoramento usou genómica funcional para compreender as 
limitações fisiológicas associados à produção de vectores retrovirais em linhas  
celulares humanas, para aperfeiçoar a sua performance produtiva usando engenharia 
metabólica reversa. 
 
Na primeira parte deste trabalho (Capítulo II), o perfil transcricional e de 
metabolitos das reacções de carbono central associados à transição ‘parental-para-
produtora’ de duas linhas celulares produtoras de vectores retrovirais – 293 FLEX e Te 
Fly – foi efectuado. Oito vias foram identificadas como sendo recrutadas na produção 
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viral: catabolismo de amino ácidos, catabolismo de carbohidratos e integração do 
metabolismo energético, metabolismo nucleotídico, metabolismo do glutationo, via 
dos fosfatos de pentose, biossíntese de poli aminas e metabolismo lipídico. A sua 
capacidade como modeladoras dos títulos virais foi validada por manipulação do meio 
de cultura, levando a aumentos de produtividade até 6 vezes. Dentro das vias 
recrutadas, uma nova estratégia exploratória foi usada para identificar potenciais alvos 
para manipulação génica tendo em vista o aumento de produtividade. Mais de 30 
genes foram identificados. 
No Capítulo III, as limitações fisiológicas subjacentes à heterofia de soro na 
produção de vectores retrovirais foram investigados. Um estudo aprofundado de 
cinética de produção viral, caracterização dos vectores e metabolismo de carbono 
central foi efectuado para as linhas celulares produtoras 293 FLEX e Te Fly usando 
diferentes concentrações de soro. A ausência da fracção lipídica do soro foi 
identificada como uma das principais causas da heterotrofia do soro. No seguimento 
destes resultados, no Capítulo IV foi realizada uma adaptação das duas linhas celulares 
à deprivação de soro, e foram analisados os efeitos nas vias de biossíntese lipídica e 
produção de vectores infecciosos. O conteúdo celular lipídico total bem como o de 
colesterol foram quantificados e a biossíntese lipídica avaliada por espectroscopia de 
ressonância magnética nuclear de Carbono 13. Os efeitos da adaptação à deprivação 
do soro apresentaram-se como sendo específicos de cada linha celular e directamente 
correlacionados com os títulos de vectores infecciosos: a linha celular 293 FLEX 
apresentou uma deprivação lipídica severa e uma redução em 68 vezes do seu título 
de vírus infecciosos. A linha celular Te Fly foi capaz de manter o conteúdo lipídico total 
através do aumento da biossíntese lipídica de novo, em particular de colesterol, com a 
consequente recuperação da produtividade de vectores infecciosos. Porém, para a 
linha celular 293 FLEX, não havia sido encontrado um bloqueio evidente na biossíntese 
de colesterol. Assim, no Capítulo V.a, foi efectuado uma análise por microarrays  em 
ambas as linhas celulares em condições de deprivação de soro. Dois pontos de 
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bloqueio na biossíntese de colesterol foram identificados, exclusivos da linha celular 
293 FLEX: os enzimas mevalonato cinase (MVK) e lanoesterol sintase (LSS).  
Na primeira parte desta tese, várias vias metabólicas e correspondentes genes 
foram identificados como alvos potenciais para o melhoramento dos títulos e 
qualidade das preparações retrovirais (por exemplo, para remoção do soro). 
 
Na segunda parte deste trabalho, (Capítulos V.b a VIII), o conhecimento reunido foi 
usado para o delineamento de estratégias racionais de manipulação metabólica 
através de sobre-expressão ou redução da expressão génica. 
No Capítulo V.b, o metabolismo lipídico da linha celular 293 FLEX foi manipulado 
através da sobre-expressão dos enzimas mevalonato cinase (MVK), lanoesterol sintase 
(LSS) e dos factores de transcrição que se ligam a elementos de regulação em esteróis 
(SREBF1 e 2). Quando sobre-expressados individualmente o MVK e o LSS, a 
heterotrofia do soro foi ligeiramente aliviada mas, quando em combinação, foi 
totalmente revertida. A sobre-expressão do SREBF2, não só promoveu a completa 
reversão da heterotrofia do soro como ainda resultou em títulos infecciosos superiores 
aos obtidos nas condições standard de suplementação. Esta acção foi específica da 
colesterolgéneses uma vez que a sobre-expressão do SREBF1, mais relacionado com a 
biossíntese de ácidos gordos, não teve qualquer efeito na produtividade viral nem na 
capacidade de reverter a heterotrofia do soro.  
No Capítulo VI, foi manipulado o metabolismo energético da linha celular 293 FLEX, 
nomeadamente pela redução do fenótipo lactogénico mediado pelo efeito de Warburg 
(WE). Um estudo de engenharia metabólica para prova de conceito foi efectuado 
baseado no abaixamento da expressão de dois efectores moleculares chave do efeito 
de Warburg: o factor indutível por hipóxia 1 (HIF1) e o enzima cinase do complexo 
piruvato desidrogenase (PDK), simultaneamente visando a redução da acumulação de 
lactato e um aumento da canalização dos intermediários glicolíticos para o ciclo dos 
ácidos tricarboxílicos (TCA). Para manipulações génicas únicas (HIF1 ou PDK), foram 
isolados clones a produzir até 30 vezes mais. Sem diferenças substanciais no consumo 
de glucose, a produção de lactato diminuiu até 4 vezes, indicando uma maior 
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canalização da glucose consumida para vias não lactogénicas. As especificidades 
fisiológicas associadas aos clones de elevados títulos na manipulação do HIF1 
demonstraram adicionalmente uma activação de vias metabólicas previamente 
identificadas com sendo recrutadas na produção de vírus.  
Para o isolamento de fenótipos de elevada produtividade dos clones manipulados 
no efeito de Warburg, centenas de outros clones de baixa produtividade foram 
individualmente analisados. A análise de clones exigiu mais de um ano, tornando 
impraticável o uso da mesma estratégia para os mais de 30 genes candidatos 
identificados na primeira parte do trabalho. Para ultrapassar esta limitação, um novo 
método foi implementado para a análise rápida da produtividade clonal individual: o 
método de clonagem e titulação num único passo (Capítulo VII). Este método faz uso 
da GFP fragmentada, uma proteína fluorescente verde separada em dois fragmentos – 
S10 e S11 – que apenas fluorescem após transcomplementação. Células produtoras 
que secretam retrovírus para a expressão de S11 são clonadas e co-cultivadas com 
células que expressam S10 e durante o período de expansão clonal os vírus S11 
infectam as células S10 reconstituindo o sinal da GFP. Apenas os clones que originam 
sinais elevados são isolados, evitando a expansão celular, constituição de banco 
celular, e estudos posteriores de crescimento e titulação de clones de baixo título. 
Mais ainda, como cada poço contém uma colónia derivada de uma única célula, os 
dados de fluorescência transcomplementada podem ser tratados como uma 
estimativa da produtividade clonal e analisados em termos de distribuição de 
densidade. Este método combina o poder resolucional da análise célula-a-célula com a 
dinâmica da análise da população de células.   
As abordagens tradicionais para engenharia celular requerem vários passos 
trabalhosos, tornando manipulações multi-génicas extremamente difíceis. O estado-
da-arte em engenharia de células de mamífero tem estado restrito a 2-3 genes. O 
desenvolvimento e implementação do método de clonagem e titulação num único 
passo abriu as portas à manipulação de múltiplos genes reduzindo o processo de 
análise clonal de um ano para duas semanas (Capítulo VIII). Nesta tese, mais de 30 
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genes foram identificados como candidatos para aumentos de produtividade e 17 
foram avaliados: lanoesterol sintase (LSS), mevalonato cinase (MVK), factores de 
ligação a elementos regulatórios de esteróis 1 e 2 (SREBF1 and SREBF2), isocitrato 
desidrogenase 1 e 2 (IDH1 and 2), glutationo sintase (GSS), cistationina β-sintase (CBS), 
cistationase (CTH), proteína de choque térmico 5 de 70 KDa (HSPA5), descarboxilase de 
ornitina 1 (ODC1) e o inibidor do seu anti-enzima (AZIN1), arginase (ARG1), 
argininosuccinato sintase (ASS1), o inibidor da subunidade α do factor indutível por 
hipóxia (HIF1AN), o factor 2 do linfoma das células B (BCL2), e a proteína de ligação à 
box  X (XBP1). Individualmente, estas manipulações originaram clones a produzir até 
15 vezes mais partículas infecciosas (por exemplo, CBS). A continuação deste trabalho 
beneficiará da análise dos genes já validados que demonstraram aumentar a 
produtividade viral, e que serão combinados em busca de novas dinâmicas 
metabólicas conducentes a elevados títulos virais. 
À parte do seu potencial terapêutico, os retrovírus representam uma classe de 
biofármacos de elevada complexidade – vírus envelopados de RNA – portanto um 
modelo de estudo atractivo para optimização metabólica. Assim, as manipulações 
genéticas conduzidas nesta tese terão provavelmente interesse para outros vírus 
envelopados que repliquem em células de mamífero (por exemplo, lentivírus). 
Adicionalmente, o conhecimento sobre as limitações metabólicas da replicação viral é 
ainda escasso, e o uso de estratégias integradas para melhorar a produtividade dos 
substratos celulares e parâmetros de bioprocesso um território sub-explorado. Esta 
tese contribuiu para alterar esse cenário: aprofundado o entendimento sobre os 
atributos metabólicos que modulam a produção viral; identificando alvos genéticos 
engenheiráveis, alavancando as ferramentas analíticas para suportar a manipulação 
génica e a análise clonal. Tudo isto foi combinado numa abordagem pioneira de 
manipulação multigénica, o estudo de engenharia metabólica mais extensivo até hoje 
conduzido em células de mamífero, contribuindo ainda para a elucidação da dinâmica 
de interacção vírus-hospedeiro. 
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1. The market of biopharmaceuticals based on recombinant virus  
Virus based biopharmaceuticals (VBBs) constitute an important segment of pharma 
industry being the vaccine field the most expressive, with an estimate market of US 
$40 Billion by 2015 and predictable sustained growth over the next 15 years (Renub 
Research 2011). More than expanding, this market is moving towards high-margin 
products based on recombinant viral particles such as the recently licensed human 
papillomavirus vaccine, Cervarix® (GSK) (Kresse and Shah 2010). Additionally, as these 
particles offer safer and more flexible platforms for antigen delivery, an increasing 
interest in non-prophylactic applications including cancer treatment (Cawood et al. 
2012) and self-antigen related diseases (Shimada et al. 2013) is emerging. More 
modest, but witnessing significant investments, is the market of gene therapy 
expected to generate a US$ 484 Million market by 2015 (Global Industry Analysts Inc 
2012). In November 2012, the European Commission has granted marketing 
authorization for the first gene therapy medicine, Glybera® (uniQure), anticipating 
active research and investment in the field over the next decade. Overall, the market 
of recombinant VBBs is not only experiencing comfortable growth as it holds the 
promise of novel prophylactic and therapeutic goods for the 21st century. 
 
1.1 Pipeline and strategic trends in biopharmaceuticals based on recombinant virus  
Virus based biopharmaceuticals (VBBs) can be defined as any virus derived 
component or virus-based particle which is able to be used with a therapeutic benefit. 
This definition includes i) free viral proteins, alone or conjugated; ii) virus-like particles 
(VLPs), viral genome-free particles assembled to mimic the viral structure; iii) 
recombinant viruses, in which the viral genome has been modified for a therapeutic 
purpose and iv) the wild type viruses, inactivated or attenuated, as in the case of many 
traditional vaccines. The large majority of VBBs of categories ii) and iii), is still in the 
early phases of clinical development, placing their market potential in the beginning of 
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next decade. Some of them are, however, in latter stages, with market potential within 
this decade. A few have already reached the market (Table I).  
 
1.1.1. Gene delivering particles – gene therapy and oncolytic virotherapy 
Gene therapy is defined as the transfer of genetic material into an individual’s cells 
or tissues, to treat or prevent a disease. Oncolytic virotherapy appears as sub-field of 
gene therapy, specifically aiming at eliminating cancer cells, typically – but not 
exclusively – by delivering suicide genes. The first gene therapy clinical trial was 
initiated in 1989, for the treatment of patients with advanced melanoma (Rosenberg 
et al. 1990). But the best well-known are those started right after to treat patients 
suffering from severe combined immunodeficiencies (SCIDs) which, despite relevant 
clinical successes, were also associated to serious adverse events (for a review see 
Fischer et al. (2013)). In both cases, genes were delivered by recombinant Murine 
Leukemia Virus (MLV) making MLV-based vectors the first ever used and probably the 
best well studied gene therapy viral vector until today. Since then, the number of viral 
vectors and treatable conditions by viral gene therapy has been growing.  
From the almost 1300 currently ongoing trials, viral vectors account for more than 
70% of gene delivery vehicles (Edelstine 2013). Among these, the top most used are 
based on: i) adenovirus, ii) retrovirus, iii) vaccinia virus, iv) poxvirus, v) adeno-
associated virus and  vi) herpes simplex virus (Ginn et al. 2013). 
Adenoviruses (AdV) have been the blockbuster vector for cancer therapy due to the 
transient nature of their transgene expression and very high transduction efficiency. 
Although they represent the most widely used gene therapy viral vector in total clinical 
trials, the growth rate of their use is dropping. The major drawback associated to these 
viruses is the strong – and potentially lethal – immune response induced to the 
patients (Raper et al. 2003). In 2004, Gendicine®, an adenoviral based vector, was the 
first human gene therapy product gaining market approval by the Chinese FDA 
(Pearson et al. 2004) (Table I). 
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Table I – Pipeline of biopharmaceuticals based on recombinant virus 
Indication Tradename Company / Institution VBB 
Clinical phase 
Cell host 
I II III Market 
Lipoprotein lipase 
deficiency 
Glybera uniQure AAV 
    
Insect cells 
Hemophilia B AMT-060 uniQure AAV 
    
Insect cells 
Alpha-1 antitrypsin 
deficiency 
AGTC-0106 
Applied Genetic 
Technologies 
AAV 
    
Insect cells 
Cardiomyopathy Mydicar Celladon AAV 
    
Insect cells 
Parkinson's disease AAV-hAADC-2 Genzyme AAV 
    
Insect cells 
Anemia Ad-MG/EPO-1 Medgenics AdV 
    
Human cells 
(HEK 293) 
Parkinson's disease ProSavin Oxford BioMedica EIAV 
    
Human cells 
(HEK 293) 
Age related macular 
degeneration 
RetinoStat 
Oxford BioMedica / 
Sanofi 
EIAV 
    
Human cells 
(HEK 293) 
Stargardt disease StarGen 
Oxford BioMedica / 
Sanofi 
EIAV 
    
Human cells 
(HEK 293) 
Usher Syndrome UshStat 
Oxford BioMedica / 
Sanofi 
EIAV 
    
Human cells 
(HEK 293) 
ADA-SCID GSK 2696273 GSK RV 
    
Human cells 
(HEK 293) 
Beta thalassemia Lentiglobin Bluebird Bio LV 
    
Human cells 
(HEK 293)  
Primary and metastatic 
disease 
GMCI Advantagene AdV 
    
Human cells 
(HEK 293/ PER.C6) 
Prostatic cancer ProstAtak Advantagene AdV 
    
Human cells 
(HEK 293/ PER.C6) 
Malignant gliomas GliAtak Advantagene AdV 
    
Human cells 
(HEK 293/ PER.C6) 
Pancreatic cancer PancAtak Advantagene AdV 
    
Human cells 
(HEK 293/ PER.C6) 
Head/neck cancer Gendicine 
Shenzhen SiBiono 
GeneTech 
AdV 
    
Human cells 
(HEK 293) 
Lung cancer Gendicine 
Shenzhen SiBiono 
GeneTech 
AdV 
    
Human cells 
(HEK 293) 
Several cancers Oncorine H101 
Shanghai Sunway 
Biotech 
AdV 
    
Human cells 
(HEK 293) 
Several cancers Oncorine H103 
Shanghai Sunway 
Biotech 
AdV 
    
Human cells 
(HEK 293) 
Prostate / malignant 
gliomas 
Ad.huIFN-β Biogen AdV 
    
Human cells 
(HEK 293) 
Solid tumors Rexin G Epeius Biotechnologies RV 
    
Human cells 
(HEK 293) 
Melanoma and 
head/neck cancer 
Talimogene 
laherparepvec 
Amgen HSV 
    
Green monkey cells 
 (Vero) 
Respiratory Syncytial 
Virus  
N/A Novavax RSV 
    
Insect cells 
Seasonal flu N/A Novavax 
(H5N1) (H7N9) 
(H7N3)     
Insect cells 
Pandemic flu N/A Novavax (H1N1) 
    
Insect cells 
HIV-AIDS ALVAC-HIV Sanofi Canarypox / HIV 
    
N/A 
Tuberculosis 
AERAS-402/ 
Crucell Ad35 
Crucell /Aeras AdV 
    
Human cells (PER.C6) 
Malaria Ad35-CS malaria Crucell/GSK AdV 
    
Human cells (PER.C6) 
HIV-AIDS Ad26.ENVA.01 Crucell / Harvard AdV 
    
Human cells (PER.C6) 
Ebola and Marburg N/A Crucell/GSK AdV 
    
Human cells (PER.C6) 
Human Papillomavirus Cervarix GSK HPV 
    
Insect cells 
Dengue N/A Sanofi-Pasteur YFV / Dengue 
    
Green monkey cells 
(Vero) 
HCMV infection N/A AlphaVax, Inc VEE 
    
Green monkey cells 
(Vero) 
HIV infection N/A AlphaVax, Inc VEE 
    
Green monkey cells 
(Vero) 
Orange: gene therapy; red: oncolytic virotherapy; blue: vaccines; N/A: not available; AAV: adeno-associated virus; AdV: adenovirus; EIAV: equine infectious 
anemia (lenti)virus; HIV: human immunodefficiency (lenti)virus; HPV: human papillomavirus; HSV: herpes simplex virus; LV: lentivirus; RSV: respiratory 
syncytial virus; RV: retrovirus; VEE: Venezuelan equine encephalitis virus; YFV: yellow fever virus. 
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Simple retroviruses (RVs) were the most widely used viral vector until 2004. This top 
position was displaced by adenovirus afterwards (Edelstein et al. 2004). Together with 
their complex counterparts, lentiviruses (LVs), retroviruses are the blockbuster vectors 
for the treatment of monogenic and infectious diseases (Edelstine 2013). The use of 
lentiviruses has been experiencing notable growth rates, from only 12 clinical trials 
between 2004-2007 to the 67 currently ongoing protocols, an impressive 500% 
increase. No other vector has grown as much and lentiviruses are likely to place over 
retrovirus in gene therapy in the years to come. Retro and lentiviral vectors most 
attractive features as gene transfer tools include minimal immune response, high 
transduction efficiency in vivo and in vitro, the ability to permanently modify the 
genetic content of the target cell and, in the case of lentiviruses, the ability to 
transduce non-dividing cells. In 2007, the Philippine FDA has granted market 
authorization for Rexin-G®, an MLV-based vector bearing cyclin G1 for the treatment 
of solid tumors (Gordon and Hall 2010) (Table I). 
Vaccina virus (VACV) has over 200 years of experience since, in 1798, Edward 
Jenner demonstrated protection from smallpox by vaccination (Niemialtowski et al. 
1996). It was first used as a gene deliver vector in 1995 as immunotherapy for cervical 
cancer (Borysiewicz et al. 1996). Vaccinia is a cytoplasmic virus with no evidence of 
latent infection, turning it particularly interesting for cancer therapy. Indeed, vaccinia 
based vectors have mainly been used for the treatment of cancer and, to a small 
extent, infectious diseases (HIV and HCV) (Edelstine 2013). However, due to the WHO 
campaign to eradicate smallpox, finished in the late 70’s, many patients over 30 years 
presents vigorous immune response to vaccinia vectors decreasing the levels of 
transgene expression and overall therapy efficacy. 
Herpes simplex virus (HSV) offers an interesting platform for gene deliver due to 
broad host range, high infectivity, ability to transduce non-dividing cells and latent but 
lifelong infection. They are specially suited for neurological disorders due to the 
natural neurotropism although the majority of clinical trials have targeted cancer 
(Edelstine 2013). In fact, their capacity to express the autologous tk gene, encoding the 
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thimidine kinase enzyme, a well characterized suicide gene, makes them particularly 
interesting for oncolytic virotherapy (Chen et al. 1995). Yet, 70-80% of population from 
low and 40-60% from improved socio-economic status carries latent HSV infection 
(Chayavichitsilp et al. 2009), raising safety concerns on reversion of replication 
deficiency by homologous recombination.  
Adeno-associated (AAVs) viral vectors were firstly used in cystic fibrosis gene 
therapy in 1994. Since then, the applications extended to hemophilia, ocular diseases, 
Alzheimer’s and Parkinson’s disease, muscular dystrophies, cardiac failure, 
dyslipidemia and cancer (Carter 2005; Mueller and Flotte 2008). AAVs are non-
pathogenic, readily transducing dividing or non-dividing cells and can persist essentially 
for the whole cell life-time. Additionally, they accommodate a myriad of modifications 
from serotype cross-species and serotype variations for versatile capsid engineering to 
achieve very specific tropism (Asokan et al. 2012). Glybera®, the first human gene 
therapy product approved in the European market, is a recombinant AAV vector for 
dyslipidemia treatment (Moran 2012). Adeno-associated viruses are, together with 
lentivirus, the gene therapy viral vector experiencing the highest growth rate, 96% in 
the period of 2007-2012 (Ginn et al. 2012) and, likely to take over a significant segment 
of the gene therapy viral vector market in the future years (Table I). Their main 
drawback is the small genetic payload they can accommodate.  
 
1.1.2. Antigen delivery and display – virus like particles and DNA vaccines 
While for gene therapy vectors, the viral biology dictates the application and, 
thereby, the trends for future usage, in antigen delivery/display one looks for the 
development of VBBs targeting diseases for which the prophylactic treatment is 
insufficient or inexistent. Thus, these are either i) virus-like particles displaying the 
antigenic proteins of the pathogen to be treated but lacking the nucleic acid content or 
ii) chimeric particles delivering the pathogen antigens genes.  
A good example of i) is the virus like particle (VLP) based vaccine from GSK for 
preventing human pappilommavirus (HPV), Cervarix® (Table I). This vaccine contains 
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the HPV L1 viral protein from HPV16 and HPV18 assembled into a HPV-like proteic 
architecture but no nucleic acid is delivered (Monie et al. 2008). 
In the category ii) fall, for instance the ALVAC-HIV or the dengue vaccine, both from 
Sanofi, under clinical testing (Table I). ALVAC-HIV is a chimeric particle comprised by a 
harmless canary poxvirus structure delivering the gag and the env genes of HIV-1. 
ALVAC-HIV was the first vaccine showing significant improvement in preventing HIV 
infection in human subjects although the results were considered modest (Rerks-
Ngarm et al. 2009). The dengue vaccine is also a chimera consisting of ENV 
glycoproteins of 4 DENV serotypes delivered by a yellow fever virus (YFV) backbone 
(and also displayed on its surface). Chimeric particles are considered a safer approach 
for antigen delivery pursued to treat life-threatening pathogens. Their safer profile is 
achieved by reducing the pathogen antigens to the minimum essential for eliciting a 
good immune response, delivered by vector backbones derived from less pathogenic 
viruses. Manufacturing issues may also be a consideration for the development of 
chimeras for viruses difficult to replicate in cell culture as hepatitis C virus (HCV). Only 
a few HCV genotypes are capable of cell culture replication and do so by accumulating 
several mutations poorly resembling those occurring in a clinical context (Bukh et al. 
2002). Thus, chimeric particles consisting of an MLV backbone delivering and 
displaying HCV E1 and E2 antigens are being tested in animal models for the 
development of a vaccine against HCV (Huret et al. 2013). 
 
 
2. Retroviral vectors: valuable therapeutic particles and dynamic study 
models 
2.1. Therapeutic and research applications of retroviral derived particles 
Gamma-retroviral vectors, commonly designated retroviral vectors, and their 
derived particles have found a myriad of applications (Fig. 1).  
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Figure 1 – Therapeutic and research applications of retroviral based particles. 
 
Replication-defective vectors have extensively been used as gene transfer tools in 
gene therapy protocols. According to the most recent updates, retroviral (together 
with lentiviral) vectors represent 23% of all the vector types and 33% of the viral 
vectors used in gene therapy clinical trials (Edelstine 2013). Approved protocols target 
haemophilia, severe combined immunodeficiency (SCID), HIV infection, Gaucher’s 
disease, β-thalassaemia, muscular dystrophy, Parkinson’s disease and cancer (Edelstine 
2013). 
Virus-like-particles (VLPs) have demonstrated promising results in the vaccinology 
field as immunogen display platforms, with the additional potential for nucleic-acid 
delivery (DNA/RNA vaccines). Indeed, retrovirus, retroVLPs included, can easily be 
pseudotyped with glycoproteins of several virus families, such as lymphocytic 
choriomeningitis virus, spleen necrosis virus, vesicular stomatitis virus, hepatitis C 
virus, human immunodeficiency virus, yellow fever virus, West Nile virus and influenza 
virus (Dalba et al. 2007).  
Replication-competent particles (RCP) were developed and efficiently used as 
oncolytic agents (Dalba et al. 2007). In fact, replicative competent RV vectors are 
particularly suited for this proposes since they can only integrate and replicate in 
dividing cells, providing an inherent means for targeting malignant cells that divide 
actively, while surrounding normal cells are generally quiescent. Furthermore, after 
transduction, each tumor cell acquires the capability to produce more vectors that will 
improve the transduction efficiency of the surrounding malignant cells. Hence, they 
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have been investigated for the treatment of a wide range of cancers including ovarian 
cancer, breast cancer, brain tumors and lung cancer.  
In research, retrovirus based particles have been used as carriers of 
conformationally-complex membrane proteins to study protein interactions (Willis et 
al. 2008) and as transduction vehicles of difficult-to-transfect cells (Lindemann and 
Schnittler 2009) including  germ-line cells for research and transgenic mice generation 
(Kanatsu-Shinohara et al. 2004). Moreover, the major breakthrough in stem cell 
biology – reprogramming adult somatic cells to a primitive embrionary state 
establishing the induced pluripotent stem cells (iPSCs) – was firstly achieved, and is still 
one of the most used means, by retroviral transduction of the Oct-3/4, SOX2, c-Myc, 
and Klf4 transcription factors (Takahashi and Yamanaka 2006).  
More recently, the interest in lentiviral (LV) vectors, derived from complex 
retroviruses such as the human immunodeficiency virus (HIV), has been growing. LVs 
embrace the majority of the advantages of simple retrovirus with the additional plus of 
transducing non-dividing cells (Lewis and Emerman 1994). For human gene therapy 
they are, in fact, considered as a safer alternative since MLV shows a strong bias to 
integrate near transcription start sites, potentially activating the expression of 
oncogenes (Mitchell et al. 2004). However, lentiviral vectors present manufacture 
challenges identical to those of simple retrovirus, with the additional drawback of high 
cytotoxicity of some of the vector components hampering stable cell line development 
(Schweizer and Merten 2010). Commonly, LVs are produced by co-transfecting HEK 
293 derived cells with three or four different plasmid constructs. However transient 
transfection systems are difficult to scale-up, irreproducible, cost-ineffective, and time 
consuming unlikely to be a valuable approach for large-scale production after the 
transition clinical-to-market. Still, stable and continuous lentiviral vector production 
has been achieved by codon-optimization of the viral constructions and their delivery 
through viral infection (Ikeda et al. 2003; Stornaiuolo et al. 2013). Although these 
approaches pose safety considerations, they should pave the way towards stable 
lentiviral vector production in a close future. Until then, and due to their similarity, 
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strategies for improved manufacture of simple retroviral vectors are a valuable study 
model, in principle, readily transferable for their complex counterparts. In fact, 
retroviral vector manufacture is, in general, a very attractive model for process 
optimization and metabolic engineering studies: i) current producer cells and upstream 
process are sub-productive offering plenty of room for improvement; ii) they are non-
cytotoxic, allowing for metabolic manipulation without the constraints of cell growth 
arrestment and iii) they represent a complex biopharmaceutical, composed by nucleic 
acids, lipids and (glycosylated) proteins. Thus, strategies for improved retrovirus 
production are likely to be of interest to other enveloped virus produced in 
mammalian cells. 
 
2.2. Retrovirus biology and life cycle 
Retroviruses are enveloped viruses characterized by the ability to “reverse-
transcribe” their genome from RNA to DNA. Virions measure 100-120 nm and contain 
a dimeric genome of identical (+)RNA strands complexed with the nucleocapsid (NC) 
proteins. The genome is enclosed into a proteic capsid (CA) that also contains 
enzymatic proteins, namely the reverse transcriptase (RT), the integrase (IN) and 
proteases (PR), required for infection. The matrix proteins (MA) form a layer outside 
the capsid core that interacts with the envelope, a lipid bilayer derived from the host 
cellular membrane (Coffin et al. 1997). Anchored on this bilayer are the viral envelope 
glycoproteins (ENV) responsible for recognizing specific receptors on the host cell and 
initiating the infection process. Envelope proteins are formed by two subunits, the 
transmembrane (TM) that anchors the protein into the lipid membrane and the 
surface (SU) which binds to the cellular receptors (Fig. 2A).   
Based on the genome structure, retroviruses are classified into simple (e.g. MLV) or 
complex retroviruses (e.g. HIV) (Coffin et al. 1997). Both encode four genes: gag (group 
specific antigen), pro (protease), pol (polymerase) and env (envelope) (Fig. 2B). The 
gag sequence encodes the three main structural proteins: MA, CA, NC. The pro 
sequence, encodes proteases (PR) responsible for cleaving Gag and Gag-Pol during 
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particles assembly, budding and maturation. The pol sequence encodes the enzymes 
RT and IN, the former catalyzing the reverse transcription of the viral genome from 
RNA to DNA during the infection process and the latter responsible for integrating the 
proviral DNA into the host cell genome. The env sequence encodes for both SU and TM 
subunits of the envelope glycoprotein.  
Retroviral genome also presents non-coding cis-acting sequences such as two long 
terminal repeats (LTRs), containing elements to drive gene expression, reverse 
transcription and integration into the host cell chromosome, a sequence named 
packaging signal (ψ) required for specific packaging of the viral RNA into newly forming 
virions, and a polypurine tract (PPT) that functions as the site for initiating the positive 
strand DNA synthesis during reverse transcription (Coffin et al. 1997).  
Retroviruses enter the cell by receptor mediated endocytosis. The viral envelope 
glycoproteins bind to specific receptors on the cell surface triggering the fusion of viral 
and cellular membranes and subsequent release of the viral core into the cytoplasm.  
Here, it is partially degraded to form a large nucleoprotein – termed pre-integration 
complex – that is transported to the nucleus. During this process, the viral RNA 
genome is reverse transcribed into double stranded proviral DNA by the viral reverse 
transcriptase enzyme (RT). Simple retroviruses are not able to pass through the 
nuclear membrane, thereby, accessing the nucleus only during mitosis when the 
nuclear membrane is disassembled. In the nucleus, the proviral DNA is stably 
integrated into the host chromosomes by the viral integrase enzymes (IN). By using the 
cellular machinery, the integrated provirus is transcribed to new viral genomic RNA 
and the viral proteins are translated. Finally, the virions assemble in cholesterol and 
sphingolipid-rich domains of the plasma membrane – the lipid rafts – being released 
out of the host cell by budding. At this stage, the virions are still immature particles, 
becoming mature infectious virus by proteolytic processing carried by the viral 
protease (PR) (Coffin et al. 1997). 
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Figure 2 – Retrovirus 
structure and genome. 
Schematic representation of 
a retroviral particle (A) and 
the retroviral genome (B). 
CA: capsid; MA: matrix; IN: 
integrase; NC: nucleocapsid; 
PR: protease; RT: reverse 
transcriptase; SU: surface 
subunit; TM: 
transmembranar subunit.  
 
 
2.3. State-of-the-art of manufacturing retroviral vectors 
2.3.1. Retroviral vector producer cell lines 
Retroviral based vectors are essentially produced in mammalian cells, typically 
murine or human derived cell lines. This can be based on a short-term transfer of the 
viral constructs, known as transient production, into exponentially growing cells 
followed by 24-72 hours vector production and harvesting, or by their stable 
integration and constitutive expression into the host cell genome, named packaging 
cell lines, for continuous production (for a review see Coroadinha et al. (2010)). 
The establishment of retroviral packaging cell lines is based on the physical 
separation of the viral genome into different transcriptional units, reducing the risk of 
generating replicative competent retrovirus (RCRs). Several packaging systems, named 
generations, have been developed. Each generation aimed at reducing the risk of RCRs 
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formation face to the previous one. Currently, 3rd generation is applied for the 
production of retroviral vectors, requiring the transfection of three independent 
expression cassettes encoding gag-pol, env and transgene functions (Fig. 3A).  
 
 
Since the 3rd generation of MLV vectors requires the expression of three genetic 
cassettes it is necessary to perform three steps of transfection and clonal selection for 
stable cell line development. This process takes an average time-frame of one year. To 
alleviate this burden, a new generation of retrovirus packaging cells (modular cell lines) 
was developed based on recombinase mediated cassette exchange (RCME) systems 
allowing for flexible switch of the transgene and/or envelope (Fig. 3B and C) 
(Coroadinha et al. 2006b; Schucht et al. 2006). A favorable chromosomal site for stable 
and high retroviral vector production is first identified and tagged. Due to the presence 
of two heterologous non-compatible flippase recombinase target (FRT) sites flanking 
the tagged retroviral genome, the subsequent re-use of this defined chromosomal site 
by means of recombinase-mediated cassette exchange (RMCE) is then performed to 
express, for instance, a therapeutic gene (Fig. 3B). To select cell clones that underwent 
 
 
Figure 3 – Retroviral vector construction for 3rd generation retroviral vector producer cell lines. Third generation split 
genome for replicative deficient RV production including the packaging functions (gag-pro-pol) retroviral backbone 
transgene and envelope (A). Schematic representation of the modular cell lines transgene based on recombinase 
mediated cassette exchange technology (B): (i) integrated retroviral transgene cassette harboring a marker gene and (ii) 
targeting therapeutic transgene plasmid allowing for fast exchange and establishment of a new retroviral producer cell. 
Strategy for the generation of the retroviral vector producer cell line with exchangeable transgene (Coroadinha et al. 
2006b) (C). 
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correct targeted integration reaction, the targeting viral vector contains a start codon 
that complements a transcriptionally inactive ATG-deficient selection marker (Fig. 3B). 
An example of a modular producing cell line is the 293 FLEX (Coroadinha et al. 2006b) 
one of the cell lines used in this PhD work. This cell line contains a LacZ transgene 
tagging a chromosomal locus of high expression that can be exchanged through RMCE 
technology, MLV gag-pol packaging functions and Gibbon Ape Leukemia Virus (GaLV) 
ecotropic envelope. The modular producer cell lines present several advantages: they 
are safer since integration of the vector within the packaging cell line is identified, the 
duration of the entire development process is reduced as there is no need for 
screening and, in addition, production conditions are favorable due to the possibility of 
pre-adaptation of the master cell line to culture conditions and media. Thus, 
therapeutic virus production from bench to bedside becomes safer, faster, and 
cheaper (Coroadinha et al. 2006b).  
The development of stable retroviral vector producer cell lines is a laborious and 
time consuming process. However, it is compensated by obtaining continuously 
producing and highly consistent cell systems, prone to single-effort bioprocess and 
product characterization, a critical consideration for market approval. Retroviral vector 
manufacture, including those used in clinical trials, has used stable cell lines for more 
than 10 years (Coroadinha et al. 2010).  
 
3.3.2. Retroviral vector production systems and process optimization 
Despite the advances in the development of suspension cultures for stirred tank 
bioreactors and its clear advantage from the bioprocess view-point, retroviral vector 
manufacture for clinical batches has mainly been based on static and, preferably, 
disposable systems, including large T-flasks, cell factories and roller bottles (Eckert et 
al. 2000; Merten et al. 2011; Przybylowski et al. 2006; Wikstrom et al. 2004). A good 
example is retroviral vector production at the National Gene Vector Laboratory, 
Indiana University, (Indianapolis, IN), a US National Institutes of Health initiative that 
has as main to mission provide clinical grade vectors for gene therapy trials (Cornetta 
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et al. 2005). These systems allow for 10 to 100 L vector production under good 
manufacturing practices (GMP) conditions, meeting the needs for initial clinical trials, 
where usually a reduced number of patients is involved.  
The first bioreaction cell culture system using cells in suspension reported for high-
titer retroviral vector production was based on a T-lymphoblastoid cell line using a 3rd 
generation packaging construct, producing MLV derived retroviral vectors 
pseudotyped with amphotropic envelope: CEMFLYA cell (Pizzato et al. 2001). These 
cells were able to produce in the range of 107 infectious units per mL and, the potential 
for scale-up production was demonstrated by continuous culture during 14 days in a 
250 mL spinner flask. After CEMFLYA, other high-titer suspension cells were reported, 
namely suspension-adapted 293GPG cells producing MLV retrovirus vector 
pseudotyped with the vesicular stomatitis virus G (VSV-G) envelope protein and 
expressing a TK-GFP fusion protein in a 3L acoustic filter-based perfusion bioreactor 
(Ghani et al. 2006). Another landmark was achieved when the same group published 
for the first time retroviral vector production in suspension and under serum-free 
conditions (Ghani et al. 2007).  
The cell culture parameters used in retrovirus manufacture may impact the virus 
titer by affecting the cellular productivities and/or vector stability. The optimal cell 
culture parameters have been shown to be cell line and viral vector dependent. 
Optimal pH range for retroviral vector production was found to be between 6.8 and 
7.2 for FLY RD18 and Te FLY A7; outside this range the cell specific productivities were 
considerable lower (McTaggart and Al-Rubeai 2000; Merten 2004) while the retroviral 
vector was observed to be stable between pH of 5.5 and 8.0 in ecotropic pseudotyped 
vectors (Ye et al. 2003). Both retroviral (MLV derived) and lentiviral vectors (HIV-1 
derived), VSV-G pseudotyped, were stable at pH 7, while decreasing rapidly for pH ≤6.0 
and pH≥ 8.0 (Higashikawa and Chang 2001). The viral half-life is also dependent on the 
temperature: at lower temperatures the vector decay kinetics are slower (Le Doux et 
al. 1999). Therefore one strategy explored in the production of retroviral vectors has 
been the reduction of the culture temperatures (28-32ºC). It was also shown that 
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lower culture temperature reduced the cholesterol content of the viral membrane, 
increasing the stability (Beer et al. 2003; Coroadinha et al. 2006c). CO2 gas 
concentration in the cultures was shown not to affect virus production in packaging 
cell lines (Kotani et al. 1994; McTaggart and Al-Rubeai 2000). The dissolved oxygen 
levels used are between 20-80% and, within this range, do not affect viral production 
unless they became limiting to cell growth (Merten 2004). 
Retroviral and lentiviral vector titers obtained in the production prior to purification 
are in the range of 106 to 107 infectious particles per mL of culture medium. 
Considering the average amount needed to treat a patient in a clinical trial, in the 
order of 1010 -1012 infectious vector (Stacey and Merten 2011), around 10-100 L of 
culture volume can be estimated for each patient. Also, viral preparations are typically 
characterized by low ratios of infectious to total particles (around 1:100-1000) which 
further reduces the therapeutic efficiency of the infectious ones (Carrondo et al. 2008). 
Additionally, these vectors are extremely sensitive losing their infectivity relatively fast: 
reported half-lives are between 8-12 hours in cell culture supernatant at 37ºC (Carmo 
et al. 2008; Higashikawa and Chang 2001; Le Doux et al. 1999). On the top, long-term 
retroviral vector production is dependent on animal blood serum, an ill-defined culture 
supplement and potential source of pathogen contaminations, hindering the safety 
and standardization standards required in clinical-grade manufacturing processes.  
The problems of low titers, short half-life and low ratios of infectious particles 
reports to the (wild type) viral biology: the infection is typically chronic and 
characterized by persistent but low titers in the blood stream, with high amounts of 
non-infectious particles contaminants and with equivalently low half-lives (Perelson et 
al. 1996; Rusert et al. 2004). Several strategies have been attempted to circumvent 
these “natural” drawbacks in packaging cell lines, including engineering mutant vectors 
with improved resistance features (Vu et al. 2008) optimizing the transcriptional 
cassettes driving retroviral vector components expression (Schambach et al. 2007) and 
understanding and optimizing the metabolic pathways leading to improved 
productivities. Studying the metabolic features supporting high titer retroviral vector 
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production is the pillar for the work developed during this PhD work and is further 
discussed in section 5. 
 
3. Metabolic changes induced by animal viruses: a virus-host interaction 
perspective 
Viruses depend upon cellular metabolism for the production of macromolecular 
substrates and energy. Thus, viral replication comes with marked metabolic changes 
representing the cellular response to the viral intrusion and, often, the virus usurping 
the cellular machinery. This section provides an overview on some of the most well 
described metabolic changes resulting from viral infection in animal cells.  
 
3.1. Lipid metabolism 
The role of cellular lipids in viral replication has long been acknowledged. In fact, 
the hijack of cellular lipid metabolism is a hallmark of many viruses, especially those 
enveloped, but also for the non-enveloped ones. All viruses rely on lipid scaffolds – 
whether it is the nucleus, the endoplasmic reticulum (ER), the golgi or the plasma 
membranes – to provide a physical support for the concentration of viral and cellular 
factors/proteins required for replication and assembly. For example, (+)RNA viruses 
rely on membrane structures derived from the secretory pathway including ER 
invaginations (e.g.: dengue virus) (Welsch et al. 2009), ER derived densely packed 
double membrane vesicles (e.g.: SARS coronavirus) (Knoops et al. 2008), vesicles 
derived from Golgi fragmentation (e.g.: HRV1A) (Quiner and Jackson 2010) and 
autophagosomes  (e.g.: HBV) (Li et al. 2011). Other viruses assemble at nuclear 
membrane such HSV and HCMV (Mettenleiter et al. 2006) or adenovirus (Wodrich et 
al. 2003). And others, like retrovirus (Ono 2010) or influenza (Nayak et al. 2004) 
assemble at the plasma membrane.  
This reliance on membrane structures often dictates significant changes in host lipid 
metabolism in benefit of maximum progeny generation. Increased biosynthetic rate of 
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fatty acids and phospholipids has been shown to occur after infection of HCMV 
(Munger et al. 2008), dengue (Heaton et al. 2010), poliovirus (Nchoutmboube et al. 
2013) and HCV (Fukasawa et al. 2006; Lambert et al. 2013). Moreover, the inhibition of 
these biosynthetic pathways often results in the impairment of viral replication or 
defective particles formation in both enveloped (Spencer et al. 2011) and non-
enveloped virus (Gaunt et al. 2013). For example, blocking sphingomyelin biosynthesis 
leads to intracellular trafficking defects of influenza glycoproteins hemagglutinin (HA) 
and neuraminidase (NA) and substantial reduction in viral production (Tafesse et al. 
2013). Increased fatty acid and phospholipid metabolism in viral replication occurs 
through the expression and activation of lipid biosynthetic enzymes (Spencer et al. 
2011), lipid biosynthesis transcriptional machinery (Waris et al. 2007) or reduced lipid 
oxidation (Seo and Cresswell 2013).   
 
3.2. Energy metabolism 
From the entrance into the cellular environment to progeny release, the entire viral 
cycle occurs at substantial energy expenses for the host. As an example, T. Ando and 
co-workers estimated ATP concentrations within HCV replicating cells to be about 5 
mM at replicating sites (and 1 mM at peripheral sites that did not appear to be 
involved in HCV replication) in contrast with the 2 mM cytoplasmic ATP levels in non-
replicating cells (Ando et al. 2012). These findings suggest that cellular energy 
resources may be diverted to support viral replication. Three main mechanisms – not 
necessarily exclusive or independent – by which viruses usurp the cellular energy 
generation machinery have been described: i) AMPK interaction, ii) Warburg effect-like 
metabolic reprogramming and iii) mobilization of lipid storages.  
Adenosine 5′ monophosphate‐activated protein kinase (AMPK) functions as a key 
regulator of the cellular energy status. AMPK activation occurs in response to ATP 
depletion leading to the inhibition of anabolic processes – including synthesis of 
protein, lipids and nucleic acid – while stimulating catabolic routes such as lipid 
oxidation and glucose uptake. AMPK activation has been demonstrated following the 
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infection of many viruses including HCMV (McArdle et al. 2012), avian reovirus (Ji et al. 
2009) and SV40 (Kumar and Rangarajan 2009). Interestingly, not all viruses report to 
AMPK activation. For instance, HCV and HIV infection has been shown to lead to AMPK 
inhibition (Mankouri et al. 2010; Zhang and Wu 2009). The mechanisms by which 
viruses interact with AMPK were suggested to depend on the type of established 
infection – acute or chronic/latent – the former predominantly associated to AMPK 
activation and the latter to AMPK inhibition (Mankouri and Harris 2011). Indeed, 
maintaining cell metabolism in a continuously anabolic status better fits the needs of 
chronic viruses. This generalization should, however, be taken carefully.   
Metabolic reprogramming with enhanced flux through glycolysis and, in some 
cases, TCA cycle, has been demonstrated for a vast majority of viruses: RSV (Singh et 
al. 1974), FLV (Bardell and Essex 1974), poliovirus (Levy and Baron 1957), KSHV 
(Delgado et al. 2010), HCMV (Munger et al. 2006), HSV-1 (Abrantes et al. 2012) and HIV 
(Hollenbaugh et al. 2011). For the later, the authors report different glycolytic 
activation behavior depending on if the infected cells were CD4+ T cells or 
macrophages demonstrating that, even the same virus can usurp the metabolic 
machinery by different means. Enhanced glycolytic flux occurs based on increased 
expression or activity of the glycolytic enzymes, namely phosphofructokinase (PFK), 
and is usually associated to an increase in cellular ATP content (Abrantes et al. 2012; 
Munger et al. 2006; Munger et al. 2008). Even in the cases cellular ATP content 
remains unchanged, increased ATP is believed to occur but used for viral replication 
(Silva da Costa et al. 2012). In other cases, such as rubella or adenovirus, ATP rapidly 
diminishes, seeping out in viral benefit (Bardeletti 1977). The lipid storages may also 
be used as an energy supply source in viral infections. For example, dengue virus was 
shown to accumulate on lipid droplets (Samsa et al. 2009) and mobilize their 
triacylglycerol content enhancing β-oxidation to ensure sufficient ATP levels for 
replication (Heaton and Randall 2010). Both metabolic reprogramming as well as lipid 
mobilization processes might be the downstream result of virus-induced AMPK 
activation.  
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3.3. Nucleic acid metabolism and pentose phosphate pathway 
Any virus carries the biological aim of, by using the cellular resources, to produce as 
many self-copies as possible, thus, strongly affecting nucleic acid metabolism of host 
cells. The modus operandi, diverges from increasing total RNA/DNA synthesis and 
substantial de novo nucleotide biosynthesis (Maassab et al. 1957; Munger et al. 2006; 
Tanaka et al. 1975), to arresting nucleic acid synthesis and hijacking nucleic acid 
content for viral replication (LaColla and Weissbach 1975; Lucas and Ginsberg 1971; 
Wagner and Roizman 1969). The former seems to be more predominant in 
latent/chronic viruses while the latter is typical of lytic and acute infections. 
Mechanisms of cellular nucleic acid content mobilization have also been described: 
poliomyelitis virus infection was shown to increase the rate of cellular RNA breakdown 
thereby, expanding the available nucleotide pool, by the possible release of a 
ribonuclease (Salzman et al. 1959). In the cases of increased de novo nucleotide 
biosynthesis, a set of metabolic rearrangements were shown to occur: increased 
consumption of nucleic acid precursor amino acids (glutamine, glycine and aspartate) 
and nucleoside backbones (Munger et al. 2006; Munger et al. 2008). These changes 
have also been associated with increased enzyme activity and/or expression of 
nucleotide biosynthesis preceding routes such as pentose phosphate pathway (PPP). 
For HCV infection increased abundance of PPP enzymes, transketolase (TKT) and 
transaldolase (TALDO1), were observed (Diamond et al. 2010) while increased activity 
of glucose 6-phosphate dehydrogenase, catalyzing the first step in PPP has been 
reported for chicken cells infected with SFV (Cassells and Burke 1973). Changes in PPP 
metabolites have also been reported in KSHV infection, including significantly elevated 
levels of ribose 5-phosphate and the ribulose 5-phosphate (and/or xylulose 5-
phosphate) (Delgado et al. 2012).  
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3.4. Oxidative stress metabolism 
Viral infections have long been recognized to induce significant oxidative stress to 
the host, mediated by reactive oxygen and nitrogen species (ROS and RNS). More 
recently, it began to be understood that this burden plays a role in viral pathogenesis 
and, what was initially conceived as an inflammation response against a foreign 
invasion, may well serve as nursing environment for virus replication (Akaike 2001).  
HCV is probably the most exhaustively described virus inducing oxidative damage.  
Several HCV proteins, including the core and NS5A appear to contribute to ROS 
generation both at mitochondria and ER level by increasing Ca2+ uptake, superoxide 
production, oxidation of the mitochondrial glutathione pool and inhibiting the electron 
transport complex I activity. The mechanisms on how HCV induces oxidative stress 
were recently reviewed in (Paracha et al. 2013). Some aspects on how it relates to viral 
pathogenesis have also been highlighted. For instance, ROS can induce viral genome 
heterogeneity, which facilitates viral escape during treatment (Seronello et al. 2011) 
and from the immune system (Forns et al. 1999). Anti-oxidants interfere with viral 
replication and are actually prescribed as part of anti-HCV therapy (Berkson 1999). For 
other viruses, e.g. influenza A, a decrease in the total concentration of anti-oxidant 
metabolites as glutathione and vitamins C and E was observed in mice after infection 
(Hennet et al. 1992). The authors also simulated a ROS-mediated inactivation of α1-
antiprotease  – a cellular protein limiting viral maturation – with an impressive 10.000-
fold increase in viral infectivity resulting from proteolytic cleavage of haemagglutinin, 
thereby, showing a beneficial role of ROS in influenza infection. Also HIV has been 
reported to lead to significant anti-oxidant defenses impairment including reduced 
levels of ascorbic acid, tocopherols, carotenoids, selenium, superoxide dismutase, and 
glutathione. Even asymptomatic HIV-infected patients at early stages of the disease 
exhibit oxidative stress indicators (Pace and Leaf 1995). In cell culture systems, 
oxidizing agents, such as H202, promote replication of HIV and antioxidants, as N-
acetyl-cysteine, have the opposite effect (Staal et al. 1990).  
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A body of evidences suggests oxidative environment as nursing milieu for viral 
replication. This conclusion may, however, not be straightforward. For example, HCMV 
was shown to induce intracellular ROS generation within minutes after infection to 
facilitate its own gene expression and replication through the activation of factor 
nuclear kappa B (NFκB). Conversely, antioxidants inhibited HCMV immediate-early 
gene expression and viral replication (Speir et al. 1996). But it has also been recently 
shown that HCMV activates cellular anti-oxidant defenses by increasing glutathione 
and glutathione synthesizing enzymes as well as detoxification enzymes such as 
superoxide dismutase (SOD) and glutathione peroxidase (GPX1). More importantly, 
this up-regulation appeared to be critical to viral replication as short-interfering RNA 
experiments for these genes significantly impaired viral titer. These results were 
postulated to show a virally-driven mechanism to maintain redox homeostasis and 
control ROS induced stress responses to favor efficient replication (Tilton et al. 2011). 
However, they might simply be the mirror of the anti-oxidant cellular defenses 
responding to the redox unbalance caused by viral infection. In fact, other viruses 
reported to generate high ROS upon infection – as influenza A and HCV – were shown 
to up-regulate the expression of anti-oxidant enzymes including MnSOD, but not 
Cu/ZnSOD, in both cases (Jacoby and Choi 1994; Qadri et al. 2004).  
 
3.5. Protein processing and post-translational modifications 
The large majority of viruses carries cellular entry through receptor-mediated 
endocytosis, following the attachment of the viral spikes to the cell surface receptors. 
For the vast majority, these receptors are glycosylated proteins. It is thus not surprising 
that viral replication significantly impacts protein processing in the ER and post-
translational modifications (PTMs) pathways. Glycosylation is one of the most relevant 
PTMs in viral replication. Several viruses have been shown to take advantage of the 
cellular glycosylation machinery to modify viral proteins and, in most viruses, 
glycosylation has a role in viral biogenesis, stability, antigenicity and infectivity. The 
importance of glycosylation to viral virulence and immune evasion has been reviewed 
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in Vigerust and Shepherd (2007). Highly glycosylated proteins include the surface 
proteins of influenza A, hemagglutinin (HA) and neuraminidase (NA), HCV E1, lassa 
virus glycoprotein (GP), Newcastle virus hemagglutinin-neuraminidase (HN), ebola 
virus glycoprotein (GP), and the envelope protein (gp120) of HIV-1 which is one of the 
most heavily glycosylated proteins in nature. More than using the available resources, 
viruses can hijack and modulate glycosylation machinery. For example, K. Nystrӧm and 
colleagues studied the transcriptional activation mediated by HSV, HCMV and varicella 
zoster virus (VZV) and demonstrated activated expression of several 
fucosyltransferases (FUT3, FUT5 and FUT6) that were either dormant or expressed at 
low levels in uninfected cells. They also found CMV, but not VZV, to induced 
transcription of FUT1, FUT7, and FUT9 (Nystrom et al. 2004; Nystrom et al. 2007).  
Another well described PTM targeted by viral infection is ubiquitination. Several 
viral factors target or mimic components of the SUMOylation (Small Ubiquitin-like 
Modifier) machinery. For example, KSHV encodes an enzyme, K-bZip, which displays E3 
SUMO ligase activity catalyzing SUMO conjugation to host targets – as p53 and 
Retinoblastoma (Rb) protein – potentially modulating host genes expression in the 
early stage of viral infection (Chang et al. 2010). Ebola virus encodes VP35, a protein 
that binds to the enzyme PIAS1 (protein inhibitor of activated STAT 1) and increases 
the SUMOylation level of IRF7 (interferon regulatory factor 7) potentially contribution 
to the dampening of the anti-viral response upon infection (Chang et al. 2009).  
 
 
3.6. Polyamines metabolism 
The role of polyamines in viral replication was most prominently studied in the late 
70’s and early 80’s. A. Raina and colleagues investigated the role of polyamines in the 
replication of HSV and SFV and observed marked inhibition of virus production in 
BHK21 cells depleted of polyamines by treatment with alpha-difluoromethylornithine, 
a specific inhibitor of polyamines synthesis. This inhibition was reversed by 
supplementation with polyamines (putrescine, spermidine and spermine) and at least 
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partially reversed by several other diamines and polyamine analogs. They also found 
the activity of viral RNA polymerase to be significantly decreased in polyamine-
depleted cells but rapidly increased after addition of spermidine to the culture medium 
(Raina et al. 1981). W. Gibson and co-workers reached similar conclusions for HCMV 
(Gibson et al. 1984). Increased activity (greater than 10-fold) of mammalian type C 
retroviral DNA polymerases was also reported (Marcus et al. 1981). The authors 
described two possible mechanisms by which polyamines could enhance polymerase 
activity: i) interaction with the enzyme-DNA complex in order to stimulate their 
synthesis or ii) interaction with the activated DNA template limiting of the formation of 
"dead-end" enzyme-DNA complexes. Although the studies were carried in vitro, the 
same mechanisms are likely to occur in vivo. Polyamines can bind to nucleic acids 
participating in their stabilization, modulate gene transcription events, play a role in 
membrane rigidity and present anti-oxidant properties (Wallace et al. 2003). These 
properties may have a beneficial effect on viral replication, particularly by stabilizing 
viral genome leading to improved encapsidation, changing viral membrane rigidity and 
preventing its lipid peroxidation.  
More recently, D.Kim reported an inhibitory effect of polyamines in the initiation 
process of SV40 DNA replication in vitro (Kim et al. 2008). Interestingly, this inhibition 
seemed to be mediated by high polyamines concentration, while at low levels the 
stimulatory effect was confirmed. It is thus difficult to state whether polyamines are 
beneficial for just a set of viruses and inhibitory for others. In fact, large quantities of 
polyamines my leverage the effects of another phenomenon – oxidation – as oxidized 
polyamines are known to exhibit potent anti-viral activity (Bachrach 2007).   
 
4. Integrated functional genomics in cell engineering: understand to 
intervene 
Engineering animal cells metabolism is far from trivial. The classical ‘target’ 
approach to cell engineering using single gene manipulation, albeit using rational 
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strategies, has yielded mixed and often disappointing results (Bro and Nielsen 2004; 
Lim et al. 2010; O'Callaghan and James 2008). The ultimate wish of cell culturists will 
be the understanding and the control of the biomolecular and physiological attributes 
of high producing cell lines for a more directed design of therapeutic producing hosts 
(Seth et al. 2006). In this context, the developments in functional genomics are 
allowing moving beyond the blind trial-and-error approaches, promoting and 
extending the potential of reverse metabolic engineering. 
Functional genomics tools comprise several methodologies: genome and DNA 
sequencing, transcriptional profiling, proteome analysis, metabolite profiling and flux 
analysis (Bro and Nielsen 2004; Sauer 2004). The fluxome allows observing the 
functional output of transcriptome, proteome and metabolome changes and links not 
only the genotype but also to environmental perturbations, thus closer to the cellular 
phenotype.  
In the last decade, with the widespread use of the omic tools, we have been 
observing a build-up of a vast number of potential genes to be used in cell engineering. 
Proteomic studies of B cells revealed the importance of genes in the secretory protein 
pathway such as XBP1 (van Anken et al. 2003) which, when expressed in CHO-K1 cells, 
resulted in an increased production capacity (Tigges and Fussenegger 2006). 
Microarrays and transcriptomics have unveiled genes: (i) conferring enhanced viability 
in serum-free media (egr1 and Gas6) (Jaluria et al. 2008), (ii) involved in cell adhesion 
(siat7 and lama4) (Jaluria et al. 2007), (iii) conferring superior productivity in myelomas 
(SLPI and Cdc6) (Dorai et al. 2007) or (iV) involved in cholesterol biosynthesis in NSO 
cells (Seth et al. 2005).  
Metabolomics (the global study of metabolite changes) has been used successfully 
in prokaryotes and plant engineering for a long time to improve production and the 
first steps are being made in animal cells (Kuystermans et al. 2007). It is a vital 
component area of the Systems Biology reflecting more closely the phenotype of a cell 
or organism than the other omics and therefore is a fundamental piece of the puzzle. It 
has been used as an assisting tool for media development, characterization of cell 
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lines, clone selection and identification of metabolic process engineering targets to 
enhance production processes (Khoo and Al-Rubeai 2007; Oldiges et al. 2007). Yet, the 
redundancy of metabolite profiling also make it more challenging to be used for gene 
engineering purposes.   
An integrative study that includes more than one omic will best address the use of 
functional genomics. In this thesis transcriptomics and metabolomics were used for a 
better understanding of the data coming from both methodologies. So far the 
application of functional genomics in the animal cell culture has been focusing on the 
production of antibodies, mostly in CHO, and hybridoma cells from murine origin. 
Thus, the field of virus based biopharmaceuticals comprising a promising market of 
vaccines, oncolytic virus for cancer treatment and gene therapy viral vectors, has been 
left underexplored. 
 
5. Metabolic optimization of cell-culture process in virus production 
Manufacturing virus based biopharmaceuticals using cell culture processes is highly 
costly. Together with the demanding downstream processing of viral preparations and 
stringent quality control on the final product, production of virus based 
biopharmaceuticals is likely to be the most expensive process in the biopharmaceutical 
industry. Thereby, increased attention is being given to process and cell engineering 
strategies maximizing titers and quality of the viral bulks. Yet, the majority of the 
studies aiming at such optimization are, predominantly, descriptive reports on 
metabolic alterations induced by the “virus producer state” using elegant flux-analysis 
schemes to suggest potential media or cell engineering targets. Less work has been 
done in effectively enhancing virus production by media or cell manipulation. This 
section reviews some of that work.  
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5.1. Media design  
For adenoviral vectors, T. Ferreira and co-workers were able to increase vector 
titers by adapting the cells to non-ammoniagenic medium, reaching 1.8-fold 
improvement in vector productivity (Ferreira et al. 2005). However, this was reported 
to be a volumetric improvement, likely to be related with increased cell density and 
not cell specific virus production.   
Other media design strategies have targeted lipid metabolism, mainly when 
producing enveloped viruses. Indeed, lipid metabolism is a relatively easy pathway to 
manipulate as, in the presence of an external source, most of cultured cells readily 
uptake lipids from the culture media (Spector et al. 1980). Lipid supplementation has 
been used to improve the production performance of retrovirus (Chen et al. 2009) and 
lentivirus (Mitta et al. 2005) based vectors. Lipid supplementation combined with 
design of experiments (DoE) was also used to improve the production of HIV Gag-
based VLPs produced in HEK 293 up to 2.4-fold (Cervera et al. 2013).  
For the case of retroviral vectors, additional efforts have been undertaken by 
culture media manipulation. The use of sugar sources alternative to glucose such as 
fructose and galactose was shown to improve retroviral production in Te FLY A7, Te 
FLY Ga 18, PG13 and Tel CeB cell lines (Coroadinha et al. 2006a; Merten 2004). The 
lactate production decreased 2- to 6-fold in galactose and fructose media and the 
vector titers increased up to 8-fold. Indeed, lactate concentrations above 5 mM can 
inhibit cell growth of Te Fly Ga18 cells and retroviral production (Merten et al. 2001). 
Additionally to the metabolic shift induced by an alternative carbon source, the effect 
of high osmotic pressure was also found to be of relevance in the improvement of viral 
titers. The high osmotic pressure obtained for some of the alternative sugars altered 
the lipid composition of cellular and viral envelope membranes decreasing the 
cholesterol to phospholipids ratio in the viral membrane, thus conferring higher 
stability to the produced vectors (Coroadinha et al. 2006c). The increment of infectious 
titers was confirmed to be the result of higher cell specific productivities, higher vector 
 
Chapter I 
 
29 
 
stability and lower production of defective non-infectious particles (Coroadinha et al. 
2006a; Coroadinha et al. 2006c).   
More recently, N. Carinhas and colleagues combined experimental data and flux 
analysis to quantify and environmentally manipulate the energy metabolism of SF9 
insect cells, producing baculovirus vectors. Culture medium supplementation with 
pyruvate or α-ketoglutarate at the time of infection resulted in 6- to 7-fold higher 
specific baculovirus yields at high cell density (Carinhas et al. 2010). 
 
5.2. Gene engineering 
Media optimization can lead to relevant titer improvements; however, it is 
inherently limited to the cell transcriptional machinery. From this perspective, gene 
engineering appears as a more powerful tool to improve the productivity of cell-
culture based processes. Indeed, average productivity improvements by gene 
engineering means in mammalian cells, range from 2- to 4-fold for single gene and up 
to 30-fold for double gene manipulation. No media optimization based in two 
metabolites or macromolecules has reached identical improvements. The efforts on 
gene-based mammalian cell engineering for improved production of 
biopharmaceuticals have been reviewed in Lim et al. (2010). Yet, the work done so far 
has mainly been conducted in the view of enhanced production of recombinant 
proteins. Reports on gene engineering strategies for improved manufacture of virus 
based biopharmaceuticals are rather scarce.  
R.Peng and colleagues were able to improve lentiviral vector production by 
increasing the secretory pathway of HEK 293 cells through the over-expression of the 
vesicle-trafficking protein munc18b (Peng et al. 2010). Another work falling into the 
gene engineering category, although not for improved viral titers, was described by 
(Hansen et al. 2005). The authors conceived a strategy to generate more stable 
retroviral vectors which, being produced by murine-derived cell lines were rapidly 
inactivated in human serum. By expressing chimeric glycosyltransferases to reduce α-
gal-epitope synthesis, they were able to increase serum stability up to 3.5-fold. More 
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recently, it was described a 9-fold improvement in influenza A production in MDCK 
cells by stable down-regulation of interferon 7 (IRF7, (Hamamoto et al. 2013). In fact, 
the idea behind this strategy – increase virus replication by blocking intracellular 
innate defense responses – had been previously described as an engineering approach 
and shown to increase the production of lentiviral and adenoviral vector particles by 5- 
to 10-fold and up to 100-fold for Sindbis virus (de Vries et al. 2008). 
All in all, gene engineering of virus producing factories is an under-explored 
territory. In fact, despite the encouraging reports on high productivity improvements – 
unlikely to be paired by media manipulation – gene engineering represents a minor 
fraction of metabolic optimization strategies conducted for animal cell hosts. The main 
reason behind it is that, contrarily to media design, gene engineering is less 
straightforward and very time consuming from the experimental point of view. 
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6. Scope of this thesis 
The work developed during this PhD thesis aimed at studying the metabolic 
constraints of retroviral vector production in human cell lines and using that 
knowledge to design gene engineering strategies for improved titers and viral 
preparation quality. The thesis is comprised by two parts: i) functional genomics 
analysis of retrovirus production using different cell lines and culture conditions and ii) 
metabolic engineering by gene manipulation of producer cell metabolism. 
In the first part, functional genomics studies were conducted, including the 
transcriptional profiling and central carbon metabolism analysis, following the changes 
in the transition ‘parental-to-producer’ of two human cell lines producing recombinant 
retrovirus. Eight pathways were identified to be recruited in the virus production state 
and their ability to modulate viral titers was experimentally validated. Additionally, the 
physiological determinants behind serum heterotrophy in vector production were also 
investigated. Serum heterotrophy was identified to be driven by an impairment of lipid 
metabolism at the level of cholesterol biosynthesis.  
In the second part of this project, the knowledge gathered from the initial 
characterization studies was used to genetically engineering producer cells, combined 
with a novel method assisting the fast identification of high-producing clones: the 
single step cloning-titration method. Engineered cells were able to improve vector 
specific productivity more than 30-fold and serum heterotrophy was reverted by re-
activating cholesterol biosynthesis through the over-expression of the enzymatic and 
transcription factor genes of de novo cholesterol biosynthetic pathway.  
This thesis comprises a frontier work, bridging fundamentals to applied research, 
contributing to enlarge the understanding on virus-host metabolic interactions and 
delivering innovative tools to translate such knowledge on the tailored design of cell 
hosts for improved manufacture of recombinant enveloped virus. 
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7. Author contribution 
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Abstract 
Biopharmaceuticals derived from enveloped virus comprise an expanding market of 
vaccines, oncolytic vectors and gene therapy products. Thus, increased attention is given 
to the development of robust high-titer cell hosts for their manufacture. However, the 
knowledge on the physiological constraints modulating virus production is still scarce and 
the use of integrated strategies to improve hosts productivity and upstream bioprocess an 
under-explored territory.  
In this work, we conducted a functional genomics study, including the transcriptional 
profiling and central carbon metabolism analysis, following the metabolic changes in the 
transition ‘parental-to-producer’ of two human cell lines producing recombinant 
retrovirus. Results were gathered into three comprehensive metabolic maps, providing a 
broad and integrated overview of gene expression changes for both cell lines. Eight 
pathways were identified to be recruited in the virus production state: amino acid 
catabolism, carbohydrate catabolism and integration of the energy metabolism, 
nucleotide metabolism, glutathione metabolism, pentose phosphate pathway, 
polyamines biosynthesis and lipid metabolism. Their ability to modulate viral titers was 
experimentally challenged, leading to improved specific productivities of recombinant 
retrovirus up to 6-fold. Within recruited pathways in the virus production state, we sought 
for metabolic engineering gene targets in the low producing phenotypes. A mining 
strategy was used alternative to the traditional approach ‘high vs. low producer’ clonal 
comparison. Instead, ‘high vs. low producer’ from different genetic backgrounds (i.e. cell 
origins) were compared. Several genes were identified as limiting in the low-production 
phenotype, including two enzymes from cholesterol biosynthesis, two enzymes from 
glutathione biosynthesis and the regulatory machinery of polyamines biosynthesis. This is 
thus a frontier work, bridging fundamentals to technological research and contributing to 
enlarge our understanding of enveloped virus production dynamics in mammalian cell 
hosts.  
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1. Introduction 
Biopharmaceuticals derived from enveloped virus produced in mammalian hosts 
comprise a myriad of valuable products from vaccines to gene therapy vectors. Such 
products have been based on different genus including gammaretrovirus (Dalba et al. 
2007), lentivirus (Cockrell and Kafri 2007; Di Nunzio et al. 2011), alphavirus (Atkins et al. 
2008), orthopoxvirus (Walsh and Dolin 2011), avulavirus (Schirrmacher and Fournier 
2009), flavivirus (Appaiahgari and Vrati 2010) and respirovirus (Griesenbach et al. 2005). 
As this market expands (Kresse and Shah 2010; Moran 2012) it increases the interest to 
develop high-titer production hosts. In this context, metabolic optimization by culture 
medium and gene manipulation are potential tools to improve both process and cell 
engineering. But metabolic intervention, particularly at the gene engineering level, 
requires a broad overview on the physiological constraints modulating the (virus) 
producing phenotype. In recombinant protein production, mammalian cell culture has 
profited from 20 years of functional genomics studies from transcriptomics to 
proteomics and metabolomics (Griffin et al. 2007; Khoo and Al-Rubeai 2007). In the case 
of recombinant virus production, however, the translation of gathered knowledge for 
the rational design of process and cell engineering is still scarce.  
In this work we mine the bases of virus induced metabolic changes and use that 
knowledge to boost viral titers. A functional genomics study was conducted – including 
transcriptional profiling and central carbon metabolism analysis – of the metabolic 
changes occurring in the transition ‘parental-to-producer’ of two different human cell 
lines, using recombinant retrovirus as an enveloped virus model. Gathered knowledge 
was used to increase viral titers by media manipulation and to identify targets for gene 
metabolic engineering for 293 FLEX cells (Coroadinha et al. 2006; Schucht et al. 2006).  
To identify gene engineering targets the traditional approach, regardless the 
bioproduct, has mainly been based on the comparison ‘producers vs. parental’ or ‘high 
vs. low producers’ for clonal cells with different productivity levels. While this strategy 
can certainly identify potential targets, their genetic manipulation may often result in 
small productivity enhancements. A gene already recruited in the transition parental-to-
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producer or in the high producing clone, is likely to be responsive to that transition or 
phenotype; it also indicates that the cells have the intrinsic capability to express it, with 
no need for further over-expression. Thus in the work herein presented, in addition to 
analyzing the transition ‘parentals-to-producers’, we followed a complementary 
approach by comparing ‘high vs. low producer’ from different genetic backgrounds (two 
different cell line origins). Comparing different genetic backgrounds for gene 
engineering has been used, for instance, to evaluate and manipulate glycosylation 
patterns of recombinant proteins (for a review see Grabenhorst et al. (1999)). To the 
best of our knowledge, such approach has never been used to mine high productivity 
transcriptome signatures.  
 
 
2. Materials and methods 
2.1. Cell lines and culture conditions 
Te Fly Ga 18 (Cosset et al. 1995; Duisit et al. 1999) and 293 FLEX (Coroadinha et al. 2006; 
Schucht et al. 2006) are human derived cell lines producing murine leukemia virus (MLV) 
based vector harbouring a LacZ reporter gene, pseudotyped with gibbon ape leukemia 
virus (GaLV). Their corresponding parental cell lines are Te671 (ATCC CCL-136) and HEK 
293 (ATCC CRL-1573), respectively. The cells were maintained in Advanced Dulbecco’s 
modified Eagle’s medium, DMEM (Gibco, Paisley, UK), with 25 mM of glucose, 
supplemented with 10% (v/v) Foetal Bovine Serum (FBS) (Gibco) and 4 mM of glutamine 
(Gibco). Te671 cell line was also used to titrate infectious retroviral particles. All cells were 
maintained in an incubator with a humidified atmosphere of 92% air and 8% CO2 at 37 °C.   
2.2. Cell growth and viral production studies 
Two types of virus production studies were performed: a 7-day batch culture for cell 
growth/virus production kinetics, transcriptome analysis and metabolite profiling and a 
48+24 hours production/harvesting process to evaluate media supplementation effect 
on viral titers. For the 7-day batch cultures, producer and parental cells were inoculated 
in t-flasks at 2x104 cells/cm2 for Te671 / Te Fly Ga 18 and 4x104 cells/cm2 for HEK 293 / 
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293 FLEX 18. Two samples were collected per day: culture supernatant was harvested, 
filtered through 0.45 μm for clarification, aliquoted and stored at -85ºC until analysis. 
Cell concentration and viability was determined by the trypan blue exclusion method. At 
day 3, total RNA was extracted for transcriptome analysis. For media supplementation 
studies, cells were inoculated in media containing one or a combination of the following 
supplements: i) amino acids (Sigma, Steinheim, Germany); ii) nucleosides (Millipore, 
Billerica, MA, U.S.A); iii) anti-oxidants (Sigma); iv) polyamines (Sigma); v) reduced 
glutathione (Sigma); a non-supplemented control was also prepared. Total RNA was 
extracted and vector infectivity decay kinetics were assessed. A detailed illustration of 
this experimental setup can be found in (Rodrigues et al. 2013). For both growth curves 
as well as for supplemented media studies, three biological replicates were used. 
2.3. Measurement of infectious and genome containing retrovirus titer 
Infectious procedure and viral titer determination were performed by limiting dilution 
infection assay, as previously described in (Rodrigues et al. 2009). Genome containing 
particles titer was determined by real-time PCR as described elsewhere (Carmo et al. 
2004). 
2.4. RNA extraction and RT-PCR 
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. The resultant RNA pellet was eluted in 100 µL of nuclease-
free water (Qiagen) and stored at -85ºC until further processing. RNA yields were 
quantified using NanoDrop 2000 (Thermo Scientific, Waltham, MA, USA) and RNA 
quality was characterized by the quotient of the 28S to 18S ribosomal RNA 
electropherogram peak using an Agilent 2100 bioanalyzer and the RNA Nano Chip 
(Agilent, Santa Clara, CA, USA). 
For real time PCR, RPL-22 was chosen as a control gene using as forward primer (F): 5’-
CTGCCAATTTTGAGCAGTTT-3’ and as reverse primer (R): 5’- CTTTGCTGTTAGCAACTACGC-
3’. Forward (F) and reverse (R) primer sequences for viral genes were the following: 
envelope (F) 5’-GGACCAAAATAGCGAATGGA-3’ / (R) 5’-GGTGAACTGTACGCCTGGAT-3’; 
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gag-pol (F) 5’-GTCCACTATCGCCAGTTGCT-3’ / (R) 5’-CTGGGTCCTCAGGGTCATAA-3’; 
transgene (F) 5’-ACTATCCCGACCGCCTTACT-3’ / (R) 5’-TAGCGGCTGATGTTGAACTG-3’. 
The reverse transcription of total RNA and qRT-PCR were performed as described in 
(Rodrigues et al. 2012). 
2.5. Amplification, labeling and BeadChip hybridization of RNA samples 
Illumina HumanHT-12 v4 Expression BeadChip microarray technology (Illumina, San 
Diego, CA, USA) was used to analyze the transcriptional profile of retrovirus production. 
Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, TX, USA) was used to 
transcribe 200 ng of RNA according to the manufacturer’s recommendation. A total of 
700 ng of cRNA was hybridized at 58°C for 16 hours to the Illumina HumanHT-12 v4 
Expression BeadChips (Illumina). BeadChips were scanned using an Illumina BeadArray 
Reader and the Bead Scan Software (Illumina). Three biological replicates were used. 
2.6. Determination of intracellular oxidative load 
Intracellular oxidative load was determined by measuring the oxidation rate of 2’7-
dicholordihydrofluorescein diacetate probe (H2DCFDA) (Invitrogen), followed by 
fluorescence emission (ex/em: 490/520 nm). Briefly, cells were seeded in DMEM phenol 
red free in 96-well plates. 36 hours later a mild permeabilization was induced by saponin 
(Sigma) at a final concentration of 0.005% (w/v) during 30 minutes at 37ºC, after which 
the probe was added to a final concentration of 10 μM. Fluorescence was measured 
every 15 minutes during 4 hours and the rate of probe oxidation (RFU/min) was 
determined. 
2.7. Metabolite profiling 
Glucose and lactate concentrations were determined with automated enzymatic 
assays (YSI 7100 Multiparameter Bioanalytical System, USA). Ammonia was quantified 
enzymatically using the UV assay kit (NZYTech, Lisbon, Portugal). Amino acids were 
quantified by high performance liquid chromatography (HPLC) using the protocol 
described in (Carinhas et al. 2010). 
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2.8. Data processing and analysis 
Data was processed using Environment for Statistical Computing (R) 2.7.0 (R 
Development Core Team 2008) in combination with Bioconductor 2.2 (Gentleman et al. 
2004). The Bioconductor lumi package (Du et al. 2008) was used for quality control. Raw 
data was log2-transformed using the lumiT() function and no background correction was 
performed (Schmid et al. 2010). Data was transformed using variance-stabilizing 
transformation (Lin et al. 2008) and quantile normalized (Bolstad et al. 2003). All 
methods used are implemented in the R package lumi.  
Differentially expressed genes were identified by False Discovery Rate using 
Significance Analysis of Microarrays (Tusher et al. 2001) and Weighted Average 
Difference (Kadota et al. 2008). The comparison between the two cell lines was 
performed using Principal Component Analysis (PCA) in Environment for Statistical 
Computing (R) 2.7.0 using the function prcom() after data transposition with the 
function t(). PCA loadings and scores were obtained with the functions pca$rotation() 
and pca$x(), respectively. Pathway analysis was performed using Ingenuity Pathway 
Analysis (IPA) (Ingenuity® Systems, www.ingenuity.com). Probes for pathway analysis 
were selected based on |WAD|>1 criterion when comparing “parentals vs. producers”. 
For the comparison between the two cell lines, probes with the absolute highest PCA 
scores were selected. 
 
3. Results and discussion 
3.1. Changes in metabolic transcriptome enrich the virus producer state  
To investigate relevant pathways for virus production the transcriptome of two 
producer cell lines – 293 FLEX and Te Fly – was compared with that of their respective 
parentals: HEK 293 and Te 671. The use of different genetic backgrounds in the 
transcriptome profiling could provide robustness and confidence to the analysis as 
relevant pathways in the producer state should emerge independently of the cell line 
origin. However, it also presented the challenge of finding a common expression signature 
in two very different transcriptomes. Two criteria were considered to identify 
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differentially expressed probes: Significance Analysis of Microarrays (SAM) (Tusher et al., 
2001) and Weighted Average Difference (WAD) (Kadota et al., 2008). SAM relies on 
repeated sample permutations to determine the percentage of genes that are identified 
as differentially expressed by chance, that is, false discovery rate (FDR). WAD is a fold-
change (FC)-based method that ranks differential expression based on average difference 
(between comparisons) and relative average signal intensity so that highly expressed 
genes are highly ranked. While the former is strictly mathematical, providing statistical 
confidence, the later better copes with the biological constrains of gene expression 
particularly evident in mammalian transcriptome analysis: modest fold-changes – usually 
not passing FDR cut-offs – can be very relevant in highly expressed genes. WAD was thus 
used for biological significance – selection of differentially expressed probes for pathway 
analysis – while FDR was used to attribute statistical significance to differentially 
expressed genes within the identified pathways. 
Differentially expressed probes were inputted in Ingenuity Pathway Analysis Software 
and the results were grouped into functional categories (Fig. 1A). Metabolic pathways 
were over-represented in this analysis comprising more than 50% of significantly enriched 
pathways common to both producers. The canonical pathways were then discriminated 
highlighting the metabolic pathways of: amino acids, nucleotides, glutathione and 
detoxification metabolism, lipids, polyamines, vitamins and co-factors, carbohydrate and 
energy integration, glycosylation and pentose phosphate pathway (Fig. 1B). These 
comprised the candidate metabolic pathways recruited in the production of a 
recombinant retrovirus. 
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Figure 1 – Enriched pathways in the analysis ‘producers vs. parentals’ for 293 FLEX and Te Fly cells. Biological 
category distribution of significantly enriched pathways (p<0.05) given by Ingenuity Pathway Analysis of WAD 
selected data when comparing producers to the respective parental cell lines (A); numbers indicate percentage of 
significantly enriched pathways common to both producers. Discrimination of pathways comprising the 
“Metabolism” category (B); left axes refer to number of metabolic functions associated to each pathway and right 
axes indicates the number of differentially expressed genes enriching such pathways.  
 
3.2. Metabolic transcriptome fingerprints in high producers 
The experimental setup in the transcriptional profiling of virus production in Te Fly and 
293 FLEX cells comprises the analysis ‘producers vs. parentals’ and the additional 
assessment of ‘high vs. low producers’, given that Te Fly cells (high-producer) present 
specific productivity performances one order of magnitude higher than 293 FLEX cells 
(low-producer). We investigated if this difference was related to specific productivity, 
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infectious to total particles ratio or limiting expression of the viral components; the 
results are summarized in Table I. 
 
Table I – Viral productivity performances and viral components expression in 293 FLEX and Te Fly cells 
 
Specific productivities were calculated by linear fit of infectious or total particles titer vs. the integral of cell number 
during the exponential growth phase as stated in Rodrigues et al. (2009). Values are shown as average ± standard 
deviation of three independent replicates. Quantification of viral gene components, gag-pol, transgene and envelope 
was performed by qRT-PCR; values are shown as average expression (relative to the control gene, RPL22) ± standard 
deviation of three independent replicates. FC refers to fold-change when comparing high (Te Fly) vs. low (293 FLEX) 
producers, where positive values denote increases and negative values denote decreases of Te Fly relatively to 293 
FLEX; fold-changes are shown for significant changes (p<0.05) based on a two-tailed non-paired t-test, whereas non-
significant changes are shown as NC (no change).  
 
Te Fly specific productivity was confirmed to be more than one order of magnitude 
higher than 293 FLEX both for infectious as well as for total particles. Viral components 
expression showed significantly lower values of gag-pol and envelope for the Te Fly, 
demonstrating that none of these is limiting the productivity in the low producer (293 
FLEX). Transgene expression, on the other hand, presented a 13-fold increase in Te Fly. 
Yet, previous work demonstrated that increased transgene expression does not lead to 
superior productivities in 293 FLEX cells (Carrondo et al. 2008).  
The pathways separating high from low producer (Te 671 vs. HEK 293 derived cells) were 
thus analyzed in the pursuit of potential targets for metabolic engineering in the low 
producer (293 FLEX) using a principal component analysis (PCA). PCA is multivariate 
statistical technique that reduces the data dimension to a small number of uncorrelated 
variables, called principal components, by orthogonal transformations while maximizing 
the variance captured (Abdi and Williams 2010). As expected, PCA separated HEK 293 
from Te 671 derived cell lines, independently of the producer status (data not shown). 
Thus, the probes with the (absolute) highest PCA scores, those responsible for the highest 
variability between the two cell lines, were analyzed using Ingenuity Pathway Analysis, to 
 
 
 
293 FLEX Te Fly FC 
Viral 
production 
 Infectious particles productivity (I.P./cell.h) 0.016 ± 0.0002 0.36 ±0.09 20 
 Total particles productivity (T.P./cell.h) 8.0 ± 1.1 131 ± 12 16 
 I.P./ 1000 T.P. 3.8 ± 0.6 4.6 ± 0.4 NC 
Viral 
components 
expression 
 Gag-Pol 5.3 ± 1.2 1.9 ± 0.8 -2.9 
 Transgene 1.7 ± 0.6 22 ± 6 13 
 Envelope 3.5 ± 0.4 0.8 ±0.3 -4.2 
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identify the biological pathways responsible for such separation. Pathway analysis showed 
signaling pathways to be the most significantly enriched for the comparison ‘high vs. low 
producers’ (data not shown). Still, metabolism was the scenario most heavily changing the 
“virus producer state”; its contribution for the increased productivity performance of 
Te671 derived cells could not be overlooked. Thus, the metabolic pathways found to be 
enriched in the producer state were scrutinized in the pathways analysis output of PCA 
filtered data (Table II).  
Nucleotide metabolism was considerably different between the two cell lines, with 
increased (purine) de novo biosynthetic capacity for Te 671/Te Fly cells and increased 
salvage biosynthesis for HEK 293/293 FLEX. For the latter, the majority of the salvage 
genes were found to be expressed more than 2-fold higher in HEK 293/293 FLEX cells 
(Table II).  
Increased glutathione mediated detoxification and reactive oxygen species scavenging 
was also found to be a distinctive transcriptional signature of Te 671 derived cells. Genes 
like glutathione synthase (GSS), glutathione reductase (GSR), isocitrate dehydrogenase 1 
(IDH1) and several glutathione transferases (GSTs) were significantly more expressed in 
these cells, the latter up to 10-fold (Table II).  
High producers presented transcriptome changes associated to increased polyamines 
(putrescine, spermine and spermidine) synthesis, marked by strong down-regulation of 
ornithine decarboxylase antizyme 1 (OAZ1) – responsible for inhibiting the first and rate-
limiting step of polyamine biosynthesis – and increased expression of antizyme inhibitor 1 
(AZIN1), promoting the opposite effect (Pegg, 2006)  
Finally, increased amino acid catabolism appeared as a distinctive marker in high-
producers particularly at the level of branched-chain amino acids (valine, leucine and 
isoleucine). The first step in this pathway – branched chain aminotransferase 1 (BCAT1) – 
was found to be over-expressed in high-producers more than 3-fold (Table II). Moreover, 
branched chain ketoacid dehydrogenase kinase (BCKDK) that inhibits the next step (Harris 
et al., 1997) (see Fig. 2), presented expression levels 3-fold lower, potentially contributing 
for increased flux through this route. The hints in the co-factors/vitamins metabolism at 
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the level of folate transformations are likely to be related to amino acid catabolism (Table 
II). 
 
Table II – Metabolic pathways distinguishing Te 671 from HEK 293 derived producers  
Metabolic pathways significantly enriched (p<0.05) given by Ingenuity Pathway Analysis of PCA filtered data. PCA was 
performed as described in materials and methods and the probes with the absolute highest PCA scores were inputted in 
Ingenuity software. Up-pointing arrow (↑) indicates up-regulation and down-pointing arrow (↓) indicates down-
regulation of the metabolic pathway. FC refers to fold-change when comparing Te671 vs. HEK293 (parentals) and Te Fly 
vs. 293 FLEX (producers), where positive values denote increases and negative values denote decreases of Te 671 / Te Fly 
relatively to 293 FLEX / HEK 293 cells. FC values are followed by false discovery rate (q-value %) in-between brackets. FC 
was considered significant for q<10% based on the False Discovery Rate given by Significance Analysis of Microarrays 
(SAM) (Tusher et al. 2001); NC, indicates no change based on the criteria q≥10%. All genes in this table can be mapped to 
one or more pathways in Figures 2 or 3. 
 
 
 
 Metabolic pathway Genes 
High vs. low producer  
(FC   q (%)) 
 
Producer Parentals 
Nucleotide  
metabolism 
 
↑ Purines (de novo) 
ADSL – adenylosuccinate lyase (ADSL) 1.5 (3.0%) NC 
IMPDH2 – inosine monophosphate 
dehydrogenase 2 
 
1.8 (0.3%) NC 
PAICS – phosphoribosylaminoimidazole 
carboxylase 
 
1.4 (2.1%) 1.3 (2.4%) 
PPAT – phosphoribosyl pyrophosphate 
amidotransferase 
1.4 (1.4%) 1.5 (7.2%) 
↓ Purines / pyrimidines 
(salvage) 
PGM2 – phosphoglucomutase 2 -1.6 (0.3%) NC 
APRT - adenine phosphoribosyltransferase -2.5 (2.1%) -2.4 (1.9%) 
HPRT – hypoxanthine 
phosphoribosyltransferase 1 
-2.5 (0.1%) -2.5 (1.9%) 
ADK – adenosine kinase (ADK) -1.6 (0.7%) -1.4 (1.4%) 
PNP – nucleoside phosphorylase -2.6 (0.3%) -2.0 (1.7%) 
UPP1 – uridine phosphorylase 1 -3.4 (0.2%) -2.9 (4.6%) 
NM3 - non-metastatic cells 3, protein expressed 
in 
-2.6 (0.3%) -2.6 (2.9%) 
Detoxification 
metabolism 
 
↑ Glutathione-mediated 
detoxification 
IDH1 – isocitrate dehydrogenase 1 (NADP+) 1.3 (1.2%) NC 
GSTM1  – glutathione S-transferase M1 9.6 (0.0%) 8.3 (1.1%) 
GSTM2  – glutathione S-transferase M2 8.6 (0.1%) 6.5 (0.8%) 
GSS – Glutathione synthetase 1.6 (2.1%) 1.4 (2.4%) 
GSR – Glutathione reductase 1.5 (3.0%) NC 
Amines  
metabolism 
 
↑ Polyamine biosynthesis 
AZIN1 – antizyme inhibitor 1 1.6 (2.1%) NC 
OAZ1 – ornithine decarboxylase antizyme 1 -1.9 (0.2%) -1.3 (5.8%) 
↓ Amines catabolism MAOA - monoamine oxidase A NC -2.8 (4.6%) 
Amino acid 
 metabolism 
 
↑ Branched chain amino acid 
catabolism 
BCAT1 -  branched chain aminotransferase 1 3.1 (0.0%) 4.0 (2.9%) 
BCKDK – branched chain ketoacid 
dehydrogenase kinase 
-3.3 (0.1%) -2.2 (0.3%) 
PCCA – propionyl Coenzyme A carboxylase, 
alpha polypeptide 
4.5 (1.0%) 5.9 (0.4%) 
↑ Citrulline/ornithine 
metabolism 
ASS1 – argininosuccinate synthetase 1 4.0 (0.2%) 3.2 (1.9%) 
↓ Serine catabolism SDSL – serine dehydratase-like -2.6 (0.0%) -1.5 (2.4%) 
↓ Aspartate transamination GOT2 – glutamic-oxaloacetic transaminase 2 -2.3 (0.3%) -1.6 (2.9%) 
Cofactors 
metabolism 
↑ Folate transformations 
MTHFD2 – methylenetetrahydrofolate 
dehydrogenase  2 
1.4 (0.3%) 1.8 (0.8%) 
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3.3. Enriched pathways modulate viral production 
Pathway analysis methods return “enriched pathways” – in which the number of 
differentially expressed genes is unlikely to be obtained randomly – rather than a direct 
correlation of such pathways with the phenotype under study.  Establishing these 
relations requires experimental testing a manual analysis on which and how certain genes 
might be contributing for the observed outputs. Therfore, enriched metabolic pathways in 
the “producer state” were analyzed to assess possible transcriptome-metabolome 
correlations and evaluated for their capacity to modulate viral production. Differential 
expression was gathered into metabolic maps colored to highlight significantly changing 
genes to better assist a visual interpretation. 
Amino metabolism 
Amino acid metabolism was one of the top enriched pathways in transcriptome analysis 
(Fig. 1B). Ammonia production and amino acid uptake/production rates were quantified 
and are summarized in Table III.  
The net amino acid consumption in Te Fly cells remained unchanged relatively to the 
parentals but ammonia production increased almost 2-fold. This indicated amino acid 
channeling to energy generation and was supported by increased gene expression 
particularly in glycine, lysine, and branched chain amino acid catabolic enzymes along 
with succinate dehydrogenase complex (SDH) – the link to oxidative phosphorylation. 293 
FLEX producers also presented identical net consumption of amino acids relatively to the 
parentals (Table III). But contrarily to Te Fly, ammonia production was decreased by more 
than 3-fold in 293 FLEX suggesting a preferential channeling of uptake amino acids 
through ammonia non-generating routes – e.g. protein synthesis. Of notice, Te Fly 
producers presented consistently higher uptake rates relatively to 293 FLEX producers 
(Table III). Moreover, some amino acids as phenylalanine, tyrosine and histidine appear to 
be blocked metabolites as their catabolic enzymes are virtually non-expressed for both 
cell lines (Fig. 2). Increased consumption can thus suggest increased protein synthesis in 
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Te Fly cells. In fact, protein synthesis initiation and elongation factors were up-regulated 
in the producer state and are extensively more expressed in Te Fly (data not shown). 
 
Table III - Growth and central carbon metabolism rates of HEK 293, Te671 and their respective retrovirus 
producer cell lines, 293 FLEX and Te Fly 
 
ND: not determined.                        
1: excluding glutamine uptake 
Specific rates were calculated by linear fit of extracellular metabolite concentration vs. the integral of cell number during the 
exponential growth phase as stated in Rodrigues et al. (2009). For metabolic rates, negative values denote uptake and positive 
values denote production rate. FC refers to fold-change in uptake or production rate of (a) 293 FLEX vs. HEK 293, (b) Te Fly vs. 
Te 671 and (c) Te Fly vs. 293 FLEX. Fold-changes are shown for significantly changing rates (* p<0.05 and ** p<0.005 given by a 
two-tailed non-paired t-test). 
 
 
 
 
 293 derived 
 
Te 671 derived 
  
 
 Parental Producer 
  
Parental Producer 
  
Producers 
Growth 
rate (h-1) 
0.019 ± 0.002 0.023 ± 0.004 
  
0.024 ± 0.003 0.026 ± 0.003 
   
 
Specific uptake or production rate 
(nmol/106 cells.h) 
FC (a) 
 
Specific uptake or production rate 
(nmol/106 cells.h) 
FC (b) 
 
FC (c) 
GLC -219 ± 23 -145 ± 23 -1.5* 
 
-371 ± 50 -320 ± 59 
  
2.2* 
LAC 271 ± 45 207 ± 41 
  
590 ± 104 536 ± 118 
  
2.6* 
LAC/GLC 1.2 ± 0.1 1.4 ± 0.1 
  
1.6 ± 0.1 1.7 ± 0.1 
  
1.2* 
GLN  -44 ± 12 -29 ± 4 
  
-75 ± 6 -79 ± 10 
  
2.8** 
AMN 32 ± 7 10 ± 1 -3.2* 
 
29 ± 6 54 ± 10 1.8* 
 
5.4* 
AMN/GLN 0.75 ± 0.05 0.35 ± 0.01 -2.1** 
 
0.39 ± 0.05 0.7 ± 0.04 1.8** 
 
2.0** 
ASP -1.2 ± 0.4 -0.59 ± 0.17 -2.0 
 
-0.76 ± 0.09 -0.81 ± 0.25 
   
GLU -1.3 ± 0.2 0.35 ± 0.17 3.6** 
 
5.1 ± 2.3 5.4 ± 0.4 
  
15** 
SER -4.6 ± 1.9 -3.8 ± 0.8 
  
-12 ± 1 -10 ± 2 
  
2.8* 
ASN -0.53 ± 0.07 -0.12 ± 0.07 -4.3** 
 
-1.7 ± 0.5 -1.8 ± 0.2 
  
14** 
GLY -1.5 ± 0.2 -2.0 ± 0.2 1.3* 
 
-4.0 ± 1.3 -3.8 ± 0.3 
  
1.9** 
HIS -0.66 ± 0.22 -0.49 ± 0.28 
  
-1.6 ± 0.1 -1.9 ± 0.03 
  
3.9* 
THR -1.3 ± 0.2 -1.8 ± 0.5 
  
-3.3 ± 0.8 -3.0 ± 0.1 
  
1.7 
ARG -4.1 ± 1.2 -2.6 ± 0.5 
  
-7.5 ± 0.4 -6.8 ± 0.6 
  
2.6** 
ALA 11 ± 2 5.5 ± 0.9 -1.9* 
 
20 ± 3 25 ± 5 
  
4.6* 
PRO 5.0 ± 0.7 3.6 ± 0.2 -1.4* 
 
5.9 ± 0.6 4.8 ± 0.9 
   
TYR -0.62 ± 0.24 -0.77 ± 0.29 
  
-2.0 ± 0.9 -2.5 ± 0.4 
  
3.3** 
VAL -2.6 ± 0.5 -2.9 ± 0.44 
  
-5.7 ± 1.0 -6.7 ± 0.3 
  
2.3** 
MET -1.4 ± 0.3 -1.1 ± 0.2 
  
-2.7 ± 0.6 -3.0 ± 0.2 
  
2.7** 
ILE -1.8 ± 0.5 -1.9 ± 0.6 
  
-5.0 ± 1.1 -5.8 ± 0.5 
  
3.1** 
LEU -3.3 ± 0.9 -2.5 ± 0.6 
  
-8.2 ± 0.5 -8.7 ± 0.6 
  
3.4** 
LYS -2.5 ± 0.6 -3.0 ± 0.3   
-9.4 ± 2.3 -6.6 ± 1.1 
  
2.2* 
PHE -1.0 ± 0.2 -1.2 ± 0.1 
  
-2.3 ± 0.5 -2.5 ± 0.4 
  
2.1* 
TRP ND ND 
  
ND ND 
   
CYS ND ND 
  
ND ND 
   
Net a.a 
uptake1 
-28 ± 8 -25 ± 6 
  
-66 ± 14 -65 ± 8 
  
2.6* 
Net a.a. 
production 
16 ± 3 9 ± 1 -1.6* 
 
31 ± 3 36 ± 3 
  
3.8** 
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The enrichment in pathway analysis of one-carbon units transfer co-factors – pyridoxal 
phosphate (PLP), tetrahydrofolate (THF) and S-adenosylmethionine (SAM) (Fig. 1B) – 
further substantiated the significance of amino acid catabolism enrichment (Nelson and 
Cox 2000). Gene expression data also suggested the THF transformation cycle to be 
partially inactive due to the absence (non-expression) of 5,10-methylenetetrahydrofolate 
reductase (MTHFR) (Fig. 2).  The balance between the THF and its oxidized forms should 
probably be controlled at the level of folate uptake from extracellular medium and/or at 
the level of serine hydroxymethyltransferase (SHMT) and methylenetetrahydrofolate 
dehydrogenase (MTHFD1/2). Indeed, the latter are highly expressed enzymes and 
additionally up-regulated in producer cells (data not shown). 
 
Carbohydrate metabolism  
Carbohydrate metabolism, namely glycolysis, was highlighted in the transcriptional 
profiling analysis of virus production (Fig. 2B and Fig.4). Thus, glucose uptake and lactate 
production were quantified (Table III). Producer cells presented lower glucose uptake and 
lactate production rates, very evident in 293 FLEX producers (Table III). Gene expression 
showed strong down-regulation of aldolase A (ALDOA) up to 2.3-fold and lactate 
dehydrogenase A (LDHA). 
The down-regulation in glycolytic enzymes can only partially explain the reduction in 
glucose uptake and lactate production in producers as these are highly expressed genes 
and their enzymatic activity mainly controlled at the post-transcriptional level (Mulukutla 
et al. 2010). In line, transcriptional controllers of glycolytic metabolism were found to be 
 
 
Figure 2 – Transcriptome changes in amino acid and integration of energy metabolism pathways. Each arrow 
represents a single reaction; reversibility is indicated by a two-arrow line according to the BioCyc database (Caspi et al. 
2010). Dashed arrows are a general representation of metabolites being channeled from or to the indicated pathways. 
Reactions are shown as a schematic representation and do not necessarily represent a unique possibility for the 
presented metabolites.  For a matter of simplicity, only the main metabolites and co-factors are shown; thus, the 
reactions are not necessarily balanced. Not all the reactions (arrows) are assigned to an enzyme, either for clearness 
purposes or because no specific enzyme has been described in the BioCyc database.  Genes are shown in corner-
rounded boxes, colored according to fold-change and metabolites are shown unboxed. Fold-changes are shown for the 
analysis “producer vs. parentals” and were considered significant for q<10% based on the False Discovery Rate given by 
Significance Analysis of Microarrays (SAM) (Tusher et al. 2001). Enzymatic complexes  and multi-gene composed    → 
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→ (Figure 2 cont)  proteins are identified by a corner-rounded dashed line surrounding the gene set. Gene sets not 
surrounded by this line represent different enzymes and/or enzyme isoforms catalyzing the same reaction. For multi-
protein complexes subject to phosphorylation activation/inactivation mechanisms, the active form is surrounded by a 
red-colored corner-rounded dashed line. ATP synthase gene (ATP5) is a multi-protein complex comprised by more than 
15 subunits; for simplicity purposes, it is represent as a single gene and expression fold-change is shown as the sum-up 
fold-change of all q<10% subunits. Genes were considered to be expressed for average expression value above 1.5-fold 
the average expression of the background probes. CoA: coenzyme A; SAH: S-adenosylhomocysteine; SAM: S-
adenosylmethionine; THF: tetrahydrofolate; DHF: dihydrofolate; Pi: inorganic phosphate; PLP: pyridoxal-5-phosphate. 
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changing towards reduced glycolysis, including the down-regulation of HIF1 (hypoxia 
inducible factor 1), the up-regulation of HIF1AN (hypoxia inducible factor 1, alpha 
subunit inhibitor) and the down-regulation of AKT1 (v-akt murine thymoma viral 
oncogene homolog 1).  
Polyamines metabolism  
Polyamines metabolism and preceding routes appeared as highly changing pathways in 
the producer state (Fig. 1B and Fig. 3). Up-regulated genes towards citrulline/ornithine 
biosynthesis – precursor metabolites for polyamines – included dimethylarginine 
dimethylaminohydrolase 1 (DDAH1) and argininosuccinate synthetase 1 (ASS1), 
although only in Te Fly producers these changes passed the q<10% cut-off (Fig. 3). 
Spermine synthase (SMS) and spermidine/spermine N1-acetyltransferase 1 (SAT1), were 
also significantly up-regulated, the former in Te Fly and the latter in 293 FLEX producers 
(Fig. 3). Te Fly producers also presented gene expression patterns suggesting increased 
polyamines biosynthesis – already suggested by the comparison “high vs. low producer’ 
(Table II). This difference could then be a metabolic advantage of these cells as a 
production substrate. To evaluate this hypothesis, polyamine biosynthesis was 
chemically inhibited using difluoromethylornithine (DFMO) an irreversible inhibitor of 
ornithine decarboxylase 1 (ODC1) (Fig. 4A).  
293 FLEX producers were more susceptible to difluoromethylornithine reducing 
infectious particles productivity, even in low doses, and the addition of polyamines 
supplement only partially restored virus production. Te Fly producers were capable of 
handling higher doses of difluoromethylornithine in polyamine non-supplemented 
medium with minor reductions in infectious particles productivity and, in polyamine 
supplemented medium, virus production was completely rescued. This was consistent 
with the lower expression of ornithine decarboxylase antizyme 1 (OAZ1) and higher 
expression of antizyme inhibitor 1 (AZIN1) (Table II). As ornithine decarboxylase 1 
(ODC1) was found to be identically expressed for both producers these differences point 
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to the ODC1 regulatory machinery between both cell lines, namely OAZ1 and AZIN1, as 
the basis for improved polyamine synthesis (Fig. 3). 
 
 
 
Figure 3 – Transcriptome changes in the metabolic pathways of polyamines, nucleotides, glutathione and pentose 
phosphate pathway. (Refer to Figure 2 caption for further details on graphical formalisms). : Glutathione S transferases 
comprise eight (indicated) classes of enzymes the majority of them with several isoforms; for a matter of simplicity, the 
isoforms numbers were omitted. SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; AMP: adenosine 
monophosphate; CTP: cytidine triphosphate; IMP: inosine monophosphate; GMP: guanosine monophosphate; MTA: 
methylthioadenosine; 1PMTR: 1-phosphomethylthioribose; PRPP: phosphorybosil pyrophosphate; UMP: uridine 
monophosphate; UTP: uridine triphosphate; XMP: xanthosine monophosphate; R-X: R may be an aliphatic, aromatic or 
heterocyclic group, and X may be a sulfate, nitrile or halide group. 
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Figure 4 – Effect of polyamines and nucleosides on virus production and oxidative load in virus producing cells. A) 
Infectious particles production after ornithine decarboxylase 1 inhibition with difluoromethylornithine (DFMO) in 
polyamine-free or polyamines supplemented (1x) medium. In both cases, medium contains an anti-oxidant (1x) 
supplement (Sigma), since polyamines present anti-oxidant properties and the inhibition of their synthesis may 
increase the oxidative burden. Values are shown as average ± standard deviation (n=3) of infectious particles specific 
productivity normalized to a polyamines/DFMO/anti-oxidants free control (not shown). B) Intracellular oxidative load 
of parentals and producer cell, given by the oxidation rate of H2DCFDA probe (fluorescence) during a 4 hour assay in 
saponine permeabilized cells; values are shown as average ± standard deviation (n=12). C) Viral production in 
nucleosides supplemented medium; values are shown as average ± standard deviation (n=3) of infectious particles 
productivity normalized to a nucleoside-free control (shown as [Nucleosides supplement] = 0). For A) and C), cell 
growth and viral production studies were performed as described in “Materials and methods” for supplemented 
medium studies.  
 
Glutathione metabolism 
Glutathione metabolism and surrounding oxidative stress scavenging machinery was 
found to be changing in the producer state (Fig. 1B and 3). Comparing to the parentals, 
reduced glutathione biosynthetic enzymes appeared as down-regulated in 293 FLEX 
producers including glutathione synthetase (GSS), glutathione reductase (GSR) and 
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isocitrate dehydrogenase 1 (IDH1), although only GSS passed the q<10% cut-off criteria 
(Fig. 3). Te Fly producers, on the other hand, had their glutathione based defenses 
increasing, namely several glutathione S-transferases and isocitrate dehydrogenase 1 
(IDH1). This led to the hypothesis that Te 671 derived producers would present 
increased anti-oxidant defenses. Reactive oxygen species were thus quantified in 
parentals and producers, for both cell lines (Fig. 4B). The results showed higher reactive 
oxygen species content in producers when compared to the parentals supporting 
increased oxidative burden in the producer state, although the differences were rather 
small. However, it was also clear that Te 671 derived cells, our high-producing cell 
model, presented superior values of intracellular oxidative burden for both parentals 
and producers (Fig. 4B), questioning the real importance of glutathione in their 
improved productivity performance. But the over expression of glutathione metabolism 
genes in 293 FLEX, translated in productivity improvements of more than one order of 
magnitude (please refer to Chapter VIII). This confirmed the importance of up-regulating 
glutathione metabolism in the producer state, although its correlation with the oxidative 
stress was not obvious. Indeed, (reduced) glutathione, in addition to the anti-oxidant 
properties, plays  a role in the pentose phosphate pathway – which provides NADPH for 
biosynthetic reactions and ribose 5-phosphate for nucleic acid synthesis – and assists 
protein folding in the endoplasmic reticulum (Chakravarthi et al. 2006). All of these 
effects are likely to contribute to increased viral production. 
Nucleotide metabolism 
The enrichment in nucleic acid metabolism occurred extensively in the “virus producer 
state” (Fig.1B and 3). The two producers behaved differently with WAD sum-up values 
indicating a predominance of de novo synthesis pathways in Te Fly and salvage pathways 
in 293 FLEX producers (Fig. 3). Both routes are equally capable of providing nucleotide 
intermediaries. In fact, salvage pathways should represent an advantage as they are 
energetically less expensive (Berg JM 2002) but they rely on an external nucleosides 
supply source, a potential disadvantage for 293 FLEX cells. We evaluated this hypothesis 
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by the addition of nucleoside supplements to the culture medium (Fig. 4C). The results 
confirmed 293 FLEX producers to be responsive to external nucleoside sources, thus 
more dependent on salvage pathways. Moreover, specific viral productivity increased 
almost 2-fold when higher nucleoside concentrations were present, confirming the 
importance of nucleotide metabolism in virus production.  
From de novo synthesis, 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase (ATIC), guanine monphosphate synthetase 
(GMPS) and IMP dehydrogenase 1 (IMPDH1) were found to be up-regulated in Te Fly. 
For 293 FLEX producers, salvage pathways seems to be mainly supported at the level of 
adenine phosphoribosyltransferase (APRT), hypoxanthine phosphoribosyltransferase 1 
(HPRT1) and nucleoside phosphorylase (PNP) which, although not differentially 
expressed in the “producer state”, are consistently more expressed in these cells (Table 
II).  
 
Pentose phosphate pathway 
Pentose phosphate pathway (PPP) appeared as significantly enriched (Fig. 1B), 
however, the analysis of differential gene expression revealed modest changes for this 
particular pathway, with only ribulose-5-phosphate-3-epimerase (RPE) being up-
regulated in Te Fly producers (Fig. 3). Overall, it was not clear the (up-regulation) 
recruitment of pentose phosphate pathway in the virus producer state. Still, both 
salvage and de novo nucleotide synthesis will necessarily rely on pentose phosphate 
pathway to supply ribose 5-phosphate for phosphoribosylpyrophosphate (PRPP) and 
ribose 1-phosphate synthesis, respectively (Fig. 3) 
 
Lipid metabolism 
Lipid metabolism was one of the most significantly enriched pathways in the 
transcriptional profiling of virus production (Fig. 1B and 5).  
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Figure 5 – Transcriptome changes in the lipid metabolism. (Refer to Figure 3 caption for further details on graphical 
formalisms). CoA: coenzyme A; HMG CoA: 3-hydroxy-3-methylglutaryl-CoA; CMP: cytidine monophosphate; CTP: cytidine 
triphosphate; ‘(c)’: cytosolic; ‘(m)’: mitochondrial.  
 
Within lipids, we discriminated cholesterol, fatty acids and phospholipids metabolism. 
In the case of the first two, it was observed a general down-regulation of the 
biosynthetic pathways, more prominent in 293 FLEX producers, particularly for the case 
of cholesterol. Down-regulating lipid biosynthesis might seem contradictory in the 
production of an enveloped virus but it was counterbalanced with the up-regulation of 
lipid uptaking machinery. Interestingly, this effect seems to be restricted to fatty acids 
and cholesterol, whereas the enzymes in phospholipid metabolism were tendencially 
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up-regulated (Fig. 5). Identical results have been reported for hepatitis C virus (Blackham 
et al. 2010).  Further studies on the lipid metabolism and retroviral vector production 
can be found on Chapters III, IV. 
3.4. Media manipulation of enriched pathways increases specific cell productivity 
without changing virus properties. 
In the last part of this work, we questioned how culture medium supplements could 
modulate viral production and impact vector components, namely at the gene 
expression level, and whether the increases in viral titers were specific or volumetric. 
Five classes of culture supplements were tested: nucleosides, amino acids, antioxidants, 
polyamines and reduced glutathione, alone or combined, mainly targeting the pathways 
distinguishing high from low producer (Fig. 6).   
In 293 FLEX producers, infectious vector specific productivity was improved from 30% 
to 110% with the different supplementation strategies, reaching a cooperative effect 
with their combination of 600% (6-fold) increase (Fig. 6). The ratio of infectious to total 
particles also improved relatively to the control: although there was an increase in total 
particles formation, the improvement in infectious particles productivity was even 
higher. For Te Fly cells, the improvements in infectious vector titers were modest and, 
excluding the cocktail condition with all the supplements, not significantly different from 
the control (Fig. 6). 
By opposite to 293 FLEX, for Te Fly cells the infectious per total particles content, was 
tendencially lower in supplemented cultures mainly derived by higher production of 
total particles (T.P.) not followed by increased infectious particles (I.P.). The analysis of 
viral components gene expression showed no significant differences (in gag-pol, 
transgene or envelope) (Fig. 6), neither any correlation of viral genes expression with 
vector titers. 
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Figure 6 – Effect of culture medium supplementation on viral titers and viral components gene expression for 293 
FLEX and Te Fly cells. Bottom left axes: specific infectious titers productivity; the numbers on the top of the bars 
indicate fold change of infectious titer specific productivity relatively to the control (non-supplemented medium). 
Bottom right axes: infectious to total particles content. Upper left axes: fold-change gene expression of viral 
components relatively to the control (non-supplemented medium). All values are shown as average ± standard 
deviation of three independent replicates; * p<0.05 and ** p<0.005 given by a non-paired two-tailed t-test. For a 
matter of simplicity, in infectious to total particles ratio (bottom right-axes) error bars were omitted, ranging 6-30% 
of the average. In 293 FLEX, all values are significantly different (p<0.05) from the control whereas for Te Fly only 
“amino acids” and “cocktail” supplementation conditions are different. Supplement concentrations and respective 
combinations are as described in (Rodrigues et al. 2013).  
 
The pathways targeted by this experimental set up, chosen to improve the low-
producer, meet those found to distinguish high from low producer. Probably because of 
this, improved productivities were achieved for the low producer (293 FLEX) whereas for 
the high producer (Te Fly), the improvements were neglectable (Fig. 6). For 293 FLEX, 
the addition of nucleosides yielded the highest titer achieved by the addition of a single 
supplement: 90% (1.9 fold). As nucleosides are the precursor of nucleotides, building 
blocks of nucleic acids, they can derive improved synthesis of vector genome, 
transcription rate of the viral components and/or other important proteins in the 
producer cell.  
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Amino acid supplementation yielded the lowest titer improvement (Fig. 6). At a first 
glance, this was a disappointing result, as amino acid metabolism was one of the most 
significantly enriched pathways in the transition parentals-to-producers (Fig, 1B and 2), 
and certainly a major distinctive marker between high and low producer (Table II). As 
metabolite profiling suggested the preferential channeling of uptaken amino acids for 
protein synthesis (Table III), these results indicate that infectious vector production is 
not being restricted at the level of protein synthesis.  
Polyamines supplementation yielded 80% (1.8 fold) improvement on viral titers. In 
addition to cell growth, polyamines can bind to nucleic acids participating in their 
stabilization, modulate gene transcription events, play a role in membrane rigidity and 
present anti-oxidant properties (Wallace et al. 2003). These properties can have a 
beneficial effect on viral production, particularly by stabilizing viral genome leading to 
improved encapsidation, changing viral membrane rigidity and preventing its lipid 
peroxidation. They have also been reported to improve viral RNA polymerase activity 
(Marcus et al. 1981). In fact, the role of polyamines in the replication of animal viruses 
was studied 3 decades ago (Raina et al. 1981), falling into oblivion afterwards. These 
results rekindle the importance of polyamines metabolism in virus production, pointing 
it as a good target for improved titers. 
The down regulation of enzymes involved in glutathione metabolism indicated that the 
“virus producer status” may increase oxidative stress, an event already described for a 
broad number of viruses (Georgakilas et al. 2010). The addition of anti-oxidant 
supplements to the culture medium can thus alleviate this burden and led to a 50% (1.5 
fold) increase in infectious virus production for 293 FLEX. In theory, this supplement 
could also influence viral preparation quality by improving particle resistance to 
oxidative stress; however, virus half-life was not improved (data not shown). When 
complemented with polyamines or reduced glutathione supplement, viral titers were 
further increased (100% (2-fold) and 110% (2.1 fold), respectively) when compared to 
supplementation with anti-oxidants alone.  
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Although substantial, a 6-fold improvement seems modest for such a high number of 
identified hints. Nevertheless, it is important to consider the short-lasting effects of 
many supplements under a batch operation mode, as these are rapidly consumed 
and/or degraded (for instance, anti-oxidant supplements).  
The targeted pathways modulated virus production in low producer cells without 
changing vector infectivity or viral genes expression: for the same amounts of vector 
components, supplemented cells managed to produce more. Such results do not 
necessarily imply a metabolic impairment of HEK 293 derived cells, except perhaps for 
the specific case of cholesterol metabolism data (Fig. 6). They suggest instead a 
metabolic pre-disposition of Te 671 derived cells for higher titer yields based on 
potentially more active pathways which, when stimulated in HEK 293 derived cells result 
in increased titers. The increment in infectious titers occurred without increases in cell 
growth or extended viability. Thus, the higher infectious titer yields were explicitly 
obtained by increasing specific and not volumetric productivity, denoting intrinsic 
changes in the metabolic status of supplemented cultures.  
 
Note: due to space constraints, many of the original publication results were not included on the 
thesis. For further details see Rodrigues et al. (2013). 
 
4. Conclusions 
In the era of Systems Biology, a global view of the biological players and their network 
integration is increasingly believed as the key to understand and rationally design a 
phenotype. In the expanding market of virus based biopharmaceuticals, the pursuit of 
robust and high-producing phenotypes will be leveraged by increasing the 
understanding on which and how biochemical pathways can drive to improved 
manufacture processes and cell hosts.   
In this work, the transcriptional profiling of an enveloped virus production (retrovirus) 
in mammalian cells was analyzed and the metabolic constraints underlying this 
phenotype scrutinized. Eight pathways were identified: amino acid catabolism, 
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carbohydrate catabolism and integration of energy metabolism, nucleotide metabolism, 
glutathione metabolism, pentose phosphate pathway, polyamines biosynthesis and lipid 
metabolism. Their orchestrated manipulation through media supplementation led 
improved productivities up to 6-fold for the lower producer 293 FLEX, although with 
minor improvements for the high producer, Te Fly. When targeted alone, nucleotides 
and polyamines metabolism manipulation resulted in the highest titer improvements.   
Analyzing mild transcriptome changes, as those arising from retrovirus production, is a 
recurrent challenge in the transition parental-to-producer for many bioproducts 
produced in mammalian hosts. In this work, we demonstrated that such changes can be 
pulled out of the massive amounts of transcriptomic data using less strict cut-offs, 
without loss of biological relevance. We additionally propose an alternative mining 
strategy for the identification of gene engineering targets towards increased titer yields 
by comparing ‘high vs. low producer’ derived from different genetic backgrounds. To the 
best of our knowledge, such approach has never been used, as transcriptome 
comparison studies seeking for gene engineering targets have traditionally used the 
‘high vs. low producer’ clonal comparison. Several genes were identified as limiting in 
the low-production phenotype, including two cholesterol biosynthesis enzymes, two 
glutathione biosynthesis enzymes and the regulatory machinery of polyamines 
biosynthesis, none of which would be found by the ‘high vs. low producer’ clonal 
comparison.  
While some of the findings herein discussed can be specifically related to the model 
virus under study, the majority of the identified pathways are likely to be of relevance 
for other (enveloped) virus producing cells. And due to the conservation of metabolic 
pathways and their similar role, regardless the bioproduct, those highlighted in the 
present work should be a solid starting point. 
 
5. Author contribution 
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Abstract 
The use of retroviral vectors for gene therapy applications demands high titer 
preparations and stringent quality standards.  However, the manufacturing of these 
vectors still represents a highly challenging task due to the low productivity of the cell 
lines and reduced stability of the vector infectivity, particularly under serum-free 
conditions. With the objective of understanding the major limitations of retroviral vector 
production under serum deprivation, a thorough study of viral production kinetics, vector 
characterization and cell growth and metabolic behavior was conducted, for 293 FLEX 18 
and Te Fly Ga 18 producer cell lines using different serum concentrations.   
The reduction of serum supplementation in the culture medium resulted in 
pronounced decreases in cell productivity of infectious vector, up to 9-fold in 293 FLEX 18 
cells and 7-fold in Te Fly Ga 18 cells. Total particles productivity was maintained, as 
assessed by measuring viral RNA; therefore, the decrease in infectious vector production 
could be attributed to higher defective particles output. The absence of the serum lipid 
fraction was found to be the major cause for this decrease in cell viral productivity. The 
use of delipidated serum confirmed the requirement of serum lipids, particularly 
cholesterol, as its supplementation not only allowed the total recovery of viral titers as 
well as additional production increments in both cell lines when comparing with the 
standard 10% (v/v) FBS supplementation.  
This work identified lower production ratios of infectious particles/ total particles as 
the main restraint of retroviral vector production under serum deprivation; this is of the 
utmost importance concerning the clinical efficacy of the viral preparations.  Lipids were 
confirmed as the key serum component correlated with the production of infective 
retroviral vectors and this knowledge can be used to efficiently design medium 
supplementation strategies for serum-free production.  
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1. Introduction 
The supplementation of mammalian cell culture media with animal sera has been 
common practice in biomedical and biotechnological research, since it provides critical 
nutrients and factors that support cell growth and proliferation. However, the ill-defined 
composition and high batch-to-batch variability of serum together with its potential 
source of contaminations, hinders safety and standardization of cell cultures, making it an 
undesirable supplement in the production of biopharmaceuticals (Falkner et al. 2006). 
Additionally, most of the animal proteins present in the serum are immunogenic, 
increasing downstream complexity to eliminate them, implying significant product losses 
and rising costs up. Regardless of intensive research efforts, serum replacement still 
constitutes a challenge for specific situations, such as the expansion of morphologically 
undifferentiated human embryonic stem cells for cell therapy (Chase and Firpo 2007; 
Chen et al. 2007) and the production of retroviral vectors for gene therapy (Chan et al. 
2001; Gerin et al. 1999a; Gerin et al. 1999b; Pizzato et al. 2001). 
Retroviral vectors are powerful tools for gene transfer purposes due to their high 
transduction efficiency, stable transgene integration and expression and low 
immunogenicity in vivo (Mountain 2000). They were the first viral vectors used in gene 
therapy clinical trials and so far account for the highest number of successful protocols 
(Edelstein et al. 2007). Nevertheless, retroviral vectors are difficult to manufacture, mainly 
due to low productivities of the producer cells and reduced stability of the particles in 
serum-free conditions (Merten 2004). The need for serum on retroviral vector production 
has controversial evidence.  (McTaggart and Al-Rubeai 2000) reported a 10-fold retroviral 
production increase in FLYRD18 packaging cell line when the percentage of serum in 
culture medium was reduced from 5% to 1%.  The authors suggested that this could be 
due to the absence of protease inhibitors present in the serum, which are thought to 
inhibit virus maturation. Nevertheless, the majority of the latest generation of packaging 
cell lines, especially those derived from HEK293 (human embryonic kidney), seem to 
require high concentrations (5-10% (v/v)) of serum in the culture medium to support high 
viral productivities for long term culture (Chan et al. 2001; Gerin et al. 1999a; Gerin et al. 
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1999b; Pizzato et al. 2001).  293 FLEX cells (Coroadinha et al. 2006) belong to a newly 
developed generation of modular retroviral producer cell lines. They are based on a tag-
and-targeting principle (Schucht et al. 2006), being highly flexible for transgene exchange 
and thus, constituting a preferential platform for the establishment of production 
processes for clinical applications. 293 FLEX cells are able to grow in suspension and 
serum-free media. However, in the absence of serum, cell viral productivities decline 
abruptly in the first passage and the production completely ceases after a few passages 
both for suspension, as well as for adherent cell culture systems (unpublished data). 
Identifying the limitations of retroviral vector production under serum deprivation 
was the main goal of this work. A thorough characterization study of viral production with 
two different human derived packaging cell lines, 293 FLEX 18 and Te Fly Ga 18, in 
response to serum reduction in the culture medium was conducted. The importance of 
serum lipids in the production medium of retroviral vectors was demonstrated and 
correlated with the viral titer.  
 
 
 
2. Materials and methods 
2.1. Cell lines and cell culture media 
Te Fly Ga 18 and 293 FLEX 18 are human derived producer cell lines producing  
MoMLV based recombinant retroviral vectors expressing GaLV ecotropic envelope and 
harbouring a LacZ reporter gene (Te Fly Ga 18 are TE 671 (ATCC CCL-136) derived cells 
established as described in Cosset et al. (1995); 293 FLEX 18 are HEK293 (ATCC CRL-1573) 
derived cells established as described in Coroadinha et al. (2006). Both cells were 
maintained in Advanced DMEM (Gibco, Paisley, UK) with 25 mM of glucose, 
supplemented with 10% (v/v) Foetal Bovine Serum (FBS) (Gibco) and 4 mM of glutamine 
(Gibco) in an incubator with a humidified atmosphere of 90% air and 10% CO2 at 37 °C.   
Te671 cell line (ATCC CCL-136) was used as the target cell to titrate infectious 
retroviral particles and was maintained in DMEM (Gibco) with 25 mM of glucose and 4 
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mM of glutamine supplemented with 10% (v/v) FBS (Gibco) in an incubator with a 
humidified atmosphere of 95% air and  5% CO2 at 37 °C.  
 
2.2.  Cell number 
Cell concentration and viability was determined by the trypan blue exclusion method 
using a 0.1% (v/v) solution prepared in phosphate-buffered saline (PBS) and counting cells 
in a Fuchs-Rosenthal hemacytometer (Brand, Wertheim, Germany) on an inverted 
microscope (Olympus, Japan). 
 
2.3. Retroviral vector production  
To study the effect of serum deprivation in cell specific viral productivity and vector 
particles characteristics, producer cells were inoculated at 2x104 cells/cm2 and 4x104 
cells/cm2 for Te Fly Ga 18 cells and 293 FLEX 18, respectively. Advanced-DMEM (Gibco) 
supplemented with 4mM of glutamine (Gibco) and 10, 5, 1 or 0.5% (v/v) of FBS (Gibco) 
was used. Several samples were collected during the growth curve: viral supernatant was 
harvested, filtered through 0.45 μm, aliquoted and stored at -85ºC until analysis.   
To evaluate vector production in delipidated medium (dFBS) with lipid supplements, 
cells were seeded at the same cell density described above and cultured for three days, in 
Advanced DMEM supplemented with 4 mM of glutamine (Gibco), a minimum serum 
percentage of 1% (v/v) for 293 FLEX 18 and 0.5% (v/v) for Te Fly Ga 18 completing the FBS 
concentration to 10% (v/v) with delipidated FBS. Additionally i) 0.3% (v/v) bovine 
lipoprotein solution (CellPro-LPS from HyClone, Logan, Utah, USA), ii) 0.1% (v/v) 
cholesterol supplement (Chemically Defined Cholesterol from Gibco) or iii) 2% (v/v) free 
fatty acids supplement (Chemically Defined Lipid Concentrate from Gibco) were added.  
After 3 days in culture, the medium was replaced, and the vectors produced during the 
following 24 hours were harvested. Sampling was performed as described above. All the 
studies in this work were performed twice and the results have shown to be reproducible.  
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2.4. Retroviral vector decay kinetics 
To evaluate vector decay kinetic, 24 hour viral vector productions were performed 
during the late phase of exponential cell growth, corresponding to the highest production 
period. For this purpose, the culture medium was replaced by fresh one and after 24 
hours, the viral supernatant was harvested and filtered through a 0.45 μm filter. Part of 
this supernatant was 1/10 diluted in Advanced DMEM with 10% (v/v) FBS, and the 
remaining supernatant was 1/10 diluted in the correspondent production medium. The 
viral suspensions were then incubated at 37 °C in a 10% CO2 incubator. Samples were 
taken at 0, 3, 6, 9, 12, 24, 36, and 48 h and stored at −85 °C for viral titer determination. 
Decay rate constants and half-lives were calculated according to a first order exponential 
decay model (Le Doux et al. 1999) 
 
2.5. Measurement of retrovirus titer 
For the infectious particle titration, Te671 cells were seeded at 5×104 cells/cm2 in 96-
well plates with DMEM with 10% (v/v) FBS and incubated overnight in a humidified CO2 
incubator at 37 °C. After 24 h, the supernatant was removed and cells were infected with 
50 μl of viral suspension. Serial dilutions were performed in DMEM with 10% (v/v) FBS 
containing 8 μg/ml of polybrene (Sigma, Steinheim, Germany). After 4h of incubation at 
37 °C to promote virus adsorption, 150 μl of DMEM with 10% (v/v) FBS were added to 
each well. Two days after infection, cells were fixed: the culture supernatant was removed 
and cells were washed with PBS and incubated with formaldehyde at 0.3% (v/v) and 
glutaraldehyde at 1.35% (v/v) in PBS for 5 min. After a washing step with PBS, staining was 
carried out using a solution of 0.2 mg/mL x-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) (Stratagene, La Jolla, USA), 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, and 1 
mM MgCl2 in PBS.  Three replicates were made for each dilution. The viral titer was 
determined by counting the stained blue cells using an inverted phase contrast 
microscope, multiplied by the dilution factor. 
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2.6. Measurement of retroviral RNA and reverse transcriptase activity 
The retroviral transgene RNA was determined by real-time reverse transcriptase PCR 
as described elsewhere (Carmo et al. 2004). To determine DNA polymerase activity the 
RetroSys C-Type RT activity kit (Innovagen, Lund, Sweden) was used. All reactions were 
linear with respect to incubation time and amount of virus added. Each measurement was 
done in duplicate. 
 
2.7. Serum delipidation and lipid analysis 
Lipids were removed from FBS by a delipidation method described elsewhere (Cham 
and Knowles 1976). Two additional steps of i) vacuum evaporation followed by ii) a 
dialysis against PBS in 100 volumes with three buffer exchanges at 4ºC were performed.  
Lipid composition of FBS and delipidated FBS was assessed by total lipid extraction as 
described by Bligh and Dyer (1959), followed by cholesterol, phospholipids, triglycerids  
and free fatty acids quantification. Concentration of total phospholipids was determined 
by a colorimetric assay based on complex formation between ammonium 
ferrothiocyanate and the phospholipid (Stewart 1980). Cholesterol, triacylglicerols and 
fatty acids were determined by enzymatic assays using: i) for cholesterol determination, 
the Amplex® Red Cholesterol Assay Kit (Invitrogen); ii) for triglycerides, the Serum 
Triglyceride Determination Kit (Sigma) and iii) for fatty acids, the Free Fatty Acids Half 
Micro Test kit (Roche Applied Science, Mannheim, Germany). All quantification 
procedures were carried out following manufacturer’s instructions. The lipid extraction 
efficiency was 95% for phospholipids, 98% for triglycerides and cholesterol and 100% for 
fatty acids.  
 
2.8. Metabolite Analysis 
Glucose, glutamine, lactate and ammonia concentration were determined using 
Bioprofile 100 plus Analyzer system (Nova Biomedical, Waltham, USA). 
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2.9. Cell specific rates determination  
To determine cell specific growth rate, metabolite uptake/consumption rate, 
productivities of I.P. (infectious particles), RNA (viral genome) and RT (reverse 
transcriptase), the Boltzmann equation was considered: 
 
C
dt
dP
P  (Eq. 1) 
 
where P represents the different parameters, either viable cell concentration, 
metabolite concentration, I.P., RNA or RT, C is the viable cell concentration, t is the time 
and μP is the cell specific rate of each parameter in study. The confidence interval 
considered was 95%.  
 
 
3. Results 
3.1. Influence of serum on retroviral vector production and cell specific 
productivity 
The effect of serum on retroviral vector production was studied by analyzing the 
impact of decreasing serum concentration in the culture medium on the infectious and 
total particles production (Fig. 1). The serum concentration in the culture medium could 
be reduced from 10% (v/v) to to 1% (v/v) for 293 FLEX 18 cells and 0.5% (v/v) for Te Fly Ga 
18 without disturbing cell growth and central carbon energy metabolism (Table I). 
Cell specific viral productivity decreased when serum concentration was reduced for 
both producer cell lines (Fig. 1). This was particularly evident for concentrations lower 
than 5% (v/v) FBS, specially for 293 FLEX 18 cells where this drop was even more 
pronounced with a 9 fold decrease in cell specific viral productivity being observed as 
serum concentrations dropped from 10% (v/v) to 1% (v/v) FBS; for Te Fly Ga 18 cells a 7 -
fold  decrease occurred from 10% (v/v) to 0.5% (v/v) FBS. The maximum viral titers 
obtained were also approximately one order of magnitude lower at the minimum 
concentration of serum for both cell lines. 
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Table I – Cell specific growth rate and central energetic metabolic yields γlac/γglc and γamm/γglu 
The errors in μgrowth correspond to a 95% confidence interval as defined in Material and Methods. The errors in γlac/γglc and 
γamm/γgln correspond to error propagation; (μgrowth) maximum cell specific growth rate, (γlac) lactate production rate, (γglc) 
glucose uptake rate, (γamm) ammonia production rate, (γgln) glutamine uptake rate. 
 
 
 
Figure 1 – Effect of serum deprivation on infectious particles titers. Infectious particles production kinetics of 293 
FLEX 18 (A) and Te Fly Ga 18 (B) cells in production medium with different serum concentrations; error bars represent 
standard deviations (n=3). Cell specific infectious particles productivities of 293 FLEX 18 (C) and Te Fly Ga 18 (D) cells in 
production medium with different serum concentrations; error bars correspond to a 95% confidence interval, as 
defined in Material and methods. 
  Production media FBS % (v/v) 
  10% 5% 1% 0.5% 
293 FLEX 18 
μgrowth (h
-1
) 0.019 ± 0.002 0.022 ± 0.002 0.018 ± 0.002 - 
γlac/γglc 1.1 ± 0.3 1.1 ± 0.3 1.3 ± 0.02 - 
γamm/γgln 0.5 ± 0.1 0.6 ± 0.2 0.6 ± 0.2 - 
         Te Fly Ga 18 
μgrowth (h
-1
) 0.020 ± 0.002 0.020 ± 0.001 0.020 ± 0.002 0.018 ± 0.002 
γlac/γglc 1.5 ± 0.4 1.2 ± 0.3 1.4 ± 0.3 1.5 ± 0.3 
γamm/γgln 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.8 ± 0.2 
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3.2. Influence of serum on retroviral vector properties 
To analyze the effect of serum concentration on vector properties, the number of 
viral RNA copies, RT activity, as well as vector stability was assessed. Table II summarizes 
cell productivities ratios calculated based on viral RNA and RT quantifications. Viral RNA in 
the supernatant was quantified as it corresponds to the encapsidated RNA, it is a measure 
of total viral particles with infectious potential. However, viral genome RNA 
measurements disregard the production of empty particles. To account for this, a second 
measure of total particles was performed, quantifying reverse transcriptase (RT) activity. 
RT activity in supernatant is also an indirect measurement of gag-pol expression and 
particles assembly.  
The ratio infectious particles/total particles (I.P./T.P.) decreased when the serum 
concentration in the culture medium was reduced, either when considering viral genome 
RNA or RT as a total particles measure, thus, indicating the production of higher amounts 
of defective vectors. For both Te Fly Ga 18 and 293 FLEX 18 cells, viral RNA production and 
encapsidation was not affected by serum deprivation which, besides attesting that there 
were no limitations in viral genome production and encapsidation, shows that the total 
number of produced particles was maintained. Conversely, the analysis of RT activity 
confirms that this is one of the particles’ components that was disturbed by serum 
reduction, but only when 293 FLEX 18 cells are used. Nevertheless, this effect is too low to 
justify the sharp decrease in infectious particles titer. 
Serum contains considerable amounts of albumin, lipoproteins and other molecules 
that are known to act as stabilizing agents of retroviral vectors.  Its presence in the culture 
medium results in a higher vector half-life, and ultimately, leads to an increase in vector 
titers. Thus, to confirm that the reduction in infectious vector titers in low-serum 
conditions was a consequence of limitations at the level of the production of the particles, 
and not an indirect effect of lower vector stability due to the absence of serum stabilizing 
agents, a detailed study of vector stability was performed. 
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Table II – Cell specific productivities of viral RNA and reverse transcriptase (RT) and the corresponding 
ratios for 293 FLEX 18 and Te Fly Ga 18 cells 
The errors in βRNA and βRT correspond to a 95% confidence interval as defined in Material and Methods. Errors in 
I.P/RNA, I.P./RT and RT/RNA represent 10% of maximum variability determined for each ratio. βRNA (cell specific 
production rate of viral RNA),  βRT (cell specific production rate of reverse transcriptase) 
 
Viral infectivity decay kinetics of vectors produced at different serum concentrations 
were assessed both in: i) the different production media and in ii) 10% (v/v) FBS medium 
(Fig. 2 and Table III). In this latter case, independently of the production medium, the 
decaying medium is the same, normalizing possible stabilization effects of medium or 
serum components. Consequently, a higher half-life indicates that the production 
condition in study generated intrinsically more stable particles.  
A 4-hour reduction in the half-life of vectors produced by Te Fly cells was observed 
from 10% to 0.5% (v/v) FBS, when assessed in the production medium; however, this 
difference disappeared when assessed in 10% (v/v) FBS medium, even for particles 
produced in reduced-serum conditions. This indicates that, for these vectors, either serum 
concentration in the production medium does not induce intrinsic stability changes, or 
that the serum stabilization effect surpasses the possible intrinsic effects induced on the 
produced particles. In the case of the vectors produced by 293 FLEX cells, higher 
concentrations of serum led to an increased stability originated both by its protective 
presence in the medium and also by generating intrinsically more stable particles.  
 
 Production media FBS % (v/v) 
  10% 5% 1% 0.5% 
2
9
3
 F
LE
X
 1
8 βRNA (copy/cell.h) 4.8 ± 0.2 4.4± 0.1 4.2 ± 0.1 - 
βRT (10
-7 ng/cell.h) 1.1 ± 0.1 0.8 ± 0.1 0.6 ± 0.1 - 
I.P./RNA (10-3 I.P./copy) 5.1 ± 0.8 4.5 ± 0.5 0.7 ± 0.1 - 
I.P./RT (104 I.P./ng ) 23 ± 2 23 ± 2 5 ± 1 - 
RT/RNA (10-6 ng /copy) 2.2 ± 0.2 1.9 ± 0.2 1.4 ± 0.1 - 
Te
 F
ly
 G
a 
18
 βRNA (copy/cell.h) 57 ± 7 54  ± 8 50 ± 8 69 ± 2 
βRT (10
-7 ng/cell.h) 1.0 ± 0.3 1.2 ± 0.2 1.2 ± 0.1 1.1 ± 0.2 
I.P./RNA (10-3 I.P./copy) 5.7 ± 0.9 4.5 ± 1.4 2.3 ± 0.8 0.7 ± 0.3 
I.P./RT (104 I.P./ng ) 315 ± 32 196 ± 20 98 ± 10 100 ± 10 
RT/RNA (10-6 ng /copy) 0.18 ± 0.01 0.23 ± 0.02 0.24 ± 0.02 0.16 ± 0.01 
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When comparing the decay kinetics of viral infectivity of vectors produced in 1% (v/v) 
FBS, either in 1% (v/v) FBS medium or 10% (v/v) FBS medium, it is evident that serum 
presence confers stability to the particle, since viral stability was enhanced from 6.5 to 8.1 
hours. This is similar to what was observed with the Te Fly Ga 18 derived vectors, and can 
be explained by the presence of albumin. When analysing the decay kinetics of viral 
infectivity of vectors produced in different serum concentrations was assessed in the 
medium supplemented with 10% (v/v) FBS, it was observed that for particles produced 
both in 5% and 1% (v/v) FBS, the vector half-life was always lower than for the particles 
produced in 10% (v/v) FBS. Therefore, and in contrast to what was observed with Te Fly 
Ga 18 derived vectors, vector infectivity decay kinetics was not completely restored when 
decaying in medium supplemented with 10% (v/v) serum. This indicates that producing at 
10% (v/v) FBS generates more stable particles in the case of 293 FLEX 18 cells.  
 
Table III - Half-life of vectors produced by 293 FLEX 18 and Te Fly Ga 18 cells 
 
 
 Vector half-life (h) 
293 FLEX 18  Te Fly Ga 18 
 Vector decay medium FBS % (v/v) 
10% 5% 1% 0.5%  10% 5% 1% 0.5% 
Production  
medium   
(FBS % (v/v)) 
10% 9.7 ± 0.4 - - -  12.0 ± 0.9 - - - 
5% 7.7 ± 0.6 8.4 ± 1.0 - -  11.7 ± 0.9 10.9 ± 1.1 - - 
1% 8.1 ± 0.6 - 6.5± 0.5 -  12.5 ± 0.3 - 10.6 ± 0.4 - 
0.5% - - - -  12.3 ± 1.4 - - 8.1 ± 1.1 
Vectors produced by each cell line decay either in the respective production media (diagonal) or in medium supplemented 
with 10% FBS, independently of the medium they were produced in (vertical). Errors correspond to a 95% confidence 
interval as defined in Material and methods. 
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Figure 2 – Effect of serum in retroviral vector stability. Decay kinetics of viral infectivity of 293 FLEX 18 (A and C) and Te 
Fly Ga 18 (B and D) derived vectors in the production medium (A and B) and in medium supplemented with 10% (v/v) 
FBS (C and D). In A and B, vectors produced by each cell line decay in the media they were produced in; in C and D, all 
vectors decay in medium supplemented with 10% FBS, independently of the medium they were produced in; values are 
shown as average ± standard deviation (n=3). Curves obtained by fitting with the rate constants calculated as described 
in Material and methods. 
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3.3. The role of serum lipids on viral production: delipidated serum and lipid 
supplements 
To evaluate the role of serum lipids in viral production, delipidated FBS (dFBS) was 
used. After the delipidation process, dFBS was assessed for the protein profile by SDS-
PAGE, serum total protein content, pH, osmolarity, and enzyme activity of lactate 
dehydrogenase and alkaline phosphatase (data not shown). No differences were observed 
in none of these parameters between delipidated and non-delipidated serum.  
To ensure the maintenance of cell growth, the minimum serum percentage 
previously determined was used: 1% (v/v) FBS for 293 FLEX 18 and 0.5% (v/v) FBS for Te 
Fly Ga 18 cells. dFBS was added to attain a final serum concentration of 10% (v/v), that is, 
9% (v/v) dFBS for 293 FLEX 18 and 9.5% (v/v) dFBS for Te Fly Ga 18 cells.  The use of 
delipidated serum did not perturb either cell growth or central carbon metabolism (data 
not shown) in agreement with the previous results (Table I) since the minimum serum 
percentage had already shown to be sufficient to support similar cell growth and 
metabolic patterns as 10% (v/v) FBS. However, infectious particles titers were not 
recovered by the addition of delipidated serum, and cell specific viral productivities were 
comparable to those obtained with the minimum serum percentage (Fig. 3 A and B).  
In order to appraise the effects of using delipidated serum on vector half-life a 
second stability study was conducted. In a first approach, viral infectivity decay kinetics of 
vector particles produced in 10% (v/v) FBS medium were assessed in medium 
supplemented with delipidated serum (data not shown). This allowed analyzing the effect 
of delipidated serum presence in the culture medium upon produced particles. For this 
case, the presence of delipidated serum in the culture medium was shown not to 
interfere in viral particles stability thus, confirming that the infectious particles titer drops 
observed when using dFBS medium were mainly due to limitations in actual vector 
production. To further investigate if the vectors produced in dFBS media presented 
intrinsic production changes, viral infectivity decay kinetics of vectors produced in the 
conditions described (either 10% (v/v) FBS, Min% (v/v) FBS or dFBS medium), were 
measured in 10% (v/v) FBS medium (Fig. 3 C and D).  
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Figure 3 – Effect of delipidated serum in infectious particles titers and stability. Specific productivities of infectious 
particles of 293 FLEX 18 (A) and Te Fly Ga 18 (B) cells; error bars correspond to 95% confidence interval, as defined in 
Material and methods. Decay kinetics of viral infectivity of 293 FLEX 18 (C) and Te Fly Ga 18 (D) derived vectors produced in 
medium with different serum supplementation, and assessed in 10% FBS (v/v) medium; values are shown as average ± 
standard deviation (n=3). Curves obtained by fitting with the rate constants calculated as described in Material and 
methods. Abbreviations: (dFBS) delipidated FBS; (Min% (v/v) FBS) minimum serum percentage corresponding to 1% (v/v) 
and 0.5% (v/v) FBS for 293 FLEX 18 and Te Fly Ga 18 cells, respectively.  
 
For this second case, the use of delipidated serum resulted in vector particles slightly 
less stable than those produced at 10% (v/v) FBS. These results are similar and thus, 
validate, those already found in the previous stability study (Table III): the stability of the 
viral particles produced in medium with delipidated serum was similar to that of viruses 
produced in reduced-serum conditions and lower than those produced in 10% (v/v) FBS 
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medium. Taken all together, these results strongly support the hypothesis that serum lipid 
fraction is of the utmost importance for viral production, being its deprivation the main 
cause for infectious particles titer decline. 
The removal of serum lipid content is insufficient to establish a quantitative 
relationship between serum lipids and viral production. Thus, a viral production study was 
performed in which i) 0.3% (v/v) bovine lipoprotein solution (LPS), ii) 0.1% (v/v) 
cholesterol supplement (Chol) or iii) 2% (v/v) free fatty acids (FAs) supplement were 
added to medium already supplemented with delipidated serum (Fig.4).  
 
 
 
Figure 4 – Recovery of infectious titers by adding lipid supplements. Specific productivities of infectious particles of 293 
FLEX 18 (A) and Te Fly Ga 18 (B) cells in production medium with different lipid supplements; error bars represent 
standard deviation (n=3). Abbreviations: (dFBS) delipidated FBS; (LPS) bovine lipoprotein solution; (Chol) cholesterol 
supplement; (FAs) free fatty acids supplement 
 
These concentrations correspond, in the case of cholesterol and fatty acids, to the 
best percentages for viral production (assessed in preliminary studies with reduced-serum 
media (data not shown)) and, in the case of the lipoprotein supplement, to the 
percentage that mimics serum concentration. 
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The addition of lipid supplements, particularly cholesterol, to the medium 
supplemented with delipidated serum resulted in a 6- and 9-fold increment in viral 
productivity in 293 FLEX 18 cells and Te Fly Ga 18 cells, respectively. This represents the 
total recovery of viral titers, with an additional improvements, comparatively to 10% (v/v) 
FBS supplemented medium, for both cell lines. The use of fatty acids supplements also led 
to increased productivities, when comparing with the minimum serum percentage but 
only for 293 FLEX 18 cells. Infectious particles production was very low in lipoprotein 
supplemented medium, however, viral RNA and RT activity levels were identical to the 
ones produced in 10% FBS, suggesting a post-production interference effect. 
Viral RNA and RT productivities were determined for each assay described (data not 
shown). In agreement with the results already obtained (Table II), there was no evidence 
of RNA limitations susceptible to justify the decrease in infectious particles productivity. 
However, slight differences in RT productivity were obtained depending on the lipid 
supplement used. The general tendency was a decrease in RT productivity in all the 
conditions, when comparing with the production in 10% (v/v) FBS medium. In fact, the 
exception is when cholesterol supplemented medium is used where RT productivity is 
actually increased.  
 
4. Discussion 
Serum supplementation of the culture medium is known to be crucial to support long 
term periods of vector production for the majority of the retroviral producer cell lines 
(Chan et al. 2001; McTaggart and Al-Rubeai 2000; Pizzato et al. 2001; Shen and Palsson 
1996). To understand the role of serum in retroviral vector production in general, and for 
293 FLEX and Te Fly cells derived vectors in particular, a thorough study of viral 
production patterns, vector characteristics and cell growth and metabolic behavior was 
performed for 293 FLEX 18 and Te Fly Ga 18 retroviral vector producer cell lines, in media 
supplemented with different serum concentrations.  The requirement of serum to support 
viral production by Te Fly Ga 18 cells had already been reported (Merten 2004) and since 
the vectors produced by these cells have the same characteristics than those of 293 FLEX 
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– MoMLV derived, GaLV pseudotyped,  harboring LacZ reporter gene – they are an 
adequate comparison in terms of final product.  
It was soon realized that some serum components were directly and specifically 
related with retroviral vector production: although cell growth and the central energetic 
metabolic profile were similar in all the serum concentrations tested, decreases in 
infectious particles production were always observed, being the extent of the decline 
proportional to serum reduction. The stability studies highlighted that though serum 
reduction in the culture medium could result in slight decreases in vector stability, this 
effect did not suffice to account for the sharp drop in infectious vector titers.   Moreover, 
similar results were obtained both with 293 FLEX and Te Fly cells, suggesting the pattern 
to be independent of the producer cell line and confirming that it was vector related.  
To identify the serum components which mostly affect viral production, a preliminary 
study of serum fractioning was conducted; lipoproteins were identified as the most critical 
serum for the production of infectious particles. This result was in accordance with 
previous work, where the importance of lipids and lipid metabolism of producer cells in 
viral production is shown (Amaral et al. 2008; Coroadinha et al. 2006a). Unless other 
supplements are added, serum is the only lipid source of the culture medium and, 
although cells should be able to sense lipid absence in the culture medium and activate 
biosynthetic pathways to stand up to lipid deprivation, the activation of lipid de novo 
synthesis may take hours or days, depending on the cell type (Alberts et al. 1974; Spector 
et al. 1980). In some cases, cells can no longer synthesize certain lipids, since the long-
term synthesis inhibition can induce mechanisms of gene silencing, leading to a complete 
heterotrophy of some lipid molecules (Seth et al. 2005, 2006). Therefore, changes in 
serum concentration that disturb cell membrane lipid composition will ultimately affect 
viral particle membrane properties (Rawat et al. 2003), since it is part of the host cell 
membrane, possibly resulting in a higher production of non-infectious particles.  
RNA and RT quantification results demonstrated that the infectious particles 
production decrease is actually a problem of quality, rather than quantity: in reduced-
serum conditions, the produced particles are defective and thus non-infectious. The effect 
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of lipid removal of the membrane of other enveloped virus host cells has already been 
shown to result in the disruption of the particle structure. Laliberte et al. (2006) 
demonstrated that cholesterol depletion from the host cell membrane led to the 
production of structurally damaged particles, with altered “proteins/lipids” ratios, and in 
some cases resulting in membrane holes. The authors reported also that, although 
defective and less infectious, the total number of produced particles was maintained, a 
conclusion that our results further substantiate. Membrane lipids are known to be active 
players in the complex process of viral assembling and pseudotyping that takes place at 
the host cell membrane, in which interactions of membrane lipid rafts select both 
envelope and core proteins, recruiting the later the other viral components by 
cooperative interaction. The production of infectious particles is known to rely on the 
efficiency of this process, which is dependent upon a delicate equilibrium of lipid type and 
amounts, easily disturbed by lipid deprivation (Briggs et al. 2003). In this context, it is 
noteworthy that, not only the best results for productivity recovery were obtained for 
cholesterol supplemented medium, but also that these recoveries were associated with 
an increase in RT amounts quantified in the supernatant, which can be correlated with an 
improved assembling process of the gag-pol elements. Moreover, since the limitations in 
RT were not sufficient to justify the reduced production of infectious particles, it can also 
be speculated that part of these non-infectious particles could also be due to protein 
envelope limitations. These limitations can either be due to restriction in envelope protein 
amounts or functionality, as the lipid environment in which the protein is anchored is 
known to exert strong influence on its mobility and also on the linkage strength to the 
membrane (Carmo et al. 2006).  
Retroviral vector production in serum-free conditions was recently reported for the 
first time by Ghani et al. (2007). However, the major limitations for the production of 
these particles in serum absence still remained unclear, rendering it difficult to accomplish 
without decreasing either vector titer or quality. With this study, we identified the serum 
key component correlated with high vector titers: lipids. Actually, in the work reported by 
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Ghani et al. (2007), the medium was not protein-free, containing  several components, 
including lipids and lipoproteins.  
In this work, we were able to identify the production of non-infectious particles as 
the main constraint resulting from serum withdrawal from the culture medium of 
retroviral vector producer cells. Although non-infectious, these particles should be, in 
terms of general physical structure, identical to the infectious ones, resulting the non-
infectious profile from changes in the lipid membrane content/integrity and envelope 
amounts. However, these changes are not sufficient to be exploited in the current 
purification protocols in order to separate them from the infectious ones (Rodrigues et al. 
2007). This can be important from the clinical application point of view, as a decrease in 
the transduction efficiency of the viral preparations is expected, since non-infective 
particles will interfere with and obstruct the infective ones. The outcome of this work is 
almost certainly susceptible of being extended to lentiviral vector production, concerning 
their similar biological characteristics with MLV derived vectors (Blesch 2004) particularly, 
the importance of adequate lipid environment for a correct particle assembling (Briggs et 
al. 2003). In addition, many of these results are also of interest for the production of other 
enveloped viruses. The supplementation of the reduced-serum culture medium with 
cholesterol has shown to be enough to support high viral titers with no need of adding 
further supplements establishing the potential of using cholesterol supplementation as a 
bioreaction strategy to support viral production in serum-free medium. But more than the 
technological relevance of retroviral vector production in serum-free conditions, the 
findings in this study allow a better comprehension and exploitation of the culture 
medium supplements used for the production biopharmaceuticals and its effects on the 
final product titer and quality. 
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Abstract 
The manufacture of enveloped virus, particularly retroviral and lentiviral vectors, 
faces the challenge of low titers that are aggravated under serum deprivation culture 
conditions. Also, the scarce knowledge on the biochemical pathways related with virus 
production is still limiting the design of rational strategies for improved production 
yields. This work describes the adaptation to serum deprivation of two human RV 
packaging cell lines, 293 FLEX and Te Fly and its effects on lipid biosynthetic pathways 
and infectious vector production. Total lipid content as well as cellular cholesterol were 
quantified and lipid biosynthesis was assessed by 13C-NMR spectroscopy; changes in 
gene expression of lipid biosynthetic enzymes were also evaluated. 
The effects of adaptation to serum deprivation in lipid biosynthesis were cell line 
specific and directly correlated with infectious virus titers: 293 FLEX cells faced severe 
lipid starvation – up to 50% reduction in total lipid content – along with a 68 fold 
reduction in infectious vector titers; contrarily, Te Fly cells were able to maintain 
identical levels of total lipid content by rising de novo lipid biosynthesis, particularly for 
cholesterol – 50 fold increase – with the consequent recovery of infectious vector 
productivities.  Gene expression analysis of lipid biosynthetic enzymes further confirmed 
cholesterol production pathway to be prominently up-regulated under serum 
deprivation conditions for Te Fly cells, providing a genotype-phenotype validation for 
enhanced cholesterol synthesis. These results highlight lipid metabolism dynamics and 
the ability to activate lipid biosynthesis under serum deprivation as an important feature 
for high retroviral titers. The mechanisms underlying virus production and its 
relationship with lipid biosynthesis, with special focus on cholesterol, are discussed as 
potential targets for cellular metabolic engineering. 
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1. Introduction 
Enveloped viruses, in particular retroviral derived vectors, have been extensively 
used for therapeutic purposes. Recombinant retroviral vectors have been widely used as 
gene transfer tools in gene therapy protocols (Edelstein et al. 2007). Genome free 
particles have already demonstrated promising results in the vaccinology field and 
replication-competent-particles were developed and efficiently used as oncolytic agents 
for cancer therapy (Bellier et al. 2006; Dalba et al. 2007; Dalba et al. 2005). Retrovirus 
manufacture is still a challenging task, due to the low titers of packaging cells, reduced 
vector stability and, the requirement of high amounts of serum to support high 
infectious particles production during long-term cultures (Merten 2004; Rodrigues et al. 
2009). Retrovirus, have been manufactured using mammalian cells, due to the inherent 
complexity of the biochemical pathways required for viral components production and 
assembly (Barrett et al. 2010; Delenda 1999). Among several cell lines, the selection of a 
particular host may constraint bioprocess and final product characteristics. The ultimate 
goal aims at understanding and controlling the physiological traits driving to high viral 
titers and quality, allowing for a tailored design or educated choice of cell substrates for 
virus production.  
From the biochemical pathways closely related to virus replication, lipid 
biosynthesis has gained increased attention in recent years, not only for the specific case 
of enveloped virus production (Sagan et al. 2006) but also for protein production (Sriburi 
et al. 2004) and cellular growth in general (Whitford and Manwaring 2004). Recent 
works have shown that lipid metabolism of cells infected with enveloped viruses, such as 
hepatitis C (HCV), human cytomegalovirus (HCMV) and human immunodeficiency virus I 
(HIV-1) plays a crucial role in viral replication. Both HIV-1 and HCV infection increases 
lipogenesis, in particular, cholesterol biosynthesis (Giri et al. 2006; Syed et al. 2009). 
HCMV infection appears to stimulate sphingolipid biosynthesis and to increase 
metabolic flux of citrate through the tricarboxylic cycle (TCA) and its efflux to the fatty 
acid biosynthesis pathway as malonyl-CoA (Munger et al. 2008). In all the cases, the 
modification of the host lipid metabolism seems to support viral replication both by 
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providing building blocks to the newly formed virion progeny, as well as sustaining the 
functionality of lipid microdomains where viral assembly occurs (for a review see Chan 
et al. (2010)). 
This work aimed to better understand the physiological changes occurring in two 
human cell lines producing recombinant Murine Leukemia Virus (MLV) vector, under 
serum deprivation conditions. We show that lipid metabolism dynamics of the producer 
cells is directly related to serum deprivation response and can constrain retroviral 
infectious vector production. Therefore, lipid biosynthetic pathways emerge as an 
appealing target for metabolic engineering in order to improve vector titers.  
 
2. Materials and methods 
2.1.   Cell lines and culture media 
Te Fly Ga 18 and 293 FLEX 18 are human derived cell lines producing  MLV based 
vector expressing Gibbon Ape Leukemia Virus (GaLV) ecotropic envelope and harbouring 
a LacZ reporter gene. Te Fly Ga 18 are Te 671 (ATCC CCL-136) derived (Cosset et al. 1995, 
Duisit et al. 1999) and 293 FLEX 18 are HEK 293 (ATCC CRL-1573) derived cells 
established as described in Coroadinha et al. (2006a). Both cells were maintained in 
Advanced Dulbecco’s modified Eagle’s medium, DMEM, (Gibco, Paisley, UK) with 25 mM 
of glucose, supplemented with 10% (v/v) Foetal Bovine Serum (FBS) (Gibco) and 4 mM of 
glutamine (Gibco). Te671 cell line was used as the target cell to titrate infectious 
retroviral particles and was maintained in DMEM (Gibco) with 25 mM of glucose and 4 
mM of glutamine supplemented with 10% (v/v) FBS (Gibco).  
 
2.2. Incubation with 13C-labeled glucose for 13C NMR spectroscopy analysis of lipid 
content 
For 13C-Nuclear Magnetic Resonance (NMR) spectroscopy analysis of lipid content, 
cells were inoculated at a density of 2x104 cells/cm2 and 4x104 cells/cm2 for Te Fly Ga 18 
and 293 FLEX 18 cells, respectively. Final FBS concentrations were 10%, 7.5%, 3% (v/v) or 
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the corresponding reduced serum conditions for which both adapted and non-adapted 
cells were used. 72 hours later, the culture supernatant was replaced by medium 
supplemented with 8 mM of [U-13C] glucose (Cambridge Isotope Laboratories Inc, 
Andover, MA, USA), and incubated for further 24 hours after which lipid extraction was 
performed. The glucose concentration used during this period was previously 
determined to be sufficient to avoid depletion. The new medium was prepared from 
DMEM (Gibco) with no glucose, no glutamine and no sodium pyruvate, and 
supplemented to mimic Advanced DMEM formulation. The supplements used were non-
essential amino acids solution (Gibco), reduced glutathione (Sigma, Steinheim, 
Germany), insulin-transferrin-selenium-X solution (Gibco), ascorbic acid (Sigma), 
albuMAXII® (Gibco), sodium pyruvate (Gibco) and glutamine (Gibco). All NMR cultures 
were performed using this formulation including the 10% (v/v) FBS control. 
 
2.3.   Lipid extraction 
2.3.1. Lipid extraction for quantification of total lipid and cholesterol in 
producer cells  
To determine the total lipid content of both producer cells and viruses, cells were 
seeded as described previously. Final FBS concentration was 10% (v/v) or the 
corresponding reduced serum conditions (RSC) for which both adapted and non-adapted 
cells were used. 96 hours later, cell culture supernatant containing retroviral vector was 
harvested, filtered through 0.45 μm for clarification and concentrated by 
ultracentrifugation as described in (Coroadinha et al. 2006b) and stored at -85ºC until 
further analysis. Simultaneously, cells were harvested by trypsinization, washed twice by 
successive centrifugation-ressupension in phosphate-buffered saline (PBS) to remove 
culture medium traces and stored at -20ºC until total lipid extraction. Total lipid content 
was extracted from the cellular pellets as described in (Bligh and Dyer 1959) and the 
lipid containing chloroform phase was evaporated using a speed-vac. The final lipid 
pellet was weighted and used as a total lipid content measurement. For cholesterol 
quantification, the lipid pellet was solubilised in PBS (Gibco) + 0.1% (v/v) Tween-80 
(Sigma).  
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2.3.2. Lipid extraction for 13C-NMR spectroscopy analysis 
 For 13C-NMR spectroscopy analysis, cells were seeded as described previously; after 
24 hours of incubation with medium containing 8 mM of [U-13C] glucose, lipid extraction 
was performed as described in Amaral et al. (2008).  
 
2.4.  13C NMR spectroscopy 
Lipid extracts were prepared as described in section 2.4.2 and a known amount of 
dioxane 10% (v/v) in CDCl3 was added as an internal standard to all samples. Proton-
decoupled 13C NMR spectra were acquired in a Bruker AVANCE II 500 MHz spectrometer 
operating at a frequency of 125.77 MHz, using the following parameters: 30º pulse 
angle, 25 kHz spectral width, 64-K data points, acquisition time of 1.3 s and a 0.5 s 
relaxation delay. The number of scans was typically 40.000. Relevant peaks in the 
spectra were identified and integrated. The amounts of 13C were quantified from the 
integrals of the peak areas, using dioxane at 67.40 ppm as internal standard. 
Assignments were made by comparison with chemical shifts reported in the literature 
(Pollesello et al. 1996; Tugnoli et al. 2003). The values were compared after biomass 
normalization and are relative to the total amount of glucose consumed during the 
incubation time. 
 
2.5. Retroviral vector production  
2.5.1. Adaptation to reduced serum conditions 
To analyse the long-term effects of serum deprivation in cell physiology and vector 
production, cells were seeded as described previously. The final concentration of FBS 
was either 10% (v/v) FBS or the correspondent to reduced serum conditions (1% (v/v) 
for 293 FLEX 18 cells and 0.5% (v/v) for Te Fly Ga 18). Reduced serum conditions had 
been previously determined for each cell line, as the minimum serum concentration 
allowing for the same cell growth and central energy metabolism profile than 10% (v/v) 
FBS (Rodrigues et al. 2009).  During 9 sequential passages, a new splitting was 
preformed, twice a week, maintaining the initial inoculums. In each split, the viral 
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supernatant was harvested, filtered through 0.45 μm pore membrane for clarification, 
aliquoted and stored at -85ºC for further analysis. At the 10th passage, the curve of cell 
growth and vector production was analyzed for each case: 10% (v/v) FBS, and RSC for 
both adapted and non-adapted cells. Several samples were collected during the growth 
curve and the viral supernatant was treated as described above.   
 
2.6.   Retrovirus titration 
For the infectious particle titration, Te671 were used as target cells. Infectious 
procedure and viral titer determination were performed by serial dilution infection 
assay, as previously described in Rodrigues et al. (2009). 
 
2.7.   Metabolite analysis and cholesterol quantification 
Glucose, glutamine, lactate and ammonia concentration were determined using 
Bioprofile 100 plus Analyzer system (Nova Biomedical, Waltham, USA). Cholesterol was 
quantified in purified virus and cellular total lipid content by an enzymatic assay 
(Cayman Chemical, Ann Arbor, MI, USA), following the manufacturer’s instructions.  
 
2.8.   RNA extraction and real-time quantitative PCR 
To assess gene expression of lipid biosynthetic enzymes, cells were inoculated as 
described previously either in 10% (v/v) FBS or reduced serum conditions. For reduced 
serum conditions both adapted and non-adapted cells were used. 96 hours later, 
corresponding to middle exponential phase of the growth curve, total RNA was 
extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s 
instructions. For real time PCR, RPL-22 was chosen as a control gene. Forward (F) and 
reverse (R) primer sequences for control and lipid enzyme genes are given in Table I. The 
reverse transcription of total RNA was performed according to Transcriptor High Fidelity 
cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany) protocol for cDNA 
synthesis using 2 μg of total RNA and oligo dT primer for total mRNA reverse 
transcription. The reverse transcribed (RT) product was aliquoted and stored at -20ºC 
until further processing. SYBR Green I dye chemistry was used to detect the PCR 
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products using LightCycler® 480 SYBR Green I Master (Roche Applied Science) according 
to the manufacturer’s instructions using LightCycler® 480 Real Time PCR System (Roche 
Applied Science). cDNA samples were run along with a no RT-reaction control and a no 
cDNA template sample. Three independent cultures (biological replicates) were 
analyzed, each of them run in three (technical) replicates. 
 
Table I – Primers used in Real-Time PCR  
Gene Primer orientation 5' to 3' sequence 
RPL22 Forward CTGCCAATTTTGAGCAGTTT 
Reverse CTTTGCTGTTAGCAACTACGC 
ATP citrate syntase Forward TGTAACAGAGCCAGGAACCC 
Reverse CTGTACCCCAGTGGCTGTTT 
Acetyl-CoA carboxylase Forward AACTCCAAGGACACAGTCACCAT 
Reverse CAGCTGCTCCACGAACTCAA 
Fatty acid syntase Forward GCACCAACTCCATGTTTGG 
Reverse TGGAGATCACATGCGGTTTA 
HMG-CoA reductase Forward ACAATAAGATCTGTGGTTGGAATTATGA 
Reverse GCTATGCATCGTGTTATTGTCAGAA 
HMG-CoA synthase (S) Forward CCATTGAAGAGGCTTCTGGT 
Reverse CTGCCCCTATTCTTCCCTTC 
Acetoacetyl-CoA thiolase Forward AAAAGCAGGTTGGTCACTGG 
Reverse CGACTTCTGCCCATTCTCTC 
 
 
2.9.  Cell specific rates determination  
To determine specific rates of cell growth, metabolite production/consumption and 
infectious particles (I.P.) productivities, the Boltzmann equation was considered: 
C
dt
dP
P  (Eq. 1)   
where P represents the different parameters, either viable cell concentration, 
metabolite concentration or I.P., C is the viable cell concentration, t is the culture time 
and μP is the cell specific rate of each parameter in study. The confidence interval 
considered was 95%. 
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3. Results 
3.1.      Adaptation to reduced-serum conditions 
293 FLEX 18 and Te Fly Ga 18 cell lines had been shown to significantly decrease 
infectious vector production when serum was reduced in the culture medium; this 
decrease was found to be due to a reduction in the infectious particles production, as 
the number of total particles remained unchanged, and therefore suggesting 
biochemical limitations in the viral assembly line resulting in defective particles 
(Rodrigues et al. 2009). To further investigate the physiologic response to serum 
deprivation, cell growth and infectious vector production were monitored for 9 
sequential passages under reduced serum conditions (Fig. 1). At the 10th passage, cell 
growth, central energy metabolism and infectious vector productivity were assessed 
(Fig. 2 and Table II).   
 
Table II – Cell specific growth rate and central energetic metabolic yields γlac/γglc and γamm/γglu of 
293 FLEX 18 and Te Fly Ga 18 
RSC (reduced serum conditions) correspond to 1% (v/v) FBS for 293 FLEX 18 cells and 0.5% (v/v) FBS for Te Fly 
Ga 18. RSC-Ad are cells under reduced serum conditions after an adaptation period of 10 passages, as 
described in Materials and Methods. The errors in μgrowth correspond to a 95% confidence interval as defined in 
Material and Methods; the errors in γlac/γglc and γamm/γgln correspond to error propagation; (μgrowth) maximum 
cell specific growth rate, (γlac) lactate production rate, (γglc) glucose uptake rate, (γamm) ammonia production 
rate, (γgln) glutamine uptake rate. 
 
No relevant changes were observed in cell growth or central energy metabolism 
patterns either during or after the adaptation period for both cell lines (Fig. 1A and B, Fig 
2. A and B and Table II). 
  Culture media FBS % (v/v) 
  10% RSC RSC-Ad 
293 FLEX 18 
μgrowth (h
-1
) 0.019 ± 0.002 0.018 ± 0.002 0.020 ± 0.001 
γlac/γglc 1.1 ± 0.3 1.3 ± 0.2 1.3 ± 0.3 
γamm/γgln 0.5 ± 0.1 0.6 ± 0.2 0.5 ± 0.2 
Te Fly Ga 18 
μgrowth (h
-1
) 0.020 ± 0.002 0.018 ± 0.002 0.018 ± 0.002 
γlac/γglc 1.5 ± 0.4 1.5 ± 0.3 1.6 ± 0.3 
γamm/γgln 0.4 ± 0.1 0.8 ± 0.2 0.5 ± 0.1 
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Figure 1 – Effect of passage number upon cell growth and vector productivity of 293 FLEX 18 and Te Fly Ga 18. Average cell 
growth (A and B) and infectious vector productivity (C and D) of 293 FLEX 18 (A and C) and Te Fly Ga 18 (B and D) cell lines 
during the adaptation period to reduced serum conditions (●) (RSC); 10% (v/v) FBS is shown as a control (■ ). Reduced serum 
conditions correspond to 1% (v/v) FBS for 293 FLEX 18 cells and 0.5% (v/v) FBS for Te Fly Ga 18 as defined in Rodrigues et. al. 
(2009). Error bars in A and B correspond to 10% error in cell counting, and in C and D correspond to standard deviation (n=3). 
 
However the patterns of RV production were markedly altered during the 
adaptation period to serum deprivation and opposite responses were observed for the 
two cell lines (Fig. 1C and D, Fig. 2C and D). For 293 FLEX cells, the average infectious 
vector titer decreased abruptly since the first passage under RSC, and the values were 
found to be nearly identical in subsequent passages (Fig. 1C). Infectious vector 
productivity dropped 9 fold when compared with the standard 10% (v/v) FBS conditions 
and 68 fold for the adapted cells (Fig. 2C). On the other hand, Te Fly cells adapted to 
serum deprivation and recovered infectious vector production (Fig 1D). The first passage 
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Figure 2 – Cell growth and vector productivity of 293 FLEX 18 and Te Fly Ga 18. Cell growth (A and B) and infectious 
vector productivity (C and D) of 293 FLEX 18 (A and C) and Te Fly Ga 18 (B and D) cell lines in standard 10% (v/v) FBS 
supplementation (—■ —) and in reduced serum conditions before (RSC) (∙∙∙●∙∙∙) and after the adaptation period (RSC-
Ad) (--▲ --). Reduced serum conditions correspond to 1% (v/v) FBS for 293 FLEX 18 cells and 0.5% (v/v) FBS for Te Fly 
Ga 18. Error bars in A and B correspond to 10% error, for cell counting, and in C and D correspond to a 95% 
confidence interval, as defined in Material and methods. 
 
was, indeed, where the highest decrease in infectious vector titer occurred, followed by 
an increase in the second passage; viral titers kept improving until the passage 6 and 
thereafter the average infectious vector titers remained nearly unaltered (Fig. 1D).  
Without adaptation, infectious vector productivity of Te Fly cells, decreased 7 fold under 
RSC comparatively to 10% (v/v) FBS but recovered to almost identical values after the 
adaptation period (Fig. 2D). Altogether, these results depicted a very distinct 
cellular/metabolic behavior for Te Fly and 293 FLEX cells when responding to serum 
deprivation, resulting in different viral production outcomes. 
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3.2.   Study of lipid biosynthesis by 13C-NMR spectroscopy 
The absence of the serum lipid fraction had previously been correlated with the  
decrease in infectious vector productivity for both Te Fly Ga 18 and 293 FLEX 18 cells 
(Rodrigues et al. 2009). Therefore, the recovery of infectious vector production for Te Fly 
Ga 18 after the adaptation period led to hypothesize changes in producer cells lipid 
metabolism to be the basis for the recovery in infectious vector production. Glucose is 
the major carbon source for lipid biosynthesis in cultured mammalian cells (Spector et 
al. 1980); thus, uniformly labeled glucose ([U-13C] glucose) was used to probe lipid 
biosynthetic pathways by 13C-NMR spectroscopy and to assess quantitative lipid 
biosynthesis in response to serum deprivation for both Te Fly Ga 18 and 293 FLEX 18 
cells. Table III summarizes the results of 13C incorporation into lipid molecules from cells 
cultured using different serum concentrations, including RSC for both adapted and non-
adapted cells.  
From a quantitative point of view, glucose channeling through lipid biosynthetic 
pathways occurred to a higher extent in 293 FLEX than in Te Fly cells, that is, for the 
same serum concentration in the culture medium, 293 FLEX synthesized higher amounts 
of lipids (Table III). However, these values needed to be analyzed in the context of 10% 
(v/v) FBS basal synthesis; this would translate the fold change relatively to the 
conditions under which a minimum lipid synthesis from glucose is known to occur and 
that corresponds to the lipid biosynthesis increase/capacity in response to serum 
deprivation comparable between both cell lines (Figure 3). 
The increase in lipid biosynthesis was higher in Te Fly cells for all the lipid molecules 
considered. This was particularly evident in the case of cholesterol synthesis, which had 
a 35 fold increase from 10% (v/v) to the minimum serum concentration of 0.5% (v/v) 
FBS. This value increased even further, to 50 fold in Te Fly cells adapted to RSC, 
suggesting that metabolic changes were induced by such conditions. Conversely, 293 
FLEX cells showed no appreciable changes in cholesterol synthesis neither in the 
remaining lipid molecules analyzed both before and after the adaptation period to 
serum withdrawal.  
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Table III – 
13
C incorporation in 293 FLEX 18 and Te Fly Ga 18 lipid content after [U-13C] glucose 
metabolism in the presence of different serum concentrations. 
The synthesis of each lipid was assessed by choosing one characteristic carbon and the values were compared using the 
same mark. (*) Values are relative to glucose consumption as described in Materials and methods. Errors correspond to 
10%, the error associated to the NMR quantification method. 
 
 
 
 
Figure 3 – Lipid biosynthesis in 293 FLEX 18 and Te Fly Ga 18. For reduced serum conditions, both adapted and non-
adapted cells were used; fold increase is relative to 10% (v/v) FBS. Reduced serum conditions correspond to 1% (v/v) FBS 
for 293 FLEX 18 cells and 0.5% (v/v) FBS for Te Fly Ga 18. Abbreviations: (Chol) cholesterol, (CholE) cholesterol esters, (FA) 
fatty acids, (TAG) triacylglycerols, (Phos) phospholipids. Error bars correspond to 10% error of NMR spectroscopy 
quantifications. 
 
 
13C relative* 
incorporation 
(10-6/mg protein) 
293 FLEX 18 
10% FBS 7.5% FBS 3% FBS 
1% (v/v) FBS 
Non-adapted  
cells 
Adapted  
cells 
Cholesterol 0.19 ± 0.02 0.20 ± 0.02 0.24 ± 0.02 0.41 ± 0.04 0.46 ± 0.05 
Cholesteryl Esters 0.9 ± 0.1 1.1 ± 0.1 1.9 ± 0.2 2.4 ± 0.2 2.6 ± 0.3 
Fatty Acids 2.9 ± 0.3 4.8 ± 0.5 5.4 ± 0.5 5.9 ± 0.6 6.1 ± 0.6 
Triacylglycerols 0.24 ± 0.02 0.35 ± 0.04 0.42 ± 0.04 0.59 ± 0.06 0.58 ± 0.06 
Phospholipids 2.6 ± 0.3 3.3 ± 0.3 3.7 ± 0.4 4.0 ± 0.4 4.0 ± 0.4 
13C relative* 
incorporation 
(10-6/mg protein) 
Te Fly Ga 18 
10% FBS 7.5% FBS 3% FBS 
0.5% (v/v) FBS 
Non-adapted  
cells 
Adapted 
 cells 
Cholesterol 0.004 ± 0.0004 0.02 ± 0.002 0.05 ± 0.01 0.15 ± 0.02 0.21 ± 0.02 
Cholesteryl Esters 0.39 ± 0.04 0.66 ± 0.07 1.5 ± 0.2 2.2 ± 0.2 2.4 ± 0.2 
Fatty Acids 0.79 ± 0.8 1.2 ± 0.1 1.8 ± 0.2 2.5 ± 0.3 3.0 ± 0.3 
Triacylglycerols 0.08 ± 0.01 0.12 ± 0.01 0.24 ± 0.02 0.28 ± 0.03 0.32 ± 0.03 
Phospholipids 1.0 ± 0.1 1.5 ± 0.2 1.8 ± 0.2 2.1 ± 0.2 2.4 ± 0.2 
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3.3. Total lipid and cholesterol content of RV and producer cells  
To further analyze the effects of serum deprivation adaptation total cellular lipid 
and cholesterol content was quantified (Table IV).   
 
Table IV – Lipid content of 293 FLEX 18 and Te Fly Ga 18 cells. 
  
Total lipids 
(pg/cell) 
Cholesterol 
(pg/cell) 
293 FLEX 18 
10% FBS 0.34 ± 0.004 0.031 ± 0.006 
RSC 0.22 ± 0.009 0.020 ± 0.005 
RSC Adapted cells 0.15 ± 0.003 0.016 ± 0.002 
Te Fly Ga 18 
10% FBS 0.31 ± 0.03 0.029 ± 0.001 
RSC 0.34 ± 0.02 0.017 ± 0.003 
RSC Adapted cells 0.29 ± 0.02 0.029 ± 0.003 
Reduced serum conditions (RSC) correspond to 1% (v/v) FBS for 293 FLEX 18 cells and 0.5% (v/v) FBS 
for Te Fly Ga 18. Values are shown as average ± standard deviation (n=5).  
 
Although both cell lines activated lipid biosynthesis under RSC, in the case of FLEX 
cells, it was not enough to maintain neither the total lipid nor the cholesterol content at 
the same levels than in 10% (v/v) FBS. For Te Fly cells, this decrease was only observed 
for the cholesterol content. Actually, serum withdrawal induced a cholesterol 
deprivation scenario for both cell lines. This pattern was reverted after the adaptation 
period for Te Fly cells, but not for FLEX cells, further substantiating NMR spectroscopy 
data (Fig. 3) and evidencing distinct metabolic fingerprints between these two cell lines. 
This was ultimately correlated with vector production, as these changes also affected 
viral lipid content (data not shown).  
 
3.4. Gene expression of lipid biosynthetic enzymes under reduced serum 
conditions  
13C-NMR spectroscopy and lipid quantification showed unequivocally distinct 
profiles of lipid biosynthesis and lipid content, respectively, between Te Fly and FLEX 
cells under RSC and, more importantly, in the ability of these cells to adapt to serum 
deprivation maintaining high infectious vector titers. Thus, we further investigated if 
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such differences were based in gene expression changes of key lipid biosynthetic 
enzymes (Fig. 5). 
 
 
 
Figure 4 – Gene expression changes of lipid biosynthetic enzymes of 293 FLEX 18 and Te Fly Ga 18 cells. Gene expression 
changes induced by reduced-serum conditions of six key enzymes in lipid biosynthesis: HMG-CoA reductase, HMG-CoA 
synthase (cytosolic form), acetoacetyl-CoA thiolase, acetyl-CoA carboxylase, fatty acid synthase and ATP citrate lyase. Fold 
change under reduced serum conditions (RSC) for both adapted and non-adapted cells relatively to 10% (v/v) FBS 
conditions. Reduced serum conditions correspond to 1% (v/v) FBS for 293 FLEX 18 cells and 0.5% (v/v) FBS for Te Fly Ga 
18.  For relevant fold-changes (greater than 2 or -2) * and ** give the significance of a two-tailed non-paired t-test, 
between three independent replicates; * p<0.05, ** p<0.005. 
 
 
For 293 FLEX cells, none of the lipid biosynthetic enzymes was significantly up-
regulated. Actually, non-adapted cells presented a 2 fold down-regulation of HMG-CoA 
reductase and ATP-citrate lyase whereas adapted cells had no significant changes in 
none of the six enzymes analyzed when compared to 10% (v/v) FBS.  By opposite, (non-
adapted) Te Fly cells showed a significant up-regulation in four of the six enzymes 
analyzed; for acetoacetyl-CoA thiolase and acetyl-CoA carboxylase the changes were 
higher than 4 fold increase. Interestingly, for both Te Fly and FLEX cells, changes in gene 
expression were more pronounced for non-adapted than for adapted cells, suggesting it 
to have a stress response component, which tends to be diluted after the adaptation. 
After the adaptation, only Te Fly cells sustained higher expression levels of lipid 
biosynthetic enzymes, namely HMG-CoA reductase, acetoacetyl-CoA thiolase and acetyl-
CoA carboxylase. 
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4. Discussion 
In previous work, it was demonstrated that lipids are the main serum component 
correlated with infectious retroviral vector production and its absence under reduced 
serum conditions a major cause for the accentuated decrease of titers and viral 
preparation quality (Rodrigues et al. 2009). In this work, we analyzed the physiologic 
response of the same two retrovirus producer cell lines, 293 FLEX 18 and Te Fly Ga 18, to 
serum deprivation and its effects on lipid biosynthetic pathways and infectious vector 
production. The drop in infectious viral titer occurred immediately after the first passage 
(Fig. 1) evidencing it to be based on short-term mechanisms. On the other hand, the 
ability of Te Fly cells to respond to serum starvation rescuing viral productivity after 
adaptation to serum withdrawal pointed that intrinsic metabolic or biochemical factors 
could provide a natural foundation for vector production in the absence of serum. 
The analysis of lipid biosynthesis for different serum concentrations (Table III) 
showed that both cell lines were able to activate de novo lipid synthesis when 
challenged by the lipid source removal, in accordance to what has previously been 
described (Alberts et al. 1974; Spector et al. 1980). Nevertheless, this was insufficient to 
maintain cellular lipid content in 293 FLEX cells, particularly cholesterol, at levels 
identical to those observed for 10% (v/v) FBS (Table III). Deficiency in cholesterol content 
of host cells has already been shown to impair viral infectivity of other enveloped 
viruses resulting in defective structurally damaged particles, with altered 
“proteins/lipids” ratios and/or membrane holes (Laliberte et al. 2006). Thus, it is not 
surprising that changes in cellular lipid content resulting from serum withdrawal could 
impair infectious vector production. The differences between the two cell lines after the 
adaptation to serum deprivation were, however, unexpected (Fig. 2). The response 
dynamics of lipid biosynthesis under RSC was higher in Te Fly cells than in 293 FLEX cells, 
with additional changes induced by the adaptation period particularly for cholesterol 
(Fig. 3). The ability of cholesterol synthesis under RSC can provide an explanation for the 
recovery of infectious vector production, as we have previously shown that the addition 
of cholesterol supplements under RSC is sufficient to achieve infectious vector titers 
Adaptation of retrovirus producer cells to serum deprivation 
 
112 
 
identical to those obtained with 10% (v/v) FBS for both cell lines (Rodrigues et al. 2009). 
Thus, the inability of 293 FLEX cells to synthesize cholesterol was probably the major 
cause of the very low titers obtained.  
Limitations in cholesterol biosynthesis have been previously described for cultured 
mammalian cells (Seth et al. 2006; Seth et al. 2005) and may explain the different 
adaptation profile between Te Fly and FLEX cells and consequent infectious vector 
production performances. Cholesterol biosynthesis relies on tight regulation 
mechanisms mainly targeting the LDL (low density lipoprotein) receptors and key 
enzymes of the cholesterol biosynthetic pathway such as HMG-CoA synthase and 
particularly HMG-CoA reductase (Horton et al. 2002; Rudney and Sexton 1986). Thus, 
gene expression of six key lipid biosynthetic enzymes was analyzed under RSC (Fig. 4). 
Figure 6 shows a schematic representation of lipid biosynthesis from glucose and the 
main intervenient enzymes.  ATP-citrate synthase (d) converts citrate to oxaloacetate 
and acetyl-CoA thus contributing to the flux of glucose towards lipid biosynthesis. 
Acetyl-CoA carboxylase and acetoacetyl-CoA thiolase convert acetyl-CoA to malonyl-CoA 
and acetoacetyl-CoA, initiating its commitment to fatty acid and cholesterol 
biosynthesis, respectively. Both enzymes were significantly up-regulate under RSC for Te 
Fly but not in 293 FLEX cells. HMG-CoA synthase and HMG-CoA reductase, considered 
the rate limiting enzyme in cholesterol biosynthesis definitely committing HMG-CoA to 
cholesterol production, were also increased in Te Fly cells (Fig. 4). Such results support 
the hypothesis of increased glucose flux towards cholesterol production occurring in 
these cells under RSC (Fig. 3) to be accomplished by enhanced gene expression of 
cholesterol biosynthetic enzymes induced by serum withdrawal. The up-regulation in 
gene expression of these enzymes, could be readily seen after 96 hours under RSC (Fig. 
4, Te Fly Ga 18 non-adapted cells), which goes in agreement with NMR data showing 
enhanced cholesterogenesis even before the adaptation period (Fig. 3); still, infectious 
vector productivity recovery only begins to be evident in the second passage under RSC 
(Fig. 1) suggesting a time-shifting between lipid metabolism rearrangements and 
recovery in infectious vector production. 293 FLEX cells failed to increase gene 
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expression of lipid biosynthetic enzymes in response to serum deprivation (Fig. 4), which 
can explain the lower lipid biosynthesis (Fig. 3), reflected in their absolute lipid content 
(Table IV) and ultimately in infectious vector production (Fig. 1 and 2).  
 
 
 
Figure 5 – Lipid biosynthesis from glucose in mammalian cells. (a) pyruvate dehydrogenase, (b) citrate synthase, (c) 
citrate carrier, (d) ATP-citrate lyase, (e) cytosolic malate dehydrogenase, (f) malic enzyme, (g) mitochondrial malate 
dehydrogenase, (h) acetoacetyl-CoA thiolase, (i) HMG-CoA synthase, (j) HMG-CoA reductase, (k) acetyl-CoA carboxylase, 
(l) fatty acid synthase, (m) long-chain fatty acyl elongase, (n) stearoyl-CoA desaturase, (o) glycerol 3-phosphate acyl 
transferase. Abbreviations: SREBPs (SRE binding proteins), TCA (tricarboxylic acids cycle). Adapted from Horton et al. 
(2002) and Gnoni et al (2009).  For a matter of simplicity, only the major reactions and corresponding enzymes are 
indicated 
 
The distinct cellular origin between Te Fly and 293 FLEX cells can provide a 
hypothesis for the observed differences in cholesterol biosynthesis dynamics. 293 FLEX 
cells are derived from kidney tissue, being characterized by a modest cell turnover and 
presenting low activity of cholesterol biosynthetic enzymes with a consequent low 
capacity of cholesterol synthesis (Tosi and Tugnoli 2005). Conversely, Te Fly cells are 
tumor-derived cells, retaining high proliferation markers such as enhanced 
cholesterogenesis and cholesteryl esters synthesis (Coleman 1986; Tosi and Tugnoli 
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2005), which were observed for these cells (Fig. 3). In this context, it is interesting to 
notice that long term serum free production of retro or lentiviral vectors has been based 
not only on lipid supplemented media (Broussau et al. 2008; Ghani et al. 2007) but also, 
in the case of transient systems, on highly transformed cells, namely 293T, transformed 
with SV40 large T antigen (T-Ag) or 293 EBNA, transformed with Nuclear Antigen of 
Epstein-Barr Virus (Schweizer and Merten 2010). These cells exhibit very different 
physiological features and gene expression patterns when compared to their 
counterparts, HEK 293 potentially facilitating serum independence for vector production 
(unpublished results); indeed, SV40 transformation was shown to facilitate serum-
independent proliferation (Ahuja et al. 2005). Regarding vector production, Gama-
Norton et al. (2011) have recently shown that even low levels of constitutive T-Ag 
expression can significantly increase lentiviral vectors titers in HEK 293; this effect was 
found not be exerted at the level of vector transcriptional activity but rather at the 
cellular/physiological level, through an indirect and unidentified mechanism. In fact, not 
much is known about the long-term metabolic modifications induced by T-Ag or EBNA 
transformation. However, it is probable that some of those changes target lipid 
biosynthetic pathways, given that oncogenic neoplastic transformation is typically 
characterized by an increase in lipid biosynthesis and turnover (Barger and Plas 2010; 
Swinnen et al. 2006).  
In this work we show that lipid biosynthesis and its connection to central carbon 
metabolism is more dynamic and regulated in Te Fly cell line than in 293 FLEX cells; this 
resulted in an increased capability to respond to serum deprivation and a consequent 
improvement in infectious vector production performance. The results herein presented 
highlight the need of understanding the metabolic fingerprints of producer hosts 
keeping the perspective of virus biology. Studies addressing relevant metabolic 
pathways for high-titer vector production, as the one herein presented should provide 
important knowledge to choose new cell substrate hosts, to design metabolic 
engineering strategies – genetic or environmental – and establish optimal bioprocess 
framings towards maximum vector yields and quality. 
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LIPID BIOSYNTHESIS BOTTLENECKS 
UNDERLYING SERUM HETEROTROPHY 
 
Chapter V is divided into two parts following the two main sections of this thesis: i) understanding the metabolic 
constrains of retroviral vector production and ii) use the gathered knowledge for rational gene engineering. 
Therefore, Chapter V – part A comprises transcriptome analysis of serum deprivation and Chapter V – part B focuses 
metabolic engineering of lipid biosynthesis.  
Both parts will be combined to be published as: 
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Abstract 
The need of animal blood sera to support infectious vector titers has challenged 
retroviral vector production in HEK 293 derived cells. Lipid starvation under reduced 
serum conditions was demonstrated to be a main cause for the loss of infectious 
vector titers while the ability to reactivate lipid biosynthesis, particularly cholesterol, 
was shown to allow the reversion of serum heterotrophy phenotype. Yet, HEK 293 
derived retroviral vector producer cells seem to have this pathway impaired, unable 
to rescue cholesterol biosynthesis in response to the removal of the external lipid 
supply.  
In the first part of this work, we aimed at understanding the metabolic impairments 
underlying lipid heterotrophy of 293 FLEX retroviral vector producer cells. 
Transcriptional profiling identified three potential bottlenecks in the pathway of de 
novo cholesterol biosynthesis: mevalonate kinase (MVK), lanosterol synthase (LSS) 
and sterol regulatory element binding factor 2 (SREBF2).  
In the second part of this work (refer to Chapter V Part B), these targets were over-
expressed in 293 FLEX in an attempt to reactivate cholesterol biosynthesis and revert 
serum heterotrophy. When individually over-expressing MVK and LSS, serum 
heterotrophy was mildly alleviated. When in combination, it was totally reverted. The 
over-expression SREBF2 alone, not only promoted the complete reversion of serum 
heterotrophy, as it resulted in higher infectious titers than those of standard serum 
supplementation conditions. 
The work herein described focuses the tailored design of retroviral vector 
producer cells in the pursuit of a serum-independent phenotype based on educated 
guesses driven by functional genomics studies. The results also represent, to the 
best of our knowledge, the first metabolic engineering manipulation of 
cholesterolgenesis in mammalian cell culture. 
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1. Introduction 
Retro and lentiviral vectors are powerful gene delivery tools comprising the most 
widely used viral vectors for the treatment of monogenic diseases and hematopoietic 
cell modification in gene and cell therapy (Edelstine 2013; Ginn et al. 2013). As gene 
therapy moves from clinical to market (Moran 2012; Sheridan 2011), increased 
pressure is put on the development of stable cell lines and robust manufacture 
processes for vector production. However, long-term vector production is dependent 
on animal blood serum, an ill-defined culture supplement and potential source of 
pathogen contamination, hindering the safety and standardization required in 
clinical-grade manufacture processes.  
In previous work we demonstrated that reducing serum in the culture medium of 
two human cell lines producing recombinant retrovirus leads to sharp reductions in 
infectious but not total particles titer (Rodrigues et al. 2009). Thus, serum withdrawal 
results in high contamination content of non-infectious particles likely to obstruct the 
therapeutic potential of the infectious ones. Lipids, in particular cholesterol, were 
confirmed as the key serum component correlated with the production of infectious 
retroviral vectors (Rodrigues et al. 2009). Following these findings, an adaptation to 
serum deprivation was conducted for these two cell lines, and the effects on lipid 
biosynthetic pathways and infectious vector production were analyzed. Such effects 
were found to be cell line specific and directly correlated with infectious virus titers. 
Cells facing lipid starvation nearly inhibited infectious vector production while cells 
rising de novo lipid biosynthesis, particularly cholesterol, recovered infectious vector 
titers (Rodrigues et al. 2012). Yet, recruiting biosynthetic machinery and starting de 
novo lipogenesis, is the expectable phenotype of cultured mammalian cells in 
response to the removal of the external lipid source (Alberts et al. 1974; Spector et al. 
1980). Also, the cells found to be unable to rise up lipid biosynthesis – 293 FLEX – are 
derived from HEK 293, a cell line that has been cultured under serum-free conditions 
in the past two decades (Berg et al. 1993). Therefore, retroviral vector production 
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appears to induce a particular serum heterotrophy phenotype, not derived from the 
original parental cells. 
The hint on the possible source of serum heterotrophy arose from the 
transcriptome comparison between producer and non-producer parental cells 
(Rodrigues et al. 2013). Retroviral vector production was found to induce a general 
down-regulation of the lipid biosynthetic pathways, more prominent in case of 
cholesterol; this effect appeared to be counterbalanced with the up-regulation of 
lipid uptaking machinery partially explaining the heavy reliance of retroviral vector 
producer cells on external lipid sources. More importantly, two particular enzymes 
were found to be limiting the pathway function. One was mevalonate kinase (MVK), 
with gene expression values near the non-transcription threshold. The other was 
lanosterol synthase (LSS) as it was strongly down-regulated in the transition 
“parental-to-producer” in 293 derived producers (Rodrigues et al. 2013). 
In the first part of this work, we conducted transcriptome analysis for the two 
retroviral vector producer cells of the above mentioned studies – 293 FLEX and Te Fly 
Ga – under serum deprivation conditions. The results were crossed with those of the 
transcriptional profile of “parental-to-producer” transition. We found that the re-
activation of both enzymes, MVK and LSS, is an exclusive ability of Te Fly producers, 
those capable of rescuing cholesterol biosynthesis in response to serum depletion. 
Therefore, these enzymes appear as over-expression targets to revert cholesterol 
(serum) heterotrophy in 293 FLEX producers. 
 
2. Materials and methods 
Cell lines and culture conditions 
Te Fly Ga 18 (Cosset et al. 1995; Duisit et al. 1999) and 293 FLEX (Coroadinha et al. 
2006; Schucht et al. 2006) are human derived cell lines producing murine leukemia 
virus (MLV) based vector harbouring a LacZ reporter gene, pseudotyped with gibbon 
ape leukemia virus (GaLV). The cells were maintained in Advanced Dulbecco’s 
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modified Eagle’s medium, DMEM (Gibco, Paisley, UK), with 25 mM of glucose, 
supplemented with 10% (v/v) Foetal Bovine Serum (FBS) (Gibco) and 4 mM of 
glutamine (Gibco). The final concentration of FBS was changed for the different 
studies of retroviral vector production. Te671 (ATCC CCL-136) cell line was used to 
titrate infectious retroviral particles. All cells were maintained in an incubator with a 
humidified atmosphere of 92% air and 8% CO2 at 37 °C.   
 
Cell growth and viral production studies 
Cells were inoculated at a density of 2x104 cells/cm2 and 4x104 cells/cm2 for Te Fly 
Ga 18 and 293 FLEX 18 cells, respectively. Final FBS concentrations were 10% (v/v) 
or the corresponding reduced serum conditions (RSC). Reduced serum conditions 
had been previously determined for each cell line, as the minimum serum 
concentration allowing for the same cell growth and central energy metabolism 
profile than 10% (v/v) FBS (Rodrigues et al. 2009). Two samples were collected per 
day: culture supernatant was harvested, filtered through 0.45 μm for clarification, 
aliquoted and stored at -85ºC until analysis. Cell concentration and viability was 
determined by the trypan blue exclusion method. At day 3, total RNA was extracted 
for transcriptome analysis.  
 
RNA extraction, amplification, labeling and BeadChip hybridization  
RNA extraction, amplification, labeling and BeadChip hybridization were 
performed as described in Chapter II (Rodrigues et al. 2013). 
 
Data processing and analysis 
Data was processed by log2 and variance-stabilizing transformation and quantile 
normalized as described in Chapter II  (Rodrigues et al. 2013). 
Differentially expressed genes were considered for a |FC|≥ 1.5 fold-change 
criterion. Pathway analysis was performed using Ingenuity Pathway Analysis (IPA) 
(Ingenuity® Systems, www.ingenuity.com).  
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3. Results 
3.1.      Transcriptional profiling of retroviral vector production under serum 
deprivation 
To evaluate the effects of serum deprivation on global gene expression of 293 FLEX 
and Te Fly retroviral vector producer cells, a whole-transcriptome microarray analysis 
was conducted comparing 10% (v/v) FBS standard conditions to reduced serum 
conditions for each of the cell lines: 1% (v/v) for 293 FLEX and 0.5% (v/v) for Te Fly 
(Rodrigues et al. 2009). A fold-change (FC) criterion was set, considering as 
differentially expressed genes those for which |FC|≥ 1.5-fold. Differentially expressed 
genes were analyzed by Ingenuity Pathway Analysis software. Figure 1 shows 
metabolic pathways significantly enriched for each of the cell lines.  
 
 
 
Figure 1 – Metabolic pathways enriched under serum deprivation. Significantly enriched pathways (p<0.05) given 
by Ingenuity Pathway Analysis of differentially expressed genes under serum deprivation and number of genes 
enriching the pathways. Note that only metabolic, and not signaling, pathways are shown. Differentially expressed 
genes were considered for a |FC|≥1.5 criterion for each of the comparisons 10% (v/v) FBS vs. reduced serum 
conditions for Te Fly and 293 FLEX cells. FC: fold-change. 
 
Cholesterol biosynthesis was the top significantly enriched metabolic pathway 
under serum deprivation. It was also the only category common to 293 FLEX and Te 
Fly. All of these genes were cholesterol biosynthetic enzymes, reporting to up-
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regulation and, thus, indicating strong activation of the pathway under serum 
deprivation. The number of up-regulated genes in Te Fly producers (11) 
substantially exceeded those in 293 FLEX (5).  
Since both 293 FLEX and Te Fly up-regulated cholesterol biosynthesis gene in 
repose to serum deprivation, we further inquired on gene expression patterns 
specific to each producer that could explain the impairment of cholesterol 
biosynthesis in 293 FLEX. Cholesterol biosynthetic proteins were analyzed in terms of 
absolute expression and fold-change, between 10% (v/v) FBS and reduced serum 
conditions (Fig. 2). Given our previous results indicating cholesterol biosynthesis 
arrestment in the transition “parental-to-producer” (Rodrigues et al. 2013),  gene 
expression in parental cells was also analyzed. 
The results confirmed that producer cells down-regulated cholesterol biosynthesis 
enzymes – relatively to non-producers. Mevalonate kinase (MVK) appeared as nearly 
non-expressed in both producers and non-producers. A very drastic reduction was 
observed for lanosterol synthase (LSS) in 293 FLEX also near to the non-expression 
threshold, comparatively to the parentals HEK 293 (Fig. 2). These results have been 
previously reported (Rodrigues et al. 2013). When challenged by serum withdrawal, 
Te Fly cells up-regulated the vast majority of cholesterol biosynthetic enzymes not 
only to values identical to those of the parentals but, to even higher values.  The same 
happened in 293 FLEX with two exceptions: LSS and MVK. It was additional 
noteworthy that the transcription factor mainly associated to cholesterol biosynthesis 
activation, sterol regulatory element binding protein 2 (SREBP2), was poorly 
expressed in both cell lines – although higher in Te Fly – and was not up-regulated in 
response to serum removal. The results from Figure 2 evidence gene expression 
patterns in Te Fly cells to favor cholesterol biosynthesis under serum deprivation.  
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Figure 2 – Gene expression of cholesterol biosynthesis enzymes. Expression values of cholesterol biosynthetic 
enzymes of 293 FLEX (left side) and Te Fly (right side) retroviral vector producers and respective parental cells (HEK 
293 and Te 671). Values are relative florescence units (RFU) from Illumina BeadChip microarray after variance-
stabilizing transformation and quantile normalization as defined in Materials and methods. Genes are shown in the 
order that pathway proceeds from acetyl-CoA to cholesterol. Note that the three last proteins (SCAP and SREBF 1 
and 2) are not biosynthetic enzymes. SREBF 1 and 2 are transcription factors related to lipid biosynthesis control 
and SCAP is the chaperone of these factors. The vertical dashed line indicates the expression value corresponding to 
1.5-fold higher than the background probes. This value can be used as cut-off to distinguish expressed from non-
expressed genes. ACAT2: acetyl-Coenzyme A acetyltransferase 2;   CYP51A1: cytochrome P450, family 51, subfamily 
A, polypeptide 1; DHCR7: 7-dehydrocholesterol reductase; DHCR24: 24-dehydrocholesterol reductase; FDFT1: 
farnesyl-diphosphate farnesyltransferase 1; FDPS: farnesyl diphosphate synthase; GGPS1: geranylgeranyl 
diphosphate synthase 1; HMGCR: 3-hydroxy-3-methylglutaryl-Coenzyme A reductase; HMGCS1: 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase 1; IDI1: isopentenyl-diphosphate delta isomerase 1; LSS: lanosterol synthase; 
MVD: mevalonate (diphospho) decarboxylase; MVK:mevalonate kinase; NSDHL: NAD(P) dependent steroid 
dehydrogenase-like; PMVK: phosphomevalonate kinase;  SCAP: SREBF chaperone; SC4MOL: sterol-C4-methyl 
oxidase-like; SC5DL: sterol-C5-desaturase; SQLE: squalene epoxidase; SREBF1: sterol regulatory element binding 
transcription factor 1; SREBF2: sterol regulatory element binding transcription factor 2. 
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4. Discussion 
The need of animal blood sera to support infectious vector titers has challenged 
retroviral vector production in HEK 293 derived cells. Lipid starvation under reduced 
serum conditions was shown as a main cause for this problem (Rodrigues et al. 
2012; Rodrigues et al. 2009). In fact, previous publications on serum-free retroviral 
vector production report the supplementation of the culture medium with lipids 
and lipoproteins (Ghani et al. 2007). The problem is likely to extend to lentiviral 
vector, although the transient nature of lentiviral vector production hinders a fair 
comparison since the main effects of serum deprivation are felt on a long-term 
culture period (Rodrigues et al. 2012). Indeed, the only publication of long-term 
serum-free lentiviral vector production also reports lipid supplementation of the 
culture medium (Broussau et al. 2008).  
At the lab-scale, lipid supplements may be an interesting alternative to serum. At 
larger scales, however, animal-free derived lipid supplements translate into 
substantial manufacture costs. Also, lipids are extremely sensitive molecules, easily 
peroxidable, and a potential source of oxidative burden in the culture (Esterbauer et 
al. 1991). Therefore, understanding serum (lipid) heterotrophy is an important 
landmark to deliver improved cell lines and robust manufacture processes for 
retroviral, and most likely, lentiviral vector production.  
By using retroviral vector producer cells derived from two different origins (293 
FLEX and Te Fly), we have shown that, for both cell lines, the heavy reliance on an 
external lipid source results from the “viral producer state” which leads to a strong 
down-regulation of the lipid synthesizing machinery while up-regulating the lipid 
uptaking machinery (Rodrigues et al. 2013). But we have also shown that serum 
heterotrophy is cell line dependent, dictated by the ability to revert this “viral 
producer state” induced arrestment of lipid biosynthesis and reactivate cholesterol 
synthesis in response to serum depletion (Rodrigues et al. 2012). Therefore, in this 
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work, we conducted transcriptome analysis under serum deprivation conditions of 
these two cell lines, in an attempt to identify cholesterol biosynthesis bottlenecks in 
293 FLEX.  
Pathway analysis of differentially expressed genes readily identified cholesterol 
biosynthesis as the most significantly enriched metabolic pathway under serum 
depletion conditions (Fig. 1). In fact, for Te Fly cells, this and acyl carrier protein 
metabolism were the only enriched metabolic pathways under serum deprivation. 
We have previously hypothesized  this robustness of Te Fly cells to derive from its 
cancer origin (Rodrigues et al. 2012). Interestingly, acyl carrier protein metabolism 
pathway was enriched by the down-regulation of aminoadipate-semialdehyde 
dehydrogenase-phosphopantetheinyl transferase (AASDHPPT). This enzyme 
transfers the 4'-phosphopantetheine moiety of coenzyme A (CoA) to conserved 
serine residues of several synthase enzymes (Joshi et al. 2003), thereby, reducing 
the available pool of CoA. CoA, is actually the co-factor used in the synthesis of 
acetyl-CoA from citrate in de novo lipid biosynthesis. Down-regulating the 
expression of AASDHPPT appears, thus, a potential mechanism to reduce the 
draining of CoA to other pathways, favouring acetyl-coA synthesis for lipogenesis. 
Pathway analysis only retrieves significantly enriched pathways, those in which 
the number of differentially expressed genes is unlikely to be obtained randomly. 
Thereby, all the genes comprising cholesterol biosynthesis pathway were 
individually analyzed, not only in terms of fold-change under, but also for absolute 
expression (Fig. 2). This analysis identified mevalonate kinase (MVK) and lansterol 
synthase (LSS) as the two potential blocking points of cholesterol biosynthesis in 293 
FLEX producers. The former, given the very low values, near to non-expression 
threshold, and the latter since it was abruptly down-regulated from parental-to-
producer, and only minorly up-regulated in response to serum deprivation.  
At a first glance, arresting lipid biosynthesis might seem contradictory for cells 
replicating an enveloped virus. Yet, the up-regulation of lipid up-taking machinery 
should counter balance this effect (Rodrigues et al. 2013). From the cell point-of-
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view, lipid uptaking is more advantageous since lipids are very expensive molecules 
to synthesize, both in terms of carbon and energy and, thereby increasing 
intracellular reactive oxygen species. In fact, in the presence of an external lipid 
source, most mammalian cell lines readily uptake lipids from the culture medium 
pacing-down de novo biosynthesis (Alberts et al. 1974; Spector et al. 1980). From 
the virus point-of-view, it can also be conceived as advantageous. Carrying a 
chronic/latent infection, retroviruses do not rely on fast membrane turnover for the 
maximum progeny production in the shortest period of time. Instead, they would 
better benefit from a cell host capable of channeling the spare resources to other 
pathways serving viral replication and living longer due to the lower oxidative 
burden. However, when facing lipid deprivation, this scenario should be rapidly 
reverted to assure cell survival, as found for Te Fly producers (Fig. 2 and Chapter IV). 
The reason 293 FLEX could not reactivate MVK and LSS to cope with the need of de 
novo cholesterol biosynthesis is still not clear. Yet, the low expression levels of 
sterol regulatory element binding factor 2 (SREBF2), the transcription factor 
activated under cholesterol depletion conditions to recruit the biosynthetic 
machinery, might be a possible explanation. Therefore, in the second part of this 
work, MVK, LSS and SREBP2 were over-expressed in 293 FLEX in an attempt to 
reactivate cholesterol biosynthesis. 
 
(Please refer to chapter V part B for the continuation of this work). 
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REACTIVATION OF CHOLESTEROL 
BIOSYNTHESIS REVERTS SERUM HETEROTROPHY 
Chapter V is divided into two parts following the two main sections of this thesis: i) understanding the metabolic 
constrains of retroviral vector production and ii) use the gathered knowledge for rational gene engineering. 
Therefore, Chapter V – part A comprises transcriptome analysis of serum deprivation and Chapter V – part B focuses 
metabolic engineering of lipid biosynthesis.  
Both parts will be combined to be published as: 
 
Reversion of serum heterotrophy in retrovirus replicating cells:  
Reactivation of cholesterol biosynthesis 
Ana F. Rodrigues, Ana S. Formas-Oliveira, Paula M. Alves, Wei-Shou Hu,  
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Abstract 
The need of animal blood sera to support infectious vector titers has challenged 
retroviral vector production in HEK 293 derived cells. Lipid starvation under reduced 
serum conditions was demonstrated to be a main cause for the loss of infectious 
vector titers while the ability to reactivate lipid biosynthesis, particularly cholesterol, 
was shown to allow the reversion of serum heterotrophy phenotype. Yet, HEK 293 
derived retroviral vector producer cells seem to have this pathway impaired, unable 
to rescue cholesterol biosynthesis in response to the removal of the external lipid 
supply.  
In the first part of this work (refer to chapter V Part A), we aimed at understanding 
the metabolic impairments underlying lipid heterotrophy of 293 FLEX retroviral vector 
producer cells. Transcriptional profiling identified three potential bottlenecks in the 
pathway of de novo cholesterol biosynthesis: mevalonate kinase (MVK), lanosterol 
synthase (LSS) and sterol regulatory element binding factor 2 (SREBF2).  
In the second part of this work, these targets were over-expressed in 293 FLEX in an 
attempt to reactivate cholesterol biosynthesis and revert serum heterotrophy. When 
individually over-expressing MVK and LSS, serum heterotrophy was mildly alleviated. 
When in combination, it was totally reverted. The over-expression SREBF2 alone, not 
only promoted the complete reversion of serum heterotrophy, as it resulted in higher 
infectious titers than those of standard serum supplementation conditions. 
The work herein described focuses the tailored design of retroviral vector producer 
cells in the pursuit of a serum-independent phenotype based on educated guesses 
driven by functional genomics studies. The results also represent, to the best of our 
knowledge, the first metabolic engineering manipulation of cholesterolgenesis in 
mammalian cell culture. 
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1. Introduction 
The need of animal blood sera to support infectious vector titers has challenged 
retroviral vector production in HEK 293 derived cells. Lipid starvation under reduced 
serum conditions was shown as a main cause for this problem (Rodrigues et al. 2009). 
The ability to reactivate lipid biosynthesis, particularly cholesterol, allows the 
reversion of serum heterotrophy. Yet, HEK 293 derived retroviral vector producer 
cells seem to have this pathway impaired, unable to rescue cholesterol biosynthesis 
in response to the removal of the external lipid supply (Rodrigues et al. 2012).  
In the first part of this work, transcriptome analysis was used to identify the lipid 
biosynthesis bottlenecks underlying serum heterotrophy in 293 FLEX retroviral vector 
producer cells. Mevalonate kinase (MVK) and lanosterol synthase (LSS) were 
identified as the potential blocking points in the pathway of de novo cholesterol 
biosynthesis. The poor expression of cholesterol biosynthesis transcription factor – 
sterol regulatory element binding factor 2 (SREBF2) – was also hypothesized to 
contribute to this impairment.  Therefore, in the second part of this work, MVK, LSS 
and SREBP2 were over-expressed in 293 FLEX in an attempt to reactivate cholesterol 
biosynthesis and revert serum heterotrophy.  
 
2. Materials and methods 
2.1. Cell lines and culture conditions 
293 FLEX S11 were used for gene engineering of lipid metabolism. These cells derive 
from 293 FLEX 18 (Coroadinha et al. 2006) by recombinase mediated cassette 
exchange as described in Chapter VII. In these cells, the original LacZ transgene was 
exchanged by a fusion of LacZ with S11 fragment of the split-GFP® SandiaBiotech 
(Albuquerque, NM, U.S.A). The cells were maintained in Advanced Dulbecco’s 
modified Eagle’s medium, DMEM (Gibco, Paisley, UK), with 25 mM of glucose, 
supplemented with 10% (v/v) Foetal Bovine Serum (FBS) (Gibco) and 4 mM of 
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glutamine (Gibco). The final concentration of FBS was changed for the different 
studies of retroviral vector production.  
HEK 293T (ATCC CRL-11268) is a HEK 293 derived cell line expressing large T antigen 
from SV40 (simian vacuolating virus 40) and was used to transiently produce the 
lentiviral vectors for lipid gene delivery. Te 671 is a human rhabdomyosarcoma 
derived cell line (ATCC CCL-136) used to titrate infectious retroviral particles by LacZ 
staining. Te 671 S10 is a Te 671 derived cell line stably expressing the S10 fragment 
of the split-GFP® (SandiaBiotech) established as described in Chapter VII, used to 
titrate lipid gene lentiviral vector stocks. HEK 293T, Te 671 and Te 671 S10 cells were 
maintained in DMEM (Gibco, Paisley, UK), with 25 mM of glucose and 4mM of 
glutamine, supplemented with 10% (v/v) (FBS) (Gibco). All cell lines were 
maintained in an incubator with a humidified atmosphere of 92% air and 8% CO2 at 
37 °C.   
 
2.2. Cell growth and viral production studies 
293 FLEX S11 engineered for the over-expression of lipid metabolism genes were 
analyzed for cell growth and vector production using a 48+24 hours 
production/harvesting operation mode described in Chapter II (Rodrigues et al. 
2013). Final FBS concentrations were 10% (v/v), or the corresponding reduced 
serum conditions: 0.5% (v/v) for Te Fly Ga 18 and 1% (v/v) for 293 FLEX 18 (and S11). 
 
2.3. Plasmids for lipid gene expression and lentiviral vector production 
Mevalonate kinase (MVK), lanosterol synthase (LSS), sterol regulatory element 
binding factor 1 and 2 (SREBF1 and 2) cDNAs were acquired through DNASU Plasmid 
Repository (Biodesign Institute, Arizona State University) and cloned into a lentiviral 
backbone (pRRLSIN LacZS11, refer to Chapter VII), after removal of the LacZ as 
described in Chapter VII. S11 fragment was maintained for titer determination. A 
mock vector was obtained by re-ligating the lentiviral backbone after LacZ removal.  
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For lentiviral transient production the third generation lentiviral packaging system 
and the transfection procedure described in Dull et al. (1998) were used. Viral 
vector supernatants were filtered through 0.45 μm cellulose acetate filter for 
clarification, aliquoted and stored at -85ºC until further use. 
 
2.4. Cell transduction with lipid genes lentiviral vector 
Lipid genes were delivered by lentiviral vector infection of 293 FLEX S11. The cells 
were seeded at a density of 4 x 104 cells/cm2 24 hours before infection in 6-well 
plates. Transduction was performed by removing the cell supernatant and infecting 
with 2 mL of viral suspension using the appropriate dilution to achieve multiplicities 
of infection (infectious particles per cell) of 1, 3 and 5. Dilutions were made in fresh 
DMEM (Gibco) with 10% (v/v) FBS (Gibco) and 8 μg/mL of polybrene (Sigma). Cells 
were incubated at 37ºC overnight after which medium was exchanged. Two days 
after infection, cells were amplified to 75 cm2 t-flasks in Advanced DMEM (Gibco) 
with 1% (v/v) FBS and re-passaged 3-4 days after. At this point, part of the cells was 
frozen and the other part was seeded to assess infectious particles production of 
transduced populations (section 2.2).  
 
 
2.5. Titration of infectious particles 
For LacZ based staining titration, infectious procedure and viral titer determination 
were performed by limiting dilution infection assay, as previously described in 
chapter III (Rodrigues et al. 2009). Lipid-gene delivery lentiviral vector, were titrated 
by GFP transcomplementation in Te 671 S10 target cells as described in Chapter VII.  
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3. Results 
3.1. Over-expression of cholesterol biosynthesis genes reverts serum 
heterotrophy 
The over-expression of mevalonate kinase (MVK), lanosterol synthase (LSS) and 
sterol regulatory element binding factor 2 (SREBF2) was conducted in our recently 
established 293 FLEX S11 (please refer to Chapter VII for cell line establishment 
details). This cell line derives from 293 FLEX 18, for which 13C-NMR lipid biosynthesis 
(Chapter IV) and transcriptome analyses were conducted (Chapters II and V.a), by 
recombinase mediated cassette exchange. In these cells, the original LacZ transgene 
was exchanged by a fusion of LacZ with the S11 fragment of the split-GFP (Cabantous 
et al. 2005). As described in Chapter VII, these cells are suited to be used with the 
single step cloning-titration method for fast identification of high-producing 
phenotypes. Therefore, these were chosen for genetic manipulation since the 
resulting population can be further screened for high-titer clones under reduced 
serum conditions. 
The genes from lipid biosynthesis pathways were delivered through lentiviral vector 
infection at increasing multiplicities of infection (MOI). Infectious vector titers of the 
transduced populations under reduced serum conditions were evaluated; as a 
control, non-transduced cells were also analyzed both under 10% and 1% (v/v) serum 
supplementation (Fig. 1). MVK transduced cells exhibited titer increase responsive to 
the MOI, although not able to achieve titers similar to those of 10% FBS. LSS 
transduced cells also partially recovered infectious vector titers but did not exhibit 
this MOI responsiveness. However, by conjugating MVK and LSS over-expression 
infectious particles titers were recovered to levels identical to those of 10% (v/v) FBS 
(Fig.1A). More impressively, SREBF2 over-expression allowed for achieving the same 
performances and also to exceed the titers obtained with 10% (v/v) FBS. The over-
expression of SREBF1 did not result in titer increases.  
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Figure 1 – Over-expression of cholesterol biosynthesis enzymes reverts serum heterotrophy in 293 FLEX retroviral 
vector producer cells. Specific productivity of infectious particles titer of 293 FLEX S11 under serum deprivation 
manipulated for the over-expression of cholesterol biosynthesis genes (A). Specific productivities were calculated 
based on infectious particles titers after 48 hours culture at 1% (v/v) FBS. 10% (v/v) FBS is shown as a control. 
Values are shown as average ± standard deviation (n=3). 293 FLEX S11 were transduced with lentiviral vector 
carrying the lipid gene at increasing multiplicities of infection (MOI).  The mock control corresponds to the same 
lentiviral backbone without the lipid gene, as described in Materials and methods. Schematic representation of 
lipogenesis from acetyl-Coa (B), featuring cholesterol biosynthesis on the left side, fatty acid/phospholipid 
biosynthesis on the right side and the transcriptional control exerted by sterol regulatory element binding factors. 
ACACA: acetyl-Coenzyme A carboxylase alpha; ACAT2: acetyl-Coenzyme A acetyltransferase 2; LSS: lanosterol 
synthase; MVK: mevalonate kinase; SREBF 1 and 2: sterol regulatory element binding factor 1 and 2.  
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4. Discussion 
In the first part of this work, we conducted transcriptome analysis to identify the 
bottlenecks in cholesterolgenesis of 293 FLEX retroviral vector producer cells 
(Chapter V.a). Mevalonate kinase (MVK), lanosterol synthase (LSS) and sterol 
regulatory element binding factor 2 (SREBF2) were identified as potential targets to 
reactivate de novo cholesterol biosynthesis.  
In the second part of this work, these targets were over-expressed aiming at 
reverting serum heterotrophy (Fig. 1). One of the first evidences in the results from 
Figure 1 was the decrease in infectious particles titer to be smaller between 10% 
serum and reduced serum conditions than previously found in Chapter III (Rodrigues 
et al. 2009).  Although this might indicate increased robustness of 293 FLEX S11 to 
serum deprivation – relatively to 293 FLEX 18 – it is more likely to be related to the 
short culture period used in this assays (48 hours). In fact, when analyzing viral 
production kinetics during a growth curve we observe that, in the first 48 hours, the 
differences in infectious particles titers between standard and reduced serum 
conditions does not exceed 3-fold (Chapter III). 
When individually over-expressing MVK and LSS, serum heterotrophy was mildly 
alleviated. When combined, it was totally reverted (Fig. 1A). The over-expression 
SREBF2 alone not only promoted the complete reversion of serum heterotrophy but 
resulted in higher infectious titers than those of standard serum supplementation 
conditions. SREBF2 is expressed in response to cholesterol-depletion conditions 
activating the whole cholesterol biosynthesis machinery (Weber et al. 2004). This 
orchestrated and upstreamly regulated effect might explain not only the total 
reversion of serum heterotrophy but also the additional titer improvements 
relatively to MVK/LSS combined over-expression and even 10% FBS conditions (Fig. 
1A). In fact, SREBP2 over-expression induces all enzymes of the cholesterol 
biosynthetic pathway (Sakakura et al. 2001), most notably the mRNA for HMG 
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Coenzyme A reductase (HMGCR), which may increase as many as 75-fold (Horton et 
al. 1998).  
Reversion of serum heterotrophy was confirmed to be cholesterolgenesis-
specific since the over-expression of sterol regulatory binding factor 1 (SBRF1), more 
related to fatty-acid biosynthesis (Eberle et al. 2004), had no effect neither on viral 
productivity nor in the capability of reverting serum heterotrophy (Fig. 1A and B). 
  In the follow-up of this work, manipulated cells will be analyzed for gene 
expression to evaluate the effects of these over-expressions in the whole 
cholesterol biosynthetic pathway. Lipid biosynthesis, in particular, 
cholesterolgenesis, will also be evaluated. Taking advantage of the S11 fusion 
transgene, manipulated cells will be subjected to the single step cloning-titration 
method (see Chapter VII), conducted under serum deprivation conditions to isolate 
serum-independent high-titer clones. These clones should be challenged for vector 
production using serum-free media formulations.  
The work herein described focuses the tailored design of retroviral vector 
producer cells in the pursuit of a serum-independent phenotype based on educated 
guesses driven by functional genomics studies. By opposite to a more traditional 
trial-and-error approach, our results engage a Systems Biology concept on a global 
understanding of the biological players and their network integration to rationally 
design a phenotype. They also represent, to the best of our knowledge, the first 
gene-based metabolic engineering manipulation of cholesterolgenesis in 
mammalian cell culture. 
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Abstract 
Many cultured mammalian cell lines used in research and biopharmaceuticals 
manufacture exhibit a Warburg effect phenotype with enhanced glycolytic fluxes 
predominantly channeled to lactate formation, which reduces culture viability and 
can also affect product quality. In this work, we conducted a proof-of-concept 
metabolic engineering study in HEK 293 derived retroviral vector producer cells, 
based on the down-regulation of two key molecular effectors of the Warburg effect-
like lactogenic phenotype: hypoxia inducible factor 1 (HIF1) and pyruvate 
dehydrogenase kinase (PDK). This strategy would simultaneously tackle reduced 
lactate accumulation and enhanced channeling of the glycolytic intermediates into 
the tricarboxylic acids cycle. 
For single gene manipulation, (HIF1 or PDK), clones producing, on average, 20-
fold higher titers of infectious particles were isolated. Without substantial differences 
in glucose consumption, lactate production was diminished up to 4-fold, indicating 
the channeling of the consumed glucose into non-lactogenic routes. The 
physiological fingerprints associated to high-titer HIF1 down-regulated clones 
indicated significant recruitment of metabolic pathways related to virus production 
such as biological amines metabolism, detoxification routes – including glutathione 
metabolism – and pentose phosphate pathway. High titer clones also presented 
substantial transcriptional increases of viral components. However, this could only be 
translated into increased vector titers when conjugated with the improved metabolic 
status arising from these manipulations. The results herein presented demonstrate 
the down-regulation of the Warburg effect phenotype as a successful approach to 
improve the productivity performance of a mammalian cell line producing a highly 
complex and lactate-sensitive bioproduct, potentially extendable to other cell and/or 
products. They additionally unveiled the importance of secondary pathways affected 
in the Warburg effect which can further be explored towards an improved metabolic 
status beyond the lactogenic phenotype.  
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1. Introduction 
Many cultured mammalian cell lines exhibit a Warburg effect-like lactogenic 
phenotype with enhanced glycolytic fluxes and high lactate formation. However, this 
phenotype is typically not ascribed to a hypoxic environment, as originally described 
by Otto Warburg for cancer cells, but to a set of genetic transformations underlying 
cell immortalization – induced or spontaneous – and adaptation to the in vitro 
culture (Kondoh 2008). The over-expression of hypoxia inducible factor 1 (HIF1) is a 
major hallmark and inducer of those transformations (Fig. 1). 
 
 
 
Figure 1 – The Warburg effect-like lactogenic phenotype. HIF1 transcriptionally activates several glycolytic 
enzymes, lactate dehydrogenase (LDH) and pyruvate dehydrogenase kinase (PDK). The latter inactivates pyruvate 
dehydrogenase complex (PDH) by phosphorylation, blocking the entrance of pyruvate into the TCA at the level of 
acetyl-CoA which, combined with the enhanced expression of LDH, increases the glycolytic flux towards lactate. 
Adapted from Kondoh (2008). ALDO: aldolase; LDH: lactate dehydrogenase; ENO: enolase; GAPDH:  
glyceraldehyde-3-phosphate dehydrogenase; GPI: glucose phosphate isomerase; HIF1: hypoxia inducible factor 1; 
HK: hexokinase; PDH: pyruvate dehydrogenase; PDK; pyruvate dehydrogenase kinase; PDP: pyruvate 
dehydrogenase phosphatase; PGM: phosphoglycerate mutase; PGK: phosphoglycerate kinase; PK: pyruvate 
kinase; PFK:  phosphofructokinase. 
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While the Warburg effect-like lactogenic phenotype in cultured mammalian 
cell lines seems to offer a proliferative advantage for in vitro cell survival (Shlomi et 
al. 2011), it is undesirable from the biotechnology view-point as the accumulation 
of lactate reduces culture viability (Lao and Toth 1997; Ozturk et al. 1992) and can 
also impact product quality (Chee Furng Wong et al. 2005).  
Reducing lactate production in mammalian cell lines producing recombinant 
biopharmaceuticals has been a major goal of cell culturists. To this end, the 
majority of the approaches has focused on: i) using carbon sources alternative to 
glucose, with or without over-expressing the respective transporters (Jimenez et al. 
2011; Wlaschin and Hu 2007); ii) over-expressing anaplerotic enzymes by-passing 
the entrance of pyruvate into the TCA via pyruvate dehydrogenase (Elias et al. 
2003; Irani et al. 2002) or iii) down-regulating LDHA (Kim and Lee 2007). In this 
work, we conducted a proof-of-concept metabolic engineering study based on the 
down-regulation of two key molecular effectors of the Warburg effect: hypoxia 
inducible factor 1 (HIF1) and pyruvate dehydrogenase kinase (PDK), simultaneously 
targeting reduced lactate accumulation and enhanced channeling of the glycolytic 
intermediates into the tricarboxylic acid cycle (TCA). These are widely described 
upstream effectors of the Warburg effect-like lactogenic phenotype in cultured 
mammalian cell lines although no attempts, up to date, have been conducted in the 
view of their combined down-regulation. Down-regulating pyruvate dehydrogenase 
kinase has been reported for CHO cells producing recombinant monoclonal 
antibody (Zhou et al. 2011b). 
The study herein presented was conducted using retroviral vector producer 
cells since these particles are particularly sensitive to high lactate concentrations 
(McTaggart and Al-Rubeai 2000; Merten et al. 2001). Also, using alternative carbon 
sources steering a reduced lactogenic phenotype has previously been shown to 
improve virus production up to 6-fold (Coroadinha et al. 2006a; Coroadinha et al. 
2006b). Identical observations were reported for other complex 
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biopharmaceuticals, including recombinant protein (Altamirano et al. 2004). Thus, 
retroviral vector production appeared as a good study model to evaluate the 
impact of down-regulating the Warburg effect-like lactogenic phenotype in 
mammalian cells producing complex biopharmaceuticals. Additionally, for the 
particular case of the producer cells herein used – 293 FLEX – a previous functional 
genomics study suggested the reduction of the glycolytic metabolism as a potential 
target to improve viral titers (Rodrigues et al. 2013). 
 
2. Materials and methods 
2.1. Cell lines and culture media 
293 FLEX GFP is a human embryonic kidney (HEK293, ATCC CRL-1573)  derived 
cell line producing murine leukemia virus (MLV) based vector harboring a GFP 
reporter gene, pseudotyped with gibbon ape leukemia virus (GaLV) (Coroadinha et al. 
2006c). These cells were maintained in Advanced modified Eagle’s medium, DMEM, 
(Gibco, Paisley, UK) with 25 mM of glucose, supplemented with 10% (v/v) Foetal 
Bovine Serum (FBS) (Gibco) and 4 mM of glutamine (Gibco). Te 671 (ATCC CCL-136) 
cell line was used as the target cell to titrate infectious retroviral particles and HEK 
293T cell line (ATCC CRL-11268) was used for producing and titrating shRNA lentiviral 
vector stocks. Both were maintained in DMEM (Gibco) with 25 mM of glucose and 4 
mM of glutamine supplemented with 10% (v/v) FBS (Gibco). All cells were maintained 
in an incubator with a humidified atmosphere of 92% air and 8% CO2 at 37 °C.   
 
2.2. Plasmids and shRNA sequences 
Short hairpin (sh) RNA lentiviral vectors based on pLKO.1-puro (Moffat et al. 
2006) containing a puromycin resistance gene and targeting sequences on the 
human HIF1 (shHIF1) gene, PDK1/3 (shPDK1/3) gene and a non-target shRNA 
(ntshRNA) vector were purchased from Sigma Mission®RNAi (Sigma, St. Louis, MO, 
USA). shHIF1 hairpin sequence corresponds to the first version of the shRNA library 
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from The RNAi Consortium (TRC 1) (Broad Institute, Cambridge, MA, USA). The 
shPDK1/3 hairpin sequences were custom made and designed to target isoform 1 
(sequences A and B) and isoform 1 and 3 of the human pyruvate dehydrogenase 
kinase (sequence C). For sequences C the first 19 nucleotides hybridize with isoform 
3 and all the 21 nucleotides hybridize with isoform 1. The sequences were: (A) 5’-
CTGTCACCAGCCAGAATGTTCCTCGAGGAACATTCTGGCTGGTGACAG-3’; (B) 5’-
TAGGCGTCTGTGTGATTTGTACTCGAGTACAAATCACACAGACGCCTA-3’ and (C) 5’-
GTGATTGAATACAAGGAGAGCCTCGAGGCTCTCCTTGTATTCAATCAC-3’, in which the 
first 21 nucleotides constitute the sense sequence, the last 21 nucleotides constitute 
the anti-sense sequence and the intermediate 6 nucleotides constitute the hairpin 
loop. All sequences are additionally flanked by 5’-CCGG-3’ at the 5’ and by 5’-TTTTT-
3’ at the 3’ (for further details on general vector construct please consult 
http://www.sigmaaldrich.com/life-science/functional-genomicsandrnai/shrna/ 
library-information/vector-map.html). The original custom made plasmids contained 
a dsRED fluorescence selectable marker additional to the puromycin resistance, 
which was replaced by mCherry to minimize the cytotoxicity associated to the former 
(Zhou et al. 2011a). The vector backbone was amplified by PCR to exclude dsRED 
sequence and mCherry was cloned in its place using In-Fusion® HD Cloning Kit 
(Clontech Laboratories, Inc., Terra Bella Avenue, CA, USA). The non-target control 
used was Sigma Mission®RNAi Cat. No SHC002. This vector was used as provided and 
also modified to introduce mCherry as a second selectable marker, by replacing the 
original puromycin. In both cases, the second fluorescence selectable markers were 
conceived to perform double shRNA transduction. Cells transduced with mCherry 
containing constructions were selected by flow cytometry activated sorting (MoFlo 
High-Speed Cell Sorter, Dako Cytomation, Glostrup, Denmark). For each of the 
shRNA, lentiviral vector stocks were produced by transient co-transfection of HEK 
293T cells with pSPAX2 and pMD2G (kindly provided by Didier Trono from the Swiss 
Federal Institute of Technology (EPFL) through Addgene plasmid repository, 
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Cambridge, MA, USA), providing the packaging and the envelope functions, 
respectively.  
 
2.3. Cell growth and viral production studies 
Two types of virus production studies were performed: a 7-day batch culture for 
cell growth/virus production kinetics, transcriptome analysis and metabolite profiling 
and a 48+24 hours production/harvesting operation mode to screen individual clone 
productivity.  
For the 7-day batch culture studies, cells were inoculated at 4 x 104 cells/cm2. 
Two samples were collected per day: culture supernatant was harvested, filtered 
through 0.45 μm for clarification, aliquoted and stored at -85ºC until analysis. Cell 
concentration and viability was determined by the trypan blue exclusion method. At 
day 3, total RNA was extracted for transcriptome analysis. For further details on the 
second operation mode, please refer to Chapter II (Rodrigues et al. 2013). 
 
2.4. Titration of infectious and total particles 
For titrating infectious retroviral particles Te 671 cells were seeded at 5 x 104 
cells/cm2 in 24-well plates one day before infection. Cell concentration was 
determined at the time of infection. Transduction was performed in duplicates by 
removing the cell supernatant and infecting with 0.2 mL of viral suspension using 
several dilutions in fresh medium with 10% (v/v) FBS and 8 μg/mL of polybrene 
(Sigma). Cells were incubated at 37ºC overnight after which 0.5 mL medium was 
added. Two days after infection, cells were harvested and analyzed for GFP 
fluorescence by flow cytometry (CyFlow-space, Partec GmbH). Physical (total) 
particles were assessed by Nanoparticle Tracking Analysis using NanoSigth® NS500 
(NanoSight Ltd., Wiltshire, UK). 
 
2.5. Cell transduction and selection 
Short hairpin (shRNA) genes were delivered by lentiviral vector infection of 293 
FLEX GFP. The cells were seeded at a density of 1 x 105 cells/cm2 24 hours before 
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infection in 6-well plates. Transduction was performed by removing the cell 
supernatant and infecting with 1 mL of viral suspension using the appropriate 
dilution to achieve multiplicity of infections of approximately 1 infectious particles 
per cell. Dilutions were made in fresh DMEM (Gibco) with 10% (v/v) FBS (Gibco) and 
8 μg/mL of polybrene (Sigma). Cells were incubated at 37ºC overnight after which 
medium was exchanged. Two days after infection, the cells were amplified to 75 cm2 
t-flasks in puromycin containing medium (1.5 μg/mL) and cultured for 21 additional 
days, exchanging culture medium at each 2-3 days. Selected populations were 
analyzed as such and also cloned by limiting dilution. For double transduction, an 
identical procedure was followed, but instead of antibiotic pressure, mCherry 
expressing cells (clones and population) were isolated by flow cytometry activated 
sorting (MoFlo High-Speed Cell Sorter, Dako Cytomation, Glostrup, Denmark). 
 
 
2.6. Measurement of central carbon enzymes activity 
The activity of 13 central carbon metabolism enzymes was quantified by an 
adapted version of the method described by Janke et al. (2010). Briefly, the 
modifications included: CS: specific assay mix with pH 8; IDH: pH 7.0; incubation time 
60 min; FH: pH 7.5; GPT: pH 8.5; incubation time 30 min; GOT: pH 7.5; HK: incubation 
time 70 min; G6P standards up to 0.4 nmol; G6PD: incubation time 60 min; PFK: pH 
8.5; PK: pH 8.0; GPI: pH 8.5; MDH: pH 8.5; PDH: pH 8.0. 
 
2.7. Metabolite profiling 
Glucose and lactate concentrations were determined with automated enzymatic 
assays (YSI 7100 Multiparameter Bioanalytical System, USA). Ammonia was 
quantified enzymatically using the UV assay kit (NZYTech, Lisbon, Portugal).  
 
2.8. RNA extraction and RT-PCR 
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) according 
to the manufacturer’s instructions. The resultant RNA pellet was eluted in 100 µL of 
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nuclease-free water (Qiagen) and stored at -85ºC until further processing. RNA yields 
were quantified using NanoDrop 2000 (Thermo Scientific, Waltham, MA, USA) and 
RNA quality was characterized by the quotient of the 28S to 18S ribosomal RNA 
electropherogram peak using an Agilent 2100 bioanalyzer and the RNA Nano Chip 
(Agilent, Santa Clara, CA, USA). 
For real time PCR, RPL-22 was chosen as a control gene using as forward primer 
(F): 5’-CTGCCAATTTTGAGCAGTTT-3’ and as reverse primer (R): 5’- 
CTTTGCTGTTAGCAACTACGC-3’. Forward (F) and reverse (R) primer sequences for 
viral genes were the following: envelope (F) 5’-GGACCAAAATAGCGAATGGA-3’ / (R) 
5’-GGTGAACTGTACGCCTGGAT-3’; gag-pol (F) 5’-GTCCACTATCGCCAGTTGCT-3’ / (R) 
5’-CTGGGTCCTCAGGGTCATAA-3’; transgene (F) 5’-CAGAAGAACGGCATCAAGGT-3’ / 
(R) 5’-CTGGGTGCTCAGGTAGTGG-3’. The reverse transcription of total RNA and qRT-
PCR were performed as described in Rodrigues et al. (2012).  
 
2.9. Amplification, labelling and BeadChip hybridization of RNA samples 
RNA extraction, amplification, labelling and BeadChip hybridization were 
performed as described in Chapter II (Rodrigues et al. 2013). Three biological 
replicates were used. 
 
2.9. Microarray data processing and analysis 
Data was processed by log2 and variance-stabilizing transformation and quantile 
normalized as described in Chapter II (Rodrigues et al. 2013). Differentially expressed 
genes were identified by False Discovery Rate using Significance Analysis of 
Microarrays (Tusher et al. 2001) and Weighted Average Difference (Kadota et al. 
2008) as previously described in Rodrigues et al. (2013). Pathway analysis was 
performed using Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems, 
www.ingenuity.com).  
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3. Results 
3.1. Down-regulation of HIF1  
Down regulation of hypoxia inducible factor 1 α-subunit (HIF1) was performed 
by short-hairpin RNA interference (shRNAi) delivered by lentiviral infection. To 
minimize extensive activation of the RNAi pathway and/or interferon response (Fish 
and Kruithof 2004; Rodrigues et al. 2011), low multiplicity of infection (approximately 
1) was used. The transduced population was cloned by limiting dilution and more 
than 80 clones were isolated (Fig. 2).  
Many of the HIF1 down-regulated clones presented titer reduction, however, 
the analysis of the non-target shRNA clones (and population), revealed that this was 
an off-target effect, probably derived from the activation of the RNA interference 
pathway (Fig. 2). Notably, non-target shRNA clones and populations consistently 
delivered titer reductions, while for some shHIF1 clones productivity improvement 
up to 30-fold, relatively to the parental cells, was observed. The magnitude of titer 
increase was considerable higher when analyzed comparatively to the non-target 
control, up to 100-fold.  Some of these clones were analyzed for HIF1 gene 
expression (Fig. 3A). The results showed titer increases in response to HIF1 down-
regulation in a pyramid-like layout, in which high-titer clones appear in the upper 
apex corresponding to gene expression reductions around -2.5-fold. Above and 
below this value, titers were significantly reduced. Of notice, HIF1 expression in non-
transduced cells was relatively low and the maximum down-regulation obtained (-
3.1-fold) corresponds to nearly gene knock-out. 
Despite the fact that high-titer clones consistently presented down-regulations 
in the order of -2 to -2.5-fold, other clones with identical extension of HIF1 down-
regulation did not demonstrated titer improvements or, in some cases, even 
presented evident titer reductions. 
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Figure 2 – Down-
regulation of HIF1 in 
293 FLEX retrovirus 
producer cells. Specific 
infectious particles 
productivity of non-
manipulated parental 
cells, shHIF1 clones and 
non-target controls. 
Clone shHIF1 #21, the 
highest producing clone 
isolated from this 
screening, is shown 
separately from the 
others shHIF1 clones. * 
p<0.05 and **p<0.005 
given by a two-tailed 
non-paired t-test 
assuming unequal 
variances; for average, 
standard deviation and 
number of replicates 
refer to Table I. 
 
Therefore, we analyzed the downstream effects of HIF1, particularly, the 
Warburg effect-like lactogenic phenotype and quantified lactate dehydrogenase A 
(LDHA) gene expression (Fig. 3B), its impact on the ratio lactate production to glucose 
consumption (LAC/GLC) (Fig. 3C) and how it correlated with infectious particles titers 
(Fig. 3D). 
LDH expression correlated with HIF1 down-regulation, although some clones 
presented an outlier behaviour (Fig. 3B). Moreover, all shHIF1 clones presented 
LAC/GLC ratios lower than those of non-manipulated cells, clearly showing that HIF1 
down-regulation diminishes the lactogenic phenotype (Fig. 3C). This output was 
based on reduced lactate production (20% less, Table I) rather than in less glucose 
consumption, evidencing the channelling of the consumed glucose into non-
lactogenic routes. Increased oxygen consumption supported part of this channelling 
to be directed into the TCA cycle (data not shown). By opposite, non-target controls 
clearly presented enhanced glucose consumption and slightly increased LAC/GLC 
ratios. Interestingly, even for the same clone (shHIF1 #21), the ratio LAC/GLC was 
found to vary from 1.2 to 1.5. This variation might be related to the oscillatory 
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expression behaviour of shRNAs during cell growth that we have previously reported 
(Rodrigues et al, 2011). 
 
 
 
Figure 3 – Virus productivity and lactogenic phenotype in response to HIF1 down-regulation. Specific productivity 
of infectious retroviral particles (A), lactate dehydrogenase A (LDHA) gene expression (B) and ratio lactate 
production to glucose consumption (LAC/GLC) (C) of HIF1 down-regulated clones and non-target controls vs. HIF1 
gene expression. Values are shown as fold-change relatively to (average) non-manipulated cells. Specific infectious 
particles productivity vs. ratio lactate production to glucose consumption (LAC/GLC) (D). For all (A) – (D) grey 
shadowed area represents values outside the range “average ± standard deviation” of the controls (refer to Table I 
for further details). Gene expression represents average expression level normalized to the RPL22 housekeeping 
control and relatively to non-manipulated cells (2ΔΔCT) (n=3). 
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Some of the shHIF1 clones, although presenting substantial HIF1 down-
regulation and significant LAC/GLC reduction, saw their specific productivity 
drastically diminished. Thereby, the clones were analyzed for viral components 
expression (Fig. 4). The results showed that the viral transgene (Fig. 4A and B) and, to 
less extent, the gag-pol (Fig. 4C and D) suffered substantial expression changes. The 
envelope remained relatively unaltered (Fig. 4E and F). These changes, however, did 
not correlate with HIF1 gene expression (Fig. 4B, D and F). The changes in viral 
transgene presented some correlation with vector titers (Fig. 4A). Even some of the 
non-target controls presented increased transgene expression (Fig. 4A and B). 
Expectably, all clones with substantial decrease of viral components, whether it was 
the viral transgene, the gag-pol or the envelope, saw the infectious vector titers 
drastically reduced. Therefore, titer reduction both for shHIF1 and non-target shRNA 
cells was unequivocally related to viral components loss of expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Vector components expression in shHIF1 cells.  Specific productivity of infectious retroviral particles of 
shHIF1 clones and non-target controls vs. viral transgene (A), gag-pol (C) and envelope (E) gene expression.  Viral 
transgene (B), gag-pol (D) and envelope (F) gene expression vs. HIF1 gene expression. For all (A) – (F) grey 
shadowed area represents values outside the range of “average ± the standard deviation” of the controls (please 
refer to Table I for further details). Gene expression represents average expression level normalized to the RPL22 
housekeeping control and relatively to non-manipulated cells (2ΔΔCT) (n=3).                                                                     → 
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3.2. Downstream effects of HIF1 down-regulation in high-titer clones 
Transcriptional profiling pathway analysis 
Among HIF1 down-regulated clones, shHIF1 #21 consistently delivered titer 
improvements of more than one order of magnitude. Therefore, this clone was 
subjected to a whole-genome transcriptome analysis in an attempt to identify the 
biological pathways recruited in this high-titer phenotype. Clone shHIF1 #64, also 
delivering high-titers, the parental non-manipulated and the non-target control cells 
were also analyzed. Figure 5 shows significantly enriched metabolic pathways given 
by Ingenuity Pathway Analysis of differentially expressed genes. For all the cells, 
pathways such as amino acid catabolism, fatty acid oxidation and cholesterol 
biosynthesis appear extensively enriched, suggesting these to be pathways changing 
in response to any short hairpin expression, most probably, to the activation of RNA 
interference pathway. For the case of amino acid catabolism, gene expression 
patterns suggested increased activity of these pathways, while for fatty acid 
oxidation and cholesterol biosynthesis, indicated pathway inhibition. Pathways 
specifically associated to shHIF1 clones were the inhibition of biological amines 
catabolism, increased detoxification metabolism – including thioredoxin pathway, 
ascorbate recycling and glutathione redox reactions – increased pentose phosphate 
pathway, TCA cycle, acetyl-CoA biosynthesis by pyruvate dehydrogenase complex 
(PDH), and dolichyl-diphosphooligosaccharide biosynthesis. Some aspects of 
nucleotides/nucleosides metabolism appeared also as specific of shHIF1 clones.  
We additionally found the transcriptional neighbouring of the “glucose 6P ↔ 
fructose 6P” reaction to be changing substantially (Fig. 6). Given the reversibility of 
this reaction, the analysis of gene expression patterns suggested a reduced draining 
of fructose 6P to downstream routes, favouring those fed by glucose 6P: pentose 
phosphate pathway and those using glucose 1P.  
Glycolysis activation was exclusive of non-target cells, supporting the enhanced 
glucose consumption rates observed for these cells (Table I). 
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Figure 5 – Enriched metabolic pathways in shHIF1 and non-target shRNA cells. Significantly enriched pathways 
(p<0.05) given by Ingenuity Pathway Analysis of WAD filtered data and percentage of differentially expressed genes 
enriching such pathways. Up-regulated genes are indicated in red and down-regulated genes in blue. Note that up-
regulated (or down-regulated) genes do not necessarily imply pathway activation (or inhibition): for example, down-
regulation of inhibitory genes should lead to pathway activation. Grey shadowed pathways indicate enriched 
pathways exclusive of shHIF1 clones. For shHIF1, the clones #21 and #64 were analyzed whereas the non-target shRNA 
corresponds to the cell population. For further details on data filtering for pathway analysis and WAD algorithm please 
refer to Chapter II (Rodrigues et al, 2013). 
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Figure 6 – Schematic representation of significant transcriptional changes of metabolic pathways from 
glucose/fructose 6P. Each arrow represents a single reaction; reversibility is indicated by a two-arrow line according 
to the BioCyc database (Caspi et al. 2010). For a matter of simplicity, only the main metabolites are shown; thus, the 
reactions are not necessarily balanced. Changes are shown for the analysis shHIF1 vs. parentals and were considered 
significant for q<10% based on the False Discovery Rate given by Significance Analysis of Microarrays (SAM) (Tusher et 
al. 2001). Only gene changes occurring in shHIF1 but not in non-target shRNA are shown. Red indicates up-regulation 
and blue indicates down-regulation. ALG: members of glycosyltransferases attaching glycans to asparagines residues 
(asparigine-liked glycosylation); GALM: galactose mutarotase; GYG: glycogenin; GPI: glucose-6-phosphate isomerase; 
GNPDA: glucosamine-6-phosphate deaminase; HK: hexokinase; ISYNA: inositol-3-phosphate synthase; MPI: mannose-
6-phosphate isomerase; PGM: phosphoglucomutase; UGP: UDP-glucose 6-dehydrogenase; G6PD: glucose-6-
phosphate dehydrogenase. Note that the reaction catalyzed by GALM can also occur spontaneously. 
 
 
Central carbon enzymes activity 
Given the differences in the lactogenic phenotype of shHIF1 clones and also the 
non-target controls – although in opposite trends – we further enquired on possible 
changes on enzymes activity steering such phenotypes. Therefore, clone shHIF1 #21, 
the non-target shRNA population and non-manipulated cells were further 
characterized in terms of enzymes activity of central carbon metabolism (Fig. 7). 
Non-target shRNA cells presented increased activity of the early glycolytic enzymes, 
particularly evident for phosphofructokinase (PFK) substantiating transcriptome 
analysis (Fig. 5) and the observed enhanced glucose consumption (Table I). This 
confirms a more active glycolytic metabolism in non-target control cells, one of the 
most evident off-target effects associated to short-hairpin RNA expression (Table I). 
While down-regulating HIF1 should lead to reduced glycolytic activity, these off-
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target effects can skew such phenotype. Independently of that, a significant decrease 
of LDH activity in shHIF1 #21 clone was obtained (Fig. 7), in line with the reduction in 
LAC/GLC ratio obtained for this clone as well as for all the shHIF1 clones presenting 
lower LAC/GLC ratios (Fig. 3). Clone shHIF1 #21 also presented enhanced activity of 
glucose-6-phosphate dehydrogenase (G6PD) indicating increased channeling of the 
glycolytic intermediaries into the pentose phosphate pathway (PPP). Pathway 
analysis also indicated activation of acetyl-CoA biosynthesis at the level of pyruvate 
dehydrogenase complex (PDH) (Fig. 5) although no evidence of enhanced enzyme 
activity was found at this level. However, this enzyme could not be accurately 
quantified in none of the (manipulated and non-manipulated) cells, suggesting it to 
be out of the method sensitivity (Fig 7). Finally, for shHIF1 and non-target control, 
the amino acid aminotransferases – glutamic-pyruvate aminotransferase (GTP) and 
aspartate aminotransferase (GOT) – were found to be substantially more active. This 
phenotype further substantiates the hints on increased amino acid catabolism given 
by pathway analysis (Fig. 6) and suggests enhanced amino acid mobilization to feed 
the TCA cycle in shRNA expressing cells (shHIF1 and non-target shRNA). The analysis 
of metabolite profiling, to be performed in the follow-up of this work, should 
enlighten these findings.  
 
3.3. Down-regulation of PDK 
In 293 FLEX, the PDK isoforms found to be expressed were PDK 1 and PDK3, 
evaluated by transcriptome analysis (Chapter II). Thereby, a short-hairpin RNAi 
sequence was designed to target homology zones between these two isoforms (see 
Materials and methods). Similarly to the approach on HIF1 down-regulation, PDK 
silencing was conducted by delivering this hairpin by lentiviral infection using low 
multiplicity of infection (MOI). The transduced population was cloned by limiting 
dilution and simultaneously screened for high-titer clones using a simpler version of 
our recently implemented single-step cloning titration method. For method details, 
please refer to Chapter VII. 
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Although this simplified version delivers more than 90% of false positives, 
these can be discriminated by visual inspection of the cloning wells using a 
 
 
Figure 7 – Central carbon enzymes activity in shHIF1 and non-target shRNA cells. Schematic representation of 
central carbon reactions and respective enzymes activity of non-target shRNA cells or shHIF1 #21. Values are shown 
as activity (%) relatively to parental non-manipulated cells (first two columns) or to non-target control (last column) 
and represent average ± standard deviation of 4 to 8 replicates. Enzyme activity changes > 5% were considered of 
relevance. nq: non-quantifiable; HK: hexokinase; PGI: glucose-6-phosphate isomerase; PFK: phosphofructokinase; 
FBP: fructose-1,6-bisphosphatase; TPI: triosephosphate isomerase; GAPDH: glyceraldehyde-3-phosphate 
dehydrogenase; PK: pyruvate kinase; PDH: pyruvate dehydrogenase complex; PC: pyruvate carboxylase; CS: citrate 
synthase; ME: malic enzyme; GPT: glutamic-pyruvate transaminase; GOT: glutamic-oxaloacetic transaminase 1; 
MDH: malate dehydrogenase; FH: fumarate hydratase; IDH: isocitrate dehydrogenase; ACLY: ATP citrate lyase; PCK: 
LDH: lactate dehydrogenase.  
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fluorescence microscope, allowing the isolation of high-titer clones with comfortable 
confidence. Eleven clones were isolated (Fig. 8)  
 
The majority of the isolated clones were found to be high producers relatively to 
non-manipulated cells (Fig. 8). Even those for which titer reduction was observed, it 
occurred in small extension. These clones were analyzed for PDK1, PDK3, LDHA gene 
expression and LAC/GLC ratio (Fig. 9). 
All analyzed clones revealed significant PDK1/3 down-regulation although the 
pattern did not correlate with the extension of productivity increase (Fig. 9A). Except 
for one (low-titer) clone, all clones presented substantial reduction of the lactogenic 
phenotype (Fig.  9D), correlated with PDK1/3 down-regulation (Fig. 9C). LDHA gene 
expression was also found to be reduced, on average -1.4-fold, for all the clones but 
with no evident correlation with PDK1/3 down-regulation (Fig. 9B).  
The analysis of glucose consumption and lactate production rates revealed that 
the reduced lactogenic phenotype in shPDK1/3 clones was prominently based on 
diminished lactate production, 44% less (Table I). Lactate production rates were also 
significantly lower than those of shHIF1 #21. Non major changes were detected 
neither in glutamine consumption nor in ammonia production (data not shown). 
 
 
Figure 8 - Down-regulation 
of PDK1/3 in 293 FLEX 
retrovirus producer cells. 
Specific infectious particles 
productivity of non-
manipulated parental cells, 
PDK1/3 down-regulated 
clones and non-target 
controls. One of the 
shPDK1/3 clones, delivering 
the highest titer increase, is 
represented three times. 
*p<0.05 and **p<0.005 
given by a two-tailed non-
paired t-test assuming 
unequal variances; for 
average, standard deviation, 
number of replicates and 
statistics refer to Table I. 
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Figure 9 – Virus productivity and lactogenic phenotype in response to PDK1/3 down-regulation. Specific 
productivity of infectious retroviral particles (A), lactate dehydrogenase A (LDHA) gene expression (B) and ratio 
lactate production to glucose consumption (LAC/GLC) (C) of shPDK1/3 clones and non-target controls vs. PDK1/3 
gene expression. Values are shown as fold-change relatively to non-manipulated cells. For a matter of simplicity, 
PDK1/3 refers to the average PDK1 and PDK3 genes expression (for individual values please refer to Table I) (D) 
Specific productivity of infectious retroviral particles vs. ratio lactate production to glucose consumption (LAC/GLC). 
For all (A) – (D) grey shadowed area represents values outside the range “average ± the standard deviation” of the 
controls (please refer to Table I for further details). Gene expression represents average expression level normalized 
to the RPL22 housekeeping control and relatively to non-manipulated cells (2ΔΔCT) (n=3). 
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Clones delivering titer reduction, were, similarly to what had been observed for 
shHIF1, those losing the expression of viral components (Fig. 10A). Also here, the 
viral transgene and the gag-pol components were found to be changing substantially 
(Fig. 10B and D), with an evident positive correlation between the viral transgene and 
infectious viral titers (Fig. 10A). Once again, the changes in envelope expression were 
modest and with no evident correlation with infectious vector titers (Fig. 10E) nor 
with the extension of PDK1/3 down-regulation (Fig. 10F). 
 
3.4. Double HIF1 – PDK1/3 down-regulation 
In the third part of this work, HIF1 and PDK1/3 down-regulations were combined 
seeking for synergistic effects in infectious particles productivity. Clone shHIF1 #21 
was transduced with shPDK1/3 delivered by lentiviral vector infection. Two control 
populations were additionally analyzed: double transduction with non-target shRNA 
and clone shHIF1#21 transduced with non-target shRNA. For HIF1#21-PDK1/3 double 
transduced clones, the simpler version of the single step cloning-titration method 
was also used to select high titer clones (Fig. 11).  All clones delivered relevant titer 
improvement, relatively to non-manipulated parental cells. Yet, considering that the 
starting point was clone shHIF1 #21, producing on average 20-fold higher, the 
magnitude of improvement was rather modest.  
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Figure 10 – Vector components expression of PDK1/3 down-regulated cells.  Specific productivity of infectious 
retroviral particles of shPDK1/3 and non-target controls vs. viral transgene (A), gag-pol (C) and envelope (E) gene 
expression.  Viral transgene (B), gag-pol (D) and envelope (F) gene expression vs. PDK1/3 gene expression.          → 
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Indeed, no significant difference was detected between shHIF1 #21 and their derived 
shPDK1/3 clones (Fig. 11). One clone (#P6C6), with a 32-fold productivity increase 
relatively to non-transduced cells, was the exception. However, it cannot be 
disregard the fact that double non-target shRNA loading further reduced infectious 
particles titers relatively to single non-target shRNA transduction (Fig. 11 and Table I). 
Although PDK1/3 expression was not assessed for the majority of these clones, the 
relatively unchanged LAC/GLC ratios suggested the magnitude of shPDK1/3 
expression to be relatively small (Table I). It should be noted, however, that 
shPDK1/3 transduction was selected by flow cytometry activated sorting (see 
Materials and methods), thus excluding the possibility that the clones were not 
transduced with shPDK1/3 lentiviral vector. All clones were confirmed to express 
mCherry, the selectable marker of shPDK1/3 construction (data not shown).  
 
 
Figure 11 - Down-regulation 
of PDK1/3 in shHIF1 #21 
retrovirus producer cells. 
Specific infectious particles 
productivity of non-
manipulated parental cells, 
HIF1 down-regulated clones, 
double shHIF1#21 – shPDK1/3 
clones and non-target 
controls. For double non-
target control, only the 
population was analyzed, 
shown as a single point on the 
right side of the chart. * 
p<0.05 and **p<0.005 given 
by a two-tailed non-paired t-
test assuming unequal 
variances; for average, 
standard deviation, number of 
replicates and p-value 
statistics refer to Table I. 
 
 
 
 
→ (Figure 10 continued)   For a matter of simplicity, PDK1/3 refers to the average PDK1 and PDK3 genes 
expression (for individual values please refer to Table I). For all (A) – (F) grey shadowed area represents 
values outside the range “average ± standard deviation” of the controls (refer to Table I for further details). 
Gene expression represents average expression level normalized to the RPL22 housekeeping control 
relatively to non-manipulated cells (2ΔΔCT) (n=3). 
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3.5 Impact of shHIF1 and shPDK1/3 in viral batch quality 
The best clones from each manipulation and corresponding controls were 
analyzed for virus production in terms of total and infectious particles (Fig. 12). 
  
 
 
 
Figure 12 – Specific productivity of infectious and total particles of shRNA manipulated cells. Specific productivity 
of infectious particles (grey bars) and total particles (white bars). Values are shown as fold-change relatively to non-
manipulated cells. Error bars represent standard deviation (“n” between 2 and 11). Total particles assessed by 
Nanoparticle tracking analysis. 
 
The loss of infectious particles titers in non-target shRNA controls was found to 
be derived from sharp decreases in total particles production. In fact, for single non-
target shRNA transduction, the decrease in infectious particles arised from the 
reduction in total particles. By opposite, both shHIF1 and shPDK1/3 clones were 
shown to produce higher content of total particles, being the infectious particles 
titers those improving more significantly. 
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Table I – Resume of the parameters analyzed during this work 
  
PPParental 
cells 
shHIF1 
shHIF1 
#21 
shPDK1/3 
shHIF1#21 
+ 
shPDK1/3 
Nt shRNA               
(1x) 
Nt shRNA 
(2x) 
Specific 
infectious 
particles 
production 
(I.P./cell.h) 
μ 0.0057 0.011 0.100 0.058 0.100 0.002 0.0003 
SD 0.0052 0.025 0.033 0.049 0.054 0.001 - 
# 20 69 11 13 15 11 1 
FC - 1.9 (*) 17.6 (**) 10.2 (**) 16.9 (**) -3.4 (**) - 
Specific glucose 
consumption 
rate (μmol/106 
cells.h) 
μ 0.18 0.16 0.16 0.14 0.15 0.29 0.17 
SD 0.05 0.03 0.04 0.03 0.04 0.06 - 
# 13 32 11 11 15 5 1 
FC - - - - - 2 (*) - 
Specific lactate 
consumption 
rate (μmol/106 
cells.h) 
μ 0.31 0.25 0.25 0.17 0.22 0.48 0.23 
SD 0.08 0.06 0.06 0.09 0.06 0.11 - 
# 12 32 11 11 15 5 1 
FC - -1.2 (**) -1.3(*) -1.8 (**) -1.4 (**) 2.7 (*) - 
HIF1 gene 
expression (2ΔCT) 
μ 0.15 0.08 0.06 - 0.05 0.14 0.11 
SD 0.04 0.03 0.01 - 0.02 0.04 - 
# 6 16 5 - 3 9 1 
FC - -2.0 (**) -2.4 (**) - -3.0 (**) - - 
LDHA gene 
expression (2ΔCT) 
μ 0.74 0.68 0.51 0.54 0.49 0.86 0.68 
SD 0.16 0.25 0.07 0.07 0.11 0.17 - 
# 8 16 5 11 3 9 1 
FC - - -1.4 (**) -1.4 (*) -1.5 (*) - - 
PDK1 gene 
expression (2ΔCT) 
μ 0.033 0.034 0.035 0.013 0.014 0.039 0.036 
SD 0.006 0.005 0.008 0.007 0.002 0.013 - 
# 6 11 4 11 3 4 1 
FC - - - -2.4 (**) -2.3 (**) - - 
PDK3 gene 
expression (2ΔCT) 
μ 0.043 - 0.057 0.016 0.023 0.056 - 
SD 0.008 - 0.002 0.014 0.005 0.014 - 
# 4 - 2 11 3 2 1 
FC - - - -2.7 (**) -1.8 (*) - - 
Viral transgene 
expression (2ΔCT) 
μ 1.8 4.8 9.5 5.4 11.9 1.5 0.6 
SD 0.4 6.3 1.9 3.8 6.1 1.8 - 
# 6 15 3 12 2 7 1 
FC - - 5.2 (*) 3.0 (*) - - - 
Gag-pol gene 
expression 
μ 0.5 0.5 1.2 0.7 0.6 0.2 0.03 
SD 0.2 0.5 0.3 0.2 0.1 0.4 - 
# 6 15 3 12 2 7 1 
FC - - 2.3 (*) - - - - 
Envelope gene 
expression (2ΔCT) 
μ 1.8 2.8 2.3 1.8 1.5 1.1 1.1 
SD 0.3 2.2 0.5 0.3 0.2 0.6 - 
# 6 15 3 12 2 7 1 
FC - - - - - - - 
μ: general designation for the parameter under analysis.  
SD: standard deviation  
#: number of replicates. When only “1” replicate is shown, it refers to the cell population 
FC: fold-change, where negative values denote reduction and positive values denote increase, relatively to non-
manipulated parental cells.  
(*) p<0.05 and (**) p<0.005, given by a non-paired two-tailed t-test assuming unequal variances when comparing 
with non-manipulated parental cells. 
In non-target (Nt) shRNA controls (1x) refers to single transduction and (2x) refers to double transduction. 
Gene expression represents average expression level normalized to the RPL22 housekeeping control (2ΔCT) (n=3).  
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4. Discussion 
Reducing lactate production in mammalian cell culture producing recombinant 
biopharmaceuticals has been a major goal of cell culturists. In this work, we 
conducted a proof-of-concept metabolic engineering study in HEK 293 derived 
retroviral vector producer cells, based on the down-regulation of two key molecular 
effectors of the Warburg effect-like lactogenic phenotype: hypoxia inducible factor 1 
(HIF1) and pyruvate dehydrogenase kinase 1 and 3 (PDK1/3). This strategy would 
simultaneously tackle reduced lactate accumulation and enhanced channeling of 
glycolytic intermediates into the tricarboxylic acid cycle (TCA) (Fig. 1).  
Down-regulation of hypoxia inducible factor 1 (HIF1) originated clones with 
productivity improvements up to 20-fold whereas strong inhibitory effects were 
observed for non-target shRNA transduced cells (Fig. 2). These results evidenced the 
beneficial effects of diminishing HIF1 expression. The magnitude of titer increase was 
considerable higher when analyzed comparatively to the non-target control, up to 
100-fold. However, it is difficult to state whether these were affected by the off-
target effects observed in the controls – thus corresponding to real 100-fold increase 
mediated by HIF1 silencing – or if these were simply particular clones less affected by 
the off-target effects. From the clones analyzed for HIF1 gene expression, HIF1 down-
regulation appeared to be correlated with titer increased in a pyramid-like layout 
suggesting a fine-tuned expression value for which HIF1 reduction delivers improved 
virus production (Fig. 3A). However, this fine-tuned HIF1 down-regulation was a 
necessary, but not sufficient, condition for high viral titers. The combination of down-
stream effects of HIF1 silencing, particularly the reduction of the lactogenic 
phenotype (Fig. 3C) and relevant increases in viral components gene expression (Fig. 
4), can be the reason behind the high-titers. However the latter did not correlate 
with HIF1 expression (Fig. 4 B, D and F). In fact, even some of the non-target controls 
presented increased vector components expression, suggesting some degree of 
randomness associated to these results. Yet, only shHIF1 clones – and not non-target 
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controls – delivered titer increases (Fig. 2). Thereby, even if clonal variability is the 
explanation for the dispersion of vector components expression, it might only be 
translated into improved titers when conjugated with the downstream physiological 
effects of HIF1 down-regulation. Although, when starting this work, we were seeking 
for a reduction in the lactogenic phenotype, these downstream effects revealed to 
be broader. Microarray analysis indicated significant recruitment of metabolic 
pathways non-lactogenesis related, such as biological amines metabolism, 
detoxification routes – including glutathione metabolism – and pentose phosphate 
pathway. We have previously shown these pathways to be actively recruited in the 
production of recombinant retrovirus (Rodrigues et al. 2013). The results from both 
transcriptional profile as well as central carbon enzymes activity (Figs. 5, 6 and 7), 
also revealed the glycolytic flux to be partially drained from glycolysis towards 
pentose phosphate pathway and glucose 1P biosynthesis.  
In the second part of this work, the cells were manipulated for the down-
regulation of PDK1/3. While for shHIF1 a manual screening, shPDK1/3 clones were 
selected based on a simplified version of a method allowing for the isolation of high-
titer phenotypes. In line, the majority of the isolated clones were found to be high 
producers relatively to non-manipulated cells (Fig. 8). All analyzed clones revealed 
significant PDK1/3 down-regulation although the pattern did not correlate with the 
extension of productivity increase (Fig. 9A). However, as stated above, these clones 
were not randomly isolated, but chosen based on high-titers. Thus, more than the 
extension of PDK1/3 down-regulation, they reflect the advantageous (from this 
selection point of view) downstream effects of the manipulation, including the 
ameliorated lactogenic phenotype (Fig. 9). Interestingly, LDHA gene expression was 
found to be reduced in all shPDK1/3 (Fig. 9B). These results, support previous 
findings on a feed-back loop mechanism in which reduced lactate accumulation 
contributes to less stabilization of HIF1, potentially simulating the effects of its down-
regulation, including lowering LDH expression/activity (Lu et al. 2002). It was 
noteworthy that lactate production rates from shPDK1/3 clones were significantly 
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lower than those of shHIF1 #21, a pertinent result since LDHA down-regulation 
occurred in identical extension in both cases (Fig. 3, 9 and Table I). This evidenced 
increased metabolization of pyruvate through pyruvate dehydrogenase (PDH) to 
occur in higher extension in shPDK cells than in shHIF1, being less dependent on the 
LDH levels. Indeed, even if no LDH reduction occurs, being PDH sufficiently active, the 
channeling of pyruvate into the TCA is favored since PDH has much higher affinity for 
pyruvate than LDH (Nakae and Stoward 1997; Strumilo et al. 1999). 
Similarly to shHIF1, for shPDK1/3 clones, relevant changes in viral components 
gene expression were observed, with an evident positive correlation between viral 
transgene expression and infectious particles titers (Fig. 10A). For HIF1, a 
transcription factor targeting several hundreds of genes (Benita et al. 2009) one 
could hypothesize a transcriptional dynamics affecting the expression of many genes, 
including the viral cassettes. For PDK1/3 down-regulation, however, the 
transcriptional effects are expected to be rather limited. Still, among silenced clones, 
high expression variability was found for the viral transgene and, to less extent, for 
the gag-pol. This can be rationalized in two ways. One, by assuming that gene 
expression changes in viral components are randomly derived from the genetic 
manipulation as it could happen to any other gene. Yet, such variability occurred in 
evidently greater extension for the viral transgene and gag-pol, whereas envelope 
remained relatively unchanged. Thus, even assuming some degree of randomness, a 
second hypothesis reports to a dynamic transcriptional behaviour of retrovirus long-
terminal repeats (LTRs) promoter. In 293 FLEX GFP, both the viral transgene as well 
as the gag-pol are under the control of an LTR. Pertinently, the viral transgene is an 
MFG-LTR, known to be transcriptionally more active (Byun et al. 1996), thereby 
substantiating the greater expression changes, relatively to the non-MFG LTR 
deriving the expression of gag-pol. What leads to such high fold-changes in the mRNA 
levels of this cassette is not clear. From our results, we hypothesize a dynamic 
response of the vector cassettes steered by an improved metabolic status. This 
hypothesis arises from the observation that solely the over-expression of gag-pol or 
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the viral transgene in 293 FLEX does not translate into improved titers (Carrondo et 
al. 2008). Therefore, high titer clones should present increased vector components 
not as the cause for the enhanced productivities but as a consequence: cells with 
higher productive performance derived from an improved metabolic status are 
capable of using the extra viral components delivering higher titers (Fig. 12). 
 
 
 
Figure 12 – Improving infectious 
retrovirus production through the 
down-regulation of the Warburg 
effect: beyond the lactogenic 
phenotype. Reduced HIF1 
expression diminishes LDH 
expression/activity leading to 
reduced lactate production which 
also feed-back represses HIF1 
stabilization (Lu et al. 2002). LDH 
reduction additionally stimulates 
enhanced metabolization of 
pyruvate through PDH since PDH 
has a higher affinity for pyruvate 
than LDH (Nakae and Stoward 
1997; Strumilo et al. 1999).      
Increased flux through PDH leads 
to an improved metabolic status by feeding TCA-fed routes (e.g.: lipid biosynthesis). Reduced PDK expression results 
in similar effects although these are exerted at a downstreamer stage with the additional direct activation of PDH. 
Reduced HIF1 expression also appeared to stimulate the draining of part of the glycolytic flux to secondary pathways 
– such as pentose phosphate pathway – known to be recruited in retrovirus producer cells (Rodrigues et al. 2013). 
Therefore, also this contributes to an improved metabolic status. On the other hand, significant variability in viral 
components expression occured. When relevant increases occur in clones presenting an improved metabolic status, 
it translates in improved titers. The conjugation of these two factors – improved metabolic status and increased 
vector components – translates in higher titers. Note that improved metabolic status refers to a conjugation of active 
pathways that favours virus production. It does not imply that shHIF1 or shPDK1/3 manipulated cells are, in general, 
metabolically more active or superior to non-manipulated cells.  
 
In the third part of this work, shHIF1 and shPDK1/3 were combined seeking for 
synergistic effects in enhancing infectious particles productivity. Yet, the 
improvement was rather modest (Fig. 11). However, one cannot disregard the fact 
that double non-target shRNA loading further reduced infectious particles titers 
relatively to single non-target shRNA transduction (Fig. 11). In fact, not only for viral 
titer, but also for the lactogenic phenotype, non-target shRNA transduced cells 
revealed marked opposite behavior relatively to the clones. This was evident in 
infectious vector titers (Figs. 1 and 12), lactate production (Fig. 10 and 4) and central 
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carbon enzymes activity (Fig. 7). If such effects are also occurring in shHIF1 and 
shPDK1/3, they might bias the real extension of their down-regulation in the 
reduction of the lactogenic phenotype and improvement of infectious particles titers. 
To this end, it might also explain the hurdle in combining the expression of these two 
hairpins seeking for a synergistic (or even simply, cumulative) effect. 
The results herein presented demonstrate the down-regulation of the Warburg 
effect-like lactogenic phenotype as a successful approach to improve the productivity 
performance of a human cell line producing a highly complex and lactate-sensitive 
bioproduct, potentially extendable to other mammalian systems producing 
recombinant biopharmaceuticals. Given the evident deleterious effects observed for 
shRNA throughout this work, for the extension of this strategy to other production 
systems, avoiding RNA interference as a knock-down tool will be preferable. 
Regardless that, the results herein reported constitute, to the best of our knowledge, 
the highest fold-increase in specific productivity of a mammalian cell line producing 
complex biopharmaceuticals for single gene manipulation (20-fold, on average, for 
both shHIF1 and shPDK1/3). They have also highlighted secondary pathways affected 
in the Warburg effect, including pentose phosphate pathway and glucose 1P 
biosynthesis. Such pathways can further be explored towards an improved metabolic 
status beyond the lactogenic phenotype.  
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Abstract 
Mammalian cell line development for the production of complex 
biopharmaceuticals is a laborious and time-consuming work due to the need to screen 
for high-titer clones. The challenge increases in the case of virus producer stable cell 
lines as viral components are usually split in several expression cassettes for engineering 
and/or safety purposes. Herein, we describe a novel method for fast screening of high-
titer retrovirus producer cells by merging cell cloning and virus titration. 
The method makes use of split-GFP®, a green fluorescent protein separated in two 
fragments – S10 and S11 – which fluoresce only upon transcomplementation. A cell 
population producing infectious virus with a S11 transgene is cloned and co-cultured 
with a target cell line harboring the S10 fragment. S11 viruses produced by the clone 
infect the target cells and reconstitute the GFP signal. Only the clones yielding high 
signal are isolated, avoiding cell expansion, cell banking and posterior growth/titration 
studies, wasteful for the majority of the (low titer) clones.  
The method was validated by establishing a retrovirus producer from a nude cell 
line reducing a one year process of sequential transfection/screening of three viral 
expression cassettes to three months. Clones producing up to 1x108 infectious particles 
per mL were isolated. As transcomplemented fluorescence data provides direct 
estimation of clone’s productivity it can be analyzed in terms of density distribution, 
offering valuable information on the average productivity of the cell population. 
Thereby, it was additionally used to evaluate the production performance of different 
cell substrates – HEK 293 vs. HEK 293T – showing that the later sustain increased titers. 
The method was established using a 96-well fluorometer plate reader, giving a 
manual throughput of 200-500 clones per analysis in two weeks; if coupled to an 
automated device, this could be increased. Moreover, it should be directly applicable to 
stable cell lines producing other types of infectious virus and, with the proper 
modifications, may be extended to transient systems. We expect this approach to 
contribute to the progress of vaccine and gene therapy vector fields by accelerating cell 
line development and engineering. 
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1. Introduction 
Retroviral and lentiviral vectors are efficient gene delivery tools and the most 
widely used viral vectors for the treatment of monogenic diseases and hematopoietic 
cell modification in gene and cell therapy (Edelstine 2013). As gene therapy moves from 
clinical to market (Moran 2012; Sheridan 2011), there is an increased pressure in the 
development of stable producer cell lines to meet the demands of vector production 
standardization. For the case of retroviral vector, stable production is common practice. 
For lentiviral vector, it has been more difficult to achieve due to the cytotoxicity of some 
viral proteins namely, the protease. Still, stable and continuous lentiviral vector 
productions have also been achieved (Ikeda et al. 2003; Stornaiuolo et al. 2013). For 
both vectors, infectious titers are usually low – 105-106 infectious particles per mL – 
requiring dozens to hundreds of liters of viral supernatant for a single patient (for a 
review see Coroadinha et al. (2010) and Schweizer and Merten (2010) for vector titers 
and Seymour and Thrasher (2012) for vector dose per patient). The use of high-titer 
stable producer cells is thus an important consideration for reducing the production 
costs, increasing quality by diminishing batch-to-batch variability and improving the 
efficiency of clinical protocols. Yet, stable cell line development is laborious and time 
consuming requiring from six months to one year. 
In this work, we present a novel method for fast and high-throughput screening of 
retroviral vector producer cells by merging the two most time consuming steps in cell 
line development: cell cloning and virus titration. The method makes use of split-GFP®, a 
green fluorescent protein separated in two fragments – S10 and S11 – which fluoresce 
only upon transcomplementation. A cell population producing infectious virus with a 
S11 transgene is cloned and co-cultured with a titration cell line harboring the S10 
fragment. During the period of clone expansion, S11 viruses infect the target cells and 
reconstitute the GFP signal. Only the clones yielding high signal are isolated, avoiding 
cell expansion, cell banking and posterior growth/titration studies of the low titer 
clones. Finally, S11 vector transgene is carried in a tagging construct, allowing for rapid 
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exchange to any therapeutic gene by Recombinase Mediated Cassette Exchange (RCME) 
(Coroadinha et al. 2006; Gama-Norton et al. 2011; Schucht et al. 2006).  
Transcomplementing fluorescent proteins were initially conceived for intracellular 
localization studies (Cabantous et al. 2005). Herein, we used a transcomplementing GFP 
as a reporter gene to monitor and quantify viral infection in a co-culture system 
constituted by a virus producing colony and a layer of target cells (see Fig. 1). This setup 
provides a functional titration method, non-invasive for the producer cells and 
amenable to scale-down for high-throughput operation. A high-throughput screening 
method for retrovirus producer cells has been described by Green and Rasko (2002). 
Yet, this method needs the time to titrate clones supernatant upon the cloning 
procedure and makes use of fluorescent proteins that are expressed in the producer cell 
line, unlikely to be used in a clinical context. Another transcomplementing assay has 
been described based on the reconstitution of β-lactamase (Ou et al. 2012). This 
method, however, requires enzyme activity quantification upon substrate addition 
further analyzed by flow cytometry, limiting its high-throughput potential. The method 
implemented in this work reduces the time and manipulation required for the 
generation of high-titer producing clones since it ensures the titration and cloning 
procedures in one single step. The fluorescence signal arises exclusively and directly 
from viral infection without the need of any chemical substrate addition. Finally, the 
flexibility and swiftness of the implemented method demonstrated its usefulness for 
applications other than cell line establishment, namely, for screening for high-producing 
cell substrates and as a metabolic manipulation supporting tool, for studying the effects 
of external gene over-expression in the production dynamics of a cell population and 
allowing the isolation high-producing clones (please refer to Chapter VIII for metabolic 
engineering using this method).   
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2. Materials and methods 
2.1 Plasmids 
For all the plasmids constructed in this work primers and templates are listed in 
Table I (please refer to the end of Materials and Methods section). pCMV mGFP S10 and 
pCMV mGFP S11 contain a mammalian codon-optimized version of the GFP under the 
control of a CMV promotor, split in GFP S10 coding for the first 214 amino-acids, and 
GFP S11 for the last 15, respectively. These plasmids were acquired through 
SandiaBiotech (Albuquerque, NM, U.S.A). pIRES GALEO (kindly provided by Dr. Dagmar 
Wirth, Model Systems for Infection Research, HZI, Germany) is a murine stem cell virus 
(MSCV) based retroviral vector where LacZ is under the control of a LTR promoter and a 
fusion protein gene hygromycin B phosphotransferase/thymidine kinase (hygtk) is under 
the control of the encephalomyocaerditis virus-internal ribosome entry site (EMCV-
IRES). This vector contains two flippase recognition target (FRT) sites in the U3 of 3’LTR, 
a wild type FRT site (wt) and a spacer mutant FRT site followed by an ATG defective 
neomycin phosphotransferase gene (neo) (Verhoeyen et al. 2001). This construction is 
present as a single copy in the genome of 293 FLEX and 293 FLEX GP (Coroadinha et al. 
2006). pEmMFG (also kindly provided by Dr. Dagmar Wirth) is a recombinase mediated 
cassette exchange (RCME) targeting vector containing a FRT wt, an MLV based retroviral 
vector with an MFG-LTR deriving the expression of GFP followed by an EMCV-IRES 
element next to an ATG and F5 FRT site. ATG sequence and the F5 mutant FRT site 
complementing the neo gene in pIRES GALEO after targeting and subsequent cassette 
exchange (Coroadinha et al. 2006). pTAR LacZ S11 was derived from  pEmMFG in which 
GFP was replaced by LacZ-S11 obtained from pCMV mGFP LacZS11. pCMV mGFP 
LacZS11 codes for a fusion protein LacZ-S11 under the control of a CMV promoter and 
was obtained by cloning LacZ gene (from pIRES GALEO) into the multiple cloning site 
(MCS) of pCMV mGFP S11. LacZ was amplified by PCR and introduced into the MCS at 
AgeI site. Both retroviral backbone and LacZ-S11 were amplified by PCR, using primers 
with NotI recognition site. pRRLSIN LacZS11 and pRRLSIN S10 were derived from 
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pRRLSIN GFP backbone, kindly provided by Dr. D. Trono from the Swiss Federal Institute 
of Technology (EPFL) through Addgene plasmid repository (Cambridge, MA, USA). This 
backbone is a 3rd generation lentiviral transgene vector, driving the expression of GFP 
from the hPGK promoter (human phosphoglycerate kinase) as described in Dull et al. 
(1998). For pRRLSIN LacZS11 and pRRLSIN S10, GFP was replaced by LacZ-S11 or GFP S10 
obtained from pCMV mGFP LacZS11 or pCMV mGFP S10, respectively, isolated by PCR 
with primers carrying the NheI restriction site. pRRLSIN backbone was amplified in two 
fragments by PCR, with primers carrying NheI and PciI restriction sites. The cloning step 
involved three fragments: two fragments corresponding to the vector (PcII cloning site) 
and the insert (NheI cloning site). pSVFLPe contains FLP recombinase gene under a SV40 
promoter as described in Coroadinha et al. (2006).  pCeB is a vector containing MLV gag-
pol and a blasticidin resistance gene (bsr) both driven by the MLV 5’LTR as described in 
Cosset et al. (1995). pGaLV expresses the Gibbon Ape Leukemia virus (GaLV) envelope 
protein and a zeocin (Zeo) (Coroadinha et al. 2006). pMDLg/pRRE and pRSV-REV  are 3rd 
generation lentiviral vector packaging constructs containing HIV1 gag-pol and the 
second and third exons of HIV-1 REV, respectively. pMD2G expresses the envelope G 
glycoprotein of the vesicular stomatitis virus (VSV-G) under the control of CMV 
promoter. The three plasmids were kindly provided by Dr. D. Trono through Addgene 
and used for transient lentiviral vector production of pRRLSIN derived vectors as 
described in Dull et al. (1998).  
 
2.2 Cell lines and culture conditions 
HEK 293 is a Human Embryonic Kidney derived cell line (ATCC CRL-1573) used to 
establish HEK 293 derived retroviral vector producer cell lines in de novo cell line 
establishment. HEK 293T (ATCC CRL-11268) is a HEK 293 derived cell line expressing 
large T antigen from SV40 (simian vacuolating virus 40) used to transiently produce 
lentiviral vectors and also in de novo cell line establishment. Te 671 is a human 
rhabdomyosarcoma derived cell line (ATCC CCL-136) used to establish S10 target cell line 
and as target cells in LacZ staining titration protocol. 293 FLEX cell line is a HEK 293 
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derived cell line producing MLV based recombinant retroviral vectors expressing GaLV 
ecotropic envelope and harboring a LacZ reporter gene. 293 FLEX GP is the precursor cell 
line of 293 FLEX prior to envelope insertion; both cell lines have been described in 
(Carrondo et al. 2008; Coroadinha et al. 2006). 293 FLEX and 293 FLEX GP were used to 
establish retroviral vector LacZ-S11 transgene containing producer cells by RCME. 
All cells were maintained in Dulbecco’s modified Eagle’s medium, DMEM, (Gibco, 
Paisley, UK) with 25 mM of glucose, 4 mM of glutamine, supplemented with 10% (v/v) 
Foetal Bovine Serum (FBS) (Gibco) at 37 ◦C in a humidified atmosphere containing 8% 
CO2. In the case of fluorometer assays, DMEM without phenol red was used, containing 
20% (v/v) FBS (Gibco) and (1X) B27 supplement (Gibco). 
 
2.3 Target cell line and retroviral vector producer cell line establishment 
 The target cell line was developed by stable expression of GFP S10 gene 
mediated by lentiviral vector infection into Te 671 using pRRLSIN S10 vector. Since this 
vector does not contain a selectable marker, a multiplicity of infection (MOI) of 30 – to 
assure synchronous infection and multiple copies per cell – was used. Cells were cloned 
by limiting dilution and clones were analyzed for GFP transcomplementation after 
infection with LacZ-S11 retrovirus to select high transcomplementation clones. 
Two types of retroviral vector producer cells were developed in this work. For 
method validation, site-specific recombinase mediated cassette exchange (RCME) was 
used to exchange 293 FLEX GP transgene from LacZ to LacZ S11 using pTAR LacZ S11 
plasmid; transfection and selection procedure is described in Coroadinha et al. (2006). 
The clones were amplified and analysed for correct cassette exchange and number of 
copies of pTAR LacS11 integrated. A cell population producing GaLV pseudotyped 
infectious retroviral vector was finally established by stable transfection of pGaLV (5 μg 
of DNA per million of cells), after 3 weeks under zeocin selective pressure. This 
population was used to validate to the Single-Step Cloning Titration method. 
For de novo cell line establishment, HEK 293 and HEK 293 T were chemically 
transfected using polyethylenimine (PEI) with the retroviral vector constructions, pCeB 
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and pGaLV and infected with a transiently produced stock of LacZ-S11 retrovirus. 5 μg of 
DNA per million of cells were used for each plasmid and MOI of 8 was used for vector 
infection. 
 
2.4 Quantification of vector transgene genomic copies  
For the quantification of genomic copies of vector transgene, genomic DNA was 
isolated using the QIAamp® DNA Mini and Blood Mini Kit (Qiagen, Valencia, CA, USA) 
according to manufacturer's instructions. PCR with specific primers for LacZ and Neo 
gene (Table I, please refer to the end of Materials and methods section) was performed 
and PCR amplification products were separated in agarose gel. Depending on the PCR 
product size it was possible to confirm if cassette exchange was successful. To estimate 
the number of copies per cell, genomic DNA was quantified by qRT-PCR using primers 
for LacZ gene (Table I) on a thermocycler LightCycler ® 480 Real-Time PCR System (Roche 
Applied Science) using LightCycler® 480 SYBR Green I Master (Roche Applied Science) 
PCR kit. The number of copies per cell was quantified relatively to a single copy control 
(293 FLEX) after normalization to a control gene (RPL22) using 2-ΔΔCT method (Livak and 
Schmittgen 2001). Single copy was considered for values below 1.4 (Bodin et al. 2005).  
 
2.5 RNA extraction and quantitative real-time PCR for gene expression 
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) according to 
the manufacturer’s instructions. The resultant RNA pellet was eluted in 100 µL of 
nuclease-free water (Qiagen) and stored at -85ºC until further processing. RNA yields 
were quantified using NanoDrop 2000 (Thermo Scientific, Waltham, MA, USA). For real 
time PCR, RPL-22 was chosen as a control gene. Forward (F) and reverse (R) primer 
sequences for all the genes assessed are given in Table I (please refer to the end of 
Materials and methods section). The reverse transcription of total RNA was performed 
according to Transcriptor High Fidelity cDNA Synthesis Kit (Roche Applied Science, 
Mannheim, Germany) protocol for cDNA synthesis using 2 μg of total RNA and oligo dT 
primer for total mRNA reverse transcription. The reverse transcribed (RT) product was 
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aliquoted and stored at -20ºC until further processing. SYBR Green I dye chemistry was 
used to detect the PCR products using LightCycler® 480 SYBR Green I Master (Roche 
Applied Science) according to the manufacturer’s instructions using LightCycler® 480 
Real Time PCR System (Roche Applied Science). cDNA samples were run along with a no 
RT-reaction control and a no cDNA template sample.  
 
2.6 Viral vectors production  
For lentiviral vector transient production the 3rd generation lentiviral packaging 
system and the transfection procedure described in Dull et al. (1998) were used.  
The stocks of retroviral vector used in de novo cell line establishment harboring the 
LacZ-S11 reporter gene were obtained by polyethylenimine (PEI) mediated transient 
transfection using pCeB to provide the packaging functions, pMD2G for the VSV-G 
envelope and pTAR LacZ S11 for the transgene. A total of 5 μg of DNA per million of cells 
was used with a DNA ratio of 2:1:3. 
For retroviral vector produced with stable cell lines, clones and populations were 
screened using  a 48+24 hours production/harvesting operation described in  Chapter II 
(Rodrigues et al. 2013).  
In all the cases, viral vector supernatants were filtered through 0.45 μm cellulose 
acetate filter for clarification, aliquoted and stored at -85ºC until further use. 
 
2.7 Titration of infectious, genome-containing and total particles 
For LacZ based staining titration, infectious procedure and viral titer determination 
were performed by limiting dilution infection assay, as described in Rodrigues et al. 
(2009). Genome-containing particles were quantified by qRT-PCR using the method 
described in Carmo et al. (2004) but using LacZ primer set for qRT-PCR given in Table I. 
Physical (total) particles were assessed by nanoparticle tracking analysis using 
NanoSigth® NS500 (NanoSight Ltd., Wiltshire, UK). 
For GFP transcomplementation titration, Te 671 S10 target cells were seeded at 5 x 
104 cells/cm2 in 24-well plates 24 hour before infection. Transduction was performed by 
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removing the cell supernatant and infecting with 0.2 mL of viral suspension using several 
dilutions in fresh DMEM (Gibco) with 10% (v/v) FBS and 8 μg/mL of polybrene (Sigma). 
Cells were incubated at 37ºC overnight after which 0.5 mL of fresh supplemented 
DMEM was added. Two days after infection, cells were harvested and analyzed for GFP 
fluorescence by flow cytometry (CyFlow-space, Partec GmbH).  
 
2.8  Single-step cloning titration method procedure 
Producer cells were cloned by limiting dilution in corning CoStar black-wallet with 
clear bottom 96-well plates (Corning, New York, NY, USA). The final volume was 150 
μL/well and border-wells were avoided for cloning, filled with 280 μL of PBS to minimize 
medium evaporation from the cloning wells. Typically, 10 cloning plates were prepared, 
thereby corresponding to a total of 600 cloning wells. Cell seeding inoculum was 0.7 
cells/well. Under these conditions (see also section 2.2 for culture medium and 
supplements), the cloning efficiency was found to be around 50%, thus corresponding to 
approximately 200 clones per analysis. A negative control plate was prepared (to assess 
background) using the same cloning medium/conditions but without containing the cells 
to be cloned. After 6 days, the target cells were added at a seeding density of 250 
cells/well to all plates (including the negative control) corresponding to 50 μL of target 
cell suspension at 5 x 103 cells/mL. At day 7, day 9 and day 11 polybrene (Sigma) was 
added at a final concentration of 5 μg per mL on day 7 and 9 and 10 μg per mL on day 
11. At day 11 it was also performed an agitation period of 15-30 minutes using a rocking 
table to potentiate the spreading of viral infection through the well. At day 15 culture 
medium was aspirate off and replaced by 50 μL of PBS containing 5% (v/v) FBS (Gibco). 
Fluorescence reading was performed in a fluorometer plate reader FLx800 (Biotek, 
Vermont, USA) using a 485/20 emission and a 528/20 absorption filters (Biotek).  
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2.9 Data analysis and density distribution curves 
Fluorescence values were ordered from smaller to largest. High-GFP yielding wells 
were microscopically inspected to guarantee single colony and those containing double 
colonies were eliminated from the raw data. Raw data was background subtracted. 
Background corresponds to the average fluorescence value of the control plate 
containing only target cells, prepared and treated as the cloning plates. Background 
subtracted values yielding negative values were also removed from the raw data. The 
remaining were processed for density distribution curve generation in MATLABTM 7.10 
(The MathWorks Inc., Natick, MA, 2000), using the function ksdensity(). Kernel density 
distribution was chosen as it is a non-parametric method allowing density estimation 
without imposing any curve distribution type; for further detailed on kernel smoothing 
see Wand and Jones (1995).  
 
Table I – Primers for cloning, PCR and qRT-PCR 
Cloning primers 
Final Construct 
Insert 
Cloning vector 
Primers 
(5’ →3’ sequence) Fragment Source 
pCMV mGFP 
LacZ S11 
LacZ pIRES GALEO 
pCMV mGFP 
S11 
F - ATCCTACCGGTATCCAGCCCTCACTCCTTCTC 
R - CGACTACCGGTTGACACCAGACCAACTGGTAAT 
pTAR LacS11 LacZ-S11 
pCMV mGFP 
LacZ-S11 
pEM MFG 
F - GCGTGTACGGTGGGAGGTCTAT 
R - GGGGAGGTGTGGGAGGTTTT 
pRRLsin S10 GFP 1-10 pCMV mGFP S10 
pRRLsin eGFP 
F - GTGAACCGTCAGATCCGCTAGCCG 
R - GGCTGGCTAGCATCAGTTATCTAGATCCG 
pRRsin LacZ S11 LacZ-S11 
pCMV mGFP 
LacZ-S11 
R - GGGGAGGTGTGGGAGGTTTT 
R - GTTTTGCTAGCCAAGTAAAACCTCTACA 
PCR for cassette exchange evaluation 
Hybridization site 
Amplicon size (kb) Primers 
(5’ →3’ sequence) Before RCME After RCME 
LacZ (end) 
3.8 2.3 
F – CTACCGGATTGATGGTAGTGGT 
Neomycin (beginning) R – AGCCATGATGGATACTTTCTCG 
qRT-PCR 
Gene 
   
Primers 
(5’ →3’ sequence) 
Viral transgene (LacZ)    
F – ACTATCCCGACCGCCTTACT 
   
R – TAGCGGCTGATGTTGAACTG 
Gag-pol    
F – GTCCACTATCGCCAGTTGCT 
   
R – CTGGGTCCTCAGGGTCATAA 
Envelope    
F – GGACCAAAATAGCGAATGGA 
   
R – GGTGAACTGTACGCCTGGAT 
RPL22    
F – CTGCCAATTTTGAGCAGTTT 
   
R – CTTTGCTGTTAGCAACTACGC 
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3. Results 
To reduce the clone screening time in virus producer cell line development, a 
protocol merging the steps of cloning and titration was implemented – the single step 
cloning-titration method, SSCT, from herein on. Taking advantage of stable cell lines 
used in retroviral vector production, which favours protocol design, the method is based 
on a transcomplementation assay using a Split GFP®, where part of it is encoded by the 
retroviral vector transgene and the other part stably expressed in the cells to be infected 
(target cells) (Fig. 1).  
 
 
 
 
Figure 1 – Schematic representation of the single-step cloning titration method. Viral transgene carries S11 fragment 
fused to a gene of interest, in this case, a second reporter – LacZ . S10 fragment is stably expressed in the titration cell 
substrate. Producer cells are cloned and co-cultured with the target cells (S10 titration substrate) and during the period 
of clones expansion (two weeks) target cells are infected with the viruses produced by the clone reconstituting the GFP 
signal. Clones and target cells are cultured in black-wallet 96 well plates with clear bottom analyzable in a fluorometer 
plate reader using the 485/20 emission filter and 528/20 absorption filters. High producing clones originate high GFP 
signals. The Split GFP® used in this work is a mammalian codon-optimized version of the one described in Cabantous et 
al. (2005), a green fluorescent protein under the control of a CMV promoter separated in GFP S10 coding for the first 
214 amino acids (aa) and GFP S11 for the last 15, respectively. GOI: gene of interest, in this case, a second report – LacZ 
– for method validation.  
 
The method makes use of black-wallet 96 well plates with clear bottom where the 
retroviral vector producer clone is seeded followed by two-week incubation for cell 
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expansion. During this period target cells are co-cultured in each well being infected by 
S11 viruses produced by the clone and reconstituting the GFP signal. After two weeks 
the clones are selected based on the highest GFP signal using a fluorometer plate 
reader. The GFP signal arises from the target cell line after GFP S10 
transcomplementation with GFP S11 fragment delivered through infection of the 
retrovirus produced by the clone (Fig. 1). High producing clones can be isolated from the 
target cells by any of the viral components selectable markers.  
 
3.1 Target cell line establishment and titer calibration 
To establish the target cell line (titration substrate), Te 671 cell line routinely used 
for titrating GaLV pseudotyped retrovirus was used. Chemical transfection by 
polyethylenimine (PEI) was initially used to deliver pCMV mGFP S10, followed by 
neomycin selection of the transfected population. However, the population and its 
derived clones did not present sufficient S10 expression levels for high 
transcomplemented GFP signals (data not shown). Therefore, GFP S10 was cloned into a 
lentiviral vector (pRRLSIN S10) and used to infect Te 671 cells at high multiplicity of 
infection (MOI, approximately 30). This ensured a high number of GFP S10 gene copies 
being delivered to each cell. From this population, 21 clones were screened for GFP 
transcomplementation (Fig.2A).  
The key parameters in this screening were: i) a high number of transcomplemented 
cells for low multiplicity of infection (approx. 0.2), to guarantee a detectable signal 
under the protocol conditions (higher number of target relatively to producer cells), and 
ii) a high signal to noise ratio, to minimize the number of false positive wells. The latter 
is of particular importance as S10 expression was found to increase the background 
signal.  The majority of the clones presenting high signal to noise ratio (>10), failed to 
deliver the expected percentage of GFP+ cells (approximately 20%, according to the 
MOI). This was due to low noise rather than to high signal, thus, suggesting low S10 
levels. Also, none of the clones delivered 20% of infected cells, being the maximum 
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percentage around 6%. However, the MOI was calculated based on LacZ determined 
titer which was found to over-estimate GFP transcomplementation in about 5-fold (Fig. 
2B). Thereby, 4-6% of GFP+ cells should correspond to the maximum expectable, which 
was in fact observed (Fig. 2A). Among the clones delivering at least 4% of GFP+ cells, the 
best signal to ratio was achieved with clone #27. 
 
 
 
 
Figure 2 – Establishment of S10 titration cell substrate and comparison of GFP transcomplementation vs. LacZ 
titers. Signal to noise ratio and GFP transcomplemented positive cells of the different Te 671 S10 clones (A). Signal to 
noise was defined as the ratio of mean fluorescence intensity of GFP positive (infected) cells to non-infected cells, 
analyzed by flow cytometry. Infection was performed at multiplicity of infection of 0.2 using a defined dilution of a 
transiently produced stock of VSV-G pseudotyped retroviral particles. Serial dilutions of a stably produced LacZ_S11 
retrovirus stock were titrated by traditional LacZ staining in Te 671 cells or by GFP transcomplementation using Te 671 
S10 #27 target cells (B). Correlation coefficient (R2) = 0.999, given by least squares linear regression. Linear regression 
fit with slope=0.2 indicating a 5-fold underestimation of GFP transcomplementation relatively to LacZ titer. Average 
titer of triplicates; for a matter of simplicity error bars were omitted ranging from 1 to 6% in transcomplemented GFP 
and 5 to 17% in LacZ determinations. Average infectious particles titers of the two reporter proteins encoded by LacZ-
S11 transgene of retrovirus transientely produced and pseudotyped with GaLV and VSV-G envelope (C). Error bars 
represent standard deviation (n=3). GaLV – Gibbon Ape Leukemia Virus; VSV-G – Vesicular Stomatitis Virus G Protein. 
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Using Te 671 S10 #27, LacZ titers were compared to those obtained by GFP 
transcomplementation (Fig. 2B). Although presenting high correlation coefficient 
(R2=0.999), GFP transcomplementation yielded an absolute titer under-estimation of 5-
fold relatively to LacZ (Fig. 2B). This was also observed for different envelopes – GaLV 
and VSV-G – with an underestimation of approximately 5- and 4-fold, respectively (Fig. 
2C). Since GFP titers were lower than those obtained by LacZ we hypothesized that GFP 
titration was affected by insufficient levels of GFP S10 expression in Te 671 S10 #27 cells. 
Thus clone #27 was re-infected with lentivirus containing GFP S10 transgene (MOI of 30) 
and analyzed for GFP transcomplementation. However, GFP transcomplementation 
titers were found to be identical between Te 671 S10 #27 and its S10 re-infected derived 
population (data not shown), suggesting that the underestimation obtained by GFP 
transcomplementation was not due to insufficient S10 expression. This underestimation 
is, however, an advantage since GFP signal saturation will only occur for very high titer 
clones.  
 
3.2 Method implementation and validation  
3.2.1. Establishment of 293 FLEX GP S11 and 293 FLEX S11  
Two retroviral vector producer cell lines were established in this work: i) 293 FLEX 
GP S11 and 293 FLEX S11. Both cell lines derive from 293 FLEX cell line (Coroadinha et al. 
2006), after recombinase mediated cassette exchange (RMCE) from LacZ to LacZ-S11 
fusion retroviral transgene. 293 FLEX GP is the envelope-free precursor cells of 293 FLEX 
and was used for method validation (section 3.2.2). 293 FLEX S11 were used as a control 
of cassette exchange from LacZ to LacZ-S11. 
For method validation, recombinase mediated cassette exchange (RMCE) 
technology was used to target 293 FLEX GP and exchange the LacZ retroviral vector 
transgene to LacZ-S11 fusion transgene, establishing the 293 FLEX GP LacZ S11 (Fig. 3). 
More than 60 clones were analyzed from the exchanged population and tested for GFP 
transcomplementation. Among transcomplementing competent clones, 10 were 
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isolated and analyzed by PCR and qRT-PCR for correct targeting and copy number (Fig. 
3D).  
 
 
 
Figure 3 – Cassette 
exchange in 293 FLEX GP. 
Tagged vector transgene in 
293 FLEX as described in 
(Coroadinha et al. 2006; 
Schucht et al. 2006) (A). 
Target construct (pTAR LacZ 
S11), used to exchange 293 
FLEX GP and 293 FLEX viral 
transgene (B). Integrated 
targeting cassette after flp 
mediated cassette 
exchange (C). Correct 
cassette exchange is 
indicated by the loss of 1.5 
kb in the integrated 
cassette, relatively to the 
tagging cassette (A). 
Electrophoresis in 0.7% 
(w/v) agarose gel of the PCR 
reaction performed to 
amplify the transgene 
sequence from genomic 
DNA of 293 FLEX GP after 
transgene exchange from 
LacZ to LacZ-S11 (D). 
Numbers above the lanes 
correspond to targeted clo- 
nes 293 FLEX GP S11 (after cassette exchange). The numbers bellow the lanes indicate the ratio of copy number 
relatively to a single copy control (293 FLEX) of targeted transgene given by genomic DNA quantification by qRT-PCR 
using primers for LacZ gene. The number of copies per cell was quantified after normalization to a control gene (RPL22) 
using the 2-ΔΔCt method as defined in Materials and methods. L – ladder; G – pIRES GALEO plasmid (tagging construct); C 
– positive control of 293 FLEX GP (before cassette exchange). 
 
Transgene exchange was confirmed by the loss of approximately 1.5 kb in amplicon 
size in all 293 FLEX GP S11 clones while maintaining single copy. One of the exchanged 
clones (clone #32) was selected to establish an envelope-containing retroviral vector 
producer population by stable transfection of pGaLV. This population was used for 
method validation (please refer to section 3.2.2).  
As part of a control, 293 FLEX, the retroviral vector producer cell line derived from 
293 FLEX GP by stable insertion of the GaLV envelope (clone #18, Coroadinha et al. 
(2006)) was also subjected to RCME to exchange the LacZ retroviral vector transgene to 
LacZ-S11 fusion transgene. As described for 293 FLEX GP S11, exchanged clones were 
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tested for GFP transcomplementation and analyzed by PCR and qRT-PCR for correct 
targeting and copy number (data not shown). Finally, the selected exchanged clones, 
both from 293 FLEX GP S11 and 293 FLEX S11 were analyzed for retroviral vector 
particles production and vector components gene expression and compared to their 
respective parental non-exchanged cell lines (Table II).  
 
Table II - Retroviral vector particles production and vector components gene expression of 293 
FLEX, 293 FLEX GP and derived S11 exchanged clones 
I.P.: Infectious particles 
G.P.: genome-containing particles 
FC: fold-change relatively to non-exchanged parental cells (293 FLEX for 293 FLEX S11 and 293 FLEX GP for 293 FLEX GP 
S11) 
N/A: not applicable 
 
Cell growth kinetics was found to be relatively unchanged after cassette exchange 
for both 293 FLEX S11 and 293 FLEX GP S11. However, infectious particles production of 
293 FLEX S11 increased almost one order of magnitude relatively to the non-exchanged 
cell line. Genome-containing particles titer remained identical for 293 FLEX S11, 
suggesting that the total number of produced particles was the same. Indeed, gag-pol 
expression levels, the vector component related to the amount of physical particles 
produced, remained unaltered. Similar results were found for 293 FLEX GP S11, although 
presenting a slight increase (2-fold) in genome-containing particles titer. Envelope 
expression levels in 293 FLEX S11 remained unchanged. Vector transgene expression, on 
the other hand, was increased 3 and 4-fold for 293 FLEX S11 and 293 FLEX GP S11, 
respectively. These differences might be explained by the use of an MFG retroviral 
vector for the targeting construct (pTAR LacZ S11). Expression of a transgene from MFG 
vectors can be 10- to 50-fold higher sustained on high levels of genomic RNA (Byun et al. 
  
293 FLEX 293 FLEX S11 FC  293 FLEX GP 203 FLEX GP S11 FC 
Cell 
growth 
Duplication 
time (h) 
36 ±  4 36 ± 3 - 33 ± 3 28 ± 3 - 
Viral 
particles 
I.P./mL (106) 1.6 ± 0.4 13.0 ± 2.5 8 N/A N/A N/A 
I.P./Cell.h 0.03 ± 0.01 0.33 ± 0.08 10 N/A N/A N/A 
G.P./Cell.h 14 ± 3 17 ± 4 - 19 ± 4 32 ± 6 2 
Gene 
expression 
(2-ΔCT) 
Transgene 0.7 ± 0.3 2.2 ± 0.3 3 0.9  ± 0.1 3.9  ± 0.2 4 
Gag-Pol 2.6  ± 0.8 1.9  ± 0.2 - 4.1  ± 0.3 2.4  ± 0.1 - 
Envelope 1.1  ± 0.4 1.5 ± 0.1 - N/A N/A N/A 
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1996). These observations are in line with the results from Table II and may explain the 
reason why, for the same amount of genome containing particles, those from MFG-
expressed backbones appear to be transcriptionally more active (higher titers).  
 
3.2.2. Method validation – fast isolation of high-producing clones from a cell 
population 
For method validation, the envelope-free precursor cells of 293 FLEX (293 FLEX GP, 
Coroadinha et al. (2006)), were used (Fig. 3). These cells produce transgene containing 
but non-infectious murine leukemia virus (MLV) based virions as they lack the envelope. 
Upon envelope integration, a cell population containing clones with different 
productivity levels should be obtained. One of the exchanged clones of 293 FLEX GP S11 
was selected to establish an envelope-containing retroviral vector producer population 
by stable transfection of pGaLV. The method was validated using this selected 
population; cloning wells were microscopically inspected and the density distribution 
profile of the producing population was evaluated (Fig. 4).  
This distribution comprises about 200 clones originating, the majority of them, low 
to medium transcomplemented GFP signals (500-3000 RFU) whereas only a minority of 
them fell in high fluorescence signal range (>4000 RFU). Note that it cannot be 
confidently defined the minimum fluorescence value for which a cloning well contains a 
colony, since this would imply microscopically inspecting all the 600 wells. While the 
selected population presented an average titer of 1.6 x 106 I.P./mL, when isolating 
clones from the different fluorescence ranges, it was possible to discriminate 
productivity levels between 1x105 to 1x108 infectious particles per mL (Fig.4). Moreover, 
transcomplemented GFP signal was found to estimate well the clone productivity as 
colony size variation was considerably lower (between 0.5 and 3x the average) than titer 
variation (between 0.1 and 100x the average).  
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Figure 4 – Density distribution of 293 FLEX GP S11 GaLV population. Kernel density distribution curve of 293 FLEX GP 
S11 after GaLV envelope stable transfection. The distribution comprises approximately 200 clones corresponding to 10 
cloning plates, of 60 wells each, at a seeding density of 0.7 cells/well assuming 50% cloning efficiency. Normalized 
fluorescence indicates background subtracted values, being background the average relative fluorescence units of a 
plate containing only target cells. Fluorescence microscopy pictures show colonies of 293 FLEX GP S11 GaLV clones (in 
red) and the Te 671 S10 target cells infected with retrovirus carrying LacZ-S11 transgene produced by the clone (in 
green) after the two-week expansion period. For imaging purposes, producer cells express mCherry for a better 
visualization of the colonies. Arrows indicate typical fluorescence range associated to the mentioned titers (note that 
these are approximations) and the clones from the pictures were isolated from these ranges. 
 
 
3.3 Method applications 
3.3.1. De novo cell line establishment  
In the first part of this work, the SSCT method was implemented and validated 
using 293 FLEX GP S11, after envelope stable transfection. However, 293 FLEX have been 
developed based on a stoichiometry optimization strategy of the vector components – 
for high infectious particles titer and high infectious to total particles content – and have 
required extensive clone screening in-between viral cassettes insertion (Carrondo et al. 
2008). The potential of SSCT method was thus tested to search for identical 
performances, without the need of stoichiometric optimization or clone selection in-
between the intermediate steps of integration of the viral components. Transgene, gag-
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pol and envelope were sequentially transfected and selected into nude HEK 293. The 
final population was subjected to the SSCT. As a control, 293 FLEX S11 were also 
subjected to SSCT. 293 FLEX S11 were derived from 293 FLEX 18 (Coroadinha et al. 2006) 
through RCME to exchange the LacZ transgene to LacZ-S11 fusion as described for 293 
FLEX GP (section 3.2.1). The results are shown in Figure 5. 
Even without stoichiometric optimization, clones producing up to 1 x 108 infectious 
particles per mL were isolated. It was also evident that transcomplemented GFP signal is 
not a direct measurement of clone titer but instead an estimation. Indeed, the highest-
titer clone isolated was not the one yielding the highest transcomplemented GFP signal 
but the one before (Fig. 5B). These variations arise mainly from variations in colony 
location on the well: centered colonies yield GFP signal concentrated in the middle of 
the well where the readings are performed. Also, high-transcomplemented GFP yielding 
clones (RFU>3000) were those presenting the highest ratios of infectious to total 
particles, suggesting that the method not only allows the identification of high-titer 
clones but also low defective particles content. 
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Figure 5 – Applications of SSCT method: de novo cell line establishment.  Kernel density distribution curve of retroviral 
vector producer cells established from nude HEK 293 cells (A). Normalized fluorescence indicates background subtracted 
values. Cells were established by transfecting the three vector components (gag-pol, envelope and vector transgene) 
without clone screening and isolation in-between intermediated steps. 293 FLEX S11, derived from 293 FLEX 18 
(Coroadinha et al. 2006) through RCME to exchange the LacZ transgene to LacZ-S11 fusion as described for 293 FLEX GP 
(section 3.2.1), is shown as a control. Gag-pol and envelope were delivered by PEI chemical transfection using 5 μg of 
DNA per million of cells for each component, separately and sequentially, followed by the respective antibiotic selection. 
Vector transgene was delivered by infection, MOI of 8, using a transiently produced retrovirus stock pseudotyped with 
VSV-G envelope and using pTAR LacZ S11 viral transgene. High-titer clones isolated from de novo cell line establishment 
using viral transgene from pTAR LacZ 11 (B). Clones are ordered by (normalized) fluorescence. White bars represent 
average total particles and error bars represent standard deviation (n=4) quantified by nanoparticle tracking analysis. 
Gray bars represent average infectious particles and error bars represent standard deviation (n=3) quantified by LacZ 
staining. RFU: relative fluorescence units. Clones are named after the plate and well number (e.g.:P2E3: cloning plate 2; 
well E3). 
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3.3.2 Screening the production performance of alternative cell substrates 
The density distribution curve provides valuable information on the productivity 
performance of a cell population, both by the identification of high-producing clones, as 
well as by the density (amount of clones) falling into high transcomplemented GFP 
ranges. With this in mind, the SSCT method was used to evaluate the retroviral vector 
production performance of two different cell substrates: HEK 293 and HEK 293T. 
Recently, Gama-Norton and colleagues demonstrated that HEK 293T deliver increased 
lentiviral titers comparatively to HEK 293 (Gama-Norton et al. 2011). The authors 
suggested that this improved performance was due to physiological changes induced by 
the expression of large T antigen itself rather than by a more favorable episomal 
replication of SV40 ori containing plasmids, typically used in retro and lentiviral vector 
constructions in transient production. These observations were tested using the SSCT 
method. A de novo cell population producing retroviral vector was established as 
described in 3.3.1, using HEK 293 and HEK 293T. After selecting for each of the viral 
components, the productivity performance of both populations was assessed by the 
SSCT method (Fig 6A).  
The distribution curve of HEK 293T population presented four times higher clone 
density (8% of the population) in the range RFU>3000 – corresponding to the high-titer 
clones – than the one of HEK 293 (2% of the population). Indeed, when analyzing those 
clones, we found 3 from the 12 HEK 293T derived clones producing in the order of 108 
infectious particles per mL. For those derived from HEK 293, only 1 out of 12 produced in 
the same order of magnitude. It should be noted, however, that, in this case, the colony 
size bias a direct comparison of the fluorescence values between HEK 239 and HEK 293T 
since the later grow considerably faster than the former. Still, even when a factor for 
colony size normalization was applied, the density of high-fluorescence clones in HEK 
293T was about three times higher than in HEK 293. To eliminate the advantage of a 
more favorable episomal replication in HEK 293T, none of the viral constructions 
contained SV40 ori sequences. Still, HEK 293T present higher transfection efficiencies 
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than HEK 293, potentially favoring increased amounts of DNA integration into a stably 
selected population and derived clones. Thus, gene expression of the viral components 
was quantified by qRT-PCR (Fig.6B). 
 
 
 
Figure 6 – Applications of SSCT method II: cell substrate comparison. Kernel density distribution curves comparing the 
production performance of HEK 293 vs. HEK 293T (A). Each distribution comprises approximately 200 clones 
corresponding to 10 cloning plates, of 60 wells each, at a seeding density of 0.7 cells/well assuming 50% cloning 
efficiency. Normalized fluorescence indicates background subtracted values, being background the average relative 
fluorescence units of a plate containing only target cells. For both substrates, a cell population was established as 
described in Fig. 5.  Viral components expression vs. infectious particles titer of high-titer clones isolated from de novo 
cell line establishment using HEK 293 (□) and HEK 293T (○) cell substrates (B). Viral titers represent average infectious 
particles (n=3) quantified by LacZ staining as described in (Rodrigues et al. 2009) and vector components expression 
represents average expression level normalized to the RPL22 housekeeping control (2ΔCT) (n=2). Packaging (gag-pol) and 
envelope expression significantly higher (p<0.005) in HEK 293 than in HEK 293T clones, given by a one-tailed t-test 
assuming unequal variance.   
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The results showed that, the increased titers obtained with HEK 293T clones are not 
due to an increased viral components expression, relatively to HEK 293. Although high-
titer clones presented higher expression levels of viral transgene in HEK 293T, this was the 
exception as HEK 293 clones presented, on average, increased viral components 
expression, particularly evident in the case of the envelope and gag-pol (Fig.6B).   
 
Another application of the SSCT method is as a metabolic manipulation supporting 
tool, for studying the effects of external gene over-expression in the viral production 
dynamics and allowing the isolation high-producing clones (please refer to Chapter VIII for 
metabolic engineering using this method).   
 
4. Discussion  
The development of stable retroviral vector producer cell lines is a laborious and 
time consuming process. Additionally, stable cell lines deliver relatively lower titers than, 
for instance, transient production processes, translated in dozens to hundreds of viral 
supernatant liters for each patient to be treated (Stacey and Merten 2011). Strategies 
assisting the identification of high-producing clones will alleviate the drawbacks of the 
low-titers and the heavy time-frames in stable cell line development. On the other hand, 
cell engineering approaches (Rodrigues et al. 2013), new vector designs (Schambach et 
al. 2007) and strategies based on mutagenesis (Vu et al. 2008) are also contributing for 
improved titers, attractive viral properties (e.g., thermal stability) and increased safety. 
In all the cases, a high-throughput screening tool is of the utmost importance to identify 
high-producing clones and high-titer generating mutations or other genetic 
manipulations. 
In this work, we sought for implementing a high-throughput method handling the 
analysis of hundreds of retroviral vector producing clones in a relatively short period of 
time, to assist de novo cell line establishment, and cell/vector engineering approaches. 
This method reduces the time and manipulation required for the identification of high-
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titer clones since it ensures that the titration and cloning procedures are performed in 
one single step. Cell viability and sterility is maintained during the analysis and high-titer 
clones can be further isolated after the assay. The viral transgene can be exchanged to 
other gene of interest by recombinase mediated cassette exchange (Coroadinha et al. 
2006; Schucht et al. 2006). The LacZ-S11 transgene enables the expression of a 
fluorescence protein exclusively upon viral infection of the target cells. This is 
particularly relevant since, from our experience, conducting the SSCT method using 
producer cells carrying a complete GFP as viral transgene, increased the number of false 
positives up to 90%. The method was conceived to provide high-throughput screening in 
an academic/research environment, using commercially available plates and suited to 
any fluorometer plate reader. A single operator can easily achieve a manual throughput 
of 200-500 clones per analysis in two weeks. If coupled to an automated device, this 
output could be increased. 
The method was used to establish a retrovirus producer from a nude cell line 
reducing a one year process of sequential transfection and screening of the three viral 
expression cassettes to three months. Clones producing up to 108 infectious particles per 
mL could be isolated, on average, two orders of magnitude higher than the highest 
state-of-the-art titers obtained for stable production of GaLV pseudotyped retroviral 
vectors (Coroadinha et al. 2010) (Fig. 5). Of important notice, clones isolated based on 
the SSCT method, delivered high quality of viral bulks, characterized by high ratios of 
infectious to total particles content. This parameter is of the utmost importance for 
clinical-grade viral preparations. SSCT method transcomplemented fluorescence data 
allows the identification of high-titer clones and can additionally be treated as an 
estimation of each clone’s productivity and analyzed in terms of density distribution 
(Figs. 4, 5 and 6). This method combines the power of single-cell resolution with the 
dynamics of cell population analysis and might be used to evaluate the effect of genetic 
manipulations into viral titers. This method was the pillar for the multi-gene 
manipulation performed in Chapter VIII. Herein it was also used it to compare infectious 
vector productivity performance of HEK 293 vs. HEK 293T cell lines, as recent data 
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suggested large T antigen expression to support enhanced viral titers, not at the level of 
vector transcriptional activity but rather by indirect physiological effects on the cell 
(Gama-Norton et al. 2011). Indeed, HEK 293T derived from HEK 293 by stable insertion 
of the SV40 large T antigen acquiring distinct phenotypic characteristics, including higher 
transfectability and yielding higher titers (DuBridge et al. 1987; Rio et al. 1985). This 
performance is usually attributed to a more favorable episomal replication when SV40 
ori containing plasmids are used. However, none of the vector constructions used in de 
novo cell line establishment contained SV40 ori sequence, neither the HEK 293T derived 
clones presented obvious increased viral components expression comparatively to those 
derived from HEK 293 (Fig. 6B). Therefore, HEK 293T cells do not seem to sustain higher 
retroviral vector titers on increased vector components expression. Together with the 
data from Gama-Norton et al. (2011), our results support that higher viral titers in large 
T antigen expressing cells are, at least in part, derived from physiological traits of the 
cells themselves, making them a better substrate for virus production. The analysis of 
such changes should be an interesting research area, particularly in the growing field of 
lentiviral vector production that traditionally uses HEK 293T cells (Merten et al. 2011).  
The single step cloning-titration method herein described, demonstrated its 
applicability in important aspects of viral vector production from high-titer clone 
selection in cell line development to studying and manipulating cell metabolism (please 
refer to Chapter VIII). Other applications can be envisaged: for example, in combination 
with mutagenesis, it can be used for screening randomly generated vector component 
libraries. Moreover, although it was firstly established for retroviral vector production, it 
should be directly applicable to stable cell lines producing other types of infectious virus 
and, with the proper modifications, may be extended to transient systems. We expect 
this approach to contribute to the progress of gene therapy by accelerating vector and 
cell line development.  
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Abstract 
Metabolic gene engineering holds the potential to develop high-producing hosts 
for the manufacture of complex biopharmaceuticals. Hyperproductivity has been 
conceptualized as the orchestrated combination of superior attributes from different 
biochemical pathways. But metabolic manipulation involves labor-intensive steps, 
from the introduction of the target gene to the isolation and characterization of the 
candidate clones, turning multiple manipulations extremely difficult. 
In this work, we established the basis for multi-gene engineering of mammalian 
cell metabolism using, as study model, a human cell line producing recombinant 
retrovirus. To face the challenge of clone screening, a novel method for fast screening 
of high-titer clones was established by merging cell cloning and virus titration: the 
single step cloning-titration method (Chapter VII). Assisted by a previous study on the 
metabolic networks recruited when establishing a retrovirus producer cell line 
(Chapter II), more than 30 candidates, including metabolic and regulatory genes, were 
chosen for manipulation. Herein, 13 of those candidates have been evaluated 
including polyamines metabolism, glutathione metabolism, protein processing in the 
endoplasmic reticulum, apoptosis and energy generation metabolism. Productivity 
improvements up to 15-fold increased were obtained. Genes found to yield high-
producing phenotypes are now being combined and the resulting clones characterized. 
The diversity of metabolic pathways targeted in this study is likely to be of 
relevance to several biopharmaceuticals produced in mammalian hosts, including 
complex proteins and other types of recombinant viruses. Moreover, this work 
encompasses pioneering steps of a multi-gene manipulation approach, being the most 
extensive metabolic engineering study performed in mammalian cells, so far, further 
enlightening virus-host metabolic interaction. 
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1. Introduction 
Metabolic engineering by gene manipulation holds the promise of developing 
robust and high-yield cell-based production systems. In the omics era, gene 
engineering in simpler organisms has become more straightforward and, with the 
appearance of genome-scale metabolic models in the late 90’s, achieved high levels of 
predictability (Edwards and Palsson 1999; Kim et al. 2011). By opposite, eukaryotic 
cells, particularly mammalian’s, were found to be difficult to manipulate with similar 
levels of predictability. The productivity improvements obtained by gene manipulation 
have been modest, typically from 2- to 4-fold and, many times, based on volumetric, 
rather than specific, productivity. The most outstanding achievement was 
accomplished by Fussenegger et al. (1998), a productivity increase of 30-fold in CHO 
cells producing a secreted alkaline phosphatase by co-expressing Bcl-xL survival gene 
with a cell cycle regulator gene, cyclin-dependent kinase inhibitor (p27).  
Metabolism is redundant (Palsson 2006): the same metabolite profiling can be 
generated by different combinations of reactions not conceptualized as a pathway. 
Therefore, point manipulations are often absorbed by the network and diluted without 
obvious phenotypic differences. The problem gains relevance with the complexity, 
tight regulatory control and high level of compartmentalization of mammalian cells. 
The datasets available suggest that hyperproductivity is conferred by a collection of 
positive physiological traits encompassing changes of several genes with a broad 
spectrum of functions (Fig. 1, Seth et al. (2007)). On the other hand, gene manipulation 
involves labor-intensive steps, from the introduction of the target genes to the 
isolation and characterization of candidate clones. Moreover, high-producing 
phenotypes are typically rare events. Even when the delivered gene might contribute 
to high-productivity, its effect will depend on the number of integrated copies, 
integration loci – dictating gene expression levels – and on a combination of favorable 
downstream effects arising from that manipulation. Many times, this combinatorial 
effect can only be achieved by multiple gene manipulations (Seth et al. 2007). 
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Figure 1 – Multiple routes to hyperproductivity. Hyperproductivity requires the accumulation of multiple superior 
characteristics. While the productivity is low, acquiring some elements from one or more favorable functional classes 
(only four potential classes are shown) will enhance the productivity. Thus, many different routes can give the same level 
of productivity. To achieve a higher productivity level a large number of attributes, arising from multiple favorable 
pathways may be needed. Hyperproducers are rare, as they must acquire many attributes. In addition, there are possibly 
multiple routes that lead to the top (Seth et al. 2007). 
 
While the theoretical concept illustrated in Figure 1 is easy to understand, its 
experimental execution can be rather difficult. For a single gene, the process may take 
several months implying the screening of several hundreds of clones. For multiple 
genes, it rapidly becomes impracticable.  
In this work, we experimentally challenge the theoretical concept of ‘the multiple 
routes hyperproductivity’ to improve a mammalian cell host producing recombinant 
retrovirus. To face the burden of clone screening, a novel method was established for 
fast screening of high-titer clones by merging cell cloning and virus titration: the single 
step cloning-titration method (SSCT, Chapter VII). Assisted by a previous study on the 
metabolic networks recruited when establishing a producer cell line (Chapter II), more 
than 30 candidates, including enzymatic and regulatory genes, were chosen for 
manipulation. These candidates span across multiple pathways including energy 
generation, amino acid metabolism, glutathione metabolism, apoptosis, protein 
processing, lipid biosynthesis and nucleotide metabolism (Rodrigues et al. 2013). For 
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the genes evaluated in this work, specific productivity could be increased up 15-fold. 
High producing clones are being characterized and genes found to yield high-producing 
phenotypes are starting to be combined to mimic the routes to hyperproductivity. 
In this work the basis for a pioneering multi-gene manipulation approach were 
established. For the more than 30 genes identified as potential targets to improve 
virus production, 17 have, by now, been evaluated comprising the most extensive 
metabolic engineering study so far performed in mammalian cells. 
 
2. Materials and methods 
2.1 Cell lines and culture medium 
293 FLEX S11 were used for gene manipulation. These cells derive from 293 FLEX 
18 (Coroadinha et al. 2006) by recombinase mediated cassette exchange as described 
in Chapter VII. In these cells, the original LacZ transgene was exchanged by a fusion of 
LacZ with S11 fragment of the split-GFP® (SandiaBiotech, Albuquerque, NM, U.S.A), 
making them suitable to be screened for infectious virus production using the single 
step cloning-method.  HEK 293T (ATCC CRL-11268) is a HEK 293 derived cell line 
expressing large T antigen from SV40 (simian vacuolating virus 40) used to transiently 
produce the lentiviral vectors for metabolic gene delivery. Te 671 is a human 
rhabdomyosarcoma derived cell line (ATCC CCL-136) used to titrate infectious 
retroviral particles by LacZ staining. Te 671 S10 is a Te 671 derived cell line stably 
expressing the S10 fragment of the split-GFP® (SandiaBiotech) established as described 
in Chapter VII. These cells were used as titration cell substrate in the single step 
cloning-titration method and also to titrate metabolic gene lentiviral vector stocks.  
All cells were maintained in DMEM (Gibco, Paisley, UK)), with 25 mM of glucose 
and 4mM of glutamine, supplemented with 10% (v/v) (FBS) (Gibco). For the single step 
cloning titration method, phenol red-free DMEM supplemented with 20% FBS (Gibco) 
and 1X B27 supplement (Gibco) was used, as previously described in Chapter VII. All 
cell lines were maintained in a humidified atmosphere of 92% air and 8% CO2 at 37 °C.  
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2.2 Metabolic genes expression vectors and lentiviral production 
The cDNAs of all genes used in this work were acquired through DNASU Plasmid 
Repository (Biodesign Institute, Arizona State University, Tempe, AZ, USA) and cloned 
into a lentiviral backbone pRRLSIN LacZS11. This backbone is derived from pRRLSIN 
described by Dull et al. (1998) and was established by replacing the original GFP by 
LacZ-S11 fusion as described in Chapter VII. For cloning the metabolic genes, LacZ was 
removed and the S11 fragment was maintained for titer determination. Metabolic 
genes were cloned in the place of LacZ using In-Fusion® HD Cloning Kit (Clontech 
Laboratories, Inc., Terra Bella Avenue, CA, USA). The mock vector was obtained by re-
ligating the lentiviral backbone after LacZ removal.  
For lentiviral transient production the lentiviral packaging system and the 
transfection procedure described in Dull et al. (1998) were adopted using 
pMDLg/pRRE, pRSV-REV, pMD2G and pRRLSIN derived backbones harboring the 
different metabolic genes. pMDLg/pRRE and pRSV-REV are 3rd generation lentiviral 
vector packaging constructs containing HIV1 gag-pol and the second and third exons of 
HIV-1 REV, respectively. pMD2G expresses the envelope G glycoprotein of the 
vesicular stomatitis virus (VSV-G) under the control of a CMV promoter. The three 
plasmids were kindly provided by Dr. D. Trono through Addgene plasmid repository 
(Cambridge, MA, USA). Viral vector supernatants were clarified through 0.45 μm 
cellulose acetate filter, aliquoted and stored at -85ºC until further use. 
 
2.3 Cell growth and viral production studies 
293 FLEX S11, transduced populations and their derived clones were analyzed for 
cell growth and infectious retroviral vector production using a 48+24 hours 
production/harvesting operation mode described in Chapter II (Rodrigues et al. 2013). 
 
2.4 Retro and lentiviral vector titration 
For LacZ based staining titration (retroviral vector production from manipulated 
and non-manipulated cells), infectious procedure and viral titer determination were 
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performed by serial dilution infection assay, as previously described in Rodrigues et al. 
(2009). For GFP transcomplementation titration (lentiviral vector metabolic gene 
stocks), Te 671 S10 target cells were seeded at 5 x 104 cells/cm2 in 24-well plates 24 
hour before infection. Transduction was performed by removing the cell supernatant 
and infecting with 0.2 mL of viral suspension using several dilutions in fresh DMEM 
(Gibco) with 10% (v/v) FBS and 8 μg/mL of polybrene (Sigma). Cells were incubated at 
37ºC overnight after which 0.5 mL of fresh medium was added. Two days after 
infection, cells were harvested and analyzed for GFP fluorescence by flow cytometry 
(CyFlow-space, Partec GmbH).  
 
2.5 Cell transduction for metabolic gene delivery 
Metabolic genes were delivered by lentiviral vector infection of 293 FLEX S11. The 
cells were seeded at a density of 1 x 104 cells/cm2 24 hours before infection in 6-well 
plates. Transduction was performed by removing the cell supernatant and infecting 
with 2 mL of viral suspension using the appropriate dilution to achieve multiplicities of 
infection (infectious particles per cell) of 1, 3 and 5. Dilutions were made in fresh 
DMEM (Gibco) with 10% (v/v) FBS (Gibco) and 8 μg/mL of polybrene (Sigma). Cells 
were incubated at 37ºC overnight after which medium was exchanged. Two days after 
infection, cells were amplified to 75 cm2 t-flasks and re-passaged 3-4 days after. At this 
point, part of the cells was frozen and the other part was seeded to assess infectious 
particles production of transduced populations (section 2.3). Single step cloning 
titration method was then performed.  
 
2.6 Quantification of vector transgene genomic copies, RNA extraction and 
quantitative real-time PCR for gene expression 
Quantification of CBS genomic copies was performed using genomic DNA with the 
primer set (F): 5’ – TCATCGTGATGCCAGAGAAG – 3’ and (R): 5’ – TTGGGGATTTCGTTCTTCAG – 3’. 
Genomic DNA extraction, quantitative real-time PCR and copy number calculations 
were performed as described in Chapter VII (Section 2.4 of Materials and methods). 
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RNA extraction and quantitative real-time PCR were carried as described in Chapter VII 
(Section 2.5 of Materials and methods). 
2.7 Single step cloning-titration procedure 
Single step cloning titration method procedure was performed as described in 
Chapter VII. For the case of cystathionine-beta-synthase (CBS) and cystathionase (CTH) 
transduced cells, medium was fed with glycine, methionine and serine (Sigma) during 
the polybrene addition steps, to replenish their original concentration. These amino 
acids are used by these enzymes in glutathione biosynthesis (refer to Fig. 6) and were 
added given the long-term culture associated to the SSCT method. For the case in 
which oxidative injury was induced, tert-butyl hydroperoxide (TBHP, Sigma) was added 
at a final concentration of 5 μM 24 hours before target cell seeding. For target cell 
seeding, the medium from the wells was completely removed to eliminate THBP traces 
and the protocol was carried as described previously (Chapter VII).  
 
2.8 Data analysis and density distribution curves 
For kernel density distribution curves, the data was treated and processed in 
MATLABTM 7.10 (The MathWorks Inc., Natick, MA, 2000), using the function ksdensity() 
as described in Chapter VII.  Boxplot analysis was also performed in MATLABTM 7.10 
using the function boxplot(). 
 
 
3. Results 
In this work, genes that were previously identified as potential targets to improve 
retrovirus production were manipulated in 293 FLEX S11 producer cells. These cells 
were derived from 293 FLEX 18 through recombinase mediated cassette exchange 
(RCME) (Coroadinha et al. 2006) to exchange the LacZ transgene to LacZ-S11 fusion 
(please refer to Chapter VII for cell line establishment details). The transgene exchange 
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was carried to support the use of the single step cloning-titration method (SSCT) for 
fast screening of high-titer clones. 
The genes chosen to be manipulated in this work are given in Table I. Some of 
them were chosen based on significant differential expression between a high and a 
low producing cell substrate (Chapter II, Table II). Others, although not differentially 
expressed, presented low expression values, having been chosen in an attempt to 
further activate the reactions they are involved in. Others are specific to serum 
independence phenotype: LSS, MVK, SREBF1/2 (Chapter V). All genes belong to 
metabolic pathways recruited in the production of recombinant retrovirus (Chapter II, 
Fig. 1, Rodrigues et al. (2013)). 
 
Table I – Gene candidates to improve retroviral vector production 
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Amino acid metabolism 
   
 
                           
Co-factors metabolism 
   
 
                           
Polyamines metabolism 
   
 
                           
Nucleic acid metabolism 
   
 
                           
Pentose phosphate pathway  
 
 
                           
Glutathione metabolism 
   
 
                           
Lipid metabolism 
   
 
                           
Protein processing in the ER  
  
 
                           
Apoptosis 
   
 
                           
Energy generation 
   
 
                           
Black indicates genes that have already been tested, at least by analyzing average effects on transduced populations. 
Grey indicates genes currently under testing. ASS1: argininosuccinate synthase; ARG1: arginase 1; AZIN1: antizyme 
inhibitor 1; BCL2: B-cell CLL/lymphoma; CBS: cystathionine-beta-synthase; CS: citrate synthase; CTH: cystathionase; 
G6PD: glucose-6-phosphate dehydrogenase; GLUL: glutamate-ammonia ligase; GPX7: glutathione peroxidase 7; GSR: 
glutathione reductase; GSS: glutathione synthase; GSTM1: glutathione S-transferase mu 1; HIF1AN: hypoxia inducible 
factor 1, alpha subunit inhibitor; HSPA5: heat shock 70kDa protein 5; IDH1: isocitrate dehydrogenase 1 (cytosolic); 
IDH2: isocitrate dehydrogenase 2 (mitochondrial); LSS: lanosterol synthase; MTHFD2: methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent) 2; MVK: mevalonate kinase; OAT: ornithine aminotransferase; ODC1: ornithine 
decarboxylase; PDIA2: protein disulfide isomerase 2; PDP1/2: pyruvate dehydrogenase phosphatase, catalytic subunit 
1/2; PNP: purine nucleoside phosphorylase; RPIA: ribose 5-phosphate isomerase A; SLC29A1: solute carrier family 29 
(equilibrative nucleoside transporter), member 1; SREBF1/2: sterol regulatory element binding factor 1/2; XBP1: X-
box binding protein 1. 
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3.1  Controls 
For all the manipulations conducted in this work, genes were delivered by 
lentiviral vector transduction. For each of them, three multiplicities of infection (MOI) 
were tested: 1, 3 and 5. After 4-5 passages following transduction, cells were cloned 
and screened for high titers using the SSCT method. The productivity of infectious 
particles was also assessed for each of the populations. Before starting gene 
manipulation, two types of controls were analyzed: non-transduced and mock 
transduced cells.  
293 FLEX S11 non-transduced cells were subjected to the single step cloning-
titration method 6 independent times to evaluate the reproducibility of the density 
distribution curve (Fig. 2). These replicates include different passages and freezing 
batches.  
 
 
 
Figure 2 – Density distribution of non-transduced cells. Kernel density distribution curve of non-transduced 293 
FLEX S11. Six independent replicates are shown. Each distribution comprises approximately 200 clones 
corresponding to 10 cloning plates, of 60 wells each, at a seeding density of 0.7 cells/well assuming 50% cloning 
efficiency (see Chapter VII). 
 
The density distribution curves of 293 FLEX S11 were found to be similar, with the 
median around 150 RFU and extended tails up to 3000 RFU. The black curve 
represents the combination of these 6 replicates and was used as a representative of 
non-transduced 293 FLEX S11 density distribution curve from herein on.  
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293 FLEX S11 have additionally been transduced with the mock lentiviral vector 
simulating the MOIs used for gene manipulation (1, 3 and 5). The density distribution 
curve of mock transduced cells is shown in Figure 3, as well as specific productivity of 
the populations and their derived clones. 
 
 
 
Figure 3 – Mock transduction of 293 FLEX S11. Kernel density distribution curve of mock transduced cells (A); non-
transduced control is shown in dashed grey. Specific productivity of infectious retroviral particles from 293 FLEX non-
transduced cells, high-fluorescence yielding clones isolated from (A) and/or their corresponding populations (B). Values 
are shown as average ± standard deviation (n=3). 
 
  The major peak of mock curves fell in the same RFU region of that of non-
transduced cells, with slightly lower median (110 RFU) while the tail extended beyond 
that of the control, particularly for mock 1 and mock 3 (Fig. 3A). Therefore, the highest 
fluorescence mock clones were isolated, expanded and analyzed for infectious vector 
titers (Fig. 3B). Although the majority of these were false positives, some of the mock 
clones actually presented increased productivities. The highest producer from these 
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clones delivered 3-fold higher specific productivity of infectious particles titers. 
Therefore, this was set as a confidence threshold for significantly increased titers in 
metabolic gene manipulation.  
 
3.2 Polyamines metabolism 
For the manipulation of polyamines metabolism five genes were considered: 
ASS1, ARG1, OAT, ODC1 and AZIN1 (Fig. 4).  
 
 
 
Figure 4 – Polyamines 
metabolism. Schematic 
representation of polyamines 
metabolism and the targeted 
genes (dark grey boxes). Herein, 
ARG1, ASS1, AZIN1 and ODC1 
have been tested. White boxes 
indicate genes that are poorly 
expressed or non-expressed. For a 
matter of simplicity only the main 
metabolites are shown; thus, the 
reactions are not necessarily 
balanced. AMD1: adenosyl-
methionine decarboxylase 1; 
ASS1: argininosuccinate synthase  
1; ARG1: arginase 1; AZIN1: antizyme inhibitor 1;   CAD:   carbamoyl-phosphate synthetase; DDAH: dimethylarginine 
dimethylaminohydrolase; NOS: nitric oxid synthase; OAT: ornithine aminotransferase; OAZ: ornithine decarboxylase 
antizyme; ODC1: ornithine decarboxylase; OTC: ornithine carbamoyltransferase; PADI: peptidyl arginine deiminase; 
SAT: spermidine/spermine N1-acetyltransferase 1; SRM: spermidine synthase. 
  
Ornithine decarboxylase 1 (ODC1) catalyzes the first step in polyamines 
biosynthesis (Fig. 4). This enzyme is controlled by ornithine decarboxylase antizyme 
(OAZ) becoming inactive and antizyme inhibitor (AZIN1) becoming active (Pegg 2006). 
AZIN1 was over-expressed to promote ODC1 activation. ODC1 itself was also over-
expressed. Argininosuccinate synthase (ASS1) and arginase 1 (ARG1) feed polyamines 
precursors from amino acids. Of notice, ARG1 was found to be non-expressed in 293 
FLEX cells (Chapter II). The three enzymes and the regulatory AZIN1 protein were over-
expressed in 293 FLEX S11. Figure 5 shows density distribution profile of transduced 
cells as well as specific productivity of the populations and their derived clones. 
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Figure 5 – Transduction with ASS1, ARG1, AZIN1 and ODC1. Kernel density distribution curves of non-transduced, ASS1, 
ARG1, AZIN1 and ODC1 transduced 293 FLEX S11 (A). Specific productivity of infectious particles from high-
transcomplemented GFP yielding clones isolated from (A) and/or their corresponding populations (B). “M” stands for 
multiplicity of infection. Values are shown as average ± standard deviation (n=3). Non-transduced control corresponds to 
average of 25 independent replicates (Fig 3). Clones are ordered by fluorescence signal. Only clones with fluorescence 
signals higher than the maximum of non-transduced cells were isolated (Fig. 2). For clones producing more than 3-fold 
higher than non-transduced control, the fold-increase is shown (X-fold). 3-fold was assumed as a confidence threshold 
for specific productivities significantly higher than MOCK transduced cells (Fig. 3). ASS1: argininosuccinate synthase 1; 
ARG1: arginase 1; AZIN1: antizyme inhibitor 1; ODC1: ornithine decarboxylase. 
 
No major increases in the transduced populations were observed for any of the 
delivered genes (Fig. 5B). In fact, except for ASS1, all of the genes appeared to reduce 
average productivity (populations) when increasing MOI. Therefore, MOI 1 was chosen 
to be screened using the SSCT method (Fig. 5A).   
For MOI 1 transduced cells, AZIN1 and ARG1 seemed to displace the major peak 
to higher fluorescence values than those of the control, suggesting an overall 
improvement in infectious particles titer. Yet, no high-producing phenotypes were 
Chapter VIII 
 
221 
 
observed (extended tails beyond the non-transduced control). By opposite, ODC1 
major peak matched that of the control, but the tail extended 3000 RFU above the 
control. Clones isolated from this range were found to produce up to 8-fold higher. 
ASS1 transduced cells, presented the major peak bellow that of the control and no 
high-producing phenotypes were found.   
 
3.3 Glutathione metabolism 
For the manipulation of glutathione metabolism six genes were considered: GPX, 
GST, GSR, GSS, CBS, CTH and IDH1 (Fig. 5).  
 
 
Figure 6 – Glutathione metabolism. 
Schematic representation of 
glutathione metabolism and the 
targeted genes (dark grey boxes). 
Herein, GSS, IDH1, CBS and CTH have 
been tested. For a matter of 
simplicity only the main metabolites 
are shown; thus, the reactions are 
not necessarily balanced. CAT: 
catalase; CBS: cystathionine-beta-
synthase; CTH: cystathionase; G6PD: 
glucose-6-phosphate 
dehydrogenase; GPI: glucose-6-
phosphate isomerase; [GPX]: 
glutathione peroxidases; GSR: 
glutathione reductase; GSS: 
glutathione synthase; [GST]: 
glutathione transferases; IDH1: 
isocitrate dehydrogenase 1 
(cytosolic); SOD: superoxide 
dismutase. 
 
These genes can be divided in two groups: i) those feeding reduced glutathione, 
GSH, biosynthesis (CBS, CTH, GSS and IDH1) and ii) those serving detoxification routes 
(GPX and GST). GSR bridges these two (Fig. 6) and also glutathione metabolism to 
protein processing in the endoplasmic reticulum (refer to section 3.6). This section 
focuses the over-expression of genes from group i). GSR is currently under analysis and 
genes from group ii) are considered for the follow-up of this work. Figure 7 shows 
density distribution profile of transduced cells as well as specific productivity of the 
populations and their derived clones. 
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Figure 7 – Transduction with GSS, IDH1, CBS and CTH. Kernel density distribution curves of non-transduced, GSS, and 
IDH1 transduced 293 FLEX S11 (A). Kernel density distribution curves of non-transduced, CBS and CTH transduced 293 
FLEX S11 (B). Control AA fed refers to 293 FLEX S11 non-transduced control fed with serine and methionine as 
described in Materials and methods for CBS and CTH during SSCT procedure. Specific productivity of infectious 
particles from high-transcomplemented GFP yielding clones isolated from (A and B) and/or their corresponding 
populations (C). “M” stands for multiplicity of infection. Values are shown as average ± standard deviation (n=3). Non-
transduced control corresponds to average of 25 independent replicates (Fig. 3). Clones are ordered by fluorescence 
signal. Only clones with fluorescence signals higher than the maximum of non-transduced cells were isolated (Fig. 2). 
For clones producing more than 3-fold higher than non-transduced control, the fold-increase is shown (X-fold). 3-fold 
was assumed as a confidence threshold for specific productivities significantly higher than MOCK transduced cells (Fig. 
3). CBS: cystathionine-beta-synthase; CTH: cystathionase; GSS: glutathione synthase; IDH1: isocitrate dehydrogenase 
1 (cytosolic).  
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No major differences in the transduced populations were observed for GSS or 
IDH1 (Fig. 7B). Therefore, the intermediated MOI 3 was chosen to be screened using 
the SSCT method (Fig. 7A). IDH1 presented an extended tail, 2000 RFU above the 
control. Yet, none of the isolated clones was found to be a high producing phenotype. 
One of the clones produced 2.5-fold higher, but this falls below the mock variability 
threshold (3-fold, Fig. 3). In GSS, the tail extended 3000 RFU above the control (Fig. 
7A) and clones isolated from this range produced up to 13-fold higher (Fig. 7C). For 
CBS, not only the curve tail extended 3000 RFU above the control, as it presented 
high density in this range, denoting high amount of high producing clones (Fig. 7B). 
The majority of the clones isolated from this range presented significant titer 
improvements, up to 15-fold. For CTH clones, the behavior was more like GSS, with 
fewer amounts in high fluorescence ranges. These clones are currently under analysis 
to assess specific productivity. 
 
3.4 Protein processing in the ER 
For the manipulation of the machinery involved in protein processing in the 
endoplasmic reticulum (ER) four genes were considered: HSPA5, PDIA, XBP1 and GSR 
(Fig. 8).  
 
 
 
Figure 8 – Protein 
processing in the 
endoplasmic 
reticulum. Schematic 
representation of 
protein processing in 
the endoplasmic 
reticulum (ER) and 
the targeted genes 
(dark grey boxes). 
Herein, HSPA5 and 
XBP1 were evaluated. 
For a matter of 
simplicity only the 
main metabolites are 
shown; thus, the 
reactions are not 
necessarily balanced. 
CALC: calreticulin;  
CANX: calnexin; ERN1: endoplasmic reticulum to nucleus signaling 1; GSR: glutathione reductase; HSPA5: heat shock 
70kDa protein 5; PDIA: protein disulfide isomerase; XBP1: X-box binding protein 1 
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Figure 9 shows density distribution profile of transduced cells as well as specific 
productivity of the populations and their derived clones. 
 
 
Figure 9 – Transduction with XBP1 and HSPA5. Kernel density distribution curves of non-transduced, XBP1 and 
HSPA5 transduced 293 FLEX S11 (A). Specific productivity of infectious particles from high-transcomplemented GFP 
yielding clones isolated from (A) and/or their corresponding populations (B). “M” stands for multiplicity of infection. 
Values are shown as average ± standard deviation (n=3). Non-transduced control corresponds to average of 25 
independent replicates (Fig. 3). Clones are ordered by fluorescence signal. Only clones with fluorescence signals 
higher than the maximum of non-transduced cells were isolated (Fig. 2). For clones producing more than 3-fold 
higher than non-transduced control, the fold-increase is shown (X-fold). 3-fold was assumed as a confidence 
threshold for specific productivities significantly higher than MOCK transduced cells (Fig. 3). HSPA5: heat shock 
70kDa protein 5; XBP1: X-box binding protein 1. 
 
Transduced populations readily presented increased (average) productivities, 
both for XBP1 and HSPA5 (Fig. 9B). The intermediated MOI 3 appeared to be that with 
higher improvements and was screened with the SSCT method (Fig. 9A).   
HSPA5 presented an extended tail, 5000 RFU above the control and the majority 
of the isolated clones were high-titer phenotypes, producing up to 7-fold more. For 
XPB1, the extended tail did not exceeded 2500 RFU above the control but also high-
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titer phenotypes, producing up to 7-fold more could be isolated. The higher 
fluorescence values in HSPA5 were, in part, derived from an average larger colony size 
(data not shown).  
 
3.5 Apoptosis 
For the manipulation of apoptosis, B-cell CLL/lymphoma 2 (BCL2) gene was over-
expressed in 293 FLEX S11 using an MOI of 5. Figure 10A and C shows, respectively, the 
density distribution profile of transduced cells and specific productivity of their derived 
clones. This same population was screened using the SSCT method during the 
exposure to an oxidative stress environment (Fig. 10B). BCL2 transduced cells 
presented an extended tail, 2000 RFU above the control, although with low density 
(Fig. 10A). Still, all the clones isolated presented increased productivities, some of 
them up to 5-fold more (Fig 10C).  
When exposed to an oxidative environment, both transduced and non-transduced 
cells presented a down-shifting of the major peak and the extended tail also fell below 
that of the (non-oxidative stress exposed) control. Still, BCL2 transduced cells always 
presented higher clone density indicating increased cell survival. 
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Figure 10 – Transduction with BCL2. Kernel density distribution 
curves of BCL2 transduced 293 FLEX S11, MOI of 5, without 
exposure to TBHP (A). Kernel density distribution curves of non-
transduced and BCL2 transduced 293 FLEX S11 under oxidative e 
stress conditions (B). Cloning plates were exposed to 5 μM of tert-
butyl hydroperoxide (TBHP) during the 24 hours before target cells 
addition as described in Materials and methods. Non-exposed 293 
FLEX S11 (Fig. 2) is also shown as a negative control. For (A) each 
distribution comprises approximately 200 clones corresponding to 
10 cloning plates, of 60 wells each, at a seeding density of 0.7 
cells/well assuming 50% cloning efficiency. For (B) these 
parameters cannot be assumed since oxidative stress exposure 
should significantly reduce cloning efficiency. Specific productivity 
of infectious particles from high-transcomplemented GFP yielding 
clones isolated from (B) (C). “M” stands for multiplicity of infection. 
Values are shown as average ± standard deviation (n=3).      Non- 
transduced control corresponds to average of 25 independent replicates (Fig. 3). Clones are ordered by fluorescence 
signal. Only clones with fluorescence signals higher than the maximum of non-transduced cells were isolated (Fig. 2).  
For clones producing more than 3-fold higher than non-transduced control, the fold-increase is shown (X-fold). 3-fold 
was assumed as a confidence threshold for specific productivities significantly higher than MOCK transduced cells (Fig. 
3). BCL2: B-cell CLL/lymphoma 2. 
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3.6 Energy metabolism  
For the manipulation of the energy metabolism the approach of down-regulating 
the Warburg effect was re-assessed (Chapter VI). In our previous proof-of-concept 
study, specific productivities of 293 FLEX GFP could be improved, on average 20-fold, 
using short hairpin RNA interference against hypoxia inducible factor 1 (HIF1) and 
pyruvate dehydrogenase kinase (Chapter VI). However, the deleterious off-target 
effects of using short hairpin RNA interference limited the combination of these two 
down-regulations and, to a certain extent, may have skewed the real effect of HIF1 and 
PDK reduction in infectious virus production.  
In this part of the work, we aimed at improving the energy generation metabolism 
by i) simulating the down-regulation of HIF1 and PDK avoiding down-regulation tools 
(i.e. RNA interference) and ii) increasing the expression of potentially limiting genes 
(Fig. 11).  
 
 
Figure 11 – Manipulation of the energy 
generation metabolism.       Schematic 
representation of the integration of energy 
metabolism through glycolysis, TCA and 
oxidative phosphorylation. It is additionally 
represented the Warburg effect lactogenic 
phenotype mediated by HIF1, which activates 
glycolytic enzymes, LDH and PDK. The latter 
inactivates PDH by phosphorylation limiting the 
entrance of pyruvate into the TCA (for further 
details please refer to Chapter VI).   
Manipulation targets are shown in dark grey. 
The over expression of HIF1AN and PDP is 
expected to promote identical effects to HIF1 
and PDK down-regulation, respectively. CS and 
IDH2 over-expression is expected to push TCA 
towards citrate and NADH generating reactions. 
ACO2: aconitase 2; ATP5: ATP synthase; CS: 
citrate synthase; CYC1: cytochrome c-1; FH: 
fumarate hydratase; HIF1AN: hypoxia inducible 
factor 1, alpha subunit inhibitor; IDH2: isocitrate 
dehydrogenase 2 (mitochondrial); LDH: lactate 
dehydrogenase; MDH2: malate dehydrogenase 2 
(mitochondrial); OGDH: oxoglutarate (alpha-
ketoglutarate) dehydrogenase; PDH: pyruvate 
dehydrogenase complex; PDK: pyruvate 
dehydrogenase kinase; PDP: pyruvate 
dehydrogenase phosphatase; SUCLG2: 
succinate-CoA ligase; SDH: succinate 
dehydrogenase complex. 
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For i), the manipulation targets considered were hypoxia inducible factor 1 alpha 
subunit inhibitor (HIF1AN), pyruvate dehydrogenase phosphatase 1 and 2 (PDP 1 and 
2); for ii), citrate synthase (CS) and isocitrate dehydrogenase 2 (mitochondrial) (IDH2) 
were chosen (Fig. 11). Herein, HIF1AN and IDH2 were analyzed. 
Figure 7 shows density distribution profile of transduced cells as well as specific 
productivity of the populations and their derived clones.  
 
 
 
Figure 12 – Transduction with HIF1AN and IDH2. Kernel density distribution curves of non-transduced, HIF1AN and 
IDH2 transduced 293 FLEX S11 (A). Each distribution comprises approximately 200 clones corresponding to 10 cloning 
plates, of 60 wells each, at a seeding density of 0.7 cells/well assuming 50% cloning efficiency. Specific productivity of 
infectious particles from high-transcomplemented GFP yielding clones isolated from (A) and/or their corresponding 
populations (B). “M” stands for multiplicity of infection. Values are shown as average ± standard deviation (n=3). Non-
transduced control corresponds to average of 25 independent replicates (Fig. 3). Clones are ordered by fluorescence 
signal. Only clones with fluorescence signals higher than the maximum of non-transduced cells were isolated (Fig. 2). 
For clones producing more than 3-fold higher than non-transduced control, the fold-increase is shown (X-fold). 3-fold 
was assumed as a confidence threshold for specific productivities significantly higher than MOCK transduced cells (Fig. 
3). HIF1AN: hypoxia inducible factor 1, alpha subunit inhibitor; IDH2: isocitrate dehydrogenase 2 (mitochondrial). 
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For IDH2, no high-titer phenotypes could be isolated. However, clone density for 
fluorescence values above 500 RFU was considerably higher than that of the controls, 
suggesting average improvements (Fig. 12A). On the other hand, for HIF1AN 
transduced cells, the tail extended almost 11000 RFU above the control. Clones 
isolated from this range, were found to produce up to 7-fold higher than non-
transduced cells. Still, the majority of these clones were not analyzed. Further analysis 
will be required. 
 
3.7 Overall analysis and curve validation 
In the above sections, each of the genetic modifications was analyzed individually. 
In this section, the data was gathered into boxplots to provide a global overview of all 
the manipulations conducted. Some of the curves were re-analyzed by conducting the 
SSCT method on the same population but different passages or by establishing new 
populations with different lentiviral vector batches (Fig. 13). 
The same populations, independently analyzed, were found to yield similar 
distributions. Slight variations can arise, but the median and quartile distribution 
around the median appeared identical. For populations established with new lentiviral 
vector stocks, we found median and quartile distribution around the median to be 
shifted – to higher or lower fluorescence values – although high-producing phenotypes 
are still obtained.  
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Figure 13 – Boxplot analysis of gene manipulations conducted in this work. Grey dashed box indicates the third 
quartile of non-transduced cells (Fig. 2). Purple dashed line indicates the threshold for high-producing phenotypes 
given by maximum titer increase in mock transduced controls (Fig. 3). Average improvements were considered when 
the third quartile of manipulated cells exceeds that of non-transduced controls, while deleterious effects were 
considered for the third quartile bellow that of non-transduced cells. For CBS, ODC1 and HIF1AN, the curves were 
independently re-analyzed by repeating the SSCT procedure with the same population but different passages (first 
batch second cloning) and/or by establishing new populations but using new lentiviral vector stocks (second batch). 
“M” stands for multiplicity of infection. Genes are grouped by targeted pathway. ASS1: argininosuccinate synthase 1; 
ARG1: arginase 1; AZIN1: antizyme inhibitor 1; BCL2: B-cell CLL/lymphoma 2; CBS: cystathionine-beta-synthase; CTH: 
cystathionase; GSS: glutathione synthase; HIF1AN: hypoxia inducible factor 1, alpha subunit inhibitor; HSPA5: heat 
shock 70kDa protein 5; IDH1: isocitrate dehydrogenase 1 (cytosolic); IDH2: isocitrate dehydrogenase 2  
(mitochondrial); ODC1: ornithine decarboxylase. XBP1: X-box binding protein 1. N/A: not applicable; refers to cells 
exposed to oxidative stress injury (tert-butyl hydroperoxide, Fig. 10).  
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3.8 Impact of metabolic genes on viral production dynamics – a preliminary 
analysis with the CBS case study 
 
The over-expression of certain genes has been showing to significantly impact 
infectious virus titers. Yet, as important as identifying new (and old) genes delivering 
high titers is the understanding on the changes promoting such improvements. In this 
context, CBS over-expression was studied in deeper detail in terms of number of 
delivered copies, how it translated into gene expression levels (mRNA) and how it 
modulates vector components dynamics and infectious particles titers (Fig. 14).  
 
 
 
Figure 14 – Gene expression 
patterns and infectious viral titers 
in response to increasing CBS 
transduction load. Relative number 
of genomic copies and gene 
expression level of CBS gene in 
response to increasing multiplicities 
of infection for gene delivery (A). 
Gene expression of viral 
components and specific 
productivity of infectious viral titers 
in response to increasing 
multiplicities of infection for gene 
delivery (B). RNT indicates genomic 
copy number relatively to non-
transduced 293 FLEX S11 cells and 
was quantified after normalization 
to a control gene (RPL22) using the 
2-ΔΔCt method as defined in 
Materials and Methods. Vector 
components expression represents 
average expression level 
normalized to the RPL22 
housekeeping control (2ΔCT). Values 
are shown as ‘average ± standard 
deviation’ (n=2). Specific 
productivity refers to infectious 
retroviral particles quantified by 
LacZ staining as defined in 
Materials and methods. Values are 
shown as ‘average ± standard 
deviation’ (n=3). Increasing 
multiplicities of infection (MOI) 
were achieved by re-infecting the 
previous MOI population, with an 
MOI of 5. All MOIs represent cell 
populations.  
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CBS gene copy number appeared to directly correlate with the multiplicity of 
infection, demonstrating effective gene delivery. Gene expression of CBS also was 
found to increase but for higher MOIs, tended to reach a plateau (Fig. 14A). Infectious 
particles titers followed an identical behavior (Fig. 14B). For viral components gene 
expression, gag-pol and envelope appeared as relatively unchanged, while the viral 
transgene presented sharp increases, directly correlated with the multiplicity of 
infection (Fig. 14B). 
 
 
4. Discussion 
During the last decade a body of evidences indicates that metabolic engineering 
of mammalian cells should be conducted in a multi-gene manipulation approach to 
potentiate the combination of favorable physiological traits (Lim et al. 2010; Seth et al. 
2007; Seth et al. 2006). On the other hand, multi-gene engineering has been hampered 
by the lack of high-throughput power for clone screening, rendering the manipulation 
of more than 2-3 genes extremely difficult.  
In this work, we set up the basis for multi-gene engineering of mammalian cell 
metabolism using, as study model, a human cell line producing recombinant retrovirus. 
To face the challenge of clone screening, a novel method for fast identification of high-
titer clones was established by merging cell cloning and virus titration: the single step 
cloning-titration method (SSCT, Chapter VII). Assisted by a previous study on the 
metabolic networks recruited when establishing a retrovirus producer cell line 
(Chapter II, Rodrigues et al. (2013)), more than 30 candidates, including metabolic and 
regulatory genes, were chosen for manipulation (Table I). Currently, 17 of those 
candidates have already been evaluated. Four of these 17 genes were used to 
manipulate lipid metabolism in an attempt to revert serum heterotrophy in retroviral 
vector production (Chapter V). The remaining 13 genes were evaluated herein and 
their effects on infectious virus production are discussed bellow.  
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When analyzing non-transduced controls subject to independent SSCT rounds, we 
found that, although their density distribution curves was relatively similar, centered 
on 150 RFU, extended tails up to 3000 RFU could also be observed (Fig. 2). These tails 
may seem to contradict the fact that 293 FLEX S11 derives from a single clone. 
However, as discussed in Chapter VII, differences can arise from variations in the 
location of the colony in the cloning well during the SSCT procedure. Additionally, 
some degree of variability is inevitable: even non-transduced cells are known to 
present phenotypic variability despite repeated rounds of cloning (Barnes et al. 2006). 
These variations might be related to epigenetics (Kim et al. 2009). Apart from that, the 
transduction-induced variability had also to be taken into account. Indeed, some mock 
clones presented productivity improvements up to 3-fold, although no gene was being 
delivered. Yet, when comparing the boxplot distributions of non-transfected and 
mock-transfected controls, it become clear that these were rare and random events as 
no average improvements occurred for mock populations (Fig. 13). In fact, a slight 
reduction could be observed.  
In the manipulation of polyamines metabolism the transduction with antizyme 
inhibitor (AZIN1) and arginase 1 (ARG1) suggested an overall improvement in 
infectious particles titer although no high-producing phenotypes were observed (Fig. 
5A and Fig. 13). The upstream location of ARG1 in feeding polyamines biosynthesis is in 
line with these results since, its over-expression might not be translated into higher 
production if, for instance, the downstream machinery is limiting (Fig. 4). For AZIN1, 
however, one could expect a more evident improvement and/or high-producing 
phenotypes, considering it directly activates ornithine decarboxylase (ODC1), 
catalyzing the first step in polyamines biosynthesis (Fig. 4). When directly over-
expressing ODC1, high-producing phenotypes (up to 8-fold increase) could be isolated 
(Fig. 5B). Moreover, a second ODC1 population transduced with MOI of 3 presented an 
obvious up-shifting of the second and third quartiles to higher fluorescence values 
indicating enhanced improvements (Fig. 14). Thus, the low MOI used to deliver 
polyamines biosynthesis genes (MOI of 1) may be insufficient to evaluate the full 
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extent of their effects. Argininosuccinate synthase (ASS1) transduction seemed to 
induce an overall down-regulation on infectious particles productivity. It could be 
hypothesized that, since ASS1 feeds citrulline – unable to be converted to ornithine 
given the poor expression of ornithine carbamoyltransferase (OTC, Fig. 4) – this could 
favor other citrulline-fed pathways eventually deleterious for virus production. From 
this perspective, over-expressing ornithine synthesizing enzymes (as ARG1) would be a 
preferable approach. The over-expression of ornithine aminotransferase (OAT), 
considered for future manipulation, also fits this purpose (Fig. 4). Nevertheless, ASS1’s 
were the only transduced populations from polyamines metabolism manipulation 
presenting higher average productivities when increasing the MOI (Fig. 5B). Therefore, 
also for ASS1 higher MOIs should be evaluated by the SSCT method to better clarify 
the effects of its over-expression into virus production. In addition to cell growth, 
polyamines can bind to nucleic acids participating in their stabilization, modulate gene 
transcription events, play a role in membrane rigidity and present anti-oxidant 
properties (Wallace et al. 2003). These properties can have a beneficial effect on viral 
production, particularly by stabilizing viral genome leading to improved encapsidation, 
changing viral membrane rigidity and preventing its lipid peroxidation. They have also 
been reported to improve viral DNA polymerase activity (Marcus et al. 1981). 
Polyamines metabolism has not, up to the date, been considered in metabolic 
engineering approaches.  
In the manipulation of glutathione metabolism, the over-expression of 
glutathione synthase (GSS) could be translated in titer improvements up to 13-fold 
(Fig. 7C), while the over-expression of isocitrate dehydrogenase 1 (IDH1) only delivered 
2.5-fold. Although this does not pass the mock-set threshold (3-fold) to be considered 
significant, IDH1 over-expression translated into overall improvements (Fig. 13). 
Thereby, it is possible that this 2.5-fold increase, is effectively related to IDH1. 
Combining IDH1 over-expression on the top of GSS manipulation should be performed 
to evaluate potential cumulative effects. Still in the glutathione metabolism, 
cystathionine-beta-synthase (CBS) revealed to be a very potent gene to improve viral 
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productivity (Fig. 7B). Not only the curve tail extended above the control, as it 
presented high density in this range, denoting high amount of high producing clones, 
by opposite to more rare behavior in GSS. Indeed, the majority of the clones isolated 
from this range presented high titer improvements, up to 15-fold, relatively to non-
transduced cells. This behavior was so impressive that CBS population, MOI 3, was 
reanalyzed after a few passages. Also, a second population was established using a 
newly produced lentiviral stock (Fig. 13). In all the cases, high concentration of high-
titer phenotypes was observed. Interestingly, for the secondly transduced population, 
a shift to higher fluorescence values occurred, suggesting that, apart from the 
delivered gene, the lentiviral vector stock used to transduced the cells influences the 
final performance of infectious particles productivity. It is noteworthy that the 
manipulation of glutathione metabolism translated in the highest titer improvements 
from all the genes evaluated in this work. Indeed, glutathione metabolism is 
transversal to key pathways including glycolysis, pentose phosphate pathway and 
protein processing in the endoplasmic reticulum and serves important detoxification 
routes. All of these are likely to contribute to improved cell robustness and increased 
viral production. Glutathione metabolism has not, up to the date, been considered in 
metabolic engineering approaches. 
In the manipulation of protein processing in the endoplasmic reticulum (ER), heat 
shock 70kDa protein 5 (HSPA5, also called HSP70) manipulated cells presented an 
extended tail, 5000 RFU above the control and the majority of the isolated clones were 
high-titer phenotypes, producing up to 7-fold more. However, considering, for 
instance, CBS curve, which extended 3000 RFU above the controls and contained 
clones producing up to 15-fold higher, 7-fold increase for a 5000 RFU extension might 
seem disappointing. Yet, HSPA5 colonies were considerable higher than those of non-
transduced controls. Interestingly, these clones do not seem to grow faster, thus 
suggesting that the bigger colonies by the end of cloning procedure may result from an 
earlier replication beginning after the single cell is seeded on the well. HSP70 has been 
used for engineering mammalian cell lines producing recombinant proteins. Lasunskaia 
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et al. (2003) reported increased cell viability, stress resistance and monoclonal 
antibody stability in the culture medium by over-expressing HSP70 in NS0 hybridoma 
cells, although with no productivity increase. Later on, Ishaque et al. (2007), achieved 
enhanced secretion of recombinant factor VIII and also increased resistance to 
apoptosis in BHK-21 cells.  
Still in the manipulation of protein processing in the ER, X-box binding protein 1 
(XBP1), one of the identified genes arising from the transcriptional comparison high vs. 
low producer was also targeted. High-titer clones, producing up to 7-fold more, could 
be isolated (Fig. 9B). XBP1 is known to be a key regulator in the differentiation of B 
cells into immunoglobulin-secreting plasma cells, activating several genes of secretory 
pathway, physically expanding the ER, increasing cell size, lysosome content, 
mitochondrial mass and function, ribosome numbers and total protein synthesis 
(Shaffer et al. 2004). Thus, it appears to be a general organelle biogenesis factor more 
than a specific tool for any single pathway. XBP1 has been previously used for 
engineering CHO cells (Tigges and Fussenegger 2006). The authors reported the 
expansion of the endoplasmic reticulum and the Golgi with an increase in the overall 
production capacity. Interestingly, they also reported the same manipulation not to be 
functional in other cell lines, including HEK 293. In fact, boxplot analysis showed a 
rather limited effect on overall productivity performance of transduced cells (Fig. 13). 
However, two high-producing phenotypes, with productivity improvements up to 7-
fold were obtained, unlikely to be randomly derived from transduction-induced 
phenotypic variability. It should be noted that both HSPA5 and XPB1, by increasing the 
overall capacity of protein processing, reduce the burden of ER stress thereby 
increasing cellular resistance to apoptosis (Chakrabarti et al. 2011). In fact, viral 
replication is known to increase ER stress and unfolded protein response, potentially 
leading to apoptosis (Zhang and Wang 2012), substantiating the over-expression of 
HSPA5 and XPB1 to improve virus production. 
For the direct manipulation of apoptosis, B-cell CLL/lymphoma 2 (BCL2), also 
identified as a potential target to improve viral productivity from the transcriptional 
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comparison high vs. low producer (Chapter II), was targeted. BCL2 transduced cells 
contained high-producing phenotypes up to 5-fold increase relatively to non-
transduced cells. Additionally, we observed higher robustness to stressful conditions of 
BCL2 transduced cells, by inducing oxidative injury (Fig. 10B). Therefore, BCL2 over-
expression not only delivered more resistant cells – as already reported for other 
mammalian production systems (Meents et al. 2002) – but was confirmed as a gene 
target to improve specific productivity of infectious virus. Anti-apoptosis metabolic 
engineering has, indeed, been extensively used to increase the robustness and extend 
the life span of cultured mammalian cells producing recombinant protein. Increased 
productivities are often obtained, although mainly based on volumetric productivity 
(for a review see Majors et al. (2007)). For the specific case of virus production, the 
subject requires a finer analysis, as virus replication is already accompanied by strong 
anti-apoptotic mechanisms as part of the viral replication strategy and many viruses 
carry their own BCL2 homologs (Tschopp et al. 1998). Although this is not the case of 
murine leukemia (retro)virus, BCL2 over-expression is one of the hallmarks of 
leukemia, therefore a potentially important gene in MLV replication and pathogenesis 
(Butturini and Gale 1990). 
In the manipulation of energy metabolism we sought for improving energy 
generation by simulating the down-regulation of the Warburg effect, and by over-
expressing the TCA cycle enzymes catalyzing the reactions downstream of acetyl-CoA 
entrance to stimulate enhanced TCA activity (Fig. 11). Hypoxia inducible factor 1 
inhibitor (HIF1AN) was over-expressed an attempt to simulate hypoxia inducible factor 
1 (HIF1) down-regulation while avoiding the deleterious effects of RNA interference. 
Clones producing up to 7-fold more than non-transduced cells were obtained (Fig. 12). 
Comparatively to the average 20-fold increase obtained with 293 FLEX GFP in Chapter 
VI, 7-fold may seem modest. Yet, 293 FLEX GFP produce in the range of 0.5-2 x 106 
infectious particles per mL while 293 FLEX S11 produce one order of magnitude higher. 
For IDH2 transduction, no high-titer phenotypes could be isolated although the clone 
density for higher fluorescence values suggested average improvements (Fig. 12A). 
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This is thus a candidate gene to be added to HIF1AN high-titer clones to potentiate 
synergistic effects. The physiological implications of down-regulating the Warburg 
effect in retrovirus producer cells have been discussed in Chapter VI. From a more 
global perspective, increasing the channeling of pyruvate into TCA and improving its 
activity leads to enhanced energy generation with less formation of toxic by-products 
(e.g. lactate). For an energetically expensive product, such as viral particles, this should 
be of increased importance. Also, TCA intermediates feed important pathways, 
including lipid metabolism, relevant for several aspects of viral replication (Heaton and 
Randall 2011). Yet, it is worthy highlighting that the Warburg effect with the reduction 
of TCA activity in cultured mammalian cells is believed to provide a proliferative 
advantage based on reduced oxidative stress burden, due to low oxidative 
phosphorylation (Shlomi et al. 2011). Therefore, engineering strategies aiming at 
increasing TCA activity and energy generation at the level of oxidative phosphorylation 
should benefit from a combination with genes involved in reactive oxygen species 
scavenging, such as those of glutathione metabolism (Fig. 6). 
The over-expression of certain genes showed to significantly impact infectious 
virus titers. However, as important as identifying genes prompting higher titer, is the 
understanding on the changes promoting such improvements. In this context, CBS 
over-expression was studied in detail in terms of number of delivered copies, how it 
translated into gene expression levels (mRNA) and how it modulates vector 
components dynamics and infectious particles titers (Fig. 14). CBS gene copy number 
was found to directly increase with increasing multiplicities of infection (Fig. 14A). 
These results demonstrated not only effective gene delivery but also no signals of 
transduction inhibition in cells already infected. This is of particular relevance in the 
follow-up of this work which shall be based on multiple lentiviral transduction of 
different genes. Interestingly, for multiplicity of infection 5, the number of CBS 
genomic copies was found to be around 50-times that of non-transduced cells (Fig. 
14). Considering that genomic copy number of CBS in non-transduced cells is unlikely 
to be 10 – corresponding to karyotype quintuplication – these results indicate an 
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under-estimation of the infectious titers in metabolic gene lentiviral stocks. This 
under-estimation had been previously detected for S11 transcomplementation 
titration (Chapter VII). Gene expression of CBS (mRNA) also was found to increase but 
for higher MOIs, tended to reach a plateau (Fig. 14A). Indeed, although the genomic 
copy number could, theoretically, be increased up to the infinitum, gene expression 
would always be inherently limited by the transcriptional machinery – ribosomes, 
polymerases and nucleotides.  For viral components gene expression, gag-pol and 
envelope appeared as relatively unchanged, while the viral transgene presented sharp 
increases, directly correlated with the multiplicity of infection. Interestingly, infectious 
viral titers correlated better with CBS gene expression – also reaching a plateau – than 
with viral transgene expression, which kept increasing (Fig. 14B). This last result is of 
particular relevance for two reasons: i) it strengths a pattern observed for all the high 
titer-yielding manipulations conducted during this thesis in which high titer clones 
were intrinsically associated to enhanced viral transgene expression but more 
importantly, ii) it suggests that high viral transgene expression levels are a 
consequence of over-expressing the metabolic gene, rather than the cause for high 
titers.  
For all the clones isolated during this work, an extensive characterization is 
further required including: i) evaluation of physical and genome-containing particles 
production, ii) quantification of gene expression by qRT-PCR of the delivered genes 
and also of the viral component genes and iii) western-blotting analysis on the protein 
encoded by the delivered gene. For some of the already analyzed clones, the 
expression of the delivered genes was found to increase between 1.5- to 3-fold, in line 
with the low multiplicities of infections used and the moderate strength of the 
promoter driving metabolic genes expression (PGK). Increased protein levels were also 
confirmed (for GSS and CBS clones). All of the (high-titer) analyzed clones additionally 
revealed substantial expression changes in viral components, most notably, on viral 
transgene.  
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From the 13 genes studied, 10 are, to the best of our knowledge, herein reported 
as metabolic engineering targets for the first time. Thirteen additional targets are 
under evaluation. After this first stage on assessing average productivity effects and 
screen for high-titer phenotypes for each gene, those found to deliver significant titer 
improvement should be combined: i) on an intra-pathway basis and ii) on an inter-
pathway basis on a last stage.  
The work herein described sets the basis for a pioneer multi-gene manipulation 
approach. It is the most extensive metabolic engineering study performed in 
mammalian cells, so far, further enlightening virus-host metabolic interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VIII 
 
241 
 
5. Author contribution 
Ana Filipa A. F. Rodrigues participated on the experimental setup and design, 
performed part of the experiments, analyzed the data and wrote the chapter.  
 
6. References 
Barnes LM, Moy N, Dickson AJ. 2006. Phenotypic variation during cloning procedures: analysis of the 
growth behavior of clonal cell lines. Biotechnol Bioeng 94(3):530-7. 
Butturini A, Gale RP. 1990. Oncogenes and leukemia. Leukemia 4(2):138-60. 
Chakrabarti A, Chen AW, Varner JD. 2011. A review of the mammalian unfolded protein response. 
Biotechnol Bioeng 108(12):2777-93. 
Coroadinha AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ. 2006. The use of 
recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and 
efficiency by transgene exchange. J Biotechnol 124(2):457-68. 
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-generation 
lentivirus vector with a conditional packaging system. J Virol 72(11):8463-71. 
Edwards JS, Palsson BO. 1999. Systems properties of the Haemophilus influenzae Rd metabolic 
genotype. J Biol Chem 274(25):17410-6. 
Fussenegger M, Schlatter S, Datwyler D, Mazur X, Bailey JE. 1998. Controlled proliferation by 
multigene metabolic engineering enhances the productivity of Chinese hamster ovary cells. Nat 
Biotechnol 16(5):468-72. 
Heaton NS, Randall G. 2011. Multifaceted roles for lipids in viral infection. Trends Microbiol 
19(7):368-75. 
Ishaque A, Thrift J, Murphy JE, Konstantinov K. 2007. Over-expression of Hsp70 in BHK-21 cells 
engineered to produce recombinant factor VIII promotes resistance to apoptosis and enhances 
secretion. Biotechnol Bioeng 97(1):144-55. 
Kim JK, Samaranayake M, Pradhan S. 2009. Epigenetic mechanisms in mammals. Cell Mol Life Sci 
66(4):596-612. 
Kim TY, Sohn SB, Kim YB, Kim WJ, Lee SY. 2011. Recent advances in reconstruction and applications 
of genome-scale metabolic models. Curr Opin Biotechnol 23(4):617-23. 
Lasunskaia EB, Fridlianskaia, II, Darieva ZA, da Silva MS, Kanashiro MM, Margulis BA. 2003. 
Transfection of NS0 myeloma fusion partner cells with HSP70 gene results in higher hybridoma yield 
by improving cellular resistance to apoptosis. Biotechnol Bioeng 81(4):496-504. 
Lim Y, Wong NS, Lee YY, Ku SC, Wong DC, Yap MG. 2010. Engineering mammalian cells in 
bioprocessing - current achievements and future perspectives. Biotechnol Appl Biochem 55(4):175-
89. 
Majors BS, Betenbaugh MJ, Chiang GG. 2007. Links between metabolism and apoptosis in 
mammalian cells: applications for anti-apoptosis engineering. Metab Eng 9(4):317-26. 
Marcus SL, Smith SW, Bacchi CJ. 1981. Polyamines stimulate DNA-directed DNA synthesis catalyzed 
by mammalian type C retroviral DNA polymerases. J Biol Chem 256(7):3460-4. 
Multi-gene engineering retrovirus producer cell 
 
242 
 
Meents H, Enenkel B, Eppenberger HM, Werner RG, Fussenegger M. 2002. Impact of coexpression 
and coamplification of sICAM and antiapoptosis determinants bcl-2/bcl-x(L) on productivity, cell 
survival, and mitochondria number in CHO-DG44 grown in suspension and serum-free media. 
Biotechnol Bioeng 80(6):706-16. 
Palsson BØ. 2006. Systems biology - Properties of reconstructed networks. New York: Cambridge 
University Press. 
Pegg AE. 2006. Regulation of ornithine decarboxylase. J Biol Chem 281(21):14529-32. 
Rodrigues AF, Carmo M, Alves PM, Coroadinha AS. 2009. Retroviral vector production under serum 
deprivation: The role of lipids. Biotechnol Bioeng 104(6):1171-81. 
Rodrigues AF, Formas-Oliveiras AS, Bandeira VS, Alves PM, Hu WS, Coroadinha AS. 2013. Metabolic 
pathways recruited in the production of a recombinant enveloped virus: mining targets for process 
and cell engineering. Metabolic Engineering 20:131-145. 
Schucht R, Coroadinha AS, Zanta-Boussif MA, Verhoeyen E, Carrondo MJ, Hauser H, Wirth D. 2006. A 
new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated 
site-specific integration of retroviral vectors. Mol Ther 14(2):285-92. 
Seth G, Charaniya S, Wlaschin KF, Hu WS. 2007. In pursuit of a super producer-alternative paths to 
high producing recombinant mammalian cells. Curr Opin Biotechnol 18(6):557-64. 
Seth G, Hossler P, Yee JC, Hu WS. 2006. Engineering cells for cell culture bioprocessing--physiological 
fundamentals. Adv Biochem Eng Biotechnol 101:119-64. 
Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, Rosenwald 
A and others. 2004. XBP1, downstream of Blimp-1, expands the secretory apparatus and other 
organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21(1):81-93. 
Shlomi T, Benyamini T, Gottlieb E, Sharan R, Ruppin E. 2011. Genome-scale metabolic modeling 
elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput Biol 
7(3):e1002018. 
Tigges M, Fussenegger M. 2006. Xbp1-based engineering of secretory capacity enhances the 
productivity of Chinese hamster ovary cells. Metab Eng 8(3):264-72. 
Tschopp J, Thome M, Hofmann K, Meinl E. 1998. The fight of viruses against apoptosis. Curr Opin 
Genet Dev 8(1):82-7. 
Wallace HM, Fraser AV, Hughes A. 2003. A perspective of polyamine metabolism. Biochem J 376(Pt 
1):1-14. 
Wand MP, Jones MC. 1995. Kernel Smoothing (Chapman & Hall/CRC Monographs on Statistics & 
Applied Probability). Boca Raton, FL, USA: Chapman and Hall/CRC. 
Zhang L, Wang A. 2012. Virus-induced ER stress and the unfolded protein response. Front Plant Sci 
3:293. 
 
 
 
 
 
 
Chapter IX 
 
 
 
 
 
 
DISCUSSION AND PERSPECTIVES 
 
 
 
 
 
 
 
 
 
Discussion and perspectives 
 
244 
 
Contents 
1. Discussion and perspectives .................................................................... 245 
1.1 Metabolic determinants in retroviral vector replication: 
transcriptomics, metabolomics and pathway analysis ................................ 246 
1.2 Strategies to explore the metabolic constraints for enhanced viral 
titers: from data mining to gene delivery .................................................... 248 
1.3 Debottlenecking gene manipulation and clone screening .............. 250 
1.4 Walking the road to hyperproductivity: multi-gene manipulation and 
dynamic promoters ...................................................................................... 251 
2. Author contribution ................................................................................. 254 
3. References ............................................................................................... 254 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter IX 
 
245 
 
1. Discussion and perspectives 
Virus based biopharmaceuticals are one of the most promising products of the 
21st century medicine covering successful prophylactic, therapeutic and clinical 
applications. Retrovirus-derived particles occupy an important segment of this market, 
having found use in gene therapy (Edelstine 2013), oncolytic treatment (Dalba et al. 
2007; Russell et al. 2012) and vaccination (Dalba et al. 2007; Garrone et al. 2011).  
 
Retroviruses manufacture has always been challenging. They are characterized by 
low titers, high-content of non-infectious particles and short infectivity half-lives 
(Coroadinha et al. 2010; Merten 2004). Long-term vector production is dependent on 
animal blood serum supplementation, hindering the safety and standardization 
required in clinical-grade manufacture processes (Chan et al. 2001; Gerin et al. 1999; 
Merten 2004). Additionally, the physical separation of the viral genome into different 
expression cassettes – for safety purposes – disrupts the regulatory stoichiometry and 
the optimal ratios of viral components further reducing the titers and increasing the 
defective particles content (Bajgelman et al. 2003; Yap et al. 2000). Several strategies 
have been attempted to circumvent these drawbacks including engineering mutant 
vectors with improved stability (Vu et al. 2008), transcriptionally improving the viral 
cassettes (Schambach et al. 2007) and optimizing vector components stoichiometry 
(Carrondo et al. 2008). All of these strategies have, to some extent, focused the viral 
cassettes.  Another line of intervention, focusing the producer cell, was initiated a few 
years ago. By using alternative carbon sources Coroadinha et al. (2006a and 2006b) 
observed marked changes in retrovirus producer cell metabolism at the level of 
glycolysis, TCA cycle, glutaminolysis, synthesis of fatty acids and phospholipids, with 
specific productivity improvements up to 5-fold. More importantly, a direct correlation 
between the changes in the cellular metabolic status and the viral properties – such as 
increased stability – was demonstrated (Coroadinha et al. 2006c).  
At the same time these results encouraged our interest in exploring producer cell 
metabolism for enhanced titers, a new paradigm in mammalian cell engineering was 
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emerging. Fed by more than one decade of metabolic engineering by trial-and-error 
(reviewed in Seth et al. (2006)), and by the opportunities offered with the explosion of 
omics technologies in cell culture bioprocess (Griffin et al. 2007; Gupta and Lee 2007), 
G. Seth and colleagues envisaged an elegant concept to rationalize metabolic 
engineering when in the pursuit of higher productivities (Seth et al. 2007). This 
concept relies on the understanding that i) particular physiological/metabolic traits – 
in the limit, based on gene expression – confer superior attributes in what concerns 
productivity; ii) these attributes are, alone, insufficient to promote a hyperproducing 
phenotype, thereby requiring combination and iii) such phenotype might be achieved 
by different combinations, since there is not a unique route leading to superior 
productivities. Although these premises might, nowadays, seem obvious, it was on the 
paper of Seth et al. (2007) that they were clearly enunciated for the first time.  
 
This PhD work aimed at improving retroviral vector production in human cell lines 
through gene-based metabolic optimization of the producer host. Thereby, this thesis 
lays on four pillars: i) understanding the metabolic constraints associated to virus 
replication, ii) devising theoretical and experimental strategies to explore this 
knowledge in promoting enhanced titers, iii) debottlenecking the experimental burden 
of gene manipulation and clone screening to iv) combine these strategies in one of the 
multiple routes to hyperproductivity. Functional genomics tools, including microarray 
transcriptome analysis, metabolite profiling, lipidomics, RNA interference and genetic 
engineering, were used and inter-crossed for knowledge generation and cell 
manipulation.  
 
1.1 Metabolic determinants in retroviral vector replication: transcriptomics, 
metabolomics and pathway analysis 
To gain further insights on the metabolic constraints associated to virus 
replication, large-scale transcriptome analysis was conducted, to identify potential 
pathways recruited when going from a non-producer to a producer cell line. As gene 
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manipulation was one of the final goals of this work, transcriptomics appeared as the 
primary surveying tool. Metabolomics, including central carbon metabolite profiling 
and lipidomics, functioned as a complementary approach. Indeed, although 
metabolomics is assumed as the layer of biological information closer to the final 
phenotype, metabolite profiling is associated to a high degree of uncertainty due to 
the inherent redundancy of the metabolic networks (Palsson 2006) and limited 
number of metabolites that can be accurately quantified in a biological sample 
(Dietmair et al. 2012; Oldiges et al. 2007).  
Using pathway analysis methods, eight pathways were identified to be recruited 
in the retrovirus producer cells: amino acid catabolism, carbohydrate catabolism and 
integration of the energy metabolism, nucleotide metabolism, glutathione 
metabolism, pentose phosphate pathway, polyamines biosynthesis and lipid 
metabolism (Chapter II). In serum heterotrophy, lipids were identified as the key 
serum component associated to infectious virus titers (Chapter III). 13C-NMR lipidomics 
demonstrated cholesterol biosynthesis to be impaired in serum heterotroph cells  
(Chapter IV) while transcriptional profiling identified three potential bottlenecks of this 
pathway: mevalonate kinase (MVK), lanosterol synthase (LSS) and sterol regulatory 
element binding factor 2 (SREBF2) (Chapter V.a). 
Pathway analysis methods rely on a rather simple statistic to identify significantly 
enriched pathways. Given a certain number x of differentially expressed genes, from 
which k are assigned to a pathway (k<x), from a total number of genes y comprising 
the dataset (y>>x>k), what is the probability of, by randomly picking x genes from the 
total set y, exactly k will belong to that pathway? This problem can be described by a 
hypergeometrical distribution easily computable, the basis of pathway analysis 
software’s, such as gene set enrichment analysis (Subramanian et al. 2005), GenMAPP 
(Dahlquist et al. 2002; Salomonis et al. 2007) and Ingenuity Pathway Analysis, herein 
used. These software’s have been updated to provide other outputs than statistical 
significance associate to pathway enrichment, including metabolic maps, scores trying 
to predict pathway activation/inhibition, “leading edges” – those genes accounting for 
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the core enrichment signal – all linked to publications and databases where further 
information can be consulted. They are thus, user-friendly data analysis platforms in 
the daunting challenge of extracting biological information from the massive amounts 
of transcriptome data (reviewed in Werner (2008)). Their two main disadvantages are: 
i) giving a rather qualitative output – the pathway is or is not enriched – and ii) the 
results may be strongly biased by the databases the software uses. The latter occurs 
since extensively described and curated pathways are more likely to appear as 
significantly enriched. Also, not all pathways are equally suitable for transcriptome 
pathway analysis, particularly those controlled to a large extent by metabolites or 
protein-based events, thus less likely to appear as significantly enriched.  
Because of these biases, a user-driven gene-by-gene a posteriori analysis is 
required to rationalize the biological significance of pathway analysis outputs. 
Therefore, in this work detailed metabolic maps were built, providing a broad and 
integrated overview of absolute gene expression and fold-changes for both cell lines 
(Chapter II and Chapter V.a). Each gene was scrutinized for the biological function and 
regulatory mechanisms using the BioCyc human database (Caspi et al. 2010). 
Additionally, before stepping forward to gene manipulation, the ability of the 
identified pathways to modulate viral titers was experimentally challenged by medium 
manipulation (Chapter II and Chapter III). 
 
1.2 Strategies to explore the metabolic constraints for enhanced viral titers: 
from data mining to gene delivery 
The metabolic maps and biological analysis allowed a systematized vision on 
actively changing genes and potentially blocked pathways. Yet, this was still a simple 
descriptive analysis, enclosing a potential interpretation skew: searching for actively 
changing genes as those to be potentially engineerable. Indeed the traditional 
approach in using transcriptome data to search for gene targets has mainly been based 
on the comparison ‘producers vs. parental’ or ‘high vs. low producers’ for clonal cells. 
In this work, we proposed a different approach: to mine the basis of particular 
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transcriptomic signatures from different cell origins. The rationale behind it is the 
notion that gene already recruited in the transition parental-to-producer or in the high 
producing clone, is likely to be responsive to that transition or phenotype. It also 
indicates that the cells have the intrinsic capability to express it, with no need for 
further over-expression. In fact, as an example, when XBP1 was chosen to be over-
expressed as a metabolic engineering target in CHO cells aiming for higher protein 
secretion (Tigges and Fussenegger 2006), it was not because XBP1 had been noted to 
be up-regulated when going from parental to producer or highly expressed in high 
producing CHO clones. It was because other cells with a much higher protein secretion 
capacity (B-cells) relied on XBP1 to expand the overall secretion capacity (Iwakoshi et 
al. 2003a; Iwakoshi et al. 2003b; Shaffer et al. 2004). Taking advantage of the two 
different retroviral producer cell lines used for transcriptomic and metabolomic 
analysis and their obvious phenotypic differences in what concerned productivity and 
serum heterotrophy, Te Fly cells were used as a ‘positive control’, both for higher 
productivities and the ability to revert serum heterotrophy. For the latter case, the 
concept became very well illustrated: although both 293 FLEX and Te Fly up-regulated 
their cholesterol biosynthesis machinery in response to serum withdrawal, including 
the two blocking points MVK and LSS, the extension of up-regulation was substantially 
higher in Te Fly (Chapter V.a), previously found to be able to reactivate cholesterol 
biosynthesis (Chapter IV). Without this comparison term, MVK and LSS might not have 
been considered for manipulation in 293 FLEX. Naturally, the limitations of using a cell 
– in this case Te Fly – as a positive control should also be critically considered. Cellular 
biology is much beyond what can be rationalized using transcriptomics, proteomics 
and metabolomics.  
Having set a list of gene candidates as potential targets to improve viral titers (or 
revert serum heterotrophy), it aroused the question on how the genes would be 
delivered. For more than 30 targets, no selectable markers existed. Additionally, 
traditional transfection methods limit the tuning of the number of delivered copies as, 
after a certain DNA amount, transfection itself becomes highly cytotoxic. Therefore, 
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gene delivery by lentiviral transduction was chosen as it is less invasive and allows for a 
better control of the number of delivered copies based on multiplicity of infection. 
Also, having used self-inactivating vectors (SINs) (Miyoshi et al. 1998; Zufferey et al. 
1998), gene expression is driven by the internal non-lentiviral promoter, thus behaving 
like a plasmid-carried gene integrated by homologous recombination. From the proof-
of-concept perspective and considering the final aim to be a combination of several 
genes, this strategy offered an effective and faster approach. For future extension of 
this work, however, multiple lentiviral transduction might not be the cellular 
engineering tool of choice. In this context, multicistronic constructions can be an 
option (Greber and Fussenegger 2007). Moreover, with the advances in artificial 
chromosomes, a not so distant future might bring the possibility of the tailored design 
of a mini-chromosome harboring a few dozens of genes and their regulatory 
machinery (Kennard 2011; Kouprina et al. 2013).  
 
1.3 Debottlenecking gene manipulation and clone screening 
After choosing a group of candidate genes and setting an experimental approach 
for their deliver, an additional challenge remained. The number of integrated copies, 
integration loci and the combination of downstream effects arising from gene 
manipulation renders an enormous clonal variability very difficult to be manually 
screened. This challenge was largely felt in the down-regulation of the Warburg effect 
(Chapter VI): it required several months to individually and manually screen more than 
eighty (shHIF1) clones. More than half of those were low-titer clones and only two 
were hyperproducing phenotypes (i.e.: producing one order of magnitude higher).  
Inspired by a previously reported in situ fluorescence assay (Green and Rasko 
2002) and taking advantage of transcomplementing fluorescence proteins (Cabantous 
et al. 2005), a novel method was conceived for fast identification of high-producing 
clones at the end of the cloning period. The uniqueness of the single step cloning-
titration method (Chapter VII) relies on: i) avoiding cell expansion, cell banking and 
posterior growth/titration studies of the low titer clones and ii) providing a 
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productivity estimation on a clone-by-clone basis, which can be analyzed in terms of 
density distribution. Therefore it combines the power of single-cell resolution with the 
dynamics of cell population analysis. These two features can be explored in metabolic 
engineering to rapidly identify rare high producing phenotypes (single-cell resolution) 
and to evaluate the dynamics of the delivered gene from an average perspective 
(population analysis). The method also allowed the isolation of clones delivering 
optimal ratios of infectious to total particles: for some the highest fluorescence-
yielding clones, ratios of 1 infectious per each 4 total particles could be obtained. 
These are, to the best of our knowledge, the best I.P.:T.P. ratios ever reported for 
retroviral vector production, being 1:100 to 1:1000 those typically obtained. This 
feature is intrinsic to the method layout since it evaluates the cumulative infectivity 
effect occurring during the relatively long-period of clone expansion. Thereby, high 
infectious titers clones but with equally high titers of non-infectious virus will flood the 
cloning well with defective interfering particles limiting the infective ones. The method 
main limitation is the lack of resolution in high-producing clones, hampered by some 
noise associated to colony location on the well. Therefore it requires 8-12 clones in the 
highest fluorescence ranges to be isolated to guarantee the highest producing 
phenotype which is not always the highest fluorescence clone. The concept behind the 
single step cloning-titration method can easily be translated to stable cell lines 
producing other types of infectious virus. For secreted recombinant protein, it should 
be equally suited given a few modifications.  
 
1.4 Walking the road to hyperproductivity: multi-gene manipulation and 
dynamic promoters 
Insightful from the theoretical point of view, the multiple routes to 
hyperproductivity concept (Seth et al. 2007) was, however, limited by the 
experimental burden of gene manipulation and heavy time-frames associated to clone 
screening. The single step cloning-titration method unlocked the manipulation of 
multiple genes by reducing the nearly one year process of clone screening to two 
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weeks. Starting from a group of genes identified in the first part of this thesis and 
leveraged by the swiftness of this method, in the latter stages of the work, the basis 
for an ambitious multi-gene engineering project were set. This project comprises three 
phases. Firstly, each of the genes is individually delivered and the derived effects 
analyzed. Herein, 17 out of the 31 candidates have been evaluated. In a second stage, 
high-titer phenotypes will be further transduced with genes found to deliver – at least 
– average improvements, on an intra-pathway basis. On a later stage, high-titer 
phenotypes from each pathway, already transduced with the pathway genes 
promoting improved titers, will be delivered for genes from the other pathways, in an 
attempt to find one of the multiple routes to hyperproductivity. At each step a 
thorough downstream analysis is preformed on: i) average productivity improvements, 
ii) high-titer phenotypes, iii) the reproducibility of i) and ii) using different lentiviral 
vector batches, iv) dynamics of gene expression and viral titers in response to 
increasing metabolic gene copies, v) effects on total and genome-containing particles 
titers and vi) metabolic gene translation (protein). For the genes herein evaluated in 
the first stage, many of these parameters have been studied. Some genes delivered 
average improvements, others resulted in the appearance of high-titer phenotypes 
and a few combined both phenomena (Chapter VIII). For the characterization already 
started, the preliminary results indicate the delivered gene to contribute to an 
improved metabolic status accompanied with relevant changes in viral components 
expression – particularly the viral transgene – translated into higher content of 
infectious particles. These preliminary results may also change our current vision of 
metabolic engineering and bioproduct cassette amplification. While the accepted 
paradigm separates the transcriptional dynamics of the product from an improved 
metabolic status better coping with enhanced productivities, our results suggest a 
reciprocal control between the metabolic capabilities of the host and bioproduct 
expression, fine-tuned to deliver an enhanced producer. In this context, the dynamic 
behavior of the MFG-LTR promoter in the viral transgene cassette should play an 
important role that is worthy to investigate. In fact, 293 FLEX 18 not subjected to 
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RMCE, thereby with a simple MSCV-LTR, did not exhibit titer improvement in response 
to metabolic gene delivery with the impressive extension observed for 293 FLEX GFP 
(Chapter VI) or 293 FLEX S11 (Chapter VIII). Considering that the viral transgene, in all 
293 FLEX cells, RCME exchanged or not, is present as a single copy integrated on the 
same unique and defined chromosomal locus, expression changes of more than 20-
fold as observed in many of the manipulated clones (containing MFG-LTR), can only be 
explained hypothesizing a dynamic behavior of this promoter in response to the 
metabolic and/or transcriptional changes induced by the delivered genes. Although 
this hypothesis requires further investigation, extending this dynamic behavior to the 
other viral cassettes (gag-pol and envelope) could deliver even better production 
performances.  
This PhD thesis contributes: i) to enlarge the technical possibilities of metabolic 
engineers in the demand for high-producing cells, ii) to improve the state-of-the-art of 
retroviral and similarly enveloped vectors (e.g.: lentivirus) manufacture for gene 
therapy and vaccination and iii) to deliver new insights on the metabolic dynamics 
modulating viral replication. It is thus, a frontier work, bridging fundamentals to 
applied research and touches the fields of biotechnology, bioengineering, vectorology, 
virology, cell and molecular biology.  
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